










Remote! ischaemic! preconditioning! (RIPC)! describes! the! phenomenon! where!brief! intermittent! periods! of! limb! ischaemia! are! used! to! protect! the! heart! and!other! organs! from! subsequent! prolonged! ischaemic! insults.! RIPC! has! been!identified! as! a! promising! intervention! for! use! during! cardiac! surgery! and! has!consistently!shown!a!beneficial!effect!in!animal!models;!however,!the!results!of!early!clinical!trials!have!not!been!as!successful.!The!exact!mechanisms!involved!in!mediating!RIPC!have!not!yet!been!characterised!and!a!better!understanding!of!the!pathways!through!which!RIPC!exerts!its!protective!effects!will!be!essential!in!order! to! progress! the! translation! of! this! intervention! into! the! clinical! setting.!There! is! increasing! evidence! that! RIPC! modifies! the! inflammatory! response,!therefore! the! central! aim! of! the! research! presented! in! this! thesis! was! to!investigate!how!RIPC!affects!the!human!immune!system.!!We!performed!a!double0blind!randomised!controlled!trial!of!RIPC!in!96!high0risk!cardiac! surgery! patients! and! found! no! evidence! that! the! intervention! reduced!myocardial! injury! or! altered! peri0operative! expression! levels! of! the! key!inflammatory! cytokines,! interleukin! (IL)06,! IL08,! and! IL010,! during! simple! or!more!complex!procedures.!There!was!a!trend!towards!higher!levels!of!IL06!and!IL08!in!the!preconditioned!patients;!however,!confounding!variables!in!the!trial!design!and!the!heterogeneous!patient!population!limited!our!ability!to!interpret!the!results.!!!We! next! conducted! a! paired0analysis! trial! with! 10! healthy!male! volunteers! to!assess!the!direct!effect!of!preconditioning!on!the!early! immune!response,!away!from!any!form!of!ischaemic!injury!or!comorbidities.!We!found!that!RIPC!directly!and!significantly!decreased!serum!levels!of!the!chemokines!MIP01α!and!MIP01β,!but!did!not!increase!the!serum!concentrations!of!a!range!of!key!cytokines!or!alter!the!cytokine!producing!potential!of!peripheral!blood!leukocytes.!These!findings!strongly! suggest! that! a! cytokine! is! not! likely! to! be! the! humoral! mediator!associated!with!transmitting!the!RIPC!protective!signal.!!!
!iv!
RIPC! did! not! alter! the! immunophenotype! or! extravasation! of! peripheral!leukocyte!populations,!or!the!proliferative!and!cytokine!responses!of!peripheral!blood!mononuclear!cells!(PBMC)!to!pharmacological,!physiological,!and!antigen0specific! stimuli.! However,! preconditioning! did! appear! to! reduce! the! ability! of!monocytes! and! neutrophils! to! respond! to! activation! signals,! as! indicated! by!lower! levels! of! CD11b! expression! in! stimulated! cultures,! and! a! significant!increase!in!the!basal!production!of!IL022!was!also!detected!in!PBMC!cultured!for!6!days! following!preconditioning.!These!alterations!may!reduce!neutrophil!and!monocyte! tissue! infiltration! and! limit! the! inflammatory! response! during! the!early!window!of!RIPC0induced!protection!and!enhance!tissue!and!wound!repair!several!days!later.!A!multivariate!analysis!confirmed!that!there!was!a!significant!difference! in! the! response! between! the! control! and! RIPC! treatments! and! the!main! contributing! factors! were! identified! as! changes! in! neutrophil! and! T! cell!activation,!serum!levels!of!MIP01α!and!β,!and!production!of!IL010!and!IL022!from!PBMC!cultured!for!6!days.!!!Overall,! our! results! suggest! that! RIPC! has! a! subtle! but! direct! effect! on! the!systemic! innate! immune! response! during! the! early! window! of! protection! in!healthy!volunteers,!whereas!the!effects!on!the!adaptive!immune!system!seem!to!be! considerably! delayed.! The! changes! detected! following! RIPC! are! likely! to!contribute! to! protection! against! ischaemia0reperfusion! injury! but! not! solely!account! for! the!extent!of! the!beneficial!effects!of!RIPC!detected! in!animals.!Our!findings! reinforce! the! safety! profile! of! this! intervention! and! have! defined! a!number!of!immune!parameters!that!are!altered!by!preconditioning!for!focusing!future!research.!
! v!
Acknowledgements!
I! owe! a! great! deal! of! gratitude! to! a! number! of! important! people! and!organisations! that!have!been! invaluable! in!helping!me!complete! this!PhD.!First!and! foremost,! I! would! like! to! thank! my! primary! supervisor! A/Prof! Anne! La!Flamme,!whose!expert!guidance,!knack!for!troubleshooting,!and!general! love!of!scientific! data! has! been! an! inspiration! throughout! this! research.! It! has! been! a!privilege!to!spend!my!post0graduate!years!studying!in!the!LAF!lab.!!I! am! also! very! grateful! for! the! support! and! feedback! from! my! secondary!supervisor,! Prof! Richard! Beasley,! and! for! the! additional! supervisors! of! my!Honours! project,! Dr! Paul! Young! and! Prof! John! Miller,! who! introduced! me! to!clinical!research!and!without!whom!I!would!not!have!become!so!absorbed!in!the!concept!of!RIPC.!!!This! research!would! not! have! been! possible!without! the! generous! help! of! the!Medical! Research! Institute! of! New! Zealand,! particularly! Dr! Janine! Pilcher! and!Mathew!Williams,!who! kindly! took! care! of! our! study! volunteers! and! collected!samples!while! I! raced!around! the! lab! trying! to!do! science.!A! special! thank!you!must!also!be!mentioned!to!all!of!the!study!volunteers!who!were!kind!enough!to!participate!in!our!trials.!!!The!much! needed! sound! statistical! advice,! analyses,! and! patience! provided! by!both!Prof!Mark!Weatherall!and!Dr!Dalice!Sim!were!also!greatly!appreciated.!!!We! were! very! fortunate! to! receive! project! funding! from! the! Lotteries!Commission,!Wellington!Medical!Research!Fund,!New!Zealand!Heart!Foundation,!and! the! Joy! McNicoll! Postgraduate! Award! in! Biomedical! Science.! I! am! also!personally! grateful! to! Victoria! University! for! a! PhD! Scholarship,! and! to! the!Wellington! Medical! Research! Fund,! Maurice! and! Phyllis! Paykel! Trust,! and!Victoria! University! for! funding! to! present! our! research! at! an! overseas!conference.!!!
!vi!













1.2!The!need!for!myocardial!protection!in!cardiac!surgery........................................ 2!1.2.1!Early0phase!of!inflammation!during!cardiac!surgery................................................. 3!1.2.2!Late0phase!of!inflammation!during!cardiac!surgery .................................................. 5!1.2.3!Current!cardioprotective!strategies................................................................................... 6!1.2.3.1!Cardioplegia........................................................................................................................... 7!1.2.3.2!Volatile!anaesthetics .......................................................................................................... 7!1.2.3.3!Heparin .................................................................................................................................... 9!1.2.3.4!Statins.....................................................................................................................................10!
1.3!History!of!IPC......................................................................................................................11!
1.4!Clinical!application!of!RIPC............................................................................................13!1.4.1!Cardioprotection ......................................................................................................................13!1.4.2!Renal!protection .......................................................................................................................15!1.4.3!The!value!of!RIPC!in!the!clinical!setting .........................................................................16!
1.5!Mechanisms!involved!in!RIPC.......................................................................................25!1.5.1!Evidence!for!humoral,!neural,!and!systemic!pathways ...........................................25!1.5.2!Potential!key!initiators!and!mediators!of!RIPC...........................................................27!1.5.2.1!Adenosine.............................................................................................................................27!1.5.2.2!Bradykinin............................................................................................................................28!1.5.2.3!Reactive!oxygen!species.................................................................................................28!1.5.2.4!Opioids...................................................................................................................................29!1.5.2.5!Calcitonin!gene0related!peptide..................................................................................30!1.5.2.6!Nitric!oxide...........................................................................................................................30!
!viii!







2.3!Methods................................................................................................................................50!2.3.1!Participants.................................................................................................................................50!2.3.2!Study!blinding!and!RIPC........................................................................................................50!2.3.3!Peri0operative!management!of!patients.........................................................................51!2.3.4!Serum!collection .......................................................................................................................51!2.3.5!Troponin!levels .........................................................................................................................51!2.3.6!Cytokine!quantification .........................................................................................................51!2.3.7!Comparison!of!vacutainers!for!cytokine!recovery.....................................................52!2.3.7.1!Sample!collection ..............................................................................................................52!2.3.7.2!TNF0α!and!IL06!ELISAs....................................................................................................52!2.3.8!Statistical!analysis....................................................................................................................53!
2.4!Results ..................................................................................................................................56!2.4.1!Patient!baseline!demographic!and!operative!data ....................................................56!
! ix!







3.3!Methods................................................................................................................................85!3.3.1!Participants.................................................................................................................................85!3.3.2!Flow!cytometry .........................................................................................................................85!3.3.2.1!Immunophenotyping.......................................................................................................85!3.3.2.2!Intracellular!cytokine!staining ....................................................................................86!3.3.3!Peripheral!blood!mononuclear!cell!cultures ................................................................86!3.3.4!CyQuant!proliferation!assay ................................................................................................87!3.3.5!IL06!ELISA....................................................................................................................................88!
3.4!Results ..................................................................................................................................89!3.4.1!Flow!cytometry!of!whole!blood!samples .......................................................................89!3.4.1.1!General!flow!cytometry!techniques ..........................................................................92!3.4.1.1.1! Assessing!viability.................................................................................................92!3.4.1.1.2! Fc!receptor!blocking.............................................................................................94!3.4.1.2!Testing!the!immunophenotyping!protocol ............................................................96!3.4.1.2.1! Stimulation!of!neutrophils!for!measurement!of!activation.................96!3.4.1.3!Development!of!ICS!protocol .......................................................................................99!3.4.1.3.1! Stimulation!of!cytokine!production!and!improvements!in!antibody!!! resolution!for!intracellular!staining ..............................................................99!3.4.1.3.2! Inhibition!of!protein!transport .....................................................................106!3.4.1.3.3! Examining!neutrophil!activation!state......................................................108!
!x!




4.1!Introduction..................................................................................................................... 136!4.1.1!The!innate!immune!system!and!ischaemia0reperfusion!injury ........................137!4.1.2!Evidence!that!preconditioning!alters!the!innate!immune!response...............138!4.1.2.1!Leukocyte!activation!and!infiltration ....................................................................138!4.1.2.2!Platelets ..............................................................................................................................139!4.1.2.3!Transcription!factors....................................................................................................140!4.1.2.4!Toll0like!receptors .........................................................................................................141!4.1.2.5!Complement .....................................................................................................................142!4.1.2.6!Matrix!metalloproteinases .........................................................................................143!4.1.2.7!Cytokines ...........................................................................................................................143!4.1.3!Rationale!for!the!study........................................................................................................144!
4.2!Aims .................................................................................................................................... 145!
4.3!Methods............................................................................................................................. 146!4.3.1!Participants..............................................................................................................................146!4.3.2!Study!design!&!application!of!RIPC ...............................................................................146!4.3.3!Blood!sample!collection .....................................................................................................146!4.3.4!Immunophenotyping...........................................................................................................148!4.3.5!Serum!collection ....................................................................................................................148!4.3.6!Serum!cytokine!quantification ........................................................................................148!4.3.7!Statistical!analysis.................................................................................................................149!
! xi!




! healthy!volunteers .............................................................................. 187!
5.1!Introduction..................................................................................................................... 188!5.1.1!Evidence!that!preconditioning!alters!the!adaptive!immune!response..........188!5.1.1.1!Regulatory!T!cells...........................................................................................................189!5.1.1.2!Helper!and!cytotoxic!T!cell!responses ..................................................................190!5.1.2!T!cells!and!I/R!injury ...........................................................................................................191!
5.2!Aims.................................................................................................................................... 194!
5.3!Methods............................................................................................................................. 195!5.3.1!Intracellular!cytokine!staining ........................................................................................195!5.3.2!Culture!of!PBMC.....................................................................................................................196!5.3.2.1!PBMC!isolation ................................................................................................................196!5.3.2.2!T!cell!stimulation............................................................................................................196!5.3.3!CyQuant!proliferation!assay .............................................................................................197!5.3.4!Cell!culture!supernatant!cytokine!quantification....................................................197!5.3.5!Statistics ....................................................................................................................................198!
5.4!Results ............................................................................................................................... 199!5.4.1!Intracellular!cytokine!production!in!whole!blood!cultures................................199!5.4.1.1!Monocytes!and!neutrophils .......................................................................................199!5.4.1.2!T!cell!subsets ....................................................................................................................205!5.4.1.3!CD56+!cell!subsets..........................................................................................................209!
!xii!
5.4.2!PBMC!proliferative!response ...........................................................................................212!5.4.3!PBMC!and!polyclonal!T!cell!cytokine!responses......................................................214!5.4.3.1!PBMC!responses!to!PMA/I!stimulation ................................................................214!5.4.3.2!Response!to!anti0CD3/28!dynabead!stimulation.............................................217!5.4.4!Antigen0specific!T!cell!cytokine!response ..................................................................220!
5.5!Discussion......................................................................................................................... 223!
5.6!Conclusions!and!future!directions ........................................................................... 232!!
Chapter!6.! Assessing!the!global!response!to!RIPC!in!humans ................... 233!

















! cardiac!surgery!patients ........................................................................ 323!
Appendix!B.! Criteria!for!EuroSCORE!and!RIFLE!Evaluations.............................. 329!
Appendix!C.! Recipes ......................................................................................................... 332!
Appendix!D.! Manuscripts!resulting!from!the!trial!of!RIPC!in!highQrisk!cardiac!
! surgery!patients........................................................................................ 333!
Appendix!E.! Complete!list!of!flow!cytometry!antibodies ..................................... 348!
Appendix!F.! Flow!cytometry!data!analysis ............................................................... 349!
Appendix!G.! Supplementary!figures!for!Chapter!4 ................................................ 362!




Figure!1.1!Proposed!mechanisms!involved!in!organ!protection!with!RIPC........... 38!Figure!2.1!CONSORT!diagram!of!study!workflow.............................................................. 57!Figure!2.2!Levels!of!IL06,!IL08,!and!IL010!are!not!affected!by!RIPC!in!high0risk!cardiac!surgery!up!to!12!hours!after!cross0clamp!removal.................... 62!Figure!2.3!IL06!and!IL010!levels!are!influenced!by!surgery!complexity,!but!not!RIPC................................................................................................................................. 66!Figure!2.4!Correlation!between!bypass!time!and!cytokine!levels!in!high0risk!surgery!patients......................................................................................................... 68!Figure!2.5!The!effect!of!statins!on!post0operative!IL06!levels....................................... 70!Figure!2.6!Comparison!of!TNF0α!and!IL06!recovery!between!commercially!available!serum!vacutainers................................................................................. 72!Figure!3.1!Summary!of!the!steps!undertaken!to!test!the!immunophenotyping!protocol ......................................................................................................................... 90!Figure!3.2!Summary!of!work!performed!to!develop!the!ICS!protocol ...................... 91!Figure!3.3!Assessment!of!cell!viability!in!whole!blood!samples.................................. 93!Figure!3.4!Comparison!of!Fc!receptor0blocking!strategies!for!flow!cytometry.... 95!Figure!3.5!fMLP!stimulation!of!neutrophils!for!activation!marker!measurement ............................................................................................................................................... 97!Figure!3.6!PMA/I!stimulation!of!neutrophils!activation!marker!expression......... 98!Figure!3.7!Stimulation!of!intracellular!cytokine!production!in!40hour!cultures ................................................................................................................................................ 102!Figure!3.9!Improvement!in!IL08!antibody!resolution ................................................... 103!Figure!3.9!Titration!of!the!IL06!antibody!for!intracellular!use.................................. 104!Figure!3.10!Stimulation!of!intracellular!cytokine!production!in!270hour!cultures........................................................................................................................................... 105!Figure!3.11!Comparison!of!protein!transport!inhibitors!for!intracellular!measurement!of!IL06,!IL08,!and!IL010............................................................ 107!Figure!3.12!Activation!state!of!cultured!neutrophils..................................................... 109!Figure!3.13!Optimisation!of!flow!cytometry!application!settings ........................... 111!Figure!3.14!Summary!of!the!work!undertaken!to!test!the!methods!for!PBMC!culture!and!quantification.................................................................................. 112!
! xv!
Figure!3.15!PBMC!purity!after!Histopaque01077!isolation.........................................113!Figure!3.16!Determining!the!linear!detection!range!for!the!CyQuant!proliferation!assay.............................................................................................................................114!Figure!3.17!Stimulation!of!PBMC!with!PMA/I!and!anti0CD3/28!beads.................117!Figure!3.18!Stimulation!of!PBMC!with!the!tetanus!vaccine ........................................120!Figure!3.19!Comparison!of!PBMC!cultured!with!the!separated!or!full!tetanus!vaccine.........................................................................................................................121!Figure!3.20!Overview!of!laboratory!sample!handling!schedule ...............................124!Figure!4.1!Overview!of!treatment!administration!and!blood!sample!collection!during!study!visits..................................................................................................147!Figure!4.2!Serum!levels!of!adhesion!molecules!following!RIPC................................153!Figure!4.3!Serum!levels!of!macrophage!inhibitory!protein!1!after!RIPC ..............155!Figure!4.4!Post0RIPC!systemic!chemokine!levels ............................................................156!Figure!4.5!Serum!T!cell!cytokine!expression!after!RIPC...............................................159!Figure!4.6!Systemic!levels!of!TNFα,!IL01β,!IFN0α,!and!IL010!following!RIPC......162!Figure!4.7!Post0RIPC!systemic!levels!of!IL012p70,!LAP,!and!G0CSF.........................163!Figure!4.8!Size!and!activation!state!of!circulating!neutrophils!and!monocytes!with!and!without!RIPC .........................................................................................167!Figure!4.9!Responsiveness!of!neutrophils!and!monocytes!to!re0stimulation!after!RIPC!treatment ........................................................................................................168!Figure!4.10!Proportions!of!circulating!T!cell!subsets!after!RIPC..............................171!Figure!4.11!CD69!expression!in!T!cell!subsets!following!RIPC!treatment............172!Figure!4.12!Proportion!and!activation!of!circulating!CD56+!cells!after!RIPC......174!Figure!5.1!Size!and!activation!state!of!monocyte!and!neutrophil!populations!after!4!or!27!hours!of!culture .......................................................................................202!Figure!5.2!Early!phase!of!intracellular!IL06!and!IL08!production!in!cultured!monocytes!and!neutrophils ...............................................................................203!Figure!5.3!Late!stage!intracellular!IL06!and!IL08!production!in!cultured!monocytes!and!neutrophils ...............................................................................204!Figure!5.4!T!cell!subset!proportions!and!activation!state!after!27!hours!culture........................................................................................................................................207!Figure!5.5!Late!phase!intracellular!IL06!and!IL08!production!in!cultured!T!cell!subsets.........................................................................................................................208!
!xvi!
Figure!5.6!Intracellular!cytokine!production!in!NK!cells!cultured!for!27!hours ................................................................................................................................................ 210!Figure!5.7!Cytokine!production!in!NKT!cells!after!27!hours!of!culture................. 211!Figure!5.8!PBMC!proliferative!responses!following!RIPC!treatment ..................... 213!Figure!5.9!Production!of!Th1!type!cytokines!in!PMA/I!stimulated!PBMC........... 215!Figure!5.10!Levels!of!Th2!type!cytokines!in!PMA/I!stimulated!PBMC!cultures ................................................................................................................................................. 215!Figure!5.11!Th9/Th17/Th22!type!cytokines!in!PMA/I!stimulated!PBMC!cultures.......................................................................................................................................... 216!Figure!5.12!Levels!of!Th1!type!cytokines!in!anti0CD3/28!dynabead!stimulated!PBMC ........................................................................................................................... 218!Figure!5.13!Production!of!Th2!type!cytokines!in!anti0CD3/28!dynabead!treated!PBMC!cultures ......................................................................................................... 218!Figure!5.14!Expression!of!Th9/Th17/Th22!type!cytokines!in!PBMC!cultures!stimulated!with!anti0CD3/28!dynabeads .................................................... 219!Figure!5.15!Th1!type!cytokine!production!in!tetanus!stimulated!PBMC.............. 221!Figure!5.16!Production!of!Th2!type!cytokines!in!PBMC!cultured!with!the!tetanus!antigen ........................................................................................................................ 221!Figure!5.17!Levels!of!Th9/Th17/Th22!type!cytokines!in!tetanus!stimulated!PBMC ........................................................................................................................... 222!Figure!6.1!Levels!of!ischaemia0modified!albumin!in!study!participants .............. 243!Figure!6.2!Total!change!in!ischaemia0modified!albumin!from!baseline!to!4!hours!after!treatment ........................................................................................................ 243!Figure!6.3!Dendrogram!showing!relatedness!between!participants!and!treatment!visits............................................................................................................................. 245!Figure!6.4!Visual!representation!of!the!distance!between!datasets!based!on!multidimensional!scaling!analysis.................................................................. 246!Figure!6.5!Simplified!visual!representation!of!the!distance!between!datasets!based!on!multidimensional!scaling!analysis .............................................. 247!Figure!A.1!Protocol!for!haemodynamic!management!of!patients!in!the!first!12!hours!following!cardiac!surgery...................................................................... 327!Figure!F.1!Gating!of!monocytes!and!neutrophils!in!panel!4....................................... 350!
! xvii!
Figure!F.2!Representative!plots!of!CD63!and!CD11b!staining!in!monocytes!and!neutrophils!during!immunophenotyping ....................................................351!Figure!F.3!Gating!of!total!T!cell!populations!and!CD56+!cells!in!panel!3 ...............352!Figure!F.4!Gating!of!CD4!T!cells!in!panel!1 .........................................................................353!Figure!F.5!Gating!of!CD8!T!cells!and!NK!cells!in!panel!2 ..............................................354!Figure!F.6!Gating!of!total!live!leukocytes,!monocytes,!and!neutrophils!in!panel!7!during!ICS...................................................................................................................355!Figure!F.7!Gating!of!intracellular!cytokines!in!monocytes!and!neutrophils........356!Figure!F.8!Gating!of!intracellular!cytokines!in!CD4!T!cells!in!panel!5 ....................357!Figure!F.9!Gating!of!intracellular!cytokines!in!CD8!T!cells!in!panel!6 ....................358!Figure!F.10!Gating!of!CD69!positive!T!cells!during!intracellular!cytokine!staining .........................................................................................................................................359!Figure!F.11!Gating!of!NK!and!CD4+!NKT!cells!in!panel!5..............................................360!Figure!F.12!Gating!of!CD8+!NKT!cells!and!intracellular!cytokines!in!NK!and!NKT!cells!in!panel!6 .........................................................................................................361!Figure!G.1!Serum!cytokine!levels!for!all!study!participants .......................................364!Figure!G.2!Serum!IL017!concentrations!with!outliers!removed................................365!Figure!H.1!T!cell!subset!proportions!and!activation!state!after!4!hours!culture...............................................................................................................................................366!Figure!H.2!Intracellular!IL06!and!IL08!production!in!T!cells!cultured!for!4!hours ............................................................................................................................................367!Figure!H.3!Alternative!expressions!of!intracellular!cytokine!data!in!T!cells!cultured!for!27!hours............................................................................................368!Figure!H.4!Intracellular!cytokine!production!in!NK!cells!cultured!for!4!hours..369!Figure!H.5!Cytokine!production!in!NKT!cells!after!4!hours!of!culture ...................370!!
!xviii!
List!of!Tables!
Table!1.1!Clinical!trials!investigating!the!cardioprotective!effect!of!RIPC .............. 18!Table!1.2!Clinical!trials!investigating!the!effect!of!RIPC!on!renal!outcome!measures.......................................................................................................................... 23!Table!2.1!Patient!demographic!and!clinical!data ............................................................... 58!Table!2.2!Patient!operation!details .......................................................................................... 59!Table!2.3!Statistical!comparison!of!peri0operative!IL06,!IL08,!and!IL010!levels!between!RIPC!and!control!treated!patients ..................................................... 63!Table!2.4!Key!patient!demographic,!clinical,!and!operative!details!for!simple!and!complex!surgery!subgroups.................................................................................... 65!Table!6.1!Variables!included!in!the!multivariate!analysis .......................................... 240!Table!6.2!Baseline!demographics!of!participant!groups.............................................. 242!Table!6.3!Characteristics!of!the!ACS!patient!population.............................................. 242!Table!6.4!Variables!responsible!for!the!difference!between!control!and!RIPC!treatment!responses................................................................................................ 250!Table!6.5!Variables!responsible!for!the!differences!between!study!participants........................................................................................................................................... 251!Table!B.1!Beta!coefficients!for!the!logistic!regression!model!of!EuroSCORE...... 330!Table!B.2!RIFLE!classification!criteria ................................................................................. 331!Table!F.1!Immunophenotyping!antibody!panels!for!a!Guava!easyCyte!8HT ...... 349!Table!F.2!Overview!of!antibody!panels!used!for!ICS!on!the!FACSCanto™!II........ 349!
! xix!
List!of!Abbreviations!!80SPT! ! 80(p0sulfophenyl)theophylline!ACE! ! Angiotensin!converting!enzyme!ACS! ! Acute!coronary!syndrome!ADP! ! Adenosine!diphosphate!AF! ! Atrial!fibrillation!AF488!! Alexa!fluor!488!AKI! ! Acute!kidney!injury!Akt! ! Protein!kinase!B!Al(OH)3! Aluminium!hydroxide!AMP! ! Adenosine!monophosphate!ANOVA! Analysis!of!variance!ANCOVA! Analysis!of!covariance!APC! ! Allophycocyanin!APCs! ! Antigen!presenting!cells!ASD! ! Atrial!septal!defect!ATP! ! Adenosine!triphosphate!AUC! ! Area!under!the!curve!AVR! ! Aortic!valve!replacement!BL! ! Baseline!BMI! ! Body!mass!index!BSA! ! Bovine!serum!albumin!BV421!! Brilliant!violet!421!CABG! ! Coronary!artery!bypass!graft!CBA! ! Cytometric!bead!array!CD!! ! Cluster!of!differentiation!CGRP! ! Calcitonin!gene0related!peptide!CI! ! Confidence!interval!/!Cardiac!index!CK0MB! Creatine!kinase0MB!CPB! ! Cardiopulmonary!bypass!CRP! ! C0reactive!protein!CTCM! ! Complete!T!cell!media!cTnI! ! Cardiac!troponin!I!cTnT! ! Cardiac!troponin!T!CVP! ! Central!venous!pressure!DAMP! ! Danger0associated!molecular!pattern!DNA! ! Deoxyribonucleic!acid!dPBS! ! Dulbecco’s!phosphate!buffered!saline!DTT! ! Dithiothreitol!ECG! ! Electrocardiogram!EF! ! Ejection!fraction!ELISA! ! Enzyme0linked!immunosorbent!assay!eNOS! ! Endothelial!nitric!oxide!synthase!ERK! ! Extracellular!signal0regulated!kinase!EuroSCORE! European!system!for!cardiac!operative!risk!evaluation!FACS! ! Fluorescent!activated!cell!sorting!Fc! ! Fragment!crystallizable!
!xx!
FCS! ! Fetal!calf!serum!fMLP! ! N0formyl0methionyl0leucyl0phenylalanine!FSC! ! Forward!scatter!G0CSF! ! Granulocyte!colony0stimulating!factor!GFR! ! Glomerular!filtration!rate!HIF01α! Hypoxia0inducible!factor01!alpha!HOE0140! Hoechst!140!HSP! ! Heat!shock!protein!ICAM! ! Intercellular!adhesion!molecule! !ICS! ! Intracellular!cytokine!staining!!ICU! ! Intensive!care!unit!IFN! ! Interferon!IgG! ! Immunoglobulin!G!IL! ! Interleukin!IM! ! Ionomycin!IMA! ! Ischaemia0modified!albumin!iNKT! ! Invariant!natural!killer!T!cell!iNOS! ! Inducible!nitric!oxide!synthase!IP010! ! Interferon!gamma0induced!protein!10!IPC! ! Ischaemic!preconditioning!IQR! ! Interquartile!range!I/R! ! Ischaemia/reperfusion!IU! ! International!units!JAK! ! Janus!kinase!JNK! ! c0Jun!N0terminal!kinases!LAD! ! Left!anterior!descending!artery!LAP! ! Latency!associated!peptide!LDH! ! Lactate!dehydrogenase!LOD! ! Limit!of!detection!LPS! ! Lipopolysaccharide!MACE! ! Major!adverse!cardiovascular!events!MAP! ! Mean!arterial!pressure!MAPK! ! Mitogen0activated!protein!kinase!MCP! ! Monocyte!chemotactic!protein!MDA! ! Malondialdehyde!MDS! ! Multidimensional!scaling!MFI! ! Mean!fluorescence!intensity!MHC! ! Major!histocompatibility!complex!MIP! ! Macrophage!inflammatory!protein!MPG! ! Mercaptopropionyl0glycine!MPO! ! Myeloperoxidase!mPTP! ! Mitochondrial!permeability!transition!pore!mRNA!! Messenger!ribonucleic!acid!MVR! ! Mitral!valve!repair!or!replacement!NF0κB! ! Nuclear!factor!kappa!B!NGAL! ! Neutrophil!gelatinase0associated!lipocalin!NIR! ! Near0infrared!NK! ! Natural!killer!NO! ! Nitric!oxide!
! xxi!





















1.1 Introduction!Worldwide,!an!estimated!one!million!cardiac!surgeries!are!performed!each!year,!of!which!2500!are!completed! in!New!Zealand! (Auckland!District!Health!Board,!2008).!During!the!majority!of!these!procedures!cardiopulmonary!bypass!(CPB)!is!employed!to!replace!the!roles!of!the!heart!and!lungs,!maintaining!the!circulation!of!oxygenated!blood!to!the!body!and!allowing!the!heart!to!be!operated!on.!While!the! utility! of! CPB! is! indispensable! during! these! surgeries,! its! use! is! associated!with!periods!of!oxygen!deprivation!and!a!systemic!inflammatory!reaction,!which!together! escalate! the! response! elicited! by! the! surgical! procedure! alone!(Paparella!et!al.,!2002).!As! the! incidence!of!diabetes!and!hypertension! increase!among!an!ever0growing!aging!population!a!number!of! cardiac!surgery!patients!are!presenting!with!reduced!physiological!reserves!(Biancari!et!al.,!2009;!Etzioni!and!Starnes,!2011;!McGuinness!et!al.,!2008).!Taken!together,!these!factors!signify!an! increased!risk!of!morbidity!and!mortality! for!many!modern!cardiac!patients!and!the!need!for!novel!strategies!to!improve!clinical!outcomes!in!such!cases.!!!The!research!presented!in!this!thesis! is! focused!on!a!potential!cardioprotective!technique! known! as! remote! ischaemic! preconditioning! (RIPC).! This! general!introduction! describes! the! pathological! processes! associated! with! cardiac!surgery,!the!history!and!clinical!development!of!RIPC,!and!an!overview!of!what!is!currently!known!about!the!underlying!mechanisms!involved!in!this!technique.!A!more!detailed!summary!of!the!background!information!pertinent!to!the!research!conducted!as!part!of!this!project,!particularly!regarding!what!is!known!about!the!impact!of!RIPC!on! the! immune!system,! is! introduced! in! the!subsequent! results!chapters.!!
1.2 The!need!for!myocardial!protection!in!cardiac!surgery!There!are!two!distinct!processes!involved!in!the!unfavourable!response!to!CPB.!The!first!of!these,!termed!the!early0phase,!is!initiated!when!the!blood!encounters!the! artificial! surface! of! the! extracorporeal! bypass! circuit,! whereas! the! second!process,! the! late0phase,! is! induced! predominantly! by! ischaemia0reperfusion!(I/R)!injury!(Warren!et!al.,!2009).!!
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1.2.1 EarlyQphase!of!inflammation!during!cardiac!surgery!Interactions! between! the! blood! and! the! negatively! charged! surface! of! the! CPB!tubing! results! in! a! protein! activation! cascade! that! initiates! components! of! the!complement,! fibrinolytic,! contact,! and! coagulation! pathways,! the! last! two! of!which! lead! to! thrombin! generation! (Miller! and! Levy,! 1997).! During! CPB,!thrombin! activation! of! fibrin! and!platelets! is! the! primary! cause! of! thrombosis,!the! formation! of! blood! clots! within! blood! vessels.! Many! of! the! resulting!microemboli! re0enter! the! circulation! and! block! narrow! capillaries,! leading! to!small!pockets!of!necrosis!in!hundreds!of!loci!throughout!the!body!(Abu0Omar!et!al.,! 2004;! Edmunds,! 1998).! Introduction! of! CPB! circuits! coated! with! the!anticoagulant! heparin! have! been! shown! to! inhibit! thrombin! formation! and!reduce!activation!of!the!contact!system,!but!not!to!the!extent!required!to!prevent!stimulation! of! the! systemic! inflammatory! response! associated! with! CPB!(Baufreton!et!al.,!1998).!!!The!fibrinolytic!system!functions!to!offset!the!coagulation!system!during!CPB!by!localising!clot! formation! to! the!site!of! injury!rather! than!allowing!unrestrained!systemic!thrombosis.!The!activated!endothelium!lining!the!vasculature! initiates!plasmin! production,!which! breaks! down! blood! clots! into! soluble! products! and!reduces! platelet! adhesion! and! aggregation! (van! Hinsbergh,! 2012).! The!endothelium!thus!plays!a!key!role!in!maintaining!the!fluidity!of!the!blood!by!way!of! the! fibrinolytic! system;! however,! there! is! commonly! an! imbalance! between!coagulation!and! fibrinolysis!during!CPB!which!results! in!poor!haemostasis!and!increased!post0operative!blood!loss!(Boyle!et!al.,!1996b).!!!Complement! activation! occurs! in! response! to! a! variety! of! stimuli,! resulting! in!production!of!the!anaphylatoxins!C3a,!C4a,!and!C5a!that!lead!to!smooth!muscle!contraction! in! the! airways! and! increased! vascular! permeability,! both! of!which!result! in! hypotension! and! the! need! for! lengthened! post0operative! ventilatory!support! (Miller! and! Levy,! 1997).! Additionally,! C3a! and! C5a! can! stimulate!transcription!of!the!proinflammatory!cytokines!tumour!necrosis!factor!(TNF)0α,!interleukin! (IL)01,! and! IL06,! thus! amplifying! the! inflammatory! response! (Miller!and! Levy,! 1997).! Complement! activation! also! leads! to! formation! of! the!
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membrane!attack!complex!(MAC),!a!transmembrane!channel!responsible!for!cell!lysis!and!death!in!endothelial!cells!and!cardiac!myocytes.!Together,!C5a!and!MAC!are!potent!activators!of!neutrophils,!promoting!chemotaxis,!granule!release,!and!the!production!of!toxic!oxygen!free!radicals!(Collard!and!Gelman,!2001;!Warren!et!al.,!2009).!!!Neutrophils! are! the! key! effector! cells! of! the! inflammatory! response! and! in!addition!to!recognising!a!broad!range!of!pathogens!they!can!be!stimulated!by!a!variety! of! danger! signals! from! other! cells.! In! the! case! of! CPB! these! activation!signals! are! diffuse! and! primarily! consist! of! proinflammatory! cytokine! release!and!complement!degradation!products!(Verrier!and!Boyle,!1996).!Further,!local!activation!of!endothelial!cells!at!the!site!of!infection!or!injury!by!other!aspects!of!the! immune! response! induces! the! surface! expression! of! neutrophil! adhesion!molecules,! selectins! and! integrins! (Paparella! et! al.,! 2002).! Together,! these!responses! result! in! widespread! endothelial! activation! and! neutrophil!sequestration!into!the!lungs!and!other!organs.!!!During! CPB,! neutrophils! are! chiefly! activated! by! direct! interactions! with! the!endothelium! and! inflammatory! mediators! such! as! thrombin,! endotoxin! and!heparin!(Boyle!et!al.,!1996a).!This!activation!results!in!neutrophil!degranulation!and!release!of!enzymes!that!damage!the!structural!matrix!proteins!necessary!for!normal! cell! function.! Additional! non0specific! damage! occurs! with! neutrophil!secretion! of! reactive! oxygen! species! (ROS)! that! can! lead! to! the! destruction! of!cellular!membranes,!DNA!nicking!and!cross0linking,!the!degradation!of!proteins,!and! further! upregulation! of! endothelial! adherence! molecules! (Korthuis! and!Granger,! 1993).! These! actions! are! responsible! for!much! of! the! CPB0associated!damage!to!the!lungs,!heart!and!other!tissues,!making!neutrophils!a!major!target!for!controlling!the!inflammatory!response.!!!The! endothelium! is! not! passive! in! these! processes! but! rather! assists! through!production!of!IL08!to!attract!neutrophils!and!facilitate!transendothelial!migration!and! also! releases! vasoconstrictive! agents! (Boyle! et! al.,! 1996a).! A! key! difficulty!with!CPB!is!this!impaired!performance!of!the!systemically!activated!endothelium!
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post0surgery.! The! dysfunctional! endothelium! promotes! localised! coagulopathy!and! proinflammatory! cytokine! production,! propagating! the! inflammation! and!tissue!damage!associated!with!organ!dysfunction!such!as!cardiodepression!and!acute! renal! injury,!which! are! frequently! detected! following! CPB! (Gueret! et! al.,!2009;!Verrier!and!Boyle,!1996).!!!
1.2.2 LateQphase!of!inflammation!during!cardiac!surgery!Ischaemia!describes!the!situation!where!there!is!insufficient!blood!supply!to!an!organ! or! tissue,! thus! causing! cell! death! through! the! resulting! reduced! oxygen!delivery! and! metabolite! washout.! Although! beneficial! in! the! long! term,!reperfusion,! which! is! the! restoration! of! blood! flow! to! the! ischaemic! tissue,!initiates!both!a!local!and!systemic!inflammatory!response!that!is!associated!with!more! substantial! tissue! injury! than! that! caused!by! the! initial! ischaemia! (Abela!and! Homer0Vanniasinkham,! 2003).! This! phenomenon! is! known! as! ischaemia0reperfusion! (I/R)! injury! and! is! the! major! cause! of! peri0operative! myocardial!damage.!!!Under!hypoxic!conditions! intracellular!adenosine!triphosphate!(ATP)! levels!are!quickly!consumed!due!to!decreased!oxidative!phosphorylation.! !Cellular!energy!production! thus! shifts! toward! anaerobic! metabolism,! which! results! in!proinflammatory!cytokine!production!(Abela!and!Homer0Vanniasinkham,!2003).!The! lack! of! oxygen! also! induces! high! levels! of! endothelial! trauma,! leading! to!upregulation! of! leukocyte! adhesion! molecule! expression! and! consequently!neutrophil! sequestration! following! reperfusion,! particularly! in! the! lungs!(Asimakopoulos! et! al.,! 1999).! I/R! associated! tissue! damage! can! result! in! both!local! and! remote! organ!pathologies! and! is! largely!mediated!by! the!neutrophil0endothelial!interactions!described!earlier;!however,!free!radical!production!and!endotoxaemia! are! additional! processes! that! characterise! the! late0phase!inflammatory!response.!!The! enzymes! responsible! for! breakdown! of! the! free! radical! precursor!hypoxanthine! are! oxygen0dependent! xanthine! oxidases! (Collard! and! Gelman,!2001).! Under! hypoxic! conditions,! hypoxanthine! accumulates! and! upon!
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reperfusion!is!activated!into!ROS.!ROS!generation!can!lead!to!cellular!structural!damage! and! lipid! peroxidation,! as! well! as! enhanced! leukocyte! migration,!diapedesis!and!activation.!Additionally,!ROS!deactivate!nitric!oxide!(NO),!which!would!normally!function!to!clear!free!radicals,!inhibit!proinflammatory!cytokine!production,!and!facilitate!vasodilation!(Abela!and!Homer0Vanniasinkham,!2003).!The!resulting!cellular!oedema!and!endothelial!swelling!leads!to!the!compression!of! capillaries! and! restriction! of! blood! flow,! which! is! further! exacerbated! by!plugging!with!fibrin,!platelets,!and!leukocyte!aggregates.!These!processes!result!in!what!is!referred!to!as!the!no0reflow!phenomenon,!which!continues!to!deprive!the!tissues!of!oxygen!following!the!initiation!of!reperfusion!(Rezkalla!and!Kloner,!2002).!!!Bacterial! endotoxins! are! an! additional! potent! stimulus! for! the! development! of!systemic! inflammation! and! elevated! levels! are! frequently! detected! in! the!circulation!of!patients!as!early!as! twenty!minutes!after! initiation!of!CPB!due!to!splanchic!vasoconstriction!(Watarida!et!al.,!1994).!The!resulting!bowel!ischaemia!and! inflammatory! conditions! increase! intestinal! permeability,! allowing!absorption!of! endotoxins! into! the!portal! circulation,!which! stimulates! cytokine!production,!leukocyte!activation,!NO!release,!and!systemic!inflammation!(Swank!and! Deitch,! 1996).! The! extent! of! the! patient! response! to! endotoxaemia! varies!significantly,! mainly! due! to! each! individual’s! level! of! anti0endotoxin! core!neutralising! antibodies,! but! consistently! adds! to! an! early! response! of!proinflammatory!cytokine!production!(McGuinness!et!al.,!2008).!!!!
1.2.3 Current!cardioprotective!strategies!Since!the!first!successful!open!heart!surgery!was!performed!in!1953!enormous!research! and! technological! advances! have! significantly! improved! the! success!rate! of! these! procedures.! Despite! this! progress,! post0operative! organ! damage!still! causes! significant!morbidity! and!mortality! in! cardiac! surgery!patients! and!places! a!major! strain! on! limited! hospital! resources! (Ministry! of!Health,! 2008).!The! predominant! cause! of! myocardial! damage! during! cardiac! surgery! results!from!the!ischaemia!caused!by!cross0clamping!the!heart!that!prevents!perfusion!of! the! coronary! arteries.! At! present! there! are! a! number! of! cardioprotective!
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strategies!that!are!commonly!employed!in!an!effort!to!minimise!this!ischaemia0induced!peri0operative!myocardial!injury.!!
1.2.3.1 Cardioplegia/Cardioplegia!is!defined!as!an!elective,!rapid,!and!reversible!paralysis!of!the!heart!and!is!currently!the!gold!standard!for!cardioprotection!during!surgery.!There!are!a!variety!of!cardioplegia!solutions!commonly!used!to!infuse!the!heart!but!they!all!depend! on! the! same! basic! principle! which! uses! elevated! potassium! levels! to!depolarise! cardiac! cells! and! prevent! repolarisation! (Chambers! and! Fallouh,!2010).! This! depolarised! arrest! maintains! the! heart! in! a! non0beating! diastolic!state,!eliciting!protection!through!limiting!metabolic!activity!in!the!myocardium,!and!allowing!the!surgical!procedure!to!be!performed!(Ferguson!et!al.,!2014).!The!solutions!can!be!diluted!and!infused!using!either!an!isotonic!crystalloid!solution!or!blood;!administered!antegrade!or!retrograde,!once,!or!multiple! times;!under!hypothermic!(4!0!8!°C),!tepid!(29!0!33!°C),!or!normothermic!(37!°C)!conditions.!Despite! this! wide! variety! of! cardioplegic! strategies,! there! is! a! distinct! lack! of!clinical! research! comparing! their! effectiveness,! and! the! most! beneficial!combination!of!factors!remains!elusive!(Ferguson!et!al.,!2014).!!Although!now! a! part! of! common! clinical! practice,! the! high! levels! of! potassium!involved! in! depolarising! arrest! have! been! associated! with! a! range! of! adverse!effects! including,! but! not! limited! to,! arrhythmias! and! conduction! disturbances,!contractile! stunning,! endothelial! injury,! and! vasoconstriction! (Dobson! et! al.,!2013).! These! effects! also! further! enhance! the! peri0operative! inflammatory!response.! In! recent! years! the! concept! of! inducing! a! more! electrically! stable!polarised!form!of!arrest!using!adenosine!and!lidocaine!has!been!proposed!as!an!alternative! to! hyperkalaemic! cardioplegia! and! has! shown! promising! results! in!early! clinical! studies,! but! further! trials! are! necessary! (Dobson! et! al.,! 2013;!Onorati!et!al.,!2013).!!!
1.2.3.2 Volatile/anaesthetics/Volatile! anaesthetics! (VA)! are! administered! as! inhaled! gases! and! can! be! used!alone!or! in!combination!with!intravenous!anaesthetics.!Several!commonly!used!
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VA,! including! isoflurane! and! sevoflurane,! have! been! shown! to! confer! renal,!myocardial! and! neural! protection! during! surgical! procedures! and! clinical!ischaemic!events!(Altay!et!al.,!2012;!M.!Kim!et!al.,!2007;!Landoni!et!al.,!2007).!VA!reduce!myocardial!contractility!and!oxygen!demand,!but!a!number!of!additional!pathways! have! also! been! identified! as! contributing! to! these! protective! effects.!For! instance,! VA! have! been! shown! to! stimulate! opening! of! the! mitochondrial!adenosine! triphosphate0sensitive! potassium! (KATP)! channels! in! both! rat!trabeculae! and! human! ventricular! muscle! cells,! and! delay! opening! of! the!mitochondrial! permeability! transition! pore! (mPTP),! both! of! which! increase!cellular!resistance!to!ischaemia!(de!Ruijter!et!al.,!2003;!Jiang!et!al.,!2007;!Piriou!et! al.,! 2004).! Other! studies! have! also! implicated! the! Akt/PI3k! anti0apoptotic!pathway!and!regulation!of!the!transcription!factor,!nuclear!factor!(NF)0κβ,!in!VA0induced!organ!protection!(Raphael!et!al.,!2006;!Wang!et!al.,!2010).!Interestingly,!many! of! these! mediators! appear! to! overlap! with! those! involved! in! classic!ischaemic!preconditioning!(IPC).!!!At!present!it!is!unclear!whether!the!use!of!volatile!anaesthetics!with!IPC!or!RIPC!can!have! additive!protective! effects!during! cardiac! surgery.!Many! studies!have!reported! a! lack! of! cardioprotection! when! RIPC! is! used! in! conjunction! with!inhaled!anaesthetics!and!a!meta0analysis!by!Zhou!et#al.#(2013)!found!that!RIPC!was!less!effective!when!used!alongside!volatile!anaesthesia!(Karuppasamy!et!al.,!2011;!Rahman!et!al.,!2010).! In!contrast,!more!recently!Kottenberg!et#al.#(2012)!reported! that! RIPC! was! effective! during! anaesthesia! with! isoflurane! but! not!propofol! in! coronary! artery! bypass! graft! (CABG)! patients.! Substantial! overlap!between! the! pathways! activated! by! VA! and! IPC! could! result! in! competitive!inhibition! of! one! or! both! strategies;! therefore! a! greater! understanding! of! the!mechanisms! involved! in!both! interventions!will!be!essential! to!determine!their!utility!as!a!combined!cardioprotective!strategy.!!!Although!numerous!studies!have!reported!beneficial!effects!with! the!use!of!VA!during! cardiac! surgery,! a! number! of! studies! have! failed! to! detect! an!improvement! (Bignami! et! al.,! 2012;! De! Hert! et! al.,! 2009;! Piriou! et! al.,! 2004).!Further,! the! use! of! VA! has! been! associated! with! myocardial! depression! and!
! 9!
vasodilation,!and!use!in!patients!with!severe!preoperative!myocardial!ischaemia!or! cardiovascular! instability! was! linked! with! worse! clinical! outcome! when!compared!to!the!use!of!intravenous!anaesthetics!(Jakobsen!et!al.,!2007;!Larach!et!al.,!1990;!Van!Allen!et!al.,!2012).!Overall,!despite!the!widespread!adoption!of!VA!for! use! during! cardiac! surgery,! they! appear! to! have! several! limitations! in! the!clinical!setting.!!!
1.2.3.3 Heparin/Heparin! is! essential! as! an! anti0coagulant! during! cardiac! surgery! but! has! also!been! shown! to! exert! additional! benefits! that! are! separate! from! this! activity.!Numerous! animal0based! studies! have! demonstrated! that! both! heparin! and! N0acetyl! heparin,! a! derivative! that! lacks! the! anti0coagulant! properties,! promote!myocardial!protection!during!I/R!injury!by!reducing!infarct!size!and!myocardial!dysfunction,! whereas! administration! of! the! heparin0degrading! enzyme,!heparinase,! reverses! this! effect! (Friedrichs! et! al.,! 1994;! Kilgore! et! al.,! 1999;!Kouretas! et! al.,! 1999;!Park! et! al.,! 1999).!This!protection!was! associated!with! a!reduction!in!myocardial!neutrophil!accumulation!and!complement0mediated!cell!lysis,!and!improved!preservation!of!coronary!endothelial!function.!!!It! is! now! well! established! that! heparin! also! has! significant! anti0inflammatory!properties,!although!the!mechanisms!through!which!these!effects!occur!are!not!completely! understood.! It! appears! that! heparin! is! capable! of! binding! and!neutralising!numerous! inflammatory!mediators! including!acute!phase!proteins,!complement,! and! chemokines! (Kuschert! et! al.,! 1999;! Pangburn! et! al.,! 1991;!Young! et! al.,! 1997).! Heparin! also! reduces! neutrophil! adhesion! to! the!endothelium,! most! likely! through! binding! and! blocking! P0selectin! present! on!activated!endothelial! cells!and!platelets! (Koenig!et!al.,!1998;!Lever!et!al.,!2000;!Young! et! al.,! 1999).! Lastly,! it! has! been! shown! that! uptake! of! heparin! by!numerous! cell! types! including! the! endothelium! and! myocytes,! prevents!translocation!of!the!transcription!factor!NF0κB!into!the!nucleus,!thus!suppressing!the! expression! of! numerous! inflammatory! genes! (Hochart! et! al.,! 2006;!Manduteanu! et! al.,! 2003;! Thourani! et! al.,! 2000).! Although! the! cardioprotective!effects!of!heparin!have!not!been!studied!in0depth!in!the!clinical!environment,!the!
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use! of! heparin! coated! CPB! circuits! has! been! associated! with! significantly!improved!outcomes!following!cardiac!surgery!(Aldea!et!al.,!1997,!1996).!!!
1.2.3.4 Statins/Numerous! medications! including! potassium! channel! activators,! general! anti0inflammatory!treatments,!and!the!cholesterol! lowering!drugs,!statins,!have!also!been! investigated! for! use! during! cardiac! surgery! due! to! their! potential!cardioprotective!effects.!Statins!are!the!most!well!researched!of!these!treatments!and! while! they! are! predominantly! recognised! for! their! cholesterol0lowering!properties,! they! also! exert! pleiotropic! effects! that! promote! cardioprotection,!such! as! increased! production! of! nitric! oxide! (NO),! which! stimulates! coronary!vasodilation,! improved! thrombogenic! balance,! and! anti0inflammatory! activity!(Ma!and!Han,!2005;!reviewed!by!Williams!and!Harken,!2008).!!!Accordingly,!trials!have!reported!atorvastatin!treatment!to!be!associated!with!a!nearly! 70%! reduction! in! the! combined! relative! risk! of! cardiac0related! death,!peri0operative! myocardial! infarction! (MI),! unstable! angina,! and! stroke! in!vascular!surgery!patients,!and!use!of!simvastatin!in!CABG!patients!reduces!post0operative! thrombocytosis!and! the! incidence!of!MI! (Christenson,!1999;!Durazzo!et! al.,! 2004).!A! recent!meta0analysis! comparing! outcome!data! for! patients! that!were! either! peri0operative! statin! recipients! or! statin0naïve! determined! that!statin! use! was! associated! with! decreased! risk! of! atrial! fibrillation! in! cardiac!surgery!patients,!lower!risk!of!MI,!and!reduced!length!of!hospital!stay!with!both!cardiac!and!non0cardiac!procedures!(Chopra!et!al.,!2012).!In!contrast,!two!large!prospective! trials! of! statin! use! in! patients! with! heart! failure! did! not! detect! a!benefit!in!clinical!outcomes!with!the!use!of!rosuvastatin!(GISSI0HF!investigators,!2008;!Kjekshus!et!al.,!2007).!Like!many!of!the!other!cardioprotective!strategies!described,!the!existing!use!of!statins!is!widespread!among!patients!with!chronic!heart!disease;!therefore!these!treatments!are!unlikely!to!significantly!improve!on!current!clinical!practice,!and!novel!cardioprotective!interventions!are!required.!!
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1.3 History!of!IPC!Classic! or! local! ischaemic! preconditioning! (IPC)! refers! to! the! phenomenon! by!which!exposure! to! a!brief!period!of! ischaemia! followed!by! reperfusion! confers!protection!from!a!subsequent!sustained!ischaemic!injury!in!the!same!tissue.!This!effect!was!first!demonstrated!when!Murry!et#al.!(1986)!reported!that!dogs!that!underwent! four! cycles! of! five0minute! circumflex! artery! occlusion! with!intervening!periods!of! reperfusion!prior! to! a! forty0minute! sustained! ischaemia!suffered! only! 25%! of! the! level! of! damage! seen! in! the! animals! that! were! not!preconditioned.! Yellon! et# al.! (1993)! performed! the! first! study! in! humans,!demonstrating!that!two!three0minute!periods!of!aortic!cross0clamping!followed!by!a! two0minute! reperfusion!during!CABG!slowed! the! rate!of!ATP!depletion! in!the! myocardium,! relative! to! the! controls.! However,! the! benefits! seen! in! such!initial! studies! that! utilised! short! periods! of! aortic! cross0clamping! and!reperfusion!as!the!preconditioning!stimulus!were!offset!by!the!increased!risk!of!ventricular!dysfunction!and!generation!of!atherosclerotic!emboli!(Kloner,!2009;!Teoh!et!al.,!2002).!!!An!instrumental!study!by!Przyklenk!et#al.!(1993)!demonstrated!that!in!a!canine!model! transient! occlusion! of! the! circumflex! artery! could! reduce! the! extent! of!damage! to! the! myocardium! perfused! by! the! left! anterior! descending! artery!(LAD)!in!response!to!a!subsequent!sustained!ischaemia!via!the!latter!vessel.!This!finding,! termed! ‘regional! ischaemic! preconditioning’,! established! that! the!benefits! of! preconditioning! were! not! restricted! to! the! myocytes! in! the! region!directly! subjected! to! the! conditioning! ischaemia.! This! study! formed! the!foundation!for!subsequent!research!evaluating!the!potential!of!using!alternative!tissue!sites!for!IPC.!!!In! 1996,! Gho! et# al.! established! that! in! a! rodent! model! a! 15! minute! period! of!intestinal! ischaemia! induced! by! occlusion! of! the! anterior! mesenteric! artery!limited! myocardial! infarct! size! to! the! same! extent! as! direct! myocardial!preconditioning! in! response! to! a! 60! minute! coronary! artery! occlusion.! This!protection! was! abolished! when! the! mesenteric! artery! was! permanently!occluded,!demonstrating!the!dependence!of!the!protection!on!reperfusion!of!the!
!12!
ischaemic! tissue.! Further,! a! comparable! level! of! protection! was! afforded! by!occlusion! of! the! left! renal! artery! under! hypothermic! conditions.! This! type! of!stimulus!was!termed!‘remote!ischaemic!preconditioning’.!!!The!inception!of!RIPC!as!a!clinically!relevant!phenomenon!was!largely!the!result!of! a! study! by! Birnbaum! et# al.! (1997)! that! determined! that! skeletal! muscle!ischaemia! could! be! used! to! remotely! precondition! the! myocardium.! Using!rabbits,!it!was!shown!that!a!55065%!reduction!of!the!femoral!artery!blood!flow,!coupled! with! electrical! stimulation! of! the! gastrocnemius! muscle! to! increase!oxygen!demand!in!the!hind!limb,!afforded!a!protective!response!consistent!with!that! achieved! through! direct! coronary! artery! conditioning.! Studies! in! rats,!canines,! and! pigs! provided! further! evidence! that! the! skeletal!muscle! could! be!used!as!the!remote!organ!for!preconditioning!and!the!first!application!of!RIPC!in!humans! followed! (Gunaydin! et! al.,! 2000;! Kharbanda! et! al.,! 2002;! Liauw! et! al.,!1996;!Oxman!et!al.,!1997).!!Gunaydin! et# al.! (2000)! used! two! cycles! of! 30minute! periods! of! upper! limb!ischaemia! separated! by! two!minutes! of! reperfusion! to! induce! RIPC! in! a! small!pilot! study! with! eight! CABG! patients.! This! research! provided! the! first!biochemical!evidence!of!RIPC!through!increased!lactate!dehydrogenase!levels!in!the!preconditioned!patients,!relative!to!the!controls.!Subsequently,!Kharbanda!et#
al.! (2002)! developed! the! non0invasive! form! of! RIPC! that! has! been! routinely!adopted!for!the!majority!of!clinical! trial!work!to!date.!This! intervention!targets!the!skeletal!muscle!of!the!upper!limb!using!three!five0minute!cycles!of!inflation!of! a! blood! pressure! cuff! to! 200! mmHg,! followed! by! five0minute! periods! of!reperfusion.! It!has!been!demonstrated! in!humans! that! this! stimulus!attenuates!I/R! induced! endothelial! dysfunction! in! the! contralateral! arm,! and! in! a! porcine!model!of!MI!it!reduces!both!ventricular!dysfunction!and!infarct!size!(Kharbanda!et!al.,!2002,!2001).!!RIPC!has!been!shown!to!provide!two!windows!of!organ!protection,!which!appear!to! be! mediated! by! different! processes.! The! first! occurs! immediately,! lasting!between! two! and! four! hours! and! involving! the! release! or!modification! of! pre0
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formed! substances! (Kuzuya! et! al.,! 1993;! Loukogeorgakis! et! al.,! 2005).! The!delayed! phase,! also! referred! to! as! ‘late’! or! ‘second! window’! preconditioning,!appears!24!hours! later!and!is!generally!reported!as! lasting!up!to!48! 0!72!hours!although!recently!it!has!been!suggested!the!effects!could!persist!for!much!longer!(Baxter!et!al.,!1997;!Loukogeorgakis!et!al.,!2005;!Neckár!et!al.,!2004;!Park!et!al.,!2003).! This! second! window! appears! to! be! dependent! on! changes! in! gene!transcription!(Rizvi!et!al.,!1999).!!!
1.4 Clinical!application!of!RIPC!Although!the!first!pilot!study!of!RIPC!in!humans!was!performed!in!2000,!the!first!full! clinical! trial! was! not! reported! until! 2006,! when! Cheung! et# al.! (2006)!investigated!the!effects!of!RIPC!in!children!undergoing!repair!of!congenital!heart!defects!and!reported!that!RIPC!significantly!decreased!the!release!of!a!marker!of!cardiac!damage,! troponin!I.!Two!trials! in!adult!CABG!patients! followed!in!2007!and! 2009,! both! demonstrating! a! 43%! reduction! in! troponin! T! levels! in! the!preconditioned! patients,! compared! to! the! controls! (Hausenloy! et! al.,! 2007;!Venugopal! et! al.,! 2009).! These! initial,! highly! promising! results! attracted!worldwide!attention!and,!consequently,! there!has!been!a!surge!of!clinical! trials!and!publications! investigating!RIPC! in! the!past! two! years.! The! results! of! these!recent! studies! have! been! varied,! with! some! showing! significant! protection!against!myocardial!and!renal!damage!from!RIPC!and!others!reporting!no!benefit.!!!The!variation!in!the!methods!and!sheer!volume!of!the!human!studies! involving!RIPC!means!it!is!not!possible!to!describe!each!individually!in!detail.!Instead,!we!have! restricted! our! overview! to! trials! involving! cardiac! surgery! patients! and!presented!the!results!in!the!Tables!1.1!and!1.2.!The!description!in!the!text!will!be!limited! to! summarise! the! current! status! of! RIPC! research! regarding! clinical!endpoints! pertaining! to! the! organs! most! well! studied! to! date:! the! heart! and!kidneys.!!
1.4.1 Cardioprotection!A! review! of! the! literature! identified! 32! studies! of! RIPC! in! both! paediatric! and!adult!cardiac!surgery!patients!that!included!a!myocardial!injury!biomarker,!most!
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commonly! troponin! I! and! T! or! creatine! kinase! MB! (CK0MB),! as! an! endpoint!(Table! 1.1).! It! should! be! noted! that! myocardial! injury! was! not! the! primary!outcome!measure!for!all!of!these!studies!and!therefore!some!may!not!have!been!deliberately! powered! for! this! endpoint.! The! results! of! these! studies!were! split!evenly,! with! 16! showing! a! positive! result! with! respect! to! cardioprotection! in!patients! treated! with! RIPC! and! 16! finding! no! such! benefit.! Numerous! meta0analyses,! which! have! increased! statistical! power! compared! to! the! smaller!separate!trials,!have!reported!that!RIPC!is!associated!with!an!overall!reduction!in!the!peri0operative!release!of!cardiac!injury!biomarkers,!supporting!the!results!of!the!positive! studies! (Alreja!et! al.,! 2012;!Brevoord!et! al.,! 2012;!D’Ascenzo!et! al.,!2012;!Haji!Mohd! Yasin! et! al.,! 2014;! Pilcher! et! al.,! 2012;! Takagi! and!Umemoto,!2011;!L.!Yang!et!al.,!2014).!!!The!majority!of!the!listed!trials!individually!lack!the!design!and!power!required!to!determine!the!impact!of!RIPC!on!rare!and!more!clinically!relevant!outcomes,!although! several! publications! have! recently! addressed! this.! Meta0analyses!authored! by! Brevoord,! Yang,! Haji! Mohd! Yasin,! Zhang,! and! the! Remote!Preconditioning! Trialists’! Group! all! reported! that! RIPC! does! not! reduce! the!mortality! rate! in! cardiac! surgery! patients! or! the! length! of! intensive! care! unit!(ICU)! and! hospital! stays! (Brevoord! et! al.,! 2012;! Haji! Mohd! Yasin! et! al.,! 2014;!Remote!Preconditioning!Trialists’!Group!et!al.,!2014;!L.!Yang!et!al.,!2014;!Zhang!et! al.,! 2014).! Brevoord! et# al.! found! that! RIPC! decreased! the! incidence! of! peri0procedural! MI! in! patients! undergoing! cardiac! and! vascular! surgeries! or!percutaneous!coronary!intervention!(PCI),!but!did!not!reduce!the!rate!of!major!adverse! cardiovascular! outcomes! (MACE),! or! atrial! fibrillation.! The! remaining!meta0analyses! reported! that! RIPC! had! no! impact! on! a! variety! of! clinical!endpoints,!including!peri0operative!MI.!!The!impact!of!RIPC!on!cardioprotection!has!also!been!investigated!during!other!clinical!applications.!Multiple! trials!and!meta0analyses!have!reported! that!RIPC!reduces! the! incidence! of! peri0procedural!myocardial! infarction! during! PCI! and!also! protects! against! haemodialysis0induced! myocardial! injury,! both! of! which!
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were!indicated!through!measurement!of!troponin!levels!(D’Ascenzo!et!al.,!2014;!Park!et!al.,!2014;!Zografos!et!al.,!2014).!!!Currently,! there! is! no! evidence! confirming! that! the! reduction! in! cardiac! injury!markers!frequently!detected!following!RIPC!translates!into!an!improved!clinical!outcome! with! respect! to! the! heart;! however,! it! is! difficult! to! draw! definitive!conclusions! from! the!body!of! literature! currently! available.!There! is! enormous!heterogeneity! between! study! designs,! which! significantly! limits! the! power! of!meta0analyses.! In! the! future,! larger,! double0blinded,! randomised,! controlled!studies! of! RIPC! will! be! required! to! conclusively! determine! whether! the!intervention! can! improve! myocardial! function! following! cardiac! procedures,!compared!to!current!strategies.!!!
1.4.2 Renal!protection!Kidneys!have!a!high!energy!demand!and!are!particularly!vulnerable!to!ischaemic!damage.!The!incidence!of!acute!kidney!injury!(AKI)!following!cardiac!surgery!has!been!estimated!at!levels!as!high!as!30%,!depending!on!the!exact!definition!used,!and! is!associated!with!a!greatly! increased!risk!of!mortality!(Rosner!and!Okusa,!2006).! Numerous! RIPC! clinical! trials! have! incorporated! endpoints! examining!post0operative! renal! damage! and! function;! however,! only! a! small! number! of!studies! have! been! explicitly! designed! for! this! purpose.! Four! of! the! 11! RIPC!cardiac! surgery! studies! identified! as! including! markers! associated! with! renal!function!showed!a!benefit!from!the!intervention,!and!only!one!of!the!four!studies!specifically! designed! and! powered! to! evaluate! RIPC! on! renal! endpoints! was!positive!(Table!1.2).!Two!meta0analyses!by!Li!et#al.#(2013)!and!Yang!et#al.#(2014),!which!broadened!the!population!of!interest!to!include!both!cardiac!and!vascular!surgeries,!did! find! that!RIPC! significantly! reduced! the! incidence!of!AKI!but!did!not! alter! renal! injury! markers! such! as! creatinine! and! estimated! glomerular!filtration!rate!(GFR),!or!the!incidence!of!renal!replacement!therapy.!!A!renal!protective!effect!with!RIPC!has!more!clearly!been!observed!during!other!applications.! Ali! et# al.# (2007)! were! the! first! to! report! that! RIPC! could! induce!renal! protection! in! humans! by! demonstrating! that! the! intervention! decreased!
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the!incidence!of!AKI!by!23%!during!elective!abdominal!aortic!aneurysm!repair,!although! a! smaller! subsequent! study! by! Walsh! et# al.# (2009)! found! RIPC!attenuated!the! increase! in!urinary!biomarkers!of!renal! injury!but!did!not!affect!the! rate! of! renal! impairment.! Ischaemia! also! appears! to! contribute! to! the! AKI!frequently!observed!following!the!administration!of!contrast!during!procedures!involving!imaging.!Accordingly,!remote!conditioning!during!angioplasty!has!been!associated!with!a!sustained!improvement!in!estimated!GFR,!and!RIPC!in!patients!with!an! increased!risk!of! renal!damage!has!been!shown! to!significantly! reduce!the! incidence! of! AKI! during! elective! coronary! angiography! (Er! et! al.,! 2012;!Whittaker!and!Przyklenk,!2011).!!!As! appears! to! be! the! paradigm! with! the! current! status! of! RIPC! research,! the!precise! effect! of! preconditioning! on! renal! outcome! measures! has! not! been!established! by! the! trials! performed! to! date.! Larger! scale! studies! specifically!powered! for! clinical! indicators! of! renal! function! will! be! essential! to! clarify!whether! RIPC! is! capable! of! protecting! the! kidneys! during! cardiac! surgery! and!other!clinical!procedures!that!involve!renal!ischaemia.!!!
1.4.3 The!value!of!RIPC!in!the!clinical!setting!RIPC! has! been! described! as! one! of! the! most! promising! cardioprotective!strategies! identified! to! date,! and! is! attractive! not! only! due! to! its! potentially!significant!impact!on!clinical!outcomes,!but!also!because!of!the!practical!aspects!associated! with! its! use! in! the! clinical! setting! (Rahman! and! Bonser,! 2009).!Applying! RIPC! is! extremely! straightforward! and! inexpensive,! requiring! no!specialised!training!or!new!devices.!The!equipment!used!to!apply!RIPC!is!already!present! in! the! clinics,! hospitals! and! ambulances!where! it!would! be! utilised.! In!comparison!to!the!development!of!pharmaceutical!treatments,!RIPC!can!be!fast0tracked! into! the! clinical! environment! without! the! need! for! a! lengthy! and!expensive!approval!process.!Further,!it!has!a!solid!safety!profile!with!no!reports!of!adverse!affects!from!any!of!the!numerous!trials!performed!thus!far!and!is!not!subject!to!the!same!potential!interaction!issues!that!may!be!encountered!with!a!pharmaceutical! therapy.! Preconditioning! using! the! limbs! is! a! particularly! safe!
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1.5 Mechanisms-involved-in-RIPC-While! it! appears! that! RIPC! functions! to! prophylactically! activate! the! body’s!processes! for! responding! to! stressful! conditions,! the! exact! underlying!mechanisms! have! yet! to! be! fully! characterised.! Research! investigating! the!pathways!involved!in!RIPC!has!been!very!limited!in!the!clinical!setting,!therefore!the!majority!of!what!is!understood!about!preconditioning!stems!from!the!results!of! preCclinical! animal! work.! It! is! beyond! the! scope! of! this! thesis! to! present! a!complete!background!of!the!vast!research!carried!out!in!these!models,!therefore!the!overview!will!be! limited!to!the!aspects! that!are!the!most!well!supported! in!the!literature.!!!
1.5.1 Evidence-for-humoral,-neural,-and-systemic-pathways-The! least! well! understood! aspect! of! RIPC! is! how! the! protective! signal! is!communicated! from!the!preconditioned! tissue! to! the!other!organs!of! the!body.!Originally! there! was! much! debate! as! to! whether! the! mechanism! involved! a!humoral!factor!or!a!neural!pathway,!although!it!is!now!widely!accepted!that!both!are!likely!to!play!a!role,!along!with!systemic!antiCinflammatory!changes.!!!The!key!evidence!to!suggest!the!involvement!of!the!peripheral!nervous!system!in!RIPC! is! provided! by! a! number! of! studies! that! have! established! the! ability! of!ganglionic!blockers,! such!as!hexamethonium!and! trimetaphan,!and! the!afferent!sensory! nerve! blocker,! capsaicin,! to! abrogate! the! protective! effects! of!preconditioning! (Tomasz!Brzozowski! et! al.,! 2004;!Gho! et! al.,! 1996;! Liem!et! al.,!2002;!Loukogeorgakis!et!al.,!2005;!Schoemaker!and!van!Heijningen,!2000;!Tang!et!al.,!1999;!Wolfrum!et!al.,!2002).!Similarly,!resection!of!afferent!nerves!from!the!preconditioned! tissue,! or! vagotomy,! have! been! shown! to! inhibit! the! ability! to!induce!RIPC!(T.!Brzozowski!et!al.,!2004;!Ding!et!al.,!2001;!Dong!et!al.,!2004;!Lim!et!al.,!2010).!Interestingly,!Lim!et#al.#found!that!resection!of!the!femoral!or!sciatic!nerves!only!partially!reversed!the!effects!of!preconditioning,!whereas!combined!resection! completely! abolished! the! protection,! suggesting! multiple! neural!pathways!may!contribute.!!!
!! !26!
On! the! other! hand,! reperfusion! of! the! remotely! preconditioned! tissue! is! an!essential! component! of! the! RIPC! stimulus,! implicating! the! involvement! of! a!humoral!factor!(Gho!et!al.,!1996;!Weinbrenner!et!al.,!2002).!Further,!transfer!of!whole!blood!or!coronary!effluent! from!renal!preconditioned!rabbits!or! isolated!rabbit!hearts,! respectively,! into!a!naïve!system!significantly! reduces! the! infarct!size! associated! with! subsequent! myocardial! ischaemia! (Dickson! et! al.,! 1999a,!1999b).! These! findings! are! consistent! with! a! study! using! a! porcine! model! in!which! Konstantinov! et# al.! (2005)! found! that! a! transplanted! heart! could! be!protected!by!the!prior!application!of!RIPC!in!the!recipient.!Despite!the!evidence!that! a! circulating! humoral! factor! is! critical! for! induction! of! RIPC! and! the!identification!of!numerous!substances!that!are!involved!in!the!early!response!to!preconditioning,!the!exact!mediator!responsible!is!still!unclear.!However,!studies!using!dialysed!plasma!from!preconditioned!animals!to!confer!cardioprotection!in!isolated! perfused! hearts! have! established! that! the! factor! is! likely! to! be!hydrophobic!with!a!molecular!weight!between!3.5!and!15!kDa!(Lang!et!al.,!2006;!Serejo!et!al.,!2007;!Shimizu!et!al.,!2009).!!!Lastly,!RIPC!has!been!associated!with!significant!changes!to!circulating!leukocyte!populations,! including! alterations! in! gene! transcription,! as! well! as! neutrophil!adhesion,! phagocytosis,! and! cytokine! production! (Konstantinov! et! al.,! 2004;!Shimizu! et! al.,! 2010).! Overall,! these! changes! are! associated! with! an! antiCinflammatory! response;! however,! it! is! unclear! whether! these! are! end! effector!mechanisms!of!RIPC!or!if!they!represent!an!additional!systemic!pathway!through!which!the!RIPC!signal!is!communicated.!!!Regardless!of!the!exact!pathway!through!which!the!initial!signal!is!transmitted,!RIPCCinduced!organ!protection!is!evoked!through!three!crucial!steps:!the!release!of!key!initiating!molecules!from!the!preconditioned!ischaemic!tissue;!activation!of! cell! signalling! pathways! in! target! cells;! and! changes! to! the! end! effectors! of!RIPC! that! directly! limit! damage! or! preserve! function! in! cells! subjected! to!subsequent!ischaemia.!!!
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1.5.2 Potential-key-initiators-and-mediators-of-RIPC-Several!molecules!released!from!ischaemic!tissue!have!been!found!to!play!a!role!in!the!induction!of!RIPC,!but!the!extent!of!their!respective!importance!seems!to!vary!between!models!with!respect!to!both!species,!and!the!tissue!sites!examined.!Among! the!main! candidates! are! adenosine,! bradykinin,! opioids,! NO,! calcitonin!geneCrelated! peptide! (CGRP),! and! ROS,! but! studies! have! also! touched! on! the!possible! involvement! of! noradrenaline,! prostaglandins,! heme! oxygenaseC1,!cannabinoids,! angiotensin,! and! OClinked! βCNCacetylglucosamine! (OCGlcNAc)!(Hausenloy!and!Yellon,!2008;!Kaur!Randhawa!et!al.,!2014;!Tapuria!et!al.,!2008).!These! substances! may! travel! through! the! bloodstream! and! directly! bind!receptors!on!the!myocardium,!or!stimulate!afferent!nerves!in!the!preconditioned!tissue! that! transmit! the! signal! to! efferent! nerve! fibres! that! terminate! on! the!heart.!!!
1.5.2.1 Adenosine,Adenosine! is! a! nucleoside! that! has! been! implicated! as! a! trigger! and!mediator!during!IPC!through!both!initiating!and!propagating!the!preconditioningCinduced!signal! cascade,! respectively.! During! ischaemia,! adenosine! is! released! by! the!breakdown!of!ATP!and!exerts!a!variety!of! functions! including!dilation!of!blood!vessels! and! attenuating! increases! in! contractility,! thereby! both! improving!oxygen! delivery! and! reducing! oxygen! demand! in! the! myocardium! (Hori! and!Kitakaze,! 1991).! Evidence! for! the! involvement! of! adenosine! in! RIPC! was! first!provided! by! studies! that! demonstrated! nonCspecific! blocking! of! adenosine!receptors! with! 8C(pCsulfophenyl)theophylline! (8CSPT)! abolished! the!cardioprotective!effect!afforded!by!renal!or!mesenteric!RIPC!in!animals!(Ding!et!al.,!2001;!Liem!et!al.,!2002;!Pell!et!al.,!1998;!Takaoka!et!al.,!1999).!This!protection!could! be! inhibited! by! either! afferent! nerve! resection! or! administration! of!hexamethonium,! indicating! adenosine! activated! a! neural! pathway! (Ding! et! al.,!2001;!Dong!et!al.,!2004;!Liem!et!al.,!2002).!However,!postCRIPC!treatment!with!8CSPT,! but! not! hexamethonium,! could! abrogate! the! protective! effects,! suggesting!adenosine!may!also!directly!bind! to! receptors!on! the!myocardium!(Liem!et!al.,!2002).!Interestingly,!8CSPT!does!not!affect!the!renal!protection!induced!by!hind!
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limb!RIPC! in!rats,! suggesting! that!preconditioning! in!some!organs!may!operate!through!adenosineCindependent!pathways!(Wever!et!al.,!2011).!!!
1.5.2.2 Bradykinin,Schoemaker!and!Heijningen!(2000)!were!the! first! to!show!an!essential!role! for!bradykinin! during! RIPC! using! the! rat! mesentery.! Administration! of! the!bradykinin!B2!receptor!antagonist,!Hoechst!140!(HOEC140),!was!shown!to!inhibit!RIPCCinduced! protection,! whereas! intramesenteric! infusion! of! bradykinin!mimicked! RIPC.! This! protective! effect! could! be! abolished! by! hexamethonium,!suggesting!the!involvement!of!a!neural!pathway.!Similarly,!Wolfrum!et#al.#(2002)!found! that! RIPC! was! associated! with! an! increase! in! protein! kinase! C! (PKC)!activation,! which! was! abrogated! by! pretreatment! with! HOEC140! or!hexamethonium.!In!humans,!decreased!kinin!receptor!expression!on!circulating!neutrophils!following!RIPC!suggests!that!preconditioning!involves!kinin!receptor!activation!and!internalisation;!however,!HOEC140!does!not!appear!to!inhibit!the!effect!of!RIPC!on!vasomotor!dysfunction!in!humans!(Christian!M.!Pedersen!et!al.,!2011;!Saxena!et!al.,!2010b).!Given!these!conflicting!findings,!whether!bradykinin!contributes!to!RIPC!in!humans!remains!unclear.!!
1.5.2.3 Reactive,oxygen,species,ROS! are! generated! during! ischaemia! and! are! typically! associated! with! tissue!damage;! however,! in! 1989! it! was! determined! that! although! major! oxidative!stress!was! associated!with! inactivation! of! the! critical! cellular!messenger,! PKC,!mild!levels!of!oxidative!stress!actually!protected!the!catalytic!site!and!increased!the!PKC!enzyme!activity!(Gopalakrishna!and!Anderson,!1989).!Further,!ROS!have!been!shown!to!activate!G!proteins!independently!of!G!proteinCcoupled!receptor!binding! (Nishida! et! al.,! 2000).! Both! PKC! and! G! proteinCcoupled! receptors! are!critical! mediators! of! RIPC,! thus,! ROS! are! capable! of! indirectly! stimulating! a!number!of!beneficial!processes!through!these!effects.!!Consistent!with! these! reports,! studies! using! renal! and! skeletal!muscle! RIPC! in!animal!models!have!demonstrated!that!treatment!with!a!free!radical!scavenger,!mercaptopropionylCglycine! (MPG),! abolishes! the! cardioprotective! effect! of!
!! ! 29!
preconditioning! (Chen! et! al.,! 2005;! Weinbrenner! et! al.,! 2004).! Interestingly,!Weinbrenner! et# al.# found! that! MPG! could! sufficiently! inhibit! the! protection!afforded! by! a! single! cycle! of! RIPC,! but! not! when! three! cycles! were! used,!suggesting!the!involvement!of!additional!mediators!in!triggering!preconditioning!using! the! standard! stimulus! with! 3! cycles.! Further,! Tritto! et# al.# (1997)!established!that!administration!of!a! low!concentration!of!oxygen!radicals!could!mimic! RIPC! in! isolated! reperfused! rabbit! hearts,! improving! postCischaemic!recovery!of!contractile!function!and!reducing!the!infarct!size.!!!
1.5.2.4 Opioids,The!involvement!of!opioids!in!the!protection!afforded!by!RIPC!in!animal!models!has!been!demonstrated!by!a!number!of!studies!that!established!the!renal,!neural,!and! myocardial! benefits! could! be! abolished! by! administration! of! the! nonCselective! opioid! receptor! antagonist,! naloxone! (Patel! et! al.,! 2002;! Rehni! et! al.,!2007;! Wever! et! al.,! 2011).! Dickson! et# al.# (2002)# found! that! the! mesenteric!protection! conferred! by! transfer! of! coronary! effluent! from! preconditioned! rat!hearts! could!also!be! inhibited!by!naloxone,! and!Addison!et#al.# (2003)! reported!that!RIPCCinduced!protection!of!skeletal!muscle!could!be!reversed!by!treatment!with!naloxone,!but!not!hexamethonium.!Taken! together,! these! studies! strongly!suggest!that!opioids!produced!endogenously!in!response!to!RIPC!do!not!operate!via!a!neural!pathway!but!instead!directly!bind!receptors!in!the!target!tissues.!!!Exactly! which! receptors! are! involved! in! this! pathway! is! unclear,! with! some!studies! finding! the! δ1Copioid! receptors! to! be! essential! and! others! implicating!solely!the!κCopioid!receptors!(Addison!et!al.,!2003;!Weinbrenner!et!al.,!2004;!S.!Zhang!et!al.,!2006).!More!recently,!Surendra!et#al.#(2013)!reported!that!activation!of!both! the!δ!and!κCopioid! receptors!was!necessary! to! induce! cardioprotection!with!RIPC! in! isolated!cardiomyocytes! from!rabbits.! In!CABG!patients,!however,!administration!of!tramadol,!which!binds!the!μCopioid!receptors,!failed!to!induce!a! preconditioning! type! of! effect! and! was! actually! associated! with! increased!myocardial!injury!(Wagner!et!al.,!2010).!While!opioids!appear!to!be!essential!for!the!induction!of!RIPC!in!animals,!their!relevance!during!RIPC!in!humans!is!thus!currently!less!clear.!!
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1.5.2.5 Calcitonin,gene>related,peptide,CGRP!is!a!neurotransmitter!released!from!sensory!nerves!that!has!been!shown!to!increase!following!RIPC!in!numerous!animal!studies!(T.!Brzozowski!et!al.,!2004;!Hu! et! al.,! 2002;! Tang! et! al.,! 1999;! Wolfrum! et! al.,! 2005;! Xiao! et! al.,! 2001).! It!appears!that!a!RIPCCinduced!increase!in!NO!stimulates!CGRP!release!from!these!nerves!that!is!then!transported!to!the!heart,!where!it!stimulates!cardioprotection!through! the! activation! of! PKC! (Wolfrum! et! al.,! 2005;! Xiao! et! al.,! 2001).!Accordingly,! several! studies! have! established! that! administration! of! a! CGRP!receptor! antagonist! or! the! sensory! nerve! blocker,! capsaicin,! can! abrogate! the!protective!effects!of!RIPC!in!various!animal!models!(T.!Brzozowski!et!al.,!2004;!Rehni!et!al.,!2007;!Tang!et!al.,!1999;!Wolfrum!et!al.,!2005;!Xiao!et!al.,!2001).!At!present! there! is! no! literature! addressing! the! role! of! CGRP! during! RIPC! in!humans.!!
1.5.2.6 Nitric,oxide,NO! exhibits! a! diverse! array! of! protective! effects! that! are! relevant! during! I/R!injury! including! scavenging! of! free! radicals,! inhibiting! apoptosis,! promoting!vasodilation,! and! reducing! leukocyte! adhesion! and! platelet! aggregation!(Furchgott!and!Zawadzki,!1980;!Kim!et!al.,!2000;!Lefer!and!Lefer,!1996;!Wink!et!al.,! 1993).! Not! surprisingly,! countless! studies! have! implicated! NO! as! both! a!trigger! and! mediator! of! RIPC! using! inducible! nitric! oxide! synthase! (iNOS)!knockout!mice!or!blockade!of!iNOS!and!NO,!which!abolish!the!protection!induced!by!both!early!and! late!preconditioning! (AbuCAmara!et!al.,!2011;!Li!et!al.,!2004;!Tapuria!et!al.,!2008;!Tokuno!et!al.,!2002;!Wang!et!al.,!2001).!It!appears!that!NO!functions! through! different! pathways! during! early! and! late! RIPC,! with!endothelial!NOS!in!the!myocardium!important!during!the!former,!and!NFCκB!and!PKC! stimulated! transcription! of! iNOS! in! the! latter! (Tapuria! et! al.,! 2008).!However,!a!study!by!Petrishchev!et#al.#(2001)!using!the!intestine!for!RIPC!found!no! change! in! the! level! of! protection! following! nitric! oxide! synthase! inhibition,!suggesting!the!involvement!of!NO!may!be!tissue!dependent.!!!
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1.5.3 Intracellular-signalling-during-RIPC-Despite! the! wide! range! of! mediators! implicated! in! establishing! RIPC,! there! is!significant! redundancy! in! the! pathways! once! they! reach! the! target! cells.!Adenosine,! bradykinin,! opioids,! and! cannabinoids! all! bind! G! proteinCcoupled!receptors,!resulting!in!the!activation!of!numerous!intracellular!signalling!kinases.!Although!stimulation!of!the!mitogen!associated!protein!kinases!(i.e.!JNK,!ERK1/2,!and!p38!MAPK)!and!the!PI3/Akt!pathway!have!been!implicated!in!contributing!to!RIPC,!the!central!mediator!appears!to!be!PKC!(Heidbreder!et!al.,!2008;!Li!et!al.,!2011;!Simkhovich!et!al.,!2013).!A!comprehensive!discussion!of!the!complex!and!incompletely! understood! interactions! associated! with! each! of! the! kinases! is!beyond! the! scope! of! this! thesis,! but! a! simplified! overview! of! the! proposed!signalling! pathways! is! presented! in! Figure! 1.1,! and! several! articles! have!reviewed!the!topic!inCdepth!(refer!to!Hausenloy!and!Yellon,!2006;!Sadat,!2009).!!!Overall,!activation!of!the!PKC,!MAPK,!and!PI3/Akt!pathways!appear!to!converge!to!activate!opening!of!the!sarcolemmal!and!mitochondrial!KATP!channels,!inhibit!opening! of! the!mPTP,! reduce! apoptosis,! and! activate! key! transcription! factors!associated!with!production!of! cytoprotective! genes! (Li! et! al.,! 2000;!Ohnuma!et!al.,! 2002;! Okamura! et! al.,! 1999;! S.! Zhang! et! al.,! 2006).! The! exact! order! of! the!signalling!cascade!is!not!fully!understood,!however,!and!PKC!also!appears!to!be!activated! by! ROS! released! from! the!mitochondria,! therefore! it! is! possible! that!PKC!may!actually!be!activated!downstream!of!the!effects!on!mitochondria!before!feeding!back! into! the! system! (Pain! et! al.,! 2000).! Changes! in! gene! transcription!are!also! facilitated!by!activation!of! the! JAK/STAT!pathway! in!animal!models!of!IPC,!presumably!by!cytokine!production;!however,!only!one!study!has!implicated!STAT! involvement! in! humans! during!RIPC! and! further! research! in! this! area! is!needed! (Dawn! et! al.,! 2004;! Hattori! et! al.,! 2001;! Heusch! et! al.,! 2011).! The!combined! effect! of! these! changes! to! the! mitochondria! and! gene! transcription!significantly!promote!cellular!survival!during!I/R.!!!
1.5.4 End-effectors-of-RIPC-There!are!a!number!of!cytoprotective!effects!well!established! to!be! induced!by!RIPC.! During! the! early! response! to! preconditioning,! the!major! contribution! to!
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cardioprotection!appears!to!stem!from!effects!on!the!mitochondria!and!coronary!blood! flow,!whereas! the! second!window!of! protection! involves! changes! to! the!inflammatory! response! and! apoptosis! brought! about! by! alterations! in! gene!transcription.!!!
1.5.4.1 KATP,channels,One!of! the!major! cytoprotective!effects!of!RIPC! involves!alterations! to! the!ATP!sensitive! potassium! channels! present! in! the! plasma! membrane! of!cardiomyocytes! and! the! inner! mitochondrial! membrane! (Beavis! et! al.,! 1993;!Loukogeorgakis!et!al.,!2007).!Through!the!intracellular!loss!of!ATP,!I/R!appears!to!inhibit!the!opening!of!these!KATP!channels,!leading!to!accumulation!of!calcium!and!a!loss!of!cellular!or!mitochondrial!integrity!(Costa!et!al.,!2013).!Activation!of!the! channels! during! RIPC! appears! to! slow! the! rate! of! ATP! depletion,! preserve!intracellular!pH!and!phosphocreatinine!levels!in!the!myocardium,!and!stimulates!vasodilation,! thereby! increasing! the! resistance! of! cells! to! ischaemic! conditions!(Costa!et!al.,!2013;!Dos!Santos!et!al.,!2002;!Kaur!Randhawa!et!al.,!2014;!Takaoka!et!al.,!1999).!!!Numerous!studies!have!established!the!importance!of!changes!to!these!channels!by!demonstrating!that!administration!of!the!mitochondrial!KATP!channel!blocker,!5Chydroxydecanoate,!abolishes!the!protective!effects!of!RIPC!(Kristiansen,!et!al.,!2005;!Moses,!et!al.,!2005;!Pell,!Baxter,!Yellon,!&!Drew,!1998).!Although!the!effects!of! RIPC! on! KATP! channels! are! generally! associated! with! the! early! phase! of!preconditioning,! they! have! also! been! shown! to! play! a! role! in! the! late! stage! of!myocardial!protection!in!a!rat!model!(Y.CN.!Wu!et!al.,!2011).!Further,!opening!of!the!KATP!channels!may!also!act!as!part!of!the!RIPC!trigger!mechanism,!as!well!as!a!mediator,! through! the!production!of!ROS! and! subsequent! activation!of! protein!kinases!(Pain!et!al.,!2000).!!!
1.5.4.2 mPTP,During! I/R,! increases! in!mitochondrial! calcium! levels,! ROS,! and!NO,! combined!with!a!reduction!in!the!inner!mitochondrial!membrane!potential,!lead!to!opening!of!the!mPTP,!which!is!closed!under!physiological!conditions!(recently!reviewed!
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by!Ong!et!al.,!2014).!Opening!of!the!mPTP,!which!is!a!largeCconductance!channel,!results!in!the!uncoupling!of!oxidative!phosphorylation,!thereby!further!reducing!ATP! levels.! In! addition,! the! leakage! of! mitochondrial! proteins! such! as!cytochrome!C!and!changes! in! ion!homeostasis!activate!apoptotic!pathways!and!cause!mitochondrial! swelling,! leading! to! rupture!of! the!plasma!membrane! and!cell!death!(Ong!et!al.,!2014).!PKCε!appears!to!physically!interact!with!the!mPTP!and! significantly! reduce!mitochondrial! swelling,! strongly! suggesting! that! RIPC!may!prevent!mPTP!opening!during! I/R! (Baines!et!al.,!2003).! Indeed,!effects!on!the! pore! are! well! established! in! models! of! local! IPC,! and! early! studies! have!shown!similar!results!with!RIPC!(Halestrap!et!al.,!2007;!S.!Zhang!et!al.,!2006).!!!
1.5.4.3 Changes,in,coronary,blood,flow,Changes! to! blood! flow! following! RIPC! also! contribute! to! the! organ! protection!observed,!but!do!not!account!for!the!full!effects!of!preconditioning!(Saxena!et!al.,!2010a).!Shimizu!et#al.#(2007)! found! that! in!a!porcine!model!of!myocardial! I/R,!RIPC!significantly!decreased!resistance!in!the!LAD!and!increased!blood!flow.!In!healthy! human! volunteers,! stimulating! a! minor! I/R! injury! in! the! forearm!significantly!reduces!flowCmediated!dilation!(FMD),!whereas!RIPC!prior!to!injury!preserves!peak!radial!artery!FMD!at!similar!levels!to!those!observed!at!baseline!(Kharbanda!et! al.,! 2001).! Further,!RIPC!also! increases! flow!velocity! in! the!LAD!during!early!reperfusion!in!healthy!volunteers,!and!this!effect!appears!to!be!the!result! of! increased! coronary! blood! flow! and!myocardial! contraction,!without! a!change!in!heart!rate!(Zhou!et!al.,!2007).!!!
1.5.4.4 Gene,transcription,One!of!the!major!effects!of!RIPC!appears!to!involve!changes!in!the!expression!of!a!range! of! inflammatory! and! cytoprotective! genes.! The! importance! of! gene!transcription!for!inducing!a!beneficial!effect!during!preconditioning!was!clearly!demonstrated!by!Strohm!et#al.#(2002)!who!reported!that!IPC!could!be!abolished!by! administration! of! the! nonCspecific! transcription! inhibitor,! actinomycinCD.!Subsequent!studies!have!implicated!a!number!of!key!transcription!factors,!most!notably!hypoxic!inducible!factor!(HIF)C1α!and!NFCκB,!in!the!pathway!of!IPC,!but!less! research! has! been! performed! in! RIPC! models! to! date! (reviewed! by! Kaur!
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Randhawa! et! al.,! 2014;! Tapuria! et! al.,! 2008).! However,! the! primary! stimuli!involved! in! the! activation! of! these! factors! are! common! to! both! methods! of!preconditioning;!therefore!it!seems!likely!that!these!findings!can!be!extended!to!RIPC.!!!Alterations! in! gene! expression! are! predominantly! associated!with! the! delayed!window! of! preconditioning;! however,! changes! in! mRNA! levels! in! circulating!leukocytes!have!been!detected!15!minutes!following!RIPC!in!humans,!suggesting!it! may! also! contribute! to! the! early! phase! of! protection! (Konstantinov! et! al.,!2004).!These!changes! involve!the!upregulation!of!key!cytoprotective!mediators!such! as! heat! shock! proteins,! iNOS,! inhibitors! of! apoptosis,! and! free! radical!scavengers,! and! the! downregulation! of! many! inflammatory! genes! involved! in!leukocyte!chemotaxis,!adhesion,!and!cytokine!synthesis!(Huda!et!al.,!2005;!Igor!E.!Konstantinov!et! al.,! 2005;!Konstantinov!et! al.,! 2004;!Li! et! al.,! 2004).!The!net!effect!of!changes!in!gene!expression!during!IPC!thus!dampens!the!inflammatory!response!and!promotes!cell!survival.!!!
1.5.4.4.1# Hypoxia0inducible#factor01α#The!hypoxiaCinducible!factor!(HIF)C1α!subunit!is!targeted!for!degradation!under!normoxic! conditions! but! accumulates! during! periods! of! oxygen! deficiency! and!forms! a! dimer! with! the! constitutively! produced! HIFC1β! subunit! to! make! HIF!(Kaelin!and!Ratcliffe,!2008).!HIF!is!a!transcription!factor!that!facilitates!adaption!to!ischaemic!conditions!by!activating!key!genes!involved!in!oxygen!metabolism,!angiogenesis,! cell! survival,! and! metabolic! protection,! such! as! vascular!endothelial! growth! factor! and! glucose! transporters! (Aragonés! et! al.,! 2008;!Forsythe!et!al.,!1996;!Kaelin!and!Ratcliffe,!2008).!Not!surprisingly,!treatment!of!mice!with!HIFC1α!prior!to!myocardial!I/R!has!a!cardioprotective!effect,!reducing!infarct!size!and!improving!ventricular!function!(Czibik!et!al.,!2011).!Increases!in!HIFC1α!have!been!frequently!associated!with!organ!protective!effects!in!IPC!and!more!recently!have!also!been!implicated!in!the!mechanism!of!RIPC!(Albrecht!et!al.,!2013;!Cai!et!al.,!2008;!Eckle!et!al.,!2008).!!!
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In!rats,!inhibition!of!the!enzymes!that!label!HIFC1α!for!destruction!(i.e.!HIFCP4Hs)!mimics! the! effect! of! renal! RIPC,! whereas! administration! of! the! HIFCP4Hs!activator,! αCketoglutarate,! abolishes! the! cardioprotective! benefit! from! RIPC!(Kant! et! al.,! 2008).! This! study! also! suggested! that! HIFC1!may! stimulate! NFCκB!signalling.!Similarly,!HIFC1α!heterozygous!knockout!mice!have!been!shown!to!be!incapable! of! responding! to! RIPC,! but! the! protective! effects,! which! include!increased! plasma! ILC10! levels,! can! be! recovered! by! injection! of! a! recombinant!adenovirus!expressing!a!constitutively!active!form!of!HIFC1α.!In!the!same!study,!HIFC1!was!found!to!bind!the!ILC10!gene!in!isolated!murine!myocytes!exposed!to!repeated! intermittent! hypoxia! (Cai! et! al.,! 2013).!More! recently,! Albrecht! et# al.#(2013)! demonstrated! that! HIFC1α! levels! were! upregulated! in! the! right! atrial!tissue! of! cardiac! surgery! patients! following! RIPC! and! prior! to! commencing!bypass.!Taken!together,!these!studies!strongly!suggest!HIFC1!is!essential!for!RIPC!and! in! animal! models! may! exert! effects,! in! part,! through! inducing! ILC10!production.!!!
1.5.4.4.2# NF0κB#The!inactive!form!of!NFCκB!is!stored!bound!to!its! inhibitory!Iκβ!proteins! in!the!cytoplasm! and! is! readily! activated! in! response! to! a! number! of! mediators!including!ROS!and! inflammatory!cytokines.!Signals!resulting! from!these!stimuli!lead! to!degradation!of! the! Iκβ!proteins,! freeing! the!NFCκB! to! translocate! to! the!nucleus,!bind!to!DNA,!and!regulate!gene!expression!(Valen!et!al.,!2001).!NFCκB!is!significantly! upregulated! during! cardiac! surgery! and! induces! transcription! of!numerous! proteins! associated! with! the! inflammatory! response,! including!cytokines! and! adhesion!molecules! (Valeur! and!Valen,! 2009).! It! is! possible! that!NFCκB! contributes! to! cardioprotection! through! upregulation! of! manganese!superoxide! dismutase! and! inhibition! of! apoptosis;! however,! there! is!overwhelming! evidence! that! the! net! effect! of! NFCκB! activation! is! detrimental!during!I/R!injury!(Valeur!and!Valen,!2009).!!!Maulik! et# al.! (1998)! were! the! first! to! report! on! the! involvement! of! NFCκB! in!preconditioning!when! they! found! that! IPC! in! isolated! perfused! rat! hearts!was!associated!with! increased!nuclear! translocation!of!NFCκB!and!resistance! to! I/R!
!! !36!
injury.! Two! subsequent! studies! in! rabbits! and! mice! supported! this! finding,!demonstrating! that! IPC!was! associated!with! increased! activation!of!NFCκB! and!that! the! resulting!cardioprotection!could!be!abolished!by!administration!of! the!NFCκB! inhibitor,!diethyldithiocarbamate,! or!use!of! animals!with!deletion!of! the!NFCκB!p105!subunit!(Li!et!al.,!2004;!Xuan!et!al.,!1999).!!!Morgan!et#al.#(1999)#determined!that!the!increase!in!NFCκB!activity!during!IPC!in!rabbit! hearts!was! followed! by! inhibition! of!NFCκB! during! subsequent! I/R.! The!authors! proposed! that! the! mild! level! of! oxidative! stress! associated! with!preconditioning! led! to!NFCκB! activation! of! cytoprotective! genes,!which! in! turn!resulted! in! the!suppression!of!NFCκB!during!I/R.! Interestingly,!NFCκB! increases!cytoplasmic! levels! of! its! own! inhibitor,! IκβCα,! which! may! also! explain! how! a!preconditioningCinduced!increase!in!NFCκB!activity!can!lead!to!inhibition!of!NFCκB!during!later!prolonged!ischaemic!insults!(Tähepõld!et!al.,!2003).!In!support!of!this!possibility,! Jiang!et#al.# found!that!delayed!renal! IPC! in!rats!suppresses! I/RCinduced!NFCκB!activation!by!reducing!IκβCα!degradation!(Jiang!et!al.,!2007).!!!Further! work! in! murine! models! confirmed! that! early! IPC! attenuated! NFCκB!activation!during! I/R! injury! in!both! the! liver!and!small! intestine! (Funaki!et!al.,!2002;!Li!et!al.,!2006;!Takeshita!et!al.,!2010).!These!studies!extended!the!findings!to!show!that!the!decrease!in!NFCκB!activation!was!associated!with!a!reduction!in!ILC1β,! TNFCα,! and! intercellular! adhesion! moleculeC1! (ICAMC1)! mRNA! levels,!supporting!the!theory!that!inhibition!of!NFCκB!contributes!to!organ!protection!by!reducing! proinflammatory! gene! expression.! In! the! clinical! setting,! unstable!angina!has!been!shown!to!activate!NFCκB,!therefore!it!is!likely!that!IPC!in!humans!utilises! the!same!NFCκB!pathway!elucidated! in! the!animal! studies! (Wang!et!al.,!2007).!!
1.5.4.5 Changes,to,the,systemic,inflammatory,response,,Overall,! RIPC! appears! to! have! a! significant! suppressive! effect! on! the!inflammatory!response!to!I/R,!particularly!during!the!late!phase.!These!changes!seem! to! be!predominantly! associated!with! changes! to! gene! transcription,!with!Konstantinov! et# al.# (2004)! demonstrating! that! genes! involved! in! leukocyte!
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chemotaxis,! adhesion! and! migration,! exocytosis,! signalling! pathways! of! the!innate!immune!response,!and!apoptosis!are!suppressed!in!circulating!leukocytes!15!minutes!following!RIPC,!and!further!reduced!at!24!hours.!Accordingly,!other!studies!in!healthy!human!volunteers!have!shown!that!RIPC!alters!key!functional!properties! of! neutrophils,! including! adhesion! and! cytokine! production!(Kharbanda!et!al.,!2001;!Shimizu!et!al.,!2010).!A!more!detailed!overview!of!what!is!known!about!the!involvement!of!the!immune!response!in!I/R!injury!and!RIPC!is!presented!in!the!introductory!sections!of!the!following!results!chapters.!!While! it! is! generally! accepted! that! RIPC! modifies! the! inflammatory! response,!very!little!is!known!about!the!exact!processes!and!end!results!involved.!It!is!not!clear!whether!these!changes!constitute!a!part!of!the!trigger!mechanism!involved!in! establishing! RIPC! or!whether! they! significantly! contribute! to! the! protective!effects! themselves.! In! particular,! there! is! a! significant! gap! in! the! literature!regarding!the!involvement!of!the!immune!system!in!RIPC!in!humans,!and!during!the!early!phase!of!protection.!!
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!
Figure-1.1-Proposed-mechanisms-involved-in-organ-protection-with-RIPC-Summary!of!the!key!signalling!pathways!and!end!effector!mechanisms!reported!to! be! involved! in! organ! protection! following! RIPC.! While! the! activation! of! G!proteinCcouple! receptors! and! changes! to! mitochondria! and! gene! transcription!are!agreed!on!as!the!beginning!and!end!of!the!pathways,!respectively,!the!exact!order!of!the!signalling!kinases!in!the!cascade!in!between!is!currently!less!clear.!!!
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1.6 Overview-of-the-key-immune-cell-populations-The!immune!system!encompasses!the!innate!immune!response,!which!provides!a!nonCspecific!first!line!of!defence!against!invading!pathogens,!and!the!adaptive!immune! response,! which! is! characterised! by! antigenCspecific! protection! and! a!memory! for! previously! encountered! pathogens.! The! cells! that! mediate! these!responses,!particularly!the!neutrophils,!monocytes,!and!T!cells,!are!key!players!in!both!the!pathology!of!I/R!injury!and,!to!a!lesser!extent,!the!response!to!RIPC.!!!
1.6.1 Neutrophils-Neutrophils,! which! are! also! referred! to! as! polymorphonuclear! cells! owing! to!their! lobulated! nuclei,!make! up! approximately! 70%! of! circulating!white! blood!cells!and! therefore!are! the!most!abundant!of! the!peripheral! leukocytes.!During!infection!or!inflammation!the!neutrophil!population!often!rapidly!and!markedly!increases! in! size! (Amulic! et! al.,! 2012).! Neutrophils! are! notoriously! difficult! to!study! ex# vivo# due! to! their! extremely! short! life! span! of! approximately! 7! –! 10!hours,! and! sensitivity! to! activation! in! artificial! circumstances! (Dancey! et! al.,!1976).! In! the! experimental! setting,! neutrophils! can! be! identified! by! their! high!cell!membrane! expression! levels! of! CD16! and! the! key! adhesion! factor,! CD11b,!and!low!levels!of!CD14!(Amulic!et!al.,!2012).!!!The!primary!function!of!neutrophils!is!to!circulate!in!the!blood!and!monitor!for!signs! of! infection! or! host! distress,! which! are! normally! detected! by! pattern!recognition! receptors! (PRR)! that! bind! a! broad! range! of! pathogenCassociated!molecular!motifs!(Amulic!et!al.,!2012).!Upregulation!of!key!adhesion!molecules,!selectins! and! integrins,! on! the! endothelium!during! inflammation! facilitates! the!binding! and! transmigration! of! neutrophils! into! the! tissues! (Gearing! and!Newman,! 1993).! Numerous! inflammatory! mediators! such! as! chemokines! and!bacterial!products!direct!neutrophil!migration!and!function!during!pathological!processes.!Binding!of!these!agents!to!neutrophil!cellular!receptors,!such!as!ILC8!to! its!G!proteinCcoupled!receptor,! initiates! intracellular!signalling!cascades! that!stimulate! the! major! effector! functions! of! neutrophils! including! the! oxidative!burst,! cytokine! production,! exocytosis! of! antiCmicrobial! compounds! stored! in!cytoplasmic! granules,! and! phagocytosis! (Amulic! et! al.,! 2012;! Zarbock! and! Ley,!
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2008).!These!mechanisms!are!critical!to!pathogen!destruction!and!clearance,!but!are!nonCspecific!and!can!also!cause!extensive!damage!to!host!tissues.!!!
1.6.2 Monocytes-Monocytes!constitute!approximately!10%!of!the!nucleated!blood!cells!in!healthy!adults,!with!populations!pooled!in!the!lung!and!spleen!ready!for!mobilisation!on!demand!(Ginhoux!and!Jung,!2014).!There!are!two!major!subsets!of!monocytes!in!the! circulation,! which! both! significantly! increase! during! times! of! infection.!Classical!monocytes!express!moderate! to!high! levels!of! the!cell! surface!marker!CD14+! and! have! a! halfClife! of! around! 20! hours! in! the! blood,! whereas! a! much!smaller!population!of!nonCclassical!CD14+CD16++!monocytes!have!a!halfClife!of!up!to! 5! days! (Ginhoux! and! Jung,! 2014).! These! subsets! appear! to! exert! slightly!different! but! complementary! effects! in! pathological! states,! such! as! during! the!response!to!MI!(Nahrendorf!et!al.,!2007).!!!Like! neutrophils,! monocytes! respond! to! a! broad! range! of! pathogens! and!chemokines,! and!use! cellular! adhesion!molecules! to! bind! the! endothelium! and!infiltrate! tissues! at! sites! of! inflammation! or! infection! (Shi! and! Pamer,! 2011).!Monocytes! exert! direct! antimicrobial! effects! by! phagocytosing! pathogens! that!are!recognised!by!their!PRR!or!opsonin!receptors,!and!by!producing!numerous!inflammatory!mediators!including!ROS,!complement,!and!cytokines!such!as!ILC6,!ILC10,! and! TNFCα! (Auffray! et! al.,! 2009).! Following! extravasation,! some!monocytes!differentiate! into!macrophage!or!dendriticClike!cells,!and!others!can!enter!the!lymph!nodes!and!present!antigens!to!T!cells,!stimulating!the!adaptive!immune! response! (Ginhoux! and! Jung,! 2014;! Shi! and! Pamer,! 2011).!Monocytes!are!thus!valuable!mediators!of!the!response!to!infection!and!function!in!a!variety!of!manners!to!maintain!tissue!homeostasis.!!!
1.6.3 Natural-killer-cells-Natural!killer!(NK)!cells!are!present!as!only!a!small!population!in!healthy!adults;!they! reside! in! both! lymphoid! and! nonClymphoid! tissue! sites! and! survive! for!approximately!two!weeks!(Vivier!et!al.,!2008;!Zhang!et!al.,!2007).!NK!cells!have!traditionally!been!considered!a!part!of!the!innate!immune!response!due!to!their!
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response! to! a! broad! range! of! nonCantigenCspecific! stimuli;! however,! they! also!share!many! characteristics! common! to! the! adaptive! immune! response! such! as!the!formation!of!immunological!memory!(Vivier!et!al.,!2011).!!!NK!cells!are!a! type!of! lymphocyte!predominantly!recognised!for!their!ability! to!kill!tumour!or!infected!cells!in!response!to!expression!of!stress!signals.!They!are!differentiated! from! other! cells! and! between! the! different! subsets! by! their!expression! level! of! CD56,! along!with! CD16.! The!majority! of! the! circulating!NK!cells! are! CD56dimCD16+,! which! produce! interferon! (IFN)Cγ! and! exert! cytotoxic!effects!through!the!expression!of!perforin!(Vivier!et!al.,!2008).!NK!cells!also!act!in!a! regulatory! fashion,! significantly! influencing! the! responses! of! other! key! cells!including! dendritic! cells,! B! and! T! lymphocytes,! and! endothelial! cells! through!killing,!or!suppressing!or!enhancing!their!function!(Vivier!et!al.,!2008).!While!the!majority! of! NK! cell! activity! appears! to! be! protective,! NK! cells! have! also! been!implicated! in! tissue! injury!associated!with!certain!disease!states;! therefore!can!also!have!detrimental!effects.!!
1.6.4 T-cells-T! cells! are! the! major! subset! of! lymphocytes! and! recognise! specific! antigens!through!their!unique!T!cell!receptor!(TCR).!The!majority!of!T!cells!have!receptors!made!up!of!αβ!chains,!although!approximately!5%!of!cells!express!the!γδ!chains!instead! and! are! associated! with! protection! of! the! skin! and! mucosal! surfaces!(Ciofani!and!ZúñigaCPflücker,!2010).!The!αβ!TCR!T!cells!can!be!broadly!divided!into! two! lineages! based! on! the! cell! surface! expression! of! the! coCreceptor!molecules!CD4!and!CD8,!and!circulate!through!the!blood!and!lymphatic!system.!!!Most! commonly,! CD4+! T! cells! are! activated! through! interactions! with! antigen!presenting! cells! (APCs)! such!as!dendritic! cells,!macrophages,! and!B! cells.!APCs!phagocytose! and! digest! extracellular! pathogens! and! display! the! resulting!antigenic! peptides! on! their! cell! surface! via! major! histocompatibility! complex!(MHC)!II!molecules!(Broere!et!al.,!2011).!Upon!recognition!of!these!antigens,!CD4!cells,! also! known! as! the! T! helper! cell! population,! are! activated! from! naïve! to!effector!cells!and!produce!cytokines!that!function!to!both!destroy!infected!target!
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cells!and!mediate! the!response!of!other!effector!T!and!B!cells,! such!as! through!the!promotion!of!antibody!production!(Broere!et!al.,!2011).!!!There!are!multiple!subsets!of!T!helper!cells,!which!are!distinguishable!by! their!cytokine! profile! following! activation.! Th1! cells! are! generally! regarded! as!proinflammatory! and!produce!high! levels! of! IFNCγ! and,! to! a! lesser! extent,! ILC2!and! TNFCα,! in! response! to! intracellular! bacteria,! whereas! Th2! cells! are!commonly!associated!with!parasitic!infections!and!the!secretion!of!ILC4,!ILC5,!ILC6,! ILC10,! and! ILC13! (Broere! et! al.,! 2011;! J.! Zhu! et! al.,! 2006).! The!more! recently!identified!Th17!cells!appear! to!respond!to!extracellular!bacteria!and! fungi,!and!produce!ILC17!and!ILC22,!while!Th22!cells!can!release!ILC22!in!isolation!(Eyerich!et!al.,!2009;!Louten!et!al.,!2009).!!!!The! CD8+! cytotoxic! T! cells! recognise! antigens! displayed! on! MHC! I! molecules,!which! are! expressed! on! all! nucleated! cells! and! present! peptides! from!intracellular! pathogens.! Upon! activation,! CD8+! T! cells! rapidly! proliferate! and!destroy!infected!cells!through!the!release!of!cytolytic!granules!or!the!initiation!of!FASCmediated!apoptosis,!and!also!secrete!inflammatory!cytokines!such!as!IFNCγ!and!TNFCα!(Broere!et!al.,!2011;!Fong!and!Mosmann,!1990).!!!Regulatory!T! cells! (Treg)! encompass! several! slightly! varied! cell! types! that! can!occur!naturally!or!be! induced,!but!all! share! the!common! function!of! regulating!the! immune! response! and!preserving! immune! tolerance! (Triplett! et! al.,! 2012).!The!majority!of!Treg!are!CD4+!and!express!high!levels!of!the!alpha!chain!of!the!ILC2!receptor,!CD25.!The!exact!mechanisms!through!which!Treg!mediate!immune!responses! are! not! fully! understood,! but! they! appear! to! express! inhibitory!molecules!such!as!cytotoxic!TClymphocyte!associated!protein!4!(CTLA4),!which!dampen! down! the! effector! responses! of! other! T! cells;! secrete!immunosuppressive! cytokines! such! as! TGFCβ! and! ILC10;! and! decrease! the!expression!of!MHC!and!coCstimulatory!molecules!on!APCs!(Broere!et!al.,!2011).!!!Following! clearance! of! the! antigenic! agent,! the! immune! response! resolves! and!the!majority! of! the! T! cells! disappear;! however,! a! small! population! of! cells! are!
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preserved!as!memory!T!cells.!These!cells!persist!in!the!lymphoid!organs!for!years!and!are!capable!of!mounting!an!immediate!effector!response!should!the!antigen!be! encountered! again! (Broere! et! al.,! 2011).! It! is! this! ability! of! the! adaptive!immune!system!to!‘learn’!to!recognise!and!quickly!respond!to!specific!pathogens!that!forms!the!basis!for!vaccination.!!!










2.1.1 RIPC-in-highLrisk-cardiac-surgery-patients-Recent!years!have!seen!a!significant!change!in!the!demographics!of!the!average!cardiac! surgery! candidate,! leading! to! rising!numbers! of! highCrisk!patients.! The!factors! behind! this! shift! include! patients! being! older! and! increases! in! the!occurrence!of! coCmorbidities!such!as!diabetes,! left!ventricular! impairment,!and!the!rate!of!previous!myocardial!infarctions!(Biancari!et!al.,!2009;!Hausenloy!and!Yellon,!2012).!In!New!Zealand!alone,!the!incidence!of!heart!failure!in!people!aged!65!and!over!increased!by!14%!between!the!1970s!and!1990s,!and!the!prevalence!of! Type! 2! diabetes! has! risen! by! 35%! between! 2001! and! 2010! (Barker! et! al.,!2006;! Diabetes! New! Zealand,! 2010).! These! factors! significantly! reduce! the!patients’!physiological!reserves!and!increase!the!risk!of!postCoperative!morbidity!and!mortality!(Hausenloy!and!Yellon,!2012;!Partridge!et!al.,!2012).!!Certain!types!of!cardiac!surgery,!such!as!reCoperative!(commonly!referred!to!as!‘redo’)!and!valve!procedures,!also!pose!a!higher!risk!for!patients!in!comparison!to!straightforward!CABG!surgery!(Bridgewater!et!al.,!2008;!Wauthy!et!al.,!2003).!These! operations! are! typically! associated! with! prolonged! bypass! times! and! a!greater!level!of!structural!injury!to!the!heart!muscle!(Swaanenburg!et!al.,!2001;!van!Geene!et!al.,!2010).!Using!brief!periods!of! ischaemia! in!the!form!of!RIPC!to!prime! the! body’s! natural! protective! responses! to! ischaemia! is! therefore! a!particularly! attractive! cardioprotective! strategy! for! use! in! these! highCrisk!patients.!Further,!one!of!the!key!advantages!of!RIPC!is!the!lack!of!side!effects!or!potential! negative! interactions! with! medications,! which! is! especially!advantageous!within!this!complex!population.!!!Animal! studies! have! repeatedly! demonstrated! the! ability! of! RIPC! to! reduce!myocardial!infarct!size!by!up!to!50%!in!cardiac!I/R!injury!(Birnbaum!et!al.,!1997;!Gho! et! al.,! 1996;! Kharbanda! et! al.,! 2002);! however,! trials! of! RIPC! in! humans!undergoing! cardiac! surgery! have! not! shown! such! reproducible! results!(Karuppasamy! et! al.,! 2011;! Lomivorotov! et! al.,! 2012;! Meybohm! et! al.,! 2013;!Rahman!et!al.,!2010).!In!addition,!aspects!of!the!design!of!these!studies!such!as!
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the!use!of!incomplete!blinding!and!varied!anaesthesia!and!bypass!protocols!have!made! it! difficult! to! interpret! the! outcomes.! Further! research! using! carefully!controlled!and!considered!trial!designs!will!be!essential!to!determine!the!clinical!efficacy!of!RIPC.!!!Selecting! the!most! appropriate! and! informative! endpoints! for! trials! in! cardiac!surgery! patients! can! be! challenging.! The! average! CABG! surgery! patient! has! a!predictive! operative! mortality! risk! in! the! range! of! 3! to! 4%;! however,! the!currently! available! assessment! tools,! such! as! the! logistic! European! system! for!cardiac! operative! risk! evaluation! (EuroSCORE),! commonly! overestimate! these!rates!(Kalavrouziotis!et!al.,!2009;!Parolari!et!al.,!2009;!van!Straten!et!al.,!2010).!The! incidence! of! postCoperative! major! adverse! cardiac! events! (MACE)! are!similarly!low,!making!these!obvious!endpoints!less!than!ideal!outcome!measures!for! small! or! moderately! sized! studies.! The! majority! of! RIPC! clinical! trials,!including! the! one! described! in! this! chapter,! have! therefore! used! surrogate!endpoints! such! as! troponin! or! other! markers! of! damage,! rather! than! direct!clinical!outcome!data.!!!Troponin! is! a! protein! that! exists! predominantly! as! a! three! unit! complex!composed!of!the!different!isoforms,!I,!T,!and!C!(Barry!et!al.,!2008).!This!trimeric!complex! is! located! between! the! actin! filaments! of! cardiac!muscle! and! a! small!fraction!of!the!unbound!isoforms!can!also!be!found!in!the!cytoplasm!of!myocytes.!When! the! myocytes! are! injured,! both! the! complex! and! unbound! forms! of!troponin!are!released!into!the!serum!where!they!can!be!readily!quantified!using!commercial! assays! (Barry! et! al.,! 2008).! Currently,! troponin! I! and! T! are!considered! the! preferred! biomarkers! of! myocardial! injury! due! to! their! highly!cardiac! specific! and! sensitive! nature! (Jaffe! et! al.,! 2000;! Thygesen! et! al.,! 2007).!Although! postCoperative! troponin! levels! have! previously! been! correlated! with!increased! mortality! and! MACE,! the! magnitude! of! reduction! in! troponin! levels!required! to! improve! patient! outcome! has! not! been! established! (Adabag! et! al.,!2007;!Domanski! et! al.,! 2011;!Nesher! et! al.,! 2008).!This! limits! the!usefulness!of!troponin!as!an!indicator!of!the!effectiveness!of!cardioprotective!techniques.!!
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The!following!trial!was!designed!to!assess!the!impact!of!RIPC!in!a!population!of!highCrisk! cardiac! surgery! patients.! This! patient! population! was! selected! for! a!number! of! reasons.! First,! at! the! time! our! study! was! designed! there! were! no!reported! applications! of! RIPC! in! highCrisk! patients,! despite! their! increasing!presentation! for!cardiac!surgery.!Second,! the!compromised!physiology!of! these!individuals! prior! to! surgery! coupled! with! the! greater! anticipated! burden!associated!with! the!procedures!being!performed! identified! them!as!having! the!most! to! gain! from! the!potential!protection!afforded!by! the! intervention.!Third,!the! expected! high! levels! of! troponin! release! from! the! surgeries! undergone! by!these! patients! provided! a! greater! opportunity! to! measure! any! RIPCCinduced!benefits.!Likewise,!the!higher!estimated!frequency!of!adverse!events!allowed!the!possibility!to!detect!a!difference!in!superior!endpoint!measures,!such!as!AKI!or!death.!!!
2.1.2 Potential-role-of-cytokines-in-RIPC-The!inconsistencies!between!animal!and!human!studies,!and!variation!amongst!the!early!clinical!trials,!have!prompted!a!call! for! further!research!to! investigate!the! underlying! mechanisms! involved! in! RIPC! in! order! to! define! its! clinical!indication!and!limitations!(Morita,!2011).!There!is!mounting!evidence!that!RIPC!modulates! the! inflammatory! response,! suppressing! proinflammatory! gene!expression!in!human!leukocytes!and!activation!of!the!key!effector!cells!of!postCoperative! tissue! damage,! neutrophils! (Kharbanda! et! al.,! 2001;! Konstantinov! et!al.,!2004;!Shimizu!et!al.,!2010).!Furthermore,!the!inflammatory!cytokines!ILC6,!ILC10,! and! TNFCα! have! been! established! as! essential! for! preconditioningCinduced!cardioprotection!in!mice!(Cai!et!al.,!2012;!Dawn!et!al.,!2004;!Smith!et!al.,!2002).!In! rats,! the! protective! effects! of! late! IPC! can! also! be! abolished! by! concurrent!administration!of!antibodies!to!ILC1β!and!TNFCα!(Yamashita!et!al.,!2000).!These!studies!suggest!that!cytokines!could!be!the!as!yet!unidentified!humoral!mediator!that!transmits!the!protective!signal! from!the!preconditioned!tissue!to!the!heart!and!other!organs!of!the!body.!!!Despite! reports! of! specific! cytokines! being! obligatory! for! inducing!preconditioning,! the! animal! study! literature! overwhelmingly! suggests! that!
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preconditioning! attenuates! the! I/R! induced! release! of! key! inflammatory!cytokines.! Several! studies! in! rat! and! pig! models! have! demonstrated! that! IPC!significantly! reduces! systemic! levels! of! ILC6! and! macrophage! inflammatory!protein!(MIP)C2!following!I/R!injury!(Harkin!et!al.,!2002;!Jiang!et!al.,!2003;!Peng!et!al.,!2011;!Zhang!et!al.,!2013).!Likewise,! IPC!consistently! reduces!both!mRNA!and! serum! levels! of! ILC1β! and! TNFCα,! and! mRNA! levels! of! monocyte!chemoattractant! protein! (MCP)C1,! in! pig,! rat,! and! mouse! models! of! ischaemic!damage!(Funaki!et!al.,!2002;!Simón!et!al.,!2012;!Takeshita!et!al.,!2010;!Yang!et!al.,!2013;!Yu!et!al.,!2010).!!!In! cardiac! surgery,! high! levels! of! ILC6! and! ILC8! have! been! associated! with!numerous!postCoperative!complications!including!increased!myocardial!damage!and! AKI,! yet! the! impact! of! RIPC! on! early! expression! of! these! biomarkers! in!human!adults!has!not!previously!been!characterised!(Liu!et!al.,!2009;!Wei!et!al.,!2001a).!ILC6,!ILC8,!and!other!cytokines!may!have!a!direct!role!in!the!initiation!of!RIPC!or!function!as!indirect!markers!of!preconditioning.!Alternatively,!RIPC!may!attenuate! cytokine! levels! as! part! of! the! protective! mechanism,! or! indirectly!through! a! reduction! in! myocardial! injury.! Higher! systemic! levels! of! these!mediators!are!associated!with! increasing!duration!and! invasiveness!of!surgery,!suggesting!our!highCrisk!patients!provide!an!ideal!setting!to!examine!changes!in!expression!levels!(Takayama!et!al.,!2007;!Whitten!et!al.,!1998).!In!this!study,!we!therefore! investigated! whether! RIPC! alters! cytokine! expression! in! the! periCoperative!period!in!patients!undergoing!highCrisk!cardiac!surgery.!!!
2.2 Aims-
• To!determine! the! impact!of!RIPC!on! cardiac!and! renal! endpoints! in!highCrisk!cardiac!surgery!patients.!
• To! investigate! the! effect! of! RIPC! on! inflammatory! cytokine! production!during!highCrisk!cardiac!surgery.!
• To! explore! which! surgical! factors! may! impact! inflammatory! cytokine!production!following!cardiac!procedures.!
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2.3 Methods-A!doubleCblind,!randomised,!controlled!trial!of!RIPC!was!performed!in!96!adult!highCrisk! cardiac! surgery! patients! recruited! over! 13! months! at! Wellington!Regional!Hospital,!New!Zealand.!The!study!was!registered!on!the!Australian!New!Zealand!Clinical!Trials!Registry! (ACTRN!12609000965202)!and!received!ethics!approval!from!the!Central!Regional!Ethics!Committee!(CEN/09/12/096).!!
2.3.1 Participants-Patients!over!18!years!were!invited!to!participate!if!they!were!undergoing!highCrisk! cardiac! surgery! defined! as! double,! triple! or! mitral! valve! replacement,!coronary!artery!bypass!graft!surgery!(CABG)!with!ejection!fraction!(EF)!<!50%,!CABG!+!valve(s),!or!any!redo!cardiac!operation.!These!surgeries!were!considered!highCrisk!because! they!are!generally! associated!with!extended!bypass! times!or!are!performed! in!patients!with! significantly! impaired! cardiac! function.! For! the!study! overall,! patients! with! peripheral! vascular! disease! affecting! the! upper!limbs,!or!requiring!deep!hypothermic!circulatory!arrest!or!radial!artery!conduit!harvesting! were! excluded.! Additionally,! for! the! cytokine! analyses,! patients!receiving! systemic! immunosuppressives!were! also! excluded.!Written! informed!consent!was!obtained!from!all!patients.!!
2.3.2 Study-blinding-and-RIPC-Patients!were!permutedCblock!randomized!in!groups!of!8!by!a!third!party!using!an! online! randomisation! sequence! generator!with! an! allocation! ratio! of! 1:1! to!either!RIPC!or!control.!Treatment!group!allocation!was!concealed!in!sequentially!numbered! opaque! envelopes! until! an! anaesthetic! technician! applied! the!intervention.!Each!participant!had!one!tourniquet!placed!on!their!upper!limb!and!a! second! tourniquet! wrapped! around! a! towel! next! to! them! on! the! operating!table.!The!tourniquet!setCup!was!concealed!from!the!theatre!staff!by!the!patient!draping.!RIPC!was!applied!beginning!with!the!first!surgical!incision!using!an!ATS!750!electric!tourniquet!system!(Zimmer,!Inc.,!Warsaw,!IN,!USA)!to!inflate!the!cuff!to!200!mmHg!for!5!minutes,!followed!by!5!minutes!of!deflation.!This!process!was!performed! a! total! of! 3! times,! consecutively.! For! the! control! group! the! same!intervention!was!applied!to! the!tourniquet!wrapped!around!the!towel.!Prior! to!
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the!undraping!of!the!patient,!the!tourniquet!was!disconnected!by!the!anaesthetic!technician.! Patients,! theatre! staff! (with! the! exception! of! the! anaesthetic!technician),!ICU!staff,!and!investigators!were!masked!as!to!treatment!allocation!until!data!collection!was!completed.!!!
2.3.3 PeriLoperative-management-of-patients-All! patients! received! preCmedication,! cardiac! anaesthesia! involving! the! use! of!isoflurane,! tepid! cardiopulmonary! bypass! with! blood! cardioplegia,! and! postCoperative!hemodynamic!management!according!to!standardised!study!protocols!described!in!appendix!A.!!
2.3.4 Serum-collection-Blood! samples! were! collected! from! the! radial! artery! into! BD! SST! II! Advance!vacutainers! (Becton,! Dickinson! and! Company,! Franklin! Lakes,! NJ,! USA)! preCoperatively,! and! at! 1,! 2,! 3,! 6! and!12!hours! following! crossCclamp! removal.! The!samples!were!incubated!at!room!temperature!(RT)!for!30!minutes,!centrifuged,!and!the!serum!collected!for!storage!at!C80!°C!until!analysis.!!
2.3.5 Troponin-levels-High!sensitivity!troponin!T!levels!were!measured!as!the!samples!were!collected!according!to!standard!clinical!procedures!at!the!Wellington!Hospital!Laboratory!Services.!!
2.3.6 Cytokine-quantification-The!cytokines!were!quantified!using!a!human!inflammatory!cytokine!cytometric!bead!array!(CBA)!kit!(#551811;!BD!Biosciences,!San!Jose,!CA,!USA).!The!CBA!kit!consists!of!six!bead!populations!with!distinct!fluorescence!intensities!that!can!be!resolved!in!the!red!channel!via!allophycocyanin!(APC).!Each!population!is!coated!with!capture!antibodies!specific! for! ILC1β,! ILC6,! ILC8,! ILC10,! ILC12p70!or!TNFCα.!After! these!beads!are! incubated!with! test! samples!or! standards,!phycoerythrin!(PE)Cconjugated! cytokineCspecific! detection! antibodies! are! added! to! enable! the!cytokineCbound! beads! to! be! distinguished! from! unbound! beads.! The! PE!fluorescence!intensity!of!the!resulting!sandwich!complexes!can!then!be!detected!
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in! the! yellow! channel! during! flow! cytometry! and! compared! to! a! range! of!standards!to!ascertain!the!cytokine!concentrations.!The!cytometric!assay!beads!were!mixed,!centrifuged!at!200!x!g!for!5!minutes,!the!supernatant!removed,!and!the!beads!resuspended!in!an!equal!volume!of!serum!enhancement!buffer.!After!a!30Cminute! incubation! at! RT,! the! beads!were! diluted! 2Cfold!with! assay! diluent.!Following!bead!preparation,!25!μL!of!undiluted!sample!and!duplicate!standards!ranging! from! 20! pg/mL! to! 5000! pg/mL! (prepared! according! to! the!manufacturer’s!instructions)!were!incubated!in!a!VCbottom!96Cwell!plate!with!25!μL!of!the!mixed!beads!for!1.5!hours!at!RT,!protected!from!light.!At!the!end!of!the!incubation! the! samples! were! washed! twice! by! the! addition! of! wash! buffer,!centrifugation!at!400!x!g!for!5!minutes,!and!aspiration!of!the!supernatant.!After!the! final!wash!all!but!50!μL!of! supernatant!was! removed!and!25!μL!of! the!PECconjugated!antiCcytokine!antibody!mix!diluted!2Cfold! in!assay!diluent!was! then!added! to! each! sample.! After! a! 1.5Chour! incubation,! the! samples! were! washed!twice,!resuspended!in!200!μL!wash!buffer,!and!a!minimum!of!1800!singlet!bead!events! per! sample! were! acquired! on! a! FACSCanto™! II! flow! cytometer! (BD!Biosciences).!The!data!was!analysed!with!BD!FACSDiva!and!FCAP!Array!software!(BD!Biosciences).!!!
2.3.7 Comparison-of-vacutainers-for-cytokine-recovery-!
2.3.7.1 Sample,collection,Cytokine! recovery! was! compared! between! the! BD! SST! II! Advance! and! Plastic!Plus!Serum!tubes!(Becton,!Dickinson!and!Company)!by!collecting!human!blood!into!the!vacutainers!and!adding!either!a!low!(200!pg/mL)!or!high!(1500!pg/mL)!concentration! of! recombinant! murine! TNF! and! human! ILC6! proteins.! The!samples! were! incubated! at! RT! for! 60! minutes,! centrifuged,! and! the! serum!collected! for! storage!at! C80! °C!until! analysis!by!enzymeClinked! immunosorbent!assay!(ELISA).!!!
2.3.7.2 TNF>α,and,IL>6,ELISAs,TNFCα! and! ILC6! levels! were! measured! using! a! sandwich! ELISA! in! accordance!with! the!manufacturer’s! instructions! (BD! Biosciences).! For! ILC6! detection,! 96C
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well!ELISA!plates!(Thermo!Fisher,!Waltham,!MA,!USA)!were!coated!with!1!μg/mL!purified!mouseCanti!human!ILC6!capture!antibody!in!0.1!M!Na2HPO4!(pH!9)!and!incubated!overnight!at!4!°C.!The!capture!solution!was!discarded,!and!the!plates!blocked!with!5%!blocking! solution! (5%!FCS! in!1x!PBS)! at!RT! for!2!hours.!The!plates!were!then!washed!4!times!in!ELISA!wash!buffer!(0.05%!Tween!20!(Sigma!Aldrich,! St! Louis,! MO,! USA)! in! 1x! PBS)! and! 50! μL! of! standards! and! samples!(diluted!2Cfold!in!5%!blocking!solution)!were!added!and!incubated!overnight!at!4!°C.!The!samples!and!standards!were!discarded!and!the!plates!washed!4!times!before! 0.5! μg/mL! biotin! antiChuman! ILC6! antibody! (BD!Biosciences)! diluted! in!5%! blocking! solution! was! added! and! incubated! at! RT! for! 1! hour.! After! the!secondary!antibody!solution!was!removed!and!the!plates!washed!6!times,!50!μL!of! streptavidin! horseradish! peroxidase! (SACHRP;! 1:2000;! BD! Biosciences)! was!added!and!incubated!at!RT!for!1!hour.!The!SACHRP!solution!was!then!discarded!and! the! plates! washed! 8! times.! Equal! volumes! of! OptEIA! TMB! A! and! TMB! B!solutions! (BD!Biosciences)!were!mixed!and!100!μL! immediately!added! to!each!well.! After! sufficient! colour! development,! the! reaction! was! stopped! by! the!addition! of! 100! μL/well! of! 0.18M!H2SO4! (stop! solution,! see! appendix! C).! ! The!optical! density! of! the! plates! at! 450! nm! was! measured! on! an! EnSpire! 2300!multilabel! plate! reader! (PerkinElmer,! Wellesly,! MA,! USA)! and! the! EnSpire!software! was! used! to! generate! a! standard! curve! to! determine! the! sample!concentrations.!The!same!protocol!was!used!for!TNFCα!detection,!with!4!μg/mL!of!rat!antiCmouse!TNFCα!antibody!(BD!Biosciences)!in!0.1!M!Na2HPO4!(pH!6)!for!capture,!a!5Cfold!dilution!of!samples!in!5%!blocking!solution,!and!1!μg/mL!biotin!antiCmouse!TNFCα!antibody!(BD!Biosciences)!for!detection.!!!
2.3.8 Statistical-analysis-The! primary! clinical! outcome!measures! for! the! trial! were! postCoperative! high!sensitivity! troponin! T! levels! measured! at! 6! and! 12! hours! after! crossCclamp!removal,!duration!of!noradrenaline!use!amongst!ICU!survivors,!and!worst!postCoperative! renal! injury! as! determined! by! risk,! injury,! failure,! loss! of! kidney!function,! and! endCstage! kidney! disease! (RIFLE)! criteria! (Bellomo! et! al.,! 2004).!For! the! cytokine! analysis! the! primary! endpoints!were! the! serum! levels! of! the!cytokines!measured!at!1!and!12!hours!following!crossCclamp!removal.!!
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The!power!calculation!for!the!trial!was!based!on!troponin!levels!from!a!previous!study! of! RIPC! in! CABG! patients! (Hausenloy! et! al.,! 2007).! Hausenloy! et# al.#reported! a!mean! troponin!T! concentration! in! the! control! group!at! 12!hours!of!0.69!μg/L!with!a!standard!deviation!of!0.48!μg/L!which,! in!a!sample!size!of!96!participants!split!evenly!between!two!treatments,!would!enable!detection!of!an!absolute!difference!in!troponin!T!levels!of!0.28!μg/L.!This!level!of!change!would!correspond! to! a! difference! in! troponin! T! between! treatment! groups! of! 40%,!which! is! less! than! that! observed! in! previous! trials,! with! 80%! power! and! 5%!significance!(Hausenloy!et!al.,!2007;!Venugopal!et!al.,!2009).!!!Professor! Mark! Weatherall! completed! the! technical! aspects! of! the! statistical!analysis! for! the! trial! in! collaboration!with! the! study! investigators.! Continuous!baseline!demographic!variables!were!compared!between!treatment!groups!using!tCtests,!and!categorical!baseline!variables!were!analysed!with!the!ChiCsquare!test.!The!cytokine,!vasopressor!support,!and!troponin!data!distributions!were!skewed!to!the!right!and!normality!assumptions!were!better!met!with!natural!logarithm!transformation.! The! log! transformed! cytokine! concentrations! were! compared!using! tCtests! and! analysis! of! covariance! (ANCOVA).! The! exponent! of! the!difference! in! logarithms!shown!in!the!results! is!equivalent!to!the!ratio!of!mean!values! for! the! two! groups.! These! exploratory! analyses! were! each! carried! out!with! a! type! I! error! rate! of! 5%! and! no! adjustment! was! used! for! multiple!comparisons.!!!For! the! primary! analyses! of! troponin! levels! and! noradrenaline! duration!comparisons!between!treatment!groups!were!made!using!tCtests.!The!incidence!of!postCoperative!renal!injury!was!analysed!using!contingency!table!analysis!and!the! ChiCsquare! test.! A! Bonferroni! correction!was! used! to! account! for!multiple!comparisons,!therefore!the!adjusted!pCvalue!for!accepting!statistical!significance!for! these! clinical! outcome! variables! was! 0.0083! and! the! corresponding!confidence! intervals!were! estimates! at! the! 99.17%! level.! A! secondary! analysis!using! ANCOVA! was! also! performed! to! account! for! the! effect! of! potential!confounding! variables! on! troponin! levels.! The! preCspecified! confounding!
!! ! 55!
variables!were!sulphonylurea!and!statin!use,!EuroSCORE,!crossCclamp!and!total!bypass!times,!and!the!number!of!procedures!performed.!!Lastly,! the! correlation! between! bypass! time! and! cytokine! expression! was!analysed! using! twoCtailed! Pearson’s! correlation! coefficients,! and! the! effect! of!statin!use!on!ILC6!production!was!examined!using!an!independent!samples!tCtest.!The! data! analysis! was! performed! using! R! (R! Development! Core! Team,! New!Zealand)!or!SPSS!Statistics!(IBM!Corporation,!Armonk,!NY,!USA),!and!the!graphs!produced!using!GraphPad!Prism!5!(GraphPad!Software!Inc.,!La!Jolla,!CA,!USA).!!!!!!!!!!!!!!!!!!!!!!!!!!
!! !56!
2.4 Results-!
2.4.1 Patient-baseline-demographic-and-operative-data-PeriCoperative! serum! samples! were! collected! from! a! total! of! 96! patients;!however,!one!individual!was!excluded!from!the!final!cytokine!data!analysis!due!to! the!use!of! an! immunosuppressive! therapy.!The! final!dataset! consisted!of!47!patients!who!received!the!RIPC!treatment,!and!48!patients!in!the!control!group!(Figure!2.1).!!!The! randomisation! appeared! successful,! with! a! similar! distribution! of! key!baseline! characteristics! between! the! two! treatment! groups.! There! were! no!statistically!significant!differences!between!the!RIPC!and!control!treated!groups!with!respect!to!age,!sex,!ethnicity,!or!medication!use!(Table!2.1).!A!set!of!clinical!variables!were!collected!and!used!to!calculate!the!EuroSCORE!for!each!patient!as!a!predictive!measure!of!cardiac!operative!risk!(Nashef!et!al.,!1999;!Roques!et!al.,!2003).!Again,!there!were!no!differences!between!the!groups!with!respect!to!the!overall!mean!EuroSCORE,!or! the!distribution!of!key!contributing! factors!(Table!2.1).!
 While!the!two!treatment!groups!were!well!matched!with!respect!to!the!baseline!characteristics,! there!were!some!notable!differences!with! the!operative!details.!There!was!a!trend!towards!a!more!complex!set!of!surgeries!being!performed!in!the!RIPC!patients,!with!5!out!of!47!patients!undergoing!3!or!more!procedures,!compared!to!0!out!of!48!patients!in!the!control!group!(p!=!0.057;!Table!2.2).!In!addition,! the!durations!of!bypass!and!aortic! crossCclamping!were! longer! in! the!preconditioned! patients,! although! this! difference! did! not! reach! statistical!significance!(crossCclamp!time:!117!±!50.8!vs.!105!±!40.6!minutes!in!the!control!group,!p!=!0.193;!bypass!time:!151!±!59.0!vs.!135!±!49.1!minutes!in!the!control!group,!p!=!0.185;!Table!2.1).!!!!!
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! RIPC!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!n=47! Control!!!!!!!!!!!!!!!!!!!!!!!!!!!!!n=48! PCvalue!Demographics! ! ! !!!!!!!Age!(mean,!years)! 65.3!±!12.8! 64.3!±!14.5! 0.726!!!!!!!Female!sex! 18!(38)! 17!(35)! 0.771!!!!!!!BMI!(mean,!kg/m2)! 28.5!±!5.2! 28.6!±!5.9! 0.869!!!!Ethnicity! ! ! !!!!!!!European! 31!(66)! 38!(79)!!!!!!!Maori! 7!(15)! 7!(15)!!!!!!!Other! 9!(19)! 3!(6)! 0.157!Clinical!details! ! ! !!!!Medications! ! ! !!!!!!!Beta!blockers! 34!(72)! 29!(60)! 0.219!!!!!!!ACE!inhibitors! 24!(51)! 25!(52)! 0.921!!!!!!!Statins! 27!(57)! 30!(63)! 0.615!!!!!!!Sulfonylureas! 4!(9)! 1!(2)! 0.161!!!!!!!Digoxin! 5!(11)! 10!(21)! 0.173!EuroSCORE!variables! ! ! !!!!Left!ventricular!function! ! ! !!!!!!!EF!>50%! 28!(60)! 30!(63)!!!!!!!EF!30!C!50%! 19!(40)! 14!(29)!!!!!!!EF!<30%! 0!(0)! 4!(8)! 0.090!!!!Unstable!angina! 0!(0)! 0!(0)! !EuroSCORE!(mean)! 7.07!±!6.10! 6.58!±!6.08! 0.694!
-
Table-2.1-Patient-demographic-and-clinical-data-Values! are! reported!as!mean!±! standard!deviation!or!number! (%).!Continuous!variables!were!analysed!using! tCtests! and! categorical! variables!were! compared!using!the!ChiCsquare!test.!BMI!=!body!mass!index,!ACE!=!angiotensin!converting!enzyme,!EF!=!ejection!fraction.!!!!!
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! RIPC!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!n=47! Control!!!!!!!!!!!!!!!!!!!!!!!!!!!!!n=48! PCvalue!Operation! ! ! !!!!AVR! 4!(9)! 2!(4)!!!!MVR! 8!(17)! 10!(20)!!!!AVR,!MVR! 4!(9)! 6!(13)!!!!MVR,!TA! 2!(4)! 5!(10)!!!!AVR,!MVR,!TA! 2!(4)! 0!(0)!!!!AVR,!CABG! 11!(23)! 14!(29)!!!!MVR,!CABG! 4!(9)! 2!(4)!!!!AVR,!MVR,!CABG! 1!(2)! 0!(0)!!!!AVR,!MVR,!TA,!CABG! 1!(2)! 0!(0)!!!!AVR,!MVR,!TA,!ASD!repair! 1!(2)! 0!(0)!!!!CABG!with!EF!<50%! 9!(19)! 9!(19)!
0.571!
Number!of!procedures! ! ! !!!!One! 21!(45)! 21!(44)!!!!Two! 21!(45)! 27!(56)!!!!Three!or!more! 5!(11)! 0!(0)! 0.057!Bypass!variables! ! ! !!!!Total!bypass!time!(mean,!minutes)! 151!±!59.0! 135!±!49.1! 0.185!!!!CrossCclamp!time!(mean,!minutes)! 117!±!50.8! 105!±!40.6! 0.193!!!!CrossCclamp!fibrillation! 2!(4)! 2!(4)! 0.983!
-
Table-2.2-Patient-operation-details-Values! are! reported!as!mean!±! standard!deviation!or!number! (%).!Continuous!variables!were!analysed!using! tCtests! and! categorical! variables!were! compared!using! the!ChiCsquare! test.! AVR!=! aortic! valve! replacement,!MVR!=!mitral! valve!repair! or! replacement,! TA! =! tricuspid! annuloplasty,! CABG! =! coronary! artery!bypass!graft,!ASD!=!atrial!septal!defect,!EF!=!ejection!fraction.!!!!
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2.4.2 Clinical-outcome-measures-The!principal! investigator!of! the!study,!Dr!Paul!Young,!was!responsible! for! the!overall!study!design!and!analysis!of!the!clinical!data.!The!detailed!clinical!results!of!the!trial,!including!the!secondary!endpoints!as!analysed!and!presented!by!Dr!Young!are!included!in!full! in!appendix!D.!Reproduction!of!the!clinical!results! in!this!thesis!will!be!limited!to!the!three!primary!outcomes!measured!in!the!study;!high!sensitivity! troponin!T,!duration!of!noradrenaline!use,!and!the! incidence!of!AKI!as!determined!by!RIFLE!criteria!(Bellomo!et!al.,!2004).!!!The! results! from! the! clinical! endpoints! did! not! indicate! any! protective! benefit!from!RIPC!for!the!patients!in!our!study!(Young!et!al.,!2012).!The!point!estimates!showed!nonCsignificantly!higher!troponin!levels!in!the!RIPC!group!at!both!6!and!12!hours!following!crossCclamp!removal!(6!hours:!1533!(SD!1784)!vs.!828!ng/L!(540),!ratio!of!means!1.41,!p!=!0.035;!12!hours:!1608!(2361)!vs.!715!ng/L!(586),!ratio! of! means! 1.56,! p! =! 0.014)! and! adjustment! for! baseline! troponin! levels,!sulphonylurea! and! statin! use,! EuroSCORE,! cross! clamp! and! total! bypass! times,!and! the! number! of! procedures! performed! reduced! both! the! degree! of! the!difference!and! the!p!values! for! the! troponin! levels!at!6!and!12!hours! (6!hours:!ratio!of!means!1.23!(99.17%!CI!0.88!to!1.72),!p!=!0.10;!12!hours:!ratio!of!means!1.30! (0.92! to! 1.84),! p! =! 0.05).! Overall,! the! RIPC! patients! demonstrated! higher!requirements! for! postCoperative! ICU! support,! with! an! increased! duration! of!noradrenaline! treatment! (21! (IQR!7! C! 45)! vs.! 9! hours! (3! –! 19),! ratio! of!means!1.70! (99.17%! CI! 0.86! to! 3.34),! p! =! 0.04)! and! use! of! vasopressin! (17! vs.! 0%,!absolute! risk! difference! of! 17%! (95%! CI! 6! to! 28),! p! =! 0.006).! There! was! no!difference!in!the!incidence!of!AKI!between!the!two!treatment!groups!(raw!data!not!shown,!p!=!0.82).!!!
2.4.3 RIPC- and- systemic- levels- of- ILL6,- ILL8,- and- ILL10- during- highLrisk-
cardiac-surgery-My! Honours! project! in! 2010! involved! developing! a! protocol! for! assessing!inflammatory!biomarker!expression!in!highCrisk!cardiac!surgery!patients!for!this!trial! (Williams,! 2010).! This! project! involved! selecting! the! markers! and! time!points! of! interest,! collecting! serum! samples,! and! optimising! a! cytometric! bead!
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array!(CBA)!with!appropriate!controls!to!quantify!the!cytokines.!The!majority!of!the!trial!patients!were!recruited!throughout!the!following!year;! therefore!aside!from! the! initial! optimisation! and! validation! of! the! CBA! assay,! almost! all! of! the!experimental! work! and! all! of! the! analyses! were! conducted! during! my! PhD!studies.!Only!the!work!arising!from!my!PhD!studies!are!included!in!this!thesis.!!The!serum!ILC6,!ILC8,!and!ILC10!levels!increased!considerably!from!baseline!in!all!patients! following! surgery.! In! contrast,! ILC1β,! ILC12p70! and! TNFCα!concentrations!did!not!increase!and!were!below!the!level!of!detection!of!the!CBA!(7.2,! 1.9,! and! 3.7! pg/mL,! respectively;! data! not! shown).! The! inflammatory!cytokines,! ILC6! and! ILC8,! peaked! between! 1! and! 3! hours! postCreperfusion! and!remained!increased!at!12!hours!(Figure!2.2A!and!B).!To!reduce!the!incidence!of!type! I!error,! statistical! testing!of! the!cytokine!data!was! limited! to! the!1!and!12!hour!time!points,!which!were!deemed!the!most!informative.!The!point!estimates!were! consistent! with! the! hypothesis! that! there! were! higher! levels! of! the!proinflammatory! mediators! present! in! the! RIPC! patients,! compared! to! the!controls.! However,! the! confidence! intervals! were! wide! and! there! were! no!statistically!significant!differences!in!mean!log!ILC6!and!ILC8!levels!between!the!RIPC!and!control!groups!at!1!or!12!hours!(Table!2.3)!or!in!the!total!area!under!the!curve!(AUC;!ILC6:!ratio!of!means!1.32![95%!CI!0.84C2.05],!p!=!0.22;!ILC8:!1.17![0.79C1.72],!p!=!0.43).!!!An! ANCOVA! model! was! used! to! determine! if! accounting! for! potential!confounding!variables!altered!the!difference!between!the!two!treatment!groups.!Adjustment!for!baseline!interleukin!levels,!age,!EuroSCORE!predicted!mortality,!bypass! and! crossCclamp! times,! surgery! type! (CABG! only! versus! all! other!procedures),!and!statin!use!did!not!alter!the!absence!of!a!statistically!significant!difference!seen!with!the!univariate!analysis!(Table!2.3;!Roques!et!al.,!2003).!!!Levels! of! the! immunosuppressive! cytokine,! ILC10,! peaked! at! 1! hour! postCreperfusion!and!then!steadily!declined!(Figure!2.2C).!ILC10!levels!were!similar!in!the!RIPC!and!control!groups!(AUC:!ratio!of!means!1.13![0.70C1.80],!p!=!0.62)!and!this!was!not!affected!by!adjustment!for!confounding!variables!(Table!2.3).!!
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Figure-2.2-Levels-of- ILL6,- ILL8,-and- ILL10-are-not-affected-by-RIPC- in-highL
risk-cardiac-surgery-up-to-12-hours-after-crossLclamp-removal-Serum!samples!were!isolated!from!blood!collected!preCoperatively!and!1,!2,!3,!6,!and!12!hours!after!crossCclamp!removal.!A!CBA!and!flow!cytometry!were!used!to!quantify! the! serum! levels! of! (A)! ILC6,! (B)! ILC8,! and! (C)! ILC10.! The! data! was!natural!log!transformed!to!meet!normality!assumptions!and!shown!are!the!mean!and!SEM!of!n!=!48!controls!and!n!=!47!RIPC!patients.!!
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! ! Mean!Conc,!pg/mL!(SD)! Mean!Log!Conc!!!!!!!!!!!(SD)!! RIPC! Control! RIPC! Control! Difference!(95%!CI),!P! Adjusted*!!Estimate!!!!!(95%!CI),!P!ILC6! !PreCop! 7.17!(8.14)! 5.75!(6.36)! 1.62!(0.79)! 1.41!(0.74)! !1!h! 865.7!(1573)! 391.3!(620.0)! 5.90!(1.23)! 5.52!(0.81)! 0.37!(C0.05!to!0.80),!0.09! 0.23!(C0.15!to!0.62),!0.23!12!h! 508.3!(865.5)! 273.2!(273.0)! 5.57!(1.11)! 5.28!(0.78)! 0.29!(C0.10!to!0.68),!0.15! 0.21!(C0.18!to!0.60),!0.28!ILC8! !PreCop! 18.2!(14.5)! 13.6!(8.25)! 2.66!(0.69)! 2.47!(0.54)! !1!h! 239.8!(423.1)! 130.8!(113.4)! 4.89!(1.01)! 4.56!(0.76)! 0.31!(C0.06!to!0.68),!0.10! 0.22!(C0.13!to!0.58),!0.22!12!h! 164.0!(233.6)! 96.5!(99.3)! 4.60!(0.91)! 4.29!(0.70)! 0.32!(C0.02!to!0.65),!0.06! 0.20!(C0.11!to!0.50),!0.20!ILC10! !PreCop! 1.92!(1.71)! 2.58!(2.88)! 0.02!(1.44)^! 0.44!(1.25)^! !1!h! 228.8!(218.1)! 231.2!(242.6)! 4.89!(1.21)! 4.88!(1.20)! 0.01!(C0.48!to!0.51),!0.97! 0.00!(C0.51!to!0.51),!0.99!12!h! 13.7!(12.5)! 20.7!(47.7)! 2.25!(0.86)! 2.26!(1.03)! C0.01!(C0.39!to!0.38),!0.98! C0.03!(C0.43!to!0.37),!0.89!
-
Table- 2.3- Statistical- comparison- of- periLoperative- ILL6,- ILL8,- and- ILL10-
levels-between-RIPC-and-control-treated-patients-Serum! samples! were! isolated! from! blood! collected! preCoperatively! and! after!crossCclamp!removal!and!cytokine! levels!were!quantified!using!a!CBA!and! flow!cytometry.! Statistical! testing! was! limited! to! the! 1! and! 12! hour! time! points! to!reduce! type! I! error! from! repeated! measures.! The! data! was! natural! log!transformed!to!meet!normality!assumptions!and!shown!are!the!results!from!n!=!48! controls! and! n! =! 47! RIPC! patients.! CI! =! confidence! interval.! *! Adjusted! for!baseline!interleukin!levels,!age,!EuroSCORE!predicted!mortality,!total!bypass!and!crossCclamp! times,! type! of! surgery,! and! statin! use.! ^! 12/47! RIPC! and! 7/48!control!patients!had!concentrations!of!zero,!therefore!these!were!given!a!value!of!0.1!to!allow!for!logarithm!transformation.!!
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2.4.4 Effect-of-RIPC-on-periLoperative-cytokine-expression-in-simple-versus-
complex-surgery-A!postChoc!analysis!investigated!whether!RIPC!differentially!modulates!cytokine!expression!depending!on!the!complexity!of!the!surgery!undergone.!In!this!study!and!in!previous!work,!we!observed!troponin!release!and!bypass!duration!varied!with!surgical!procedure!(Swaanenburg!et!al.,!2001;!van!Geene!et!al.,!2010).!Both!Swaaneburg! et# al.! and! van! Geene! et# al.! reported! substantially! lower! postCoperative!levels!of!troponin!in!patients!undergoing!straightforward!CABG!±!AVR!surgery,!compared!to!procedures!involving!the!mitral!valve.!Participants!in!our!study! were! therefore! categorised! and! divided! based! on! whether! they! were!having! either! simple! surgery:! CABG! with! EF! <! 50%! or! CABG! ±! aortic! valve!surgery;!or!complex!surgery:!MVR!±!any!other!procedure.!ANCOVA!with!baseline!interleukin! levels! and! treatment! randomisation! as! coCvariates! was! used! to!compare!cytokine!levels.!!!As! expected,! there! were! notable! differences! in! the! baseline! and! operative!variables! for! the! two! surgery! subgroups! (Table! 2.4).! The! patients! undergoing!complex!surgery!had!significantly!longer!bypass!durations!and!were!more!often!prescribed! beta! blockers! and/or! statins,! compared! to! patients! in! the! simple!procedure!group.!The!mean!age!of!the!patients!in!the!simple!surgery!group!was!significantly!higher!and!the!number!of!female!patients!significantly!lower.!There!was! no! difference! between! the! two! groups! with! respect! to! treatment! group!allocation!or!the!mean!EuroSCORE!(Table!2.4).!!!Complex!surgery!was!associated!with!significantly!higher!levels!of!ILC6!(ratio!of!means! 2.14! [95%! CI! 1.45C3.16];! P! <! 0.001)! and! ILC10! (1.82! [1.05C3.19];! p! =!0.033)!at!1!hour!postCbypass!and!in!the!total!AUC!(ILC6:!ratio!of!means!1.54![95%!CI!1.02C2.34],!P!=!0.04;!ILC10:!1.97![1.16C3.35],!P!=!0.012;!Figure!2.3A!and!B).!By!12!hours,!there!was!no!evidence!of!a!difference!in!the!estimates!(ILC6:!0.91![0.64C1.31],!P!=!0.62;!ILC10:!1.08![0.72C1.63],!P!=!0.69).!RIPC!did!not!alter!expression!of!these! cytokines! in! either! simple! or! complex! surgeries! (Figure! 2.3C! C! F).! There!was!no!difference!in!ILC8!levels!between!the!simple!and!complex!surgery!groups!(data!not!shown).!!
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! Simple!!!!!!!!!!!!!!!!!(n=49)! Complex!!!!!!!!!!!!!!!(n=46)! P#Treatment!allocation! ! ! !RIPC! 24!(49)! 23!(50)!Control! 25!(51)! 23!(50)! 0.92!Demographics! ! ! !Age!(mean,!yrs)! 69.3!±!9.75! 60.1!±!15.5! <0.01!Female!sex! 10!(20)! 25!(54)! <0.01!Ethnicity! ! ! !European! 42!(85)! 27!(59)!Maori! 4!(9)! 10!(22)!Other! 3!(6)! 9!(20)! 0.01!Medications! ! ! !Beta!blockers! 10!(20)! 22!(48)! 0.01!ACE!inhibitors! 22!(45)! 24!(52)! 0.48!Statins! 8!(16)! 30!(65)! <0.01!EuroSCORE!(mean)! 6.76!±!6.24! 6.90!±!5.95! 0.91!Operative!details! ! ! !Bypass!time!(mean,!mins)! 120!±!29.4! 168!±!63.7! <0.01!
Values! are! reported! as! mean! ±! standard! deviation! or! number! (%).! ACE! =!angiotensin!converting!enzyme.!





not-RIPC-Serum! samples! were! isolated! from! blood! collected! preCoperatively! and! after!crossCclamp!removal!and!cytokine! levels!were!quantified!using!a!CBA!and! flow!cytometry.!(A)!ILC6!and!(B)!ILC10!levels,!in!simple!(n!=!49)!versus!complex!(n!=!46)! surgeries.! (C! &! E)! ILC6! levels! by! treatment! group! in! simple! and! complex!surgery!patients,!respectively.!(D!&!F)!ILC10!levels!by!treatment!group!in!simple!and!complex!surgery!patients,!respectively.!Data!are!shown!as!group!means!with!SEM.! *! p! <! 0.05! for! differences! in! the! total! AUC! using! ANCOVA!with! baseline!interleukin!levels!and!treatment!randomisation!as!covariates.!!!!!!!!
!! ! 67!
2.4.5 Relationship- between- bypass- duration- and- the- expression- of-
cytokines-Given! the! nonCsignificantly! longer! mean! bypass! time! in! our! preconditioned!patients! compared! to! the! controls! (p! =! 0.185),!we! sought! to! determine! if! this!might!account!for!the!increased!cytokine!levels!detected!in!these!patients.!In!our!study!ILC6!levels!were!weakly!correlated!with!the!total!bypass!time!in!the!early!reperfusion!period! (Figure! 2.4A! C! C).! This! relationship!was!more! significant! in!the!patients!from!the!RIPC!treatment!group!(1!hr:!Control!r!=!0.304,!p!<!0.05!vs.!RIPC!r!=!0.474,!p!<!0.01;!2!hrs:!Control!r!=!0.136,!p!>!0.05!vs.!RIPC!r!=!0.367,!p!<!0.05).! In!contrast,! the!strongest!relationship!between!ILC8!and!bypass!duration!was! seen! at! the! 6! and! 12Chour! time! points! (Figure! 2.4D! C! F).! This! positive!correlation!was!low!overall,!but!appeared!slightly!stronger!in!the!preconditioned!patients!(6!hrs:!Control!r!=!0.163,!p!>!0.05!vs.!RIPC!r!=!0.446,!p!<!0.01;!12!hrs:!Control! r!=!0.308,!p!<!0.05!vs.!RIPC! r!=!0.429,!p!<!0.01).! Interestingly,!we!also!detected!a!correlation!between!ILC10!levels!at!3!and!6!hours,!and!the!total!bypass!time!(Figure!2.4G!C!I).!The!correlation!was!weak!but!significant!and!did!not!differ!between!the!two!treatment!groups!(3!hrs:!Control!r!=!0.334,!p!<!0.05!vs.!RIPC!r!=!0.390,!p!<!0.01;!6!hrs:!Control!r!=!0.385,!p!<!0.01!vs.!RIPC!r!=!0.391,!p!<!0.01).!!The!higher!mean!bypass!time!in!the!RIPC!patients!may!have!contributed!to!the!increased! levels! of! ILC6! and! ILC8! detected! in! the! point! estimates! for! these!patients;!however,!our!adjusted!estimates!using!the!ANCOVA!model!with!bypass!time!as!a!variable!would!have!successfully!accounted!for!such!weak!correlations.!!
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Figure- 2.4- Correlation- between- bypass- time- and- cytokine- levels- in- highL
risk-surgery-patients-Serum! samples! were! isolated! from! blood! collected! preCoperatively! and! after!crossCclamp!removal!and!cytokine! levels!were!quantified!using!a!CBA!and! flow!cytometry.! (A! C! C)! ILC6! vs.! total! bypass!duration! at! baseline,! and!1!hour! and!2!hours!after!crossCclamp!removal,!respectively.!(D!–!F)!ILC8!vs.!total!bypass!time!at!baseline,!and!6!and!12!hours!after!crossCclamp!removal,!respectively.!(G!–! I)!ILC10! vs.! total! bypass! time! at! baseline,! and! 3! and! 6! hours! after! crossCclamp!removal,! respectively.! Shown! are! the! Pearson’s! correlation! coefficients! from! a!twoCtailed!analysis!of!n!=!48!controls!and!n!=!47!RIPC!patients!at!baseline!and!2,!6,! and! 12! hours! after! crossCclamp! removal,! n! =! 47! controls! and! n! =! 47! RIPC!patients!at!1!hour,!and!n!=!47!controls!and!n!=!46!RIPC!at!3!hours.!!
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2.4.6 Relationship-between-statin-usage-and-ILL6-expression-In!a!preliminary!analysis!performed!with! the!data! from!the! first!32!patients!as!part!of!my!Honours!project,!it!was!observed!that!statin!usage!in!our!patients!was!associated! with! a! significant! reduction! in! the! postCoperative! ILC6! levels!measured! at! 1,! 2,! and! 3! hours! after! crossCclamp! removal.! We! therefore!investigated!the!association!between!the!use!of!statins!and!ILC6!levels!using!the!full!dataset.!!In! the! pooled! patient! population! there! was! no! significant! difference! in! the!expression! levels! of! ILC6! between! those! who! were! and! those! who! were! not!taking! statins,! at! any! time! point! (Figure! 2.5A).! In! the! control! group! patients!alone,!there!was!a!significant!reduction!in!ILC6!expression!at!1!hour!postCbypass!in! the!patients!who!were!prescribed! a! statin! compared! to! those! that!were!not!(log! ILC6!at!1!hour:!5.87!(SD!0.92)!vs.!5.33!(0.68),!p!=!0.024),!whereas!no!such!differences!were!detected!in!the!preconditioned!patients!(Figure!2.5B!and!C).!!!Any!effect!of!statins!on!ILC6!production!in!our!study!appeared!to!be!very!limited.!In!the!event!that!statin!use!did!influence!ILC6!levels,!the!distribution!of!patients!taking! these!medications! was! even! across! the! two! treatment! groups! (refer! to!Table!2.1)!and!the!adjusted!estimates!using!the!ANCOVA!model!with!statin!use!as!a! variable! would! have! accounted! for! this! modest! affect.! It! is! therefore! highly!unlikely!that!statin!use!contributed!to!a!difference!in!ILC6!levels!between!our!two!treatment!groups.!!!!!!!!!
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Figure-2.5-The-effect-of-statins-on-postLoperative-ILL6-levels-Serum! samples! were! isolated! from! blood! collected! preCoperatively! and! after!crossCclamp! removal! and! ILC6! levels! were! quantified! using! a! CBA! and! flow!cytometry.!Log!ILC6!levels!for!patients!that!were!and!were!not!taking!statins!are!shown! for! (A)! all! patients,! (B)! control! group! patients,! and! (C)! RIPC! group!patients.! Shown! are! the!means! and! SEM! for! n! =! 47! controls! and! n! =! 48! RIPC!patients.! Comparisons! were! made! using! an! independent! samples! tCtest.! *! p! <!0.05.!!
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available-serum-vacutainers-Blood! samples!were! collected! into! BD! SST! II! Advance! (yellow)! or! Plastic! Plus!Serum! tubes! (red)! and! spiked! with! low! (200! pg/mL)! or! high! (1500! pg/mL)!concentrations!of!cytokines.!Cytokine!levels!in!the!resulting!serum!samples!were!determined! by! ELISA! and! are! shown! for! (A)! murine! TNFCα! and! (B)! human!recombinant! ILC6.! Shown! are! the! results! from! one! individual! and! one!experiment.!!!!!!!!!!!!!!!!!!!!
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2.5 Discussion-This! study!was! the! first! to! show! that! RIPC! does! not! reduce! troponin! levels! in!highCrisk!cardiac!surgery!patients,!or!alter!expression!of!a!panel!of!inflammatory!cytokines! during! the! first! 12! hours! postCbypass.! Although! the! point! estimates!favoured!the!hypothesis!that!there!were!higher!levels!of!ILC6!and!ILC8!in!the!RIPC!group,!the!differences!were!not!statistically!significant!even!after!adjustment!for!confounding! variables! such! as! statin! use,! EuroSCORE,! and! total! bypass! time.!Consistent!with!previous!research,!we!confirmed!that!periCoperative!ILC6!levels!were!higher!with!complex!valvular!surgery!compared!to!straightforward!CABG!and! AVR! procedures,! and! both! ILC6! and! ILC8! were! weakly! correlated! to! the!duration!of!bypass!(Kawahito!et!al.,!2000).!In!addition!we!found!that!the!release!of!the!antiCinflammatory!cytokine,!ILC10,!was!also!enhanced.!A!postChoc!analysis!indicated! that! RIPC! did! not! alter! ILC6! and! ILC10! expression! in! patients!undergoing! simple! procedures! or! the! more! complex! surgeries! that! are!associated! with! higher! cytokine! levels.! As! this! was! an! exploratory! study,! one!limitation! is! that! multiple! comparisons! were! performed! and! therefore! it! is!possible!that!some!of!the!statistically!significant!differences!may!represent!type!I!errors.!!!The!precise!mechanism!of!RIPC!has!yet!to!be!fully!elucidated;!however,!there!are!data!supporting!the!hypothesis!that!an!unidentified!humoral!factor!transmits!the!protective! signal! from! the! remote! preconditioned! tissue! to! the! myocardium!(Dickson!et!al.,!1999b;!Gho!et!al.,!1996;!I.!E.!Konstantinov!et!al.,!2005).!Cytokines!are! a! prime! candidate! for! such! a! factor! given! their! function! as! endocrine!signalling!peptides;!however,!our! finding!that!RIPC!does!not!modify!expression!of! the! key! cytokines! ILC6,! ILC8,! and! ILC10,! suggests! this!mechanism! is! unlikely.!This!extends!previous!research!by!Karuppasamy!et#al.! (2011)!and!Saxena!et#al.#(2013),#which!showed!that!systemic!concentrations!of!these!cytokines!were!not!altered!following!each!cycle!of!ischemia!during!RIPC!application,!or!directly!after!the!full!preconditioning!stimulus,!respectively.!In!contrast,!a!trial!by!Albrecht!et#
al.# (2013)# detected! subtle! but! significant! increases! in! ILC1β,! ILC8,! and! TNFCα!levels!of!cardiac!surgery!patients!after!preconditioning,!although!the!high!level!of!interCpatient! variability! limited! the! power! and! interpretation! of! these! results.!
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One! possible! explanation! for! our! findings! is! that! the! systemic! cytokine! levels!induced!by!highCrisk!cardiac!procedures!are!too!high!to!be!significantly!altered!by!the!RIPC!treatment!in!this!setting.!!Four!additional!studies!have!reported!on!cytokine!expression!following!RIPC!in!children!undergoing!repair!of!congenital!heart!defects.!Three!applied!lower!limb!RIPC! and! reported! ILC6,! ILC8,! ILC10,! and! TNFCα! levels! were! not! significantly!different!from!the!controls!(Cheung!et!al.,!2006;!McCrindle!et!al.,!2014;!Pavione!et! al.,! 2012).! The! fourth,! which! applied! RIPC! both! one! day! and! one! hour! preCoperatively,! found! that! levels! of! proinflammatory! and! antiCinflammatory!cytokines!were!weakly!attenuated!postCoperatively! (Zhou!et!al.,!2010).!All! four!studies!differ!substantially!from!our!own!in!that!bypass!times!were!dramatically!shorter,! the!earliest!samples!corresponded!to!time!points!after!detection!of!the!peak!period!of!cytokine!expression!in!our!study,!and!the!RIPC!interventions!were!fundamentally!different!to!the!standard!stimulus!applied!in!the!majority!of!trials,!including!our!own,!making! it!difficult! to! relate! this!earlier!work! to! the!present!findings.!!!TNFCα!is!reportedly!expressed!in!patients!with!heart!failure!and!unstable!angina;!however,!we!did!not!detect!measurable! levels! in!our!cardiac!patients!before!or!after!surgery!with!CPB!(Levine!et!al.,!1990;!Wang!et!al.,!2007).!To!confirm!that!our!methodology!was!capable!of!detecting!TNFCα!we!included!a!plasma!sample!with! known! levels! of! TNFCα! in! each! assay! run! and! confirmed! the! vacutainers!used! achieved! adequate! recovery! of! TNFCα! into! serum! samples.! Having!performed! these! additional! checks! we! were! confident! that! there! were! no!measurable!levels!of!TNFCα!present!in!the!serum!of!our!surgery!patients.!
 The!literature!regarding!TNFCα!expression!during!cardiac!surgery!in!humans!is!conflicting.!A!small!number!of!studies!have!demonstrated!an!increase!in!TNFCα!levels!following!removal!of!the!aortic!crossCclamp,!and!Wang!et#al.#(2007)!have!reported!that!TNFCα!levels!are!higher!in!unstable!angina!patients,!of!which!there!were! none! in! our! study! (Risnes! et! al.,! 2003;!Wan! et! al.,! 1996).! The! two! RIPC!studies! that! detected! measurable! TNFCα! levels! following! cardiac! surgery!
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described! low!concentration!peaks!at! less! than!70!pg/mL!(Cheung!et!al.,!2006;!Kim!et!al.,!2012).!In!contrast,!numerous!other!trials!have!noted!only!very!low!or!unmeasurable!periCoperative!serum!levels!of!TNF,!and!Borgermann!et#al.#(2002)#found! CPB! caused! a! 78%! reduction! in! leukocyte! TNFCα! mRNA! production! in!response! to! an! ex# vivo# endotoxin! challenge! (Karuppasamy! et! al.,! 2011;!Kawamura!et!al.,!1993;!McBride!et!al.,!1995;!Saxena!et!al.,!2013;!Steinberg!et!al.,!1993;!Wan!et!al.,!1999;!Wei!et!al.,!2001a;!Zhou!et!al.,!2010).!!!On!balance,!the!weight!of!the!literature!appears!to!be!consistent!with!our!finding!that!the!systemic!levels!of!TNFCα!produced!in!response!to!cardiac!surgery!with!CPB! are! below! the! level! of! detection! or! clinical! relevance,! which! is! intriguing!given!that!in!animal!studies!preconditioningCinduced!protection!from!I/R!injury!has! been! frequently! associated! with! significant! decreases! in! plasma! levels! of!TNFCα! (Garab! et! al.,! 2014;! Xiong! et! al.,! 2011;! Zhang! et! al.,! 2013).! The!myocardium! is! known! to! be! a! major! source! of! TNFCα! release! following!reperfusion,! with! higher! levels! detected! in! human! samples! collected! from! the!coronary!sinus!compared!to!arterial!blood!(Wan!et!al.,!1996).!Models!using!small!animals! may! not! be! subjected! to! this! potential! site! sampling! bias! or,!alternatively,! preconditioning! may! operate! through! a! different! pathway! in!animals.!!!RIPC! appears! to! afford! two! windows! of! protection! that! may! involve! different!pathways.!The!first!occurs!immediately,!lasting!less!than!four!hours,!whereas!the!second! presents! 24! hours! after! the! initial! conditioning! (Loukogeorgakis! et! al.,!2005).! RIPC! is! most! feasibly! applied! in! surgery! patients! postCanaesthesia;!therefore!most!trials!to!date,!including!our!own,!have!investigated!the!efficacy!of!earlyCphase! RIPC.! Biomarkers! of! myocardial! damage! peak! six! to! eight! hours!postCbypass,! rendering! the! first! 12! hours! following! surgery! the!most! relevant!period! for! examining! factors! that! may! modify! or! mediate! myocardial! injury!(Holmvang! et! al.,! 2002;! Swaanenburg! et! al.,! 2001).! Our! time! points!were! thus!carefully! selected! to! allow! us! to! determine!whether! a! RIPCCinduced! change! in!cytokine! expression! could! contribute! to! the! protection! against! myocardial!damage! previously! described! in! the! literature.! We! were! able! to! capture! the!
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period! of! peak! periCoperative! cytokine! release! and! have! shown! no! change! in!systemic! cytokine! levels! or! clinical! outcome! measures! following! RIPC! in! the!pathophysiologically!relevant!period.!!!Related! studies! by! Karuppasamy! et# al.! (2011)! and! Saxena! et# al.# (2013)!determined! that! RIPC! does! not! alter! levels! of! ILC6,! ILC8! or! ILC10! at! 24! and! 48!hours! following!uncomplicated!CABG.!These! studies! and!our!own!demonstrate!that! ILC6! and! ILC10! levels! are! not! affected! during! early! or! lateCphase! RIPC! in!humans;! however,! there! is! a! large! body! of! evidence! forming! that! suggests!cytokines! are! essential! for! inducing! preconditioning! in! animal! models.! Using!knockout!mice,!studies!by!Dawn!et#al.#(2004),!Cai!et#al.#(2012),!and!Smith!et#al.#(2002)!have!established!that!ILC6,!ILC10,!and!TNFCα!production,!respectively,!are!obligatory!for!preconditioningCinduced!cardioprotection.!Further,!the!benefits!of!late! IPC! in! rats! can! be! abolished! by! the! simultaneous! administration! of!antibodies! to! TNFCα! and! ILC1β.! Intriguingly,! in! humans! there! is! also! evidence!that! upregulation! of! proinflammatory! cytokines! in! unstable! angina! patients! is!sufficient!to!induce!a!late!preconditioning!effect!(Wang!et!al.,!2007).!!Taken!together,!the!results!of!these!studies!have!two!key!implications.!First,!it!is!possible!that!the!mechanism!of!RIPC!may!differ!between!species,!and!to!that!of!classic!local!ischemic!preconditioning.!This!possibility!is!supported!by!the!recent!suggestion! that! the! cytokineCactivated! transcription! factors! associated! with!cardioprotection!may!differ!between!animals!and!humans!(Heusch!et!al.,!2011).!Second,!contrary!to!the!hypotheses!of!previous!research,!the!studies!by!Dawn!et#
al.#(2004)!and!Wang!et#al.!(2007)!suggest!preconditioning!would!be!expected!to!induce! protection! through! an! increase! in! ILC6! and! ILC8! levels,! rather! than! a!decrease.! Indeed,! while! RIPC! may! not! alter! systemic! ILC6! and! ILC8!concentrations,!it!is!well!established!that!the!reperfused!myocardium!is!a!major!source!of!inflammatory!cytokines!(Wan!et!al.,!1996).!The!possibility!that!the!local!inflammatory! milieu! in! the! myocardium! is! modulated! by! RIPC! cannot! be!excluded!and,!thus,!sampling!blood!from!the!coronary!sinus!may!be!of!interest!in!this!regard!for!future!studies.!!!
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Our!trial!adds!to!a!growing!number!that!have!not!shown!a!clinical!benefit!from!RIPC! in! adult! cardiac! surgery! patients! (Hong! et! al.,! 2010;! Karuppasamy! et! al.,!2011;!Li!et!al.,!2010;!Lomivorotov!et!al.,!2012;!Lucchinetti!et!al.,!2012;!Meybohm!et! al.,! 2013;! Rahman! et! al.,! 2010;! Saxena! et! al.,! 2013).! It! is! possible! that! the!absence! of! a! clinical! effect! in! our! trial! was! due! to! the! lack! of! change! in! the!cytokine!levels.!If!an!increase!in!cytokines!is!essential!to!induce!RIPC,!factors!that!alter! cytokine! production! such! as! the! use! of! antiCinflammatory! or! statin!therapies,!the!latter!of!which!have!been!shown!to!reduce!cellular!ILC6!expression!both! at! rest! and! in! response! to! LPS! challenge,! may! influence! the! ability! to!precondition!patients!(Node!et!al.,!2003;!Rosenson!et!al.,!1999).!!!Alternatively,! a! preconditioning! effect! may! have! been! activated! in! all! patients!through! secondary! pathways.! Our! study! used! a! standardised! anaesthesia!protocol! that! included! the! use! of! volatile! anaesthetics,! which! have! attracted!attention! for! their! ability! to! induce! cardiac! preconditioning! and! decrease!inflammatory! cytokine! expression! (Belhomme! et! al.,! 1999;! HarounCBizri! et! al.,!2001;!Kawamura!et! al.,! 2006).!Thus,! our! control! group!may!also!have!been,! to!some! extent,! preconditioned.! This! interpretation! would! suggest! that! the!marginal!effect!of!RIPC! in!patients!already!treated!with!volatile!anaesthetics!as!per! our! study! protocol! is! negligible,! which! is! supported! by! a! recent! metaCanalysis! that! suggested! cardioprotection! with! RIPC! is! attenuated! in! patients!treated!with! these! agents! (Zhou! et! al.,! 2013).! Furthermore,! two! recent! animal!studies! have! suggested! the! anticoagulant,! heparin,! is! also! capable! of! limiting!ischaemiaCinduced!organ!damage;!however,!when!used!in!conjunction!with!IPC,!heparin!appears! to!abolish! the!protective!effects!of!preconditioning! (Saurim!et!al.,!2014;!Warzecha!et!al.,!2012).!The!authors!postulated!that!clot!formation!may!be! essential! for! inducing!preconditioning!or! that! heparin!may! compete! for! the!pathways! targeted! by! IPC.! Several! instrumental! proofCofCconcept!preconditioning!studies! in!animals!were!performed!without! the!administration!of!heparin,!highlighting!a!potential!key!difference!between!many!of! the!animal!and!human!studies!(Birnbaum!et!al.,!1997;!Gho!et!al.,!1996;!Murry!et!al.,!1986;!Przyklenk! et! al.,! 1993).! Given! the! widespread! adoption! of! these! anaesthetic!
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agents!and!use!of!heparin!in!cardiac!surgery,!future!research!will!be!essential!to!clarify!their!relationship!with!RIPC.!!!A!particular!strength!of!our!study!was!the!use!of!double!blinding!to!ensure!the!patient!and!all!staff!involved!in!their!care!were!not!privy!to!the!treatment!group!allocation.!At!the!time!it!was!designed!our!trial!was!the!first!application!of!RIPC!in!humans! to!use! such! a! protocol,!whereas! the!majority! of! early! positive!RIPC!clinical! trials! had! incomplete! or! no! blinding! procedures.! In! the! absence! of!complete!blinding,! surgical! randomised!controlled! trials!are!vulnerable! to!both!performance! and! ascertainment! bias,! which! can! significantly! alter! the! trial!results! (Karanicolas! et! al.,! 2010).! A! metaCanalysis! found! that! RIPC! studies!without!full!blinding!reported!a!larger!estimate!of!troponin!reduction!compared!to!those!with!complete!blinding,!suggesting!more!weight!should!be!given!to!the!results!of!trials!including!an!appropriate!blinding!design!(Pilcher!et!al.,!2012).!!!!!In! addition! to! the! challenges! experienced! by! all! trials! attempting! to! translate!RIPC!from!highly!controlled!animal!models!into!a!complex!clinical!setting,!there!were!a!number!of!limitations!to!our!study.!Our!definition!of!highCrisk!was!broad,!encompassing!patients!that!were!undergoing!complex!and! long!procedures,!reCdo! surgeries,! or! having! impaired! cardiac! function! prior! to! the! operation.! This!lead! to! recruitment! of! a! very! heterogeneous! patient! population! and,! in! turn,!resulted! in! a! high! level! of! variability! in! the! responses! and! a! reduction! in!statistical!power.!Despite!these!criteria,!the!average!EuroSCORE!of!our!patients!represented! a! predicted! operative! mortality! risk! of! 7%,! which! is! significantly!lower!than!the!20%!‘highCrisk’!cutCoff!used!by!other!studies!(Kalavrouziotis!et!al.,!2009;!Vahanian!et!al.,!2008).!The!actual!rate!of!mortality!in!the!present!trial!was!2%;! further! suggesting! our! participant! population! may! not! have! been!particularly!highCrisk.!!An!additional!consequence!of!our!‘highCrisk’!inclusion!criteria!was!the!extended!duration!of!the!surgeries!performed.!The!first!phase!of!RIPCCinduced!protection!is! reported! to! last! between! two! and! four! hours! (Loukogeorgakis! et! al.,! 2005;!Yang!et!al.,!2010).!Given!the!average!bypass!time!in!our!trial!was!143!minutes,!
!! ! 79!
and! the! RIPC! intervention! was! completed! anywhere! between! five! and! 80!minutes! prior! to! commencing! bypass,! it! is! possible! that!many! of! our! patients!underwent!reperfusion!outside!of!the!first!window!of!protection!afforded!by!the!preconditioning.! If! this! contributed! to! the! lack! of! clinical! effect! of! RIPC! in! our!study,!it!would!reinforce!the!outcome!that!preconditioning!does!not!benefit!highCrisk!cardiac!surgery!patients!due!to!the!prolonged!surgical!times!encountered!in!this!population.!!!The! cardioprotective! effects! of! RIPC! stem! from! the! ability! of! this! technique! to!protect! against! damage! resulting! from! ischaemia.! The!most! common! endpoint!used! in! these!trials,! troponin,! is!released!during!cardiac!surgery! in!response!to!all!forms!of!myocardial!damage,!including!mechanical!injury!(Barry!et!al.,!2008).!In! straightforward! CABG! procedures! the! majority! of! the! myocardial! injury! is!induced! by! ischaemic! episodes;! however,! valve! surgeries! require! dissection! of!the!heart!muscle! itself.!Valve! repair!and!replacement!procedures!are! therefore!associated!with!much! higher! levels! of! troponin! release,! although! only! a! small!portion!of!this!is!attributable!to!the!ischaemic!injury!that!RIPC!may!be!capable!of!blunting.!We! proposed! that! patients! undergoing! highCrisk! surgeries!may! have!more!to!gain!from!RIPC!and!while!this!may!be!the!case,!using!a!surrogate!marker!of!clinical!outcome!such!as!troponin!levels!likely!does!not!provide!the!sensitivity!required! to! detect! such! a! benefit! in! the! case! of! the!more! complex! procedures.!Larger! scale! future! studies! that!measure! the! impact! of! RIPC! on! direct! clinical!outcome!measures,! such! as!major! adverse! cardiovascular! and! cerebrovascular!events!or!mortality,!will!be!necessary!for!more!conclusive!results.!
 Despite! the! extensive! application! of! RIPC! in! clinical! trials,! the! optimal!preconditioning! stimulus! has! not! yet! been!defined.! The!majority! of! trials! have!used!three!fiveCminute!cycles!of!upper!limb!ischaemia,!but!increasing!the!length!of!the!ischaemic!episodes,!the!number!of!cycles,!or!the!size!of!the!preconditioned!tissue! by! using! the! lower! limb! could! potentially! improve! the! RIPC! stimulus.!Indeed,!Wu!et#al.#(2011)!found!that!although!standard!RIPC!did!not!significantly!reduce!troponin!release! in!adult!MVR!surgery!patients,!combining!the!stimulus!with!two!tenCminute!cycles!of!upper!leg!ischaemia!was!protective,!suggesting!the!
!! !80!
preconditioning! stimulus! may! need! to! meet! a! certain! threshold.! Prior! to!completing!our!highCrisk!cardiac!surgery!trial,!we!designed!a!second!study!in!96!straightforward! CABG! patients! to! compare! the! efficacy! of! two,! three,! or! four!cycles! of! upper! limb! ischaemia! as! part! of! the! RIPC! regimen.! Regrettably,! on!completion!of!the!analysis!of!the!present!study!we!determined!that!we!would!not!have!the!statistical!power!required!to!draw!any!conclusive!results!from!the!doseCresponse!study!and!therefore!did!not!proceed!with!our!plans.!This!does!leave!a!notable!gap! in! the! literature!and,!again,! larger!scale!studies!will!be!required! to!investigate!and!define!the!optimal!RIPC!stimulus!in!humans.!!!

















3.1 Introduction-Following!on!from!the!results!of!the!study!in!highCrisk!cardiac!surgery!patients,!it!was! clear! that! a! greater! basic! understanding! of! the! mechanistic! processes!involved!in!RIPC!would!be!necessary!to!advance!the!clinical!side!of!the!research.!Further,!a!number!of! limitations!with!the!previous!trial,! including!the!choice!of!endpoints! and! the! complex! characteristics! of! the! highCrisk! cardiac! surgery!patient!population,!made!it!challenging!to!interpret!the!trial!results.!Our!primary!goal! for! the! next! study! was! therefore! to! construct! a! rigorous! and! focused!investigation!that!would!provide!clear!and!interpretable!answers!to!our!research!questions.!!!A! common! theme! in! the!RIPC! literature! concerns! the! heterogeneous!nature! of!the! patient! populations! studied! to! date,! which! creates! challenges! in! the! data!analysis!and!negatively!impacts!the!statistical!power.!For!this!reason,!we!decided!to!investigate!the!effect!of!RIPC!in!healthy!human!volunteers!using!a!strict!set!of!inclusion!and!exclusion!criteria,!which!would!eliminate!many!of!the!confounding!factors!seen!in!surgical!patients.!In!addition,!the!study!was!set!up!in!a!pairCwise!fashion!to!allow!participants!to!act!as!their!own!control,!thereby!increasing!the!statistical!power!in!the!face!of!a!highly!variable!interCindividual!dataset.!!!The! primary! focus! of! the! study! was! to! determine! how! RIPC! influences! the!immune!response;!therefore,!we!elected!to!look!at!systemic!cytokine!levels!and!changes! in! the! peripheral! blood! leukocytes.! The! latter! involved! measuring!changes!in!the!size,!phenotype,!and!intracellular!cytokine!production!within!the!different! cell! subsets! as! well! as! examining! the! proliferative! and! functional!changes!in!cultured!TCcells.!!In! the!absence!of!an! ischaemic! injury! it!was!anticipated! that! the!RIPC!stimulus!might!induce!only!minor,!although!potentially!significant,!changes!to!the!immune!response.! Beyond! the! usual! study! design! considerations! it! was! therefore! of!particular! importance!for!this!trial!that!the!laboratory!procedures!were!robust,!consistent,! and! reproducible! to! ensure! that! subtle! changes! in! the! endpoints!could! be! accurately! detected! and! that! the! data!was! comparable! between! both!
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treatments! and! participants.! Further,! it! was! necessary! that! the! endpoints! and!laboratory!techniques!were!carefully!selected!to!make!the!trial! feasible! for!one!individual!to!carry!out.!!!Although! there! are! existing! protocols! available! in! the! literature! describing!intracellular! cytokine! staining! (ICS),! these! tend! to! focus! on! the! analysis! of!specific! cell! populations.! In! addition,! it! is! well! established! that! even! slight!variations! in! reagents! and! equipment! between! laboratories! can! significantly!influence! assay! performance! (Nomura! et! al.,! 2008;! Welters! et! al.,! 2012).! To!examine!cytokine!production!in!T!cells,!NK!cells,!monocytes,!and!neutrophils,!the!latter! of! which! are! poorly! accounted! for! in! currently! available! protocols,! we!therefore! needed! to! test! a! system! that! catered! to! the! requirements! of! each! of!these! populations! in! a! mixed! whole! blood! sample.! Likewise,! while! broad!descriptions!of! the!conditions! for!culturing!peripheral!blood!mononuclear!cells!(PBMC)! with! polyclonal! stimulants! have! been! published! previously,! these!procedures!required!further!testing!to!ensure!they!were!suitable!for!the!purpose!of!our!study.!!!In! contrast! to! intracellular! cytokine! staining,!methods! for! stimulating! antigenCspecific!T!cell!responses!in!PBMC!from!healthy!volunteers!are!less!well!described!and! standardised.! Previous! studies! have! utilised! the! tetanus! toxin! or! tetanus!toxoid!to!stimulate!cells#in#vitro;!however,!the!former!presents!safety!challenges!and! the! latter! is! not! only!difficult! to! source,! but! the!protocols! in! the! literature!differ!enormously,!even!down!to!the!units!of!measure!(Gabrilovich!et!al.,!1997;!Landay!et!al.,!1983;!Rimaniol!et!al.,!2004).!Part!of!our!setCup!therefore!required!developing! a! novel! method! for! stimulating! isolated! PBMC! using! the! safe! and!readily!available!tetanus!booster!vaccine.!!!In!summary,!a!considerable!period!of!the!study!timeline!was!devoted!to!testing!each! aspect! of! the! laboratory! techniques! required! for! the! study! endpoints! in!order!to!collect!the!highest!quality!data!possible.!The!following!chapter!presents!an! overview! of! the! work! undertaken! and! establishes! the! foundation! for! our!confidence!in!the!data!collected!and!presented!in!Chapters!4!and!5.!
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3.2 Aims-
• To! test! the! conditions! for! immunophenotyping! human! peripheral! blood!leukocytes.!
• To!develop!a!protocol!for!detecting!intracellular!ILC6,!ILC8,!and!ILC10!levels!in!a!range!of!different!leukocytes!from!a!whole!blood!sample.!
• To! test! the! conditions! for! stimulating! and! measuring! the! proliferative!response!of!T!cells!to!polyclonal!and!antigenCspecific!agents.!


























3.3.1 Participants-Healthy!male! volunteers!were! invited! to! give! blood! samples! for! testing! of! the!laboratory! techniques! if! they! were! 18! years! or! older,! nonCsmokers,! and! not!taking! any! regular!medications! or! experiencing! any! acute! illness! for! one!week!prior! to! blood! collection.! This!work! received! ethics! approval! from! the! Central!Regional! Ethics! Committee! (CEN/11/06/034),! and! written! informed! consent!was! obtained! from! all! volunteers! by! the! principal! investigator.! PhD! students!trained!in!phlebotomy!collected!the!blood!samples.!!!
3.3.2 Flow-cytometry-Blood!samples!for!flow!cytometry!were!collected!in!heparinised!vacutainers.!All!antibodies! were! purchased! from! BD! Bioscience! or! Biolegend! (San! Diego,! CA,!USA)! and!were! first! titrated! in! order! to!maximise! the! resolution! between! cell!populations! and! minimise! the! background! level! of! fluorescence.! Refer! to!appendix!C!for!the!composition!of!buffers,!and!appendix!E!for!a!complete!list!of!antibodies!and!dilutions!used.!!
3.3.2.1 Immunophenotyping,Where! a! stimulated! sample! was! indicated,! an! aliquot! of! blood! was! either!incubated!with!fMLP!(0.001!–!10!μM;!Sigma!Aldrich)!for!10!minutes!at!37!°C!or!PMA! (50! or! 100! ng/mL;! Sigma! Aldrich)! and! ionomycin! (500! ng/mL;! Sigma!Aldrich)! for! up! to! 60!minutes! at! either! RT! or! 37! °C.! Stimulated! samples!were!cooled!on!ice!for!3!minutes!prior!to!staining,!and!unstimulated!blood!was!kept!at!RT.!Primary!antibody!mixes!were!diluted!in!FACS!buffer!to!a!total!volume!of!25!μL,!and!were!then!mixed!with!an!equal!volume!of!whole!blood.!Following!a!20!minute! incubation! at! RT,! the! samples! were! mixed! with! 1X! FACS! lyse! (BD!Biosciences)!to!eliminate!the!red!blood!cells!(RBC),!and!incubated!for!a! further!10!minutes!at!RT.!The!samples!were!then!centrifuged!at!300!x!g!for!5!minutes,!the!supernatant!aspirated,!and!either!a!second!wash!was!performed!or!the!cells!were!resuspended!in!FACS!buffer.!Samples!were!collected!on!a!Guava!easyCyte!
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8HT!using!InCyte!software!(Merck!Millipore,!Darmstadt,!Germany),!and!the!data!analysed!using!FlowJo!7.6.1!software!(Tree!Star,!Ashland,!OR,!USA).!!!
3.3.2.2 Intracellular,cytokine,staining,The! various! steps! involved! in! the! ICS! procedure! were! tested! individually,! in!accordance!with! the! following! general! protocol.! Heparinised!whole! blood!was!diluted! 5:1! with! complete! T! cell! media! (CTCM)! with! or! without! PMA! and!ionomycin! (PMA/I)! ranging! from! 10! –! 50! ng/mL! or! 500! –! 1000! ng/mL,!respectively,!and!incubated!for!4!or!27!hours!at!37!°C!with!5%!CO2.!One!of!two!different! protein! transport! inhibitors,! brefeldin!A! (5! ug/mL;! Biolegend)! or! the!monensinCbased! GolgiStop! (in! dilutions! ranging! from! 1:266! to! 1:1333;! BD!Biosciences)!was!added!for!the!final!4!hours!of!culture.!RBC!were!lysed!using!a!15! minute! incubation! with! Pharm! Lyse! (BD! Biosciences)! at! RT! followed! by!centrifugation!at!400!x!g!for!5!minutes,!and!the!samples!washed!twice!in!PBS.!A!viability!dye,!eFluor!780!(eBioscience,!San!Diego,!CA,!USA)!was!titrated!using!a!serial!2Cfold!dilution!ranging!from!1:1000!–!1:32000,!staining!for!30!minutes!on!ice! in!a!96Cwell! roundCbottom!plate!and! then!washing!once!with!PBS.! Samples!were!then!incubated!with!antiCCD16!antibody!or!FACS!buffer!for!20!minutes,!Fc!receptor! blocked! with! 2! mg/mL! intragam! P! (CSL,! Victoria,! Australia)! for! 10!minutes,!then!stained!with!the!remaining!extracellular!marker!antibodies!for!20!minutes,!all!at!RT,!protected!from!light.!Cells!were!washed!once!in!FACS!buffer,!and! fixed! in!4%!paraformaldehyde! for!15!minutes.!Samples!were! then!washed!twice! with! FACS! buffer,! resuspended! in! 0.1! or! 0.2%! saponin! buffer! for! 10!minutes,!then!centrifuged!at!400!x!g!for!5!minutes!and!the!supernatant!aspirated.!The!samples!were!incubated!with!intracellular!staining!mixes!in!a!total!volume!of!50!μL!for!20!minutes!at!RT,!washed!once!with!saponin!buffer!and!once!with!FACS! buffer.! Samples! were! resuspended! in! FACS! buffer! and! filtered! through!nylon! mesh! before! acquisition! on! a! FACSCanto™! II! with! Diva! software! (BD!Biosciences).!The!data!was!analysed!with!FlowJo!7.6.1!software!(Tree!Star).!!
3.3.3 Peripheral-blood-mononuclear-cell-cultures-PBMC! were! isolated! from! heparinised! blood! samples! following! the!manufacturer’s!instructions!for!HistopaqueC1077!(Sigma!Aldrich).!The!viable!cell!
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concentration!was!determined!by!mixing!a!sample!of!cells!1:1!with!0.4%!Trypan!blue! (Sigma!Aldrich)! and! counting!on!an! improved!Neubauer!haemocytometer!with! a! compound!microscope! (CX41;! Olympus,! PA,! USA).! Isolated! PBMC!were!cultured! in!duplicate! in! a! final! volume!of!200!μL! in!96Cwell! flatCbottom!plates,!with! or! without! stimulants.! A! range! of! concentrations! of! cells! (0.8! –! 2! x! 106!cells/mL),!PMA!(5!and!10!ng/mL),!and! ionomycin! (200!and!500!ng/mL),!were!compared! to! find! the! optimal! stimulation! conditions.! Dilutions! of! the! ADT!Booster!vaccine! (containing! the! tetanus! toxoid,! ranging! from!1:5!–!1:160;!CSL)!and!antiCCD3/CD28!Expander!Beads!(Life!Technologies,!Grand!Island,!NY,!USA)!to! cell! ratios! (1:1,! 0.5:1,! or! 0.2:1)!were! also! tested.! The! antiCCD3/CD28! beads!were! prepared! by! washing! in! Dulbecco’s! phosphate! buffered! saline! (dPBS),!pelleting!for!1!minute!on!a!magnet,!aspirating!the!supernatant,!and!resuspending!in!CTCM.!The!PMA/I,!and!antiCCD3/CD28Cstimulated!samples!were!incubated!for!24! hours! at! 37! °C,! 5%! CO2,! then! centrifuged! at! 400! x! g! for! 5! minutes.! The!supernatant!was!harvested!and!stored!at!C20!°C,!and!the!pelleted!cells!at!C80!°C,!for! further! analyses.! The! tetanusCstimulated! samples!were! cultured! for! 6! days!and! in! some! experiments! (as! specified! in! the! results)! the! tetanus! vaccine!was!added!to!the!unstimulated!samples!immediately!prior!to!the!centrifugation!at!the!end!of!the!incubation!period.!The!supernatant!and!cells!were!stored!as!described!above.!!!
3.3.4 CyQuant-proliferation-assay-The! CyQuant! reagent! (Life! Technologies)! was! prepared! at! 1X! and! 2X!concentration! in! cell! lysis! buffer! and! nuclease! free! distilled! water,! as! per! the!manufacturer’s! instructions.! The! cell! samples! were! thawed! and! 200! μL! of!reagent!was!added!per!well,!and!left!to!equilibrate!in!the!dark!for!3!minutes.!A!control! sample! was! used! to! run! an! optimisation! assay! on! an! EnSpire! 2300!multilabel! plate! reader! (PerkinElmer)! and,! based! on! these! results,! the!fluorescence!was!measured!at!excitation!of!480!nm!and!emission!of!520!nm.!The!background! absorbance! level! (taken! from! the! control!wells!without! cells)!was!subtracted!from!the!samples!and!the!stimulation!index!calculated!by!expressing!the!mean!fluorescence! intensity!(MFI)!of!each!replicate!as!a!ratio!to!that!of! the!corresponding!control.!!!
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3.3.5 ILL6-ELISA-ILC6! levels!were!measured!using! a! sandwich!ELISA,! as! described!previously! in!section!2.3.7.2.!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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3.4 Results-The! work! presented! in! this! chapter! was! largely! designed! to! test! the! effect! of!minor!alterations!to!existing!protocols!available!in!the!literature.!For!this!reason,!the!results!were!obtained!from!individual!experiments!that!were!not!repeated!or!subjected!to!statistical!analyses;!therefore!the!conclusions!drawn!from!this!work!should!be!interpreted!with!caution.!Further!repeats!of!the!experiments!would!be!necessary!in!order!to!use!these!results!to!generate!fully!optimised!protocols.!!
-
3.4.1 Flow-cytometry-of-whole-blood-samples-Two! flow! cytometry! protocols! were! examined! in! parallel;! an!immunophenotyping! procedure! for! determining! changes! in! the! size! and!activation! of! the! peripheral! leukocyte! subsets,! and! an! ICS! protocol! for!investigating!ILC6,!ILC8,!and!ILC10!production!in!whole!blood!samples.!Overviews!of!the!steps!undertaken!for!each!of!these!methods!are!presented!in!Figures!3.1!and! 3.2.! The! procedures! that! overlapped! between! the! two! protocols! are!presented!first,!followed!by!the!specific!experiments!performed!for!the!testing!of!the!protocols!for!immunophenotyping!and,!lastly,!ICS.!!!!
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Figure- 3.1- Summary- of- the- steps- undertaken- to- test- the-









































3.4.1.1.1# Assessing#viability#NonCspecific!binding!of!antibodies! to!apoptotic!and!dead!cells! can!create! falseCpositive! data,! therefore! it! was! critical! to! develop! protocols! that! allowed! nonCviable!cells!to!be!excluded!from!the!final!flow!cytometry!analyses!(Givan,!2000;!O’Brien!and!Bolton,!1995).!We!addressed!this! issue!by!incorporating!a!viability!marker,!eFluor!780,!into!our!staining!panels.!The!eFluor!780!dye!was!titrated!by!combining! fresh!blood!with!an!equal!volume!that!had!undergone! two!cycles!of!freezing!at!C80!°C!for!15!minutes,!in!order!to!create!a!sample!with!clear!live!and!dead! cell! populations.! At! the! lowest! dilution,! corresponding! to! the!manufacturer’s! recommended! concentration! for! use,! the! background!fluorescence!was!considerably! increased! in!all!cell!populations,!and!a!subset!of!dead!cells!was!only!visible!as!a!tail!of!fluorescence!on!the!major!peak!(Fig!3.3A).!At!the!higher!dilutions,!a!second!peak!of!dead!cells!became!visible!at!the!end!of!the!axis!(Fig!3.3B!C!F).!When!gated!and!viewed!on!a!SSC!vs.!FSC!dot!plot,!it!was!clear! that! these! cells! were! highly! fluorescent! neutrophils,! and! the! lower! peak!were! lymphocytes! (data! not! shown).! The! best! resolution! for! detecting! both!populations! of! nonCviable! cells! was! seen! between! the! 1:8000! and! 1:16000!dilutions!(Fig!3.3D!and!E),!therefore!a!dilution!of!1:10000!was!selected!for!use!in!the!final!ICS!protocol.!!!Given! the!23!hour!difference!between! the! two! time!points! selected! for! the! ICS!protocol,! the! viability! and! surface! staining! had! to! be! performed! separately! for!the!two!sets!of!cultures.!The!viability!dye!was!prepared!for!the!first!time!point,!then!stored!at!4!°C!overnight!and!used!again!for!the!second!time!point.!To!check!that!this!overnight!storage!did!not!affect!the!ability!to!detect!and!gate!out!nonCviable!cells,!a!sample!of!dye!prepared!one!day!earlier!was!compared!to! freshly!made! stock.! The! difference! between! the! two! dye! stocks! was! found! to! be!negligible!(data!not!shown).!!!For! the! immunophenotyping! procedure,! whole! blood! samples! were! used!immediately! after! collection.! Not! surprisingly,! the! viability! dye! stained! only! a!
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very! small! population! of! nonCviable! cells! (less! than! 0.5%)! in! fresh! blood;!therefore! it! was! not! included! in! the! final! immunophenotyping! protocol! (Fig!3.3G).!!!
!
!
Figure-3.3-Assessment-of-cell-viability-in-whole-blood-samples-FreezeCkilled!and/or!fresh!blood!were!combined!in!equal!volumes!and!the!RBC!lysed!with! Pharm! Lyse! solution.! Samples!were! incubated!with! the! eFluor! 780!viability!dye!at!various!concentrations!for!30!minutes!on!ice!and!then!acquired!on! a! flow! cytometer.! (A! C! F)! Titration! of! the! viability! dye! (red)! compared! to!unstained!samples!(blue);!(G)!fresh!whole!blood!stained!with!viability!dye!at!the!concentration!deemed!optimal!from!the!titration!(1:10000).!Shown!are!the!data!from!an!individual!experiment.!!
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3.4.1.1.2# Fc#receptor#blocking#NonCspecific!binding!of!monoclonal!antibodies!to!cells!that!express!a!high!level!of!fragment! crystallisable! (Fc)! receptors! on! their! surface! can! be! mitigated! by!incubating!the!cells!with!serum!or!an!alternative!blocking!agent!prior!to!staining!for!flow!cytometry;!however,!care!must!be!taken!when!CD16!(a!low!affinity!IgG!receptor!III)!is!a!parameter!of!interest,!as!blocking!will!also!prevent!the!binding!of! the!CD16Cspecific!antibody.!To!determine!whether!a!blocking!step!would!be!necessary! while! performing! our! immunophenotyping! procedure! using! fresh!whole! blood,! we! tested! and! compared! three! common! methods;! washing! the!sample! with! a! 0.5%! bovine! serum! albumin! (BSA)! buffer! prior! to! staining,!incubating!the!sample!with!intragam!P!(human!IgG),!or!no!blocking.!!!In!the!lymphocyte!population,!where!Fc!receptor!expression!is!low,!no!difference!in! staining! and! background! fluorescence! was! detected! between! the! three!methods! (Figure! 3.4A).! Monocytes! have! a! much! higher! level! of! Fc! receptor!expression! and! in! our! neutrophil! and! monocyte! populations! it! appeared! the!background!fluorescence!was!slightly!lower!in!the!sample!treated!with!intragam!P! (Figure! 3.4B).! This! subtle! difference! did! not! have! any! impact! on! the! data!analysis!and!results!(data!not!shown).!!!Including!intragam!P!in!our!immunophenotyping!protocol!would!have!required!preCstaining!with!CD16,!blocking,!and!then!completing!the!extracellular!staining,!as!three!separate!steps.!A!key!focus!of!our!laboratory!work!was!to!mimic!the!in#
vivo! environment! as! best! we! could,! and! keep! the! artificial! conditions! and!stimulations!to!a!minimum.!It!was!felt!that!this!extended!method!could!introduce!more! neutrophil! activation! and! variability! then! the! act! of! blocking! would!prevent,! therefore! it! was! decided! not! to! use! a! blocking! agent! in! the!immunophenotyping!protocol!for!the!purposes!of!our!study.!!For! the! ICS! protocol! involving! isolated,! cultured! cells! and! a! larger! number! of!antibodies,! it!was!felt! that!blocking!was!necessary!to!obtain!the!highest!quality!data.!For! these!samples,!we!did!preCstain!with!CD16!before!adding! intragam!P,!and!then!the!remaining!surface!staining!antibodies.!!
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Figure- 3.4- Comparison- of- Fc- receptorLblocking- strategies- for- flow-
cytometry-Whole!blood!samples!were!washed!with!0.5%!BSA!buffer!(green),!preCincubated!with!2!mg/mL!intragam!P!for!10!minutes!(blue),!or!left!unblocked!(red)!prior!to!staining!with!a!PerCP/Cy5.5!conjugated!isotype!control!antibody!and!acquisition!on!a!flow!cytometer.!The!resulting!fluorescence!in!the!red!channel!is!shown!for!(A)! lymphocytes! and! (B)! monocytes! and! neutrophils.! Data! shown! are! from! a!single!experiment.!!!!!!!!!!!!!!!!!!!!
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3.4.1.2 Testing,the,immunophenotyping,protocol,!




Figure- 3.5- fMLP- stimulation- of- neutrophils- for- activation- marker-
measurement-Whole!blood!was!stimulated!with!0.001!–!10!µM!fMLP!at!37!°C! for!10!minutes!before! staining! for! activation! markers,! RBC! lysis,! and! acquisition! on! a! flow!cytometer.! (A)! Stimulated! granulocytes!were! gated! using! SSC! vs.! FSC;! (B)!MFI!was! calculated! for! the! PE! (CD63)! and! AF488! (CD11b)! channels! in! the!granulocyte!population,!including!a!small!population!of!autofluorescent!cells!that!were!detected!in!all!samples;!(C)!SSC!vs.!FSC!of!autofluorescent!cells;!(D)!CD11b!and!(E)!CD63!staining!in!unstimulated!(blue)!and!0.1!μM!fMLPCstimulated!nonCautofluorescent! granulocytes! (red);! (F)!MFI! of! CD63! and! CD11b! expression! in!the! granulocytes! from! the! whole! blood! samples.! Shown! is! data! from! an!individual!experiment.!!
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Figure-3.6-PMA/I-stimulation-of-neutrophils-activation-marker-expression--Whole!blood!was!stimulated!with!100!ng/mL!PMA!and!500!ng/mL!ionomycin!at!RT!or!37!°C!before!staining!for!activation!markers,!RBC!lysis,!and!flow!cytometry.!(A)! Stimulated! cells! gated! using! FSC! vs.! SSC;! (B)! gating! of! CD14+CD16C/low!monocytes! and!CD14CCD16high! neutrophils;! unstimulated! (blue)! and! stimulated!(15!mins;!red)!staining!for!CD63!(C,!E,!G,!and!I)!and!CD11b!(D,!F,!H,!and!J)!at!RT!(C!–!F)!and!37!°C!(G!–!J)!in!monocytes!(C,!D,!G,!and!H)!and!neutrophils!(E,!F,!I!and!J).!MFIs!of!CD63!(K!and!L)!and!CD11b!(M!and!N)!in!PMA/I!stimulated!neutrophils!(K!and!M)!and!monocytes!(L!and!N).!Data!is!from!an!individual!experiment.!
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3.4.1.3 Development,of,ICS,protocol,!
3.4.1.3.1# Stimulation# of# cytokine# production# and# improvements# in# antibody#
# resolution#for#intracellular#staining#Two!culture!durations!were!selected!for!investigating!the!intracellular!cytokine!production! in! peripheral! leukocyte! populations! following! RIPC.! The! first,! 4!hours,! was! designed! to! provide! insight! as! to! how! RIPC! immediately! affects!cytokine!production!during!the!first!window!of!protection,!whereas!the!second,!27!hours,!allowed! for!any!effect!of!RIPC!on!gene!expression! to! take!effect.!The!earlier!time!point!was!better!suited!to!measuring!production!of!ILC6!and!ILC8!in!the!innate!cells!and!the!later!time!point!was!targeted!towards!the!monocytes!and!lymphocytes,! and! the! measurement! of! ILC10.! The! culture! conditions! for! these!two!time!points!were!separately!tested!to!best!address!the!different!cell!subsets!and!cytokines!relevant!to!each.!!!The! intracellular! antibodies! were! initially! titrated! using! a! general! staining!protocol!based!on!the!existing! literature.!The!relative!staining! intensities!could!be! distinguished! between! the! monocyte! and! neutrophil! populations! by! the!marker! CD45,! which! is! present! at! a! higher! density! on! monocytes! than!neutrophils! (Figure!3.7D!and!E;!Loken!et!al.,!1990).!Using! the!concentration!of!ILC8! antibody! that! performed! best! in! our! titration! experiment,! we! found! a!marked!increase!in!ILC8!production!in!the!neutrophils!and!monocytes!stimulated!with!PMA/I!for!4!hours,!relative!to!the!unstimulated!control!(Figure!3.7G).!The!highest! levels! of! production!were! detected! in! the! cells! treated!with! 20! ng/mL!PMA!and!1!µg/mL! ionomycin,! but! all! three! conditions! similarly! increased! ILC8!staining!beyond!the!levels!detected!in!the!isotype!control!samples!(Figure!3.7G).!In! contrast,! the! MFI! of! ILC8! was! significantly! below! the! level! of! the! isotype!control! antibody! in! the! cells! cultured!with!media! alone.!Cell! viability! exceeded!94%! in! all! of! the! 4Chour! cultures! and! did! not! substantially! differ! between! the!different!concentrations!of!PMA/I!tested!(Figure!3.7I).!!!Over! the! course! of! adjusting! our! ICS! protocol,! changes! to! the! flow! cytometer!settings!and!buffers! resulted! in!a! substantial! improvement! in! the! resolution!of!
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intracellular! ILC8! staining.! Doubling! the! concentration! of! saponin! used! in! the!permeability! buffer! from!0.1%! to! 0.2%! to! facilitate! entry! of! the! comparatively!bulky!PE! fluorophore! through! the! cell!pores!was!particularly!beneficial.! Figure!3.8! shows!a! comparison!of! ILC8! staining! in! samples! from! the!early! experiment!used!to!examine!stimulation!conditions,!and!our!last!experiment!to!test!our!final!ICS! protocol.! Both! samples! were! cultured! with! the! same! concentrations! of!stimulants!and!stained!with!the!same!antibody!dilution.!The!staining! improved!from! 105%! of! the! level! detected! in! the! isotype! control! to! 419%! following!adjustments!to!the!protocol!(Figure!3.8A!and!B).!!!When! we! used! the! ILC6! antibody! concentration! deemed! optimal! during! our!preliminary! titration! to! compare! the! efficacy! of! different! stimulant!concentrations!on! ILC6!production! in!neutrophils!and!monocytes,! there!was!no!clear!difference!between!the!conditions.!The!level!of!ILC6!staining!detected!in!the!unstimulated!sample!was!markedly!higher!than!the!isotype!control,!suggesting!a!level! of! constitutive! ILC6! production! in! neutrophils! and! monocytes,! which!appeared!not!to!be!augmented!by!PMA/I!treatment!(Figure!3.7H).!However,!the!ILC6!antibody!was!subsequently!reCtitrated!using!our!amended!ICS!protocol,!and!the!use!of!a!higher!concentration!of!antibody!was!found!to!detect!a!clear!increase!in!ILC6!levels!in!monocytes!and!neutrophils!stimulated!with!PMA/I,!compared!to!the! baseline! levels! seen! in! the! unstimulated! samples! (Figure! 3.9D).! The! ILC6!antibody!dilution!selected!for!use!in!the!study!was!1:25.!!!Given! the! minimal! difference! between! the! three! combinations! of! PMA/I!concentrations!that!we!tested!on!intracellular!ILC6!and!ILC8!production!and!cell!viability,!we!elected!to!stimulate!the!blood!with!50!ng/mL!PMA!and!500!ng/mL!ionomycin.!These!concentrations!are! the!most!commonly!used! in! the! literature!and! resulted! in! a! good! level! of! ILC8! production! and! cell! viability! in! our!experiment.!!!After! 26! hours! of! culture! ILC10! production! was! most! clearly! measured! in!leukocytes! that! were! stimulated! with! 20! or! 50! ng/mL! PMA! and! 500! ng/mL!ionomycin;!however,!these!conditions!resulted!in!a!marked!decrease!in!viability!
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of!the!CD45+!cells!(Figure!3.10G!and!H).!A!closer!look!at!the!leukocyte!population!using!FSC!vs.!SSC!revealed!a!notable!reduction!in!the!proportion!of!granulocytes!detected! in! the! samples! treated!with! the! lowest! dose! of! stimulants,! 10! ng/mL!PMA!and!500!ng/mL!ionomycin,!and!this!was! further!enhanced!when!the!PMA!concentration! was! increased! to! 50! ng/mL,! with! no! distinguishable! neutrophil!population!(Figure!3.10D!C!F).!!!Although! the! higher! concentrations! of! stimulants! increased! the! level! of! ILC10!staining,! relative! to! the! isotype! control,! the! associated! death! in! particular!leukocyte!subsets!was!not!acceptable!for!addressing!our!research!questions.!For!this! reason,!we!decided! to! stimulate! the!27Chour!cultures!with!10!ng/mL!PMA!and!500!ng/mL!ionomycin!during!the!study.!These!conditions!stimulated!ILC10!production! while! maintaining! an! overall! leukocyte! viability! of! approximately!92%.!!!!!!!!!!!!!!!!
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Figure- 3.7- Stimulation- of- intracellular- cytokine- production- in- 4Lhour-








Figure-3.9-Titration-of-the-ILL6-antibody-for-intracellular-use-Whole! blood! samples!were! cultured! for! 4! hours!with!50!ng/mL!PMA!and!500!ng/mL!ionomycin,!or!27!hours!with!10!ng/mL!PMA!and!500!ng/mL!ionomycin,!with!GolgiStop! (1:1000)! for! the! final! 4! hours.! Samples!were! then! stained!with!CD45! and! ILC6! according! to! our! partially! tested! ICS! protocol! and! assessed! by!flow!cytometry.!(A)!Viable!leukocytes!stimulated!for!4!hours!were!gated;!(B)!the!neutrophil!and!monocyte!populations!were!gated!using!SSC!vs.!FSC;!(C)!the!MFI!of!ILC6CAPC!(red)!was!compared!to!the!isotype!control!(blue)!in!the!neutrophils!and! monocytes;! (D)! titration! of! the! ILC6CAPC! antibody! in! neutrophils! and!monocytes! in! 4! and! 27! hour! cultures,! expressed! as! the! percentage! of! the!corresponding!isotype!control!sample.!Shown!are!the!data!from!one!experiment.!!!!!!
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Figure- 3.10- Stimulation- of- intracellular- cytokine- production- in- 27Lhour-
cultures-Whole!blood!was!incubated!with!various!concentrations!of!PMA/I!for!27!hours!in! the! presence! of! GolgiStop! (1:1000)! for! the! final! 4! hours! of! culture,! then!stained!for!viability!and!intracellular!cytokines!and!analysed!by!flow!cytometry.!(A)! CD45+! leukocytes! were! gated;! (B)! nonCviable! CD45+! leukocytes! were!excluded;!(C)!the!MFI!of!ILC10!BV421!(red)!was!compared!to!the!isotype!control!(blue)! in! the! live!CD45+! leukocytes.!Changes! in! the! leukocyte!populations!were!observed!on!SSC!vs.!FSC!in!samples!that!were!unstimulated!(D),!or!treated!with!10!ng/mL!PMA!and!500!ng/mL!ionomycin!(E)!or!!50!ng/mL!PMA!and!500!ng/mL!ionomycin! (F).! Production! of! ILC10! (G)! and! the! viability! (H)! in! cultured!leukocytes! were! expressed! as! the! percentage! of! the! corresponding! isotype!control!sample.!Shown!are!the!data!from!one!experiment.!
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Figure- 3.11- Comparison- of- protein- transport- inhibitors- for- intracellular-
measurement-of-ILL6,-ILL8,-and-ILL10-Whole!blood!was!stimulated!in!the!presence!of!either!brefeldin!A!(5!µg/mL)!or!GolgiStop! (1:1000)! for! the! final! 4! hours! of! culture.! Samples! were! stained! for!intracellular! cytokines! and! viability,! and! analysed! by! flow! cytometry.! (A)! ILC6!and! ILC8! production! in! 4Chour! cultures! stimulated! with! PMA! (50! ng/mL)! and!ionomycin!(500!ng/mL);!(B)!26Chour!cultures!stimulated!with!PMA!(20!ng/mL)!and!ionomycin!(1!µg/mL),!and!assessed!for!ILC10;!(C)!cell!viability!at!the!end!of!culture;! (D)! ILC6! levels! (red)! compared! to! isotype! control! (blue)! in! 4Chour!cultures! stimulated!with! PMA! (50! ng/mL)! and! ionomycin! (500! ng/mL)! in! the!presence!of!varied!dilutions!of!GolgiStop.!Cytokine!results!presented!as!MFI!are!expressed!as!a!percentage!of!the!corresponding!isotype!control!stained!sample,!and!viability!as!the!percentage!of!CD45+!cells.!Data!is!from!a!single!experiment.!
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3.4.1.3.3# Examining#neutrophil#activation#state#Neutrophils! are! highly! sensitive,! shortClived! cells! that! can! become! activated! in!response! to! a! multitude! of! stimuli,! including! temperature! fluctuations,!mechanical! disturbances,! and! contact! with! antiCcoagulants! (Repo! et! al.,! 1995;!van!Eeden!et! al.,! 1999).!Particular! care!was! taken! to!minimise! such! sources!of!activation! during! our! experimental! procedures;! however,! it! was! necessary! to!confirm!that!the!neutrophils!in!our!unstimulated!samples!were!both!expressing!the!resting!phenotype!that!we!expected!and!were!still!responsive!to!stimulation.!!!Whole! blood! samples!were! collected! and! processed! according! to! our! final! ICS!protocol.!The!samples!were!stained!for!CD11b!and!assessed!with!flow!cytometry.!As!expected,!after!4!hours!in!culture!our!unstimulated!samples!showed!only!low!CD11b!expression!in!neutrophils,!and!these!levels!were!clearly!upregulated!upon!stimulation! (MFI! 937! in! the! unstimulated! vs.! 1909! in! the! stimulated;! Figure!3.12A).!After!27!hours! in!culture! the!baseline! level!of!CD11b!expression! in! the!unstimulated! samples! increased,! relative! to! the! 4Chour! samples;! however,!stimulation!with!PMA/I!still!elicited!a!further,!small!increase!in!CD11b!(1338!vs.!1912;! Figure! 3.12B).! This! suggested! that! our! laboratory! procedures! alone! did!not!activate!or! inhibit!neutrophils! to! the!extent! that! they!could!not! respond!as!expected!to!subsequent!stimulation!in#vitro.#!!!!
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Figure-3.12-Activation-state-of-cultured-neutrophils-Whole! blood!was! cultured!with! or!without! stimulants! and!GolgiStop! (1:1000),!then! processed! according! to! our! ICS! protocol! in! duplicate! to! assess! CD11b!expression.! (A)! Neutrophils! from! 4Chour! cultures! were! either! unstimulated!(blue)!or!PMA/I!treated!(50!ng/mL!/!500!ng/mL;!red);!(B)!27Chour!cultures!of!unstimulated!neutrophils!(blue)!or!PMA/I!treated!neutrophils!(10!ng/mL!/!500!ng/mL;! red).! Data! is! shown! for! a! representative! replicate! from! a! single!experiment.!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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Figure-3.13-Optimisation-of-flow-cytometry-application-settings-Blood!was!cultured!for!4!hours!with!media!or!PMA/I!(50!ng/mL!/!500!ng/mL)!in!the!presence!of!GolgiStop!(1:1000),!then!stained!intracellularly!and!acquired!on!the! flow! cytometer.! (A)! Unstimulated! cells! gated! as! lymphocytes! (red),!neutrophils!(green),!and!monocytes!(blue);!(B)!unstimulated!cells!gated!using!a!total!leukocyte!gate!(purple);!(C)!rSDEN!in!the!unstimulated!and!stimulated!total!leukocytes,!compared!to!target!values;!(D!C!K)!histograms!showing!detection!of!brightest!antibodies!for!each!channel.!Data!is!from!a!single!experiment.!!
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3.4.2.1 Testing,the,Histopaque>1077,PBMC,isolation,method,PBMC! were! isolated! from! heparinised! whole! blood! using! HistopaqueC1077,!according!to!the!manufacturer’s! instructions.!Following! isolation!the!cells!were!stained!with!cell!surface!markers!and!analysed!with!flow!cytometry!to!validate!the!purity.!As!expected,!the!sample!was!predominantly!composed!of!CD3+!T!cells,!with! a! smaller! population! of! CD14+! monocytes! (Figure! 3.15B).! There! was! no!clear! neutrophil! population! visible! on! the! SSC! vs.! FSC! plot;! however,! a!proportion!of!the!CD14CCD3C!cells!did!stain!positively!for!CD16!(Figure!3.15A!and!B).! The! low! position! of! these! cells! on! the! SSC! axis! was! not! consistent! with!neutrophils,! and! these! cells! were! most! likely! CD16+! NK! cells,! and! a! small!population! of! CD14lowCD16+! monocytes! (Figure! 3.15C).! The! remaining! CD3CCD14C! events! were! consistent! with! the! characteristics! expected! of! B! cells! and!CD16CCD56++! NK! cells.! Overall,! the! HistopaqueC1077! method! of! isolation!provided!a!sufficiently!pure!PBMC!population,!with!little!evidence!of!neutrophil!contamination.!!!
!
Figure-3.15-PBMC-purity-after-HistopaqueL1077-isolation-PBMC!were! isolated! from!heparinised!whole!blood!using! the!HistopaqueC1077!density! gradient! centrifugation! method,! then! stained! in! duplicate! with! cell!surface! markers! and! analysed! by! flow! cytometry.! (A)! Total! isolated! cells;! (B)!CD14!vs.!CD3! in! total! isolated! cells;! (C)!CD16!expression! in! the!CD3CCD14C! cell!population.! Shown! are! data! from! a! representative! replicate! for! a! single!experiment.!!!!!!
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3.4.2.2 CyQuant,proliferation,assay,The! CyQuant! proliferation! assay! utilises! a! dye! that! exhibits! enhanced!fluorescence! when! bound! to! cellular! nucleic! acids! in! order! to! quantify! cell!numbers.!When!used!according!to!the!manufacturer’s!instructions,!the!assay!has!a! reported! linear! detection! range! from! 50! to! 5! x! 104! cells,! and! increasing! the!concentration!of!the!dye!can!extend!this!span.!To!determine!the!number!of!cells!that!could!be!accurately!quantified!in!our!PBMC!samples!we!tested!the!ability!of!the! CyQuant! assay! to! detect! up! to! 2! x! 105! cells!when! used!with! 1X! or! 2X! the!recommended! dye! concentration.! As! expected,! both! concentrations! of! dye!showed!a!linear!relationship!between!fluorescence!and!the!number!of!cells,!up!to!5! x! 104! cells! per! sample.! Beyond! 5! x! 104! cells,! the! fluorescence! in! the! 1X! dye!samples! began! to! plateau! and! was! best! modelled! by! nonClinear! regression!(goodness!of!fit!=!0.9727!vs.!0.9338!for!linear!regression),!whereas!the!samples!incubated!with!the!2X!dye!had!a!reasonably!linear!relationship!up!to!the!highest!number!of!cells!tested,!2!x!105,!with!a!linear!regression!goodness!of!fit!measure!of!0.9680!(vs.!0.9744!for!nonClinear!regression;!Figure!3.16).!For! the!study,!we!opted!to!use!the!dye!at!2X!concentration,!and!plate!the!cells!no!higher!than!1!x!105! cells/sample,! in! order! to! allow! the! final! cell! number! to! remain!within! the!linear!range!of!detection!following!stimulation!of!proliferation.!!
!




3.4.2.3.1# PMA#and#ionomycin#NonCspecific!cellular!activation!can!be!induced!using!the!pharmacological!agents,!PMA/I.! In! the! literature,! the!most! commonly!used!concentrations!of!PMA/I! for!stimulating! cells! in! culture! are! 5! or! 10! ng/mL,! and! 200! or! 500! ng/mL,!respectively! (Kruisbeek! et! al.,! 2004).! We! compared! all! four! combinations! of!these!concentrations!with!cells!plated!at!5!x!104!per!well!and!found!no!significant!proliferation!in!any!of!the!conditions!after!24!hours!of!culture.!In!fact,!all!of!the!stimulated! samples! had! lower! CyQuant! values! than! the! unstimulated! samples!(Figure! 3.17A).! This! was! not! unexpected,! as! the! recommended! incubation!duration!for!measuring!significant!levels!of!T!cell!proliferation!is!normally!in!the!range!of!3!to!6!days!(Kruisbeek!et!al.,!2004).!For!this!particular!study!we!were!focused! on! the! shortCterm! impact! on! T! cell! function,! particularly! cytokine!production,!therefore!elected!to!use!a!shorter!culture!period.!Indeed,!high!levels!of!ILC6!production!were!detected!in!the!supernatants!from!all!four!cultures!and!the!specific!concentration!of!stimulants!used!did!not!substantially! impact!these!levels!(Figure!3.17B).!Based!on!these!results,!the!concentrations!of!5!ng/mL!PMA!and!200!ng/mL!ionomycin!were!selected!for!use!in!the!cultures,!and!cells!were!plated!at!1!x!105/well!to!improve!the!accuracy!of!the!CyQuant!assay.!!!
3.4.2.3.2# Anti0CD3/28#beads#Polyclonal! yet! physiologically! relevant! T! cell! activation! can! be! achieved! using!beads!with!antibodies!specific!for!the!TCRCCD3!complex!and!the!coCstimulatory!molecule!CD28.!The!manufacturer’s!instructions!recommend!stimulating!T!cells!with! a! ratio! of! antiCCD3/28!dynabeads! to! cells! of! 1:1.! Given!we!were!working!with! a! mixed! population! of! PBMC! (comprised! of! approximately! 60%! T! cells)!rather! than! isolated! T! cells,! we! tested! three! ratios! of! beads! to! cells,! and! two!concentrations!of!cells,!to!determine!the!best!method!of!dynabead!stimulation.!!The!highest! proliferative! response!was!detected! in! the! sample!plated!with!8! x!104! cells,! and! there!was!negligible! difference!between! the!1:1,! 0.5:1,! and!0.2:1!bead!to!cell!ratios!in!the!samples!plated!at!1.33!x!105!cells/well!(Figure!3.17C).!
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As! expected,! there! were! higher! levels! of! ILC6! detected! in! the! samples! with!133,000! cells! per! well,! and! a! doseCresponse! relationship! was! seen! with! the!dilution! of! the! beads.! The! sample! with! fewer! cells! also! produced! significant!levels! of! ILC6! (Figure! 3.17D).! The! best! combination! of! proliferation! and! ILC6!production!was!seen!when!8!x!104!PBMC!were!plated!with!beads!at!a!1:1!bead!to!cell!ratio,!and!these!were!the!conditions!chosen!for!use!in!the!study.!!!!!!!!!!!!!
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Figure-3.17-Stimulation-of-PBMC-with-PMA/I-and-antiLCD3/28-beads-Isolated! PBMC! were! cultured! for! 24! hours! with! or! without! stimulants,! then!proliferation!was!measured!with!the!CyQuant!assay!and!culture!supernatant!ILC6!levels!quantified!by!ELISA.! (A)!Stimulation! index!and! (B)! ILC6! levels! in!5!x!104!cells/well! stimulated! with! various! concentrations! of! PMA/I.! (C)! Stimulation!index! and! (D)! ILC6! levels! for! cells! plated! at! differing! concentrations! and! antiCCD3/28! bead:cell! ratios.! Stimulation! indices! were! calculated! relative! to! the!unstimulated! controls.! Shown! are! the!means! and! SEM! for! duplicates! from!one!experiment.!!!!!!!!!!!!!!!!
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3.4.2.4 Stimulating,memory,T,cells,with,the,tetanus,antigen,In! order! to! determine! whether! RIPC! affected! the! memory! response,! we!developed!an!assay!to!assess!antigenCspecific!responses!to!tetanus!using!the!ADT!Booster! vaccine.! This! antigenic! target! was! selected! because! it! is! part! of! the!childhood! vaccination! schedule! in! New! Zealand! and! booster! vaccinations! are!recommended! at! 11! years! of! age,! resulting! in! a! high! proportion! of! individuals!with! the! ability! to! recognise! and! mount! an! immunological! response! to! the!tetanus!toxin.!We!chose!to!use!the!booster!vaccine!to!stimulate!our!cells,!as!this!was! readily! available,! safe,! and! provided! the! exact! antigen! recognised! by!immunised!individuals.!!!There!was!no!previously!described!protocol!for!using!the!ADT!booster!vaccine!to!stimulate!cells!available!in!the!literature.!Therefore,!the!vaccine!was!first!titrated!in!a!volunteer!who!had!recently!(in!the!last!10!years)!had!a!tetanus!booster!and!an! individual! who! had! not! received! a! recent! tetanus! booster.! A! consistent!proliferative!response!was!detected!in!both!individuals,!which!was!lost!once!the!vaccine!was!diluted!beyond!1:20!(Figure!3.18A).!It!was!possible!that!the!memory!response! was! still! significant! in! the! participant! that! had! not! recently! been!immunised;! however,! it! was! noted! that! the! vaccine! had! a! slightly! cloudy!appearance,!and!that!this!may!have!impacted!the!CyQuant!assay!readings.!!!To!determine!whether!the!vaccine!itself!may!be!influencing!the!CyQuant!assay,!a!comparison!was!made!between!using! the! full! vaccine,! or! a! ‘separated’! vaccine,!where! the! vaccine! was! left! for! 10! minutes! to! allow! the! particulate! matter! to!settle!and!the!remaining!clear!solution!was!aspirated!for!use.!With!the!samples!treated!with!the!full!vaccine,!the!vaccine!was!also!added!to!the!control!wells!at!the!end!of!the!culture!period,!immediately!prior!to!centrifugation!and!freezing!of!the!cells,!in!order!to!keep!the!opacity!of!the!samples!comparable.!!!There!was!no!proliferation!detected!in!the!samples!cultured!with!the!separated!vaccine,!and!addition!of!the!vaccine!to!the!control!wells!used!with!the!full!vaccine!samples!prior!to!running!the!proliferation!assay!altered!the!background!level!in!the! control! wells! but! did! not! affect! the! conclusions! drawn! from! the! CyQuant!
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results! (Figure! 3.18B).! Further,! microscopic! examination! of! the! cultured! cells!showed! clustering! only! in! the! samples! incubated! with! the! full! vaccine,! and!isolated!cells!in!the!samples!with!the!separated!vaccine!or!media!alone!(3.19!A!C!C).! Clustering! of! the! cells! is! consistent! with! a! recall! response,! suggesting! that!separating! the! vaccine! removed! the! tetanus! antigen! (Chtanova! et! al.,! 2009).!Taken! together,! these! results! indicated! that! the!CyQuant! levels!detected! in! the!samples! cultured! with! the! full! vaccine! were! the! result! of! a! legitimate!proliferative!response,!rather!than!simply!an!increase!in!background!due!to!the!vaccine!opacity.!!To! further! test! that! the! cells! cultured! with! the! tetanus! vaccine! were! being!stimulated! as! expected,! the! level! of! ILC6! in! the! culture! supernatants! was!measured!after!6!days!of!culture.!When!cells!were!plated!at!a!high!concentration!of!2!x!105!cells!per!well,! consistent! levels!of! ILC6!were!measured,!regardless!of!the! tetanus! vaccine! dilution! (Figure! 3.18C).! Notably! in! this! data,! there! was! a!pronounced! difference! in! the! response! between! the! individual! that! did! have! a!recent!tetanus!booster,!and!the!volunteer!who!did!not.!When!the!number!of!cells!was!reduced!to!1!x!105!per!well,!an!improved!resolution!of!ILC6!production!could!be! seen,! and! showed! a! doseCresponse! relationship! with! the! concentration! of!vaccine! (Figure! 3.18D).! This! concentration! of! cells! also! ensured! that! following!proliferation,! the!CyQuant!assay!would!still!be!operating!well!within! the! linear!range!previously!identified!(refer!to!section!3.4.2.2).!!!Based!on!these!results,!it!was!determined!that!the!best!conditions!for!stimulating!PBMC!with!the!tetanus!vaccine!were!at!a!final!dilution!of!1:5,!with!1!x!105!cells!per!well,!and!that!adding!the!vaccine!to!the!control!wells!prior!to!performing!the!CyQuant! assay! was! necessary! to! ensure! the! background! was! comparable!between!the!samples.!!!!
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Figure-3.18-Stimulation-of-PBMC-with-the-tetanus-vaccine-Isolated! PBMC! were! plated! with! various! dilutions! of! the! tetanus! vaccine! and!cultured! for! 6! days.! Cell! proliferation!was!measured! using! the! CyQuant! assay,!and!supernatant! ILC6! levels!quantified!by!ELISA.!Left:!comparison!and!titration!of! (A)! tetanusCinduced! proliferation! and! (C)! ILC6! production! between! ‘nonCtetanus! boosted’! and! ‘tetanus! boosted’! individuals! with! cells! plated! at! 2! x!105/well.! Right:! cells!were! plated! at! 1! x! 105! cells/well! and! shown! are! (B)! the!comparison!of!proliferative! responses! to! the!separated!and! full!versions!of! the!vaccine,! and! (D)! ILC6! production! in! the! full! vaccine! stimulated! PBMC! from! a!tetanusCboosted! individual.! Shown! are! the!means! and! SEM! of! duplicates! from!one!experiment.!!!
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Figure- 3.19- Comparison- of- PBMC- cultured- with- the- separated- or- full-















3.4.3.1 Laboratory,workflow,and,patient,management,A! critical! element! in! designing! the! study! in! healthy! volunteers!was! creating! a!laboratory!workflow! that! could! be! reasonably! and! repeatedly! performed! by! a!single! individual.! In! the! initial! phase! of! study! design,! the! endpoints! and! time!points!were!carefully!selected! for! this!purpose;!however,!after!we!performed!a!pilot!run!testing!the!finalised!laboratory!protocols,!problematic!aspects!of!timing!involved!with!the!workflows!were!further!amended,!as!necessary.!!!Initially,!we!proposed!to!examine!neutrophil!activation!by!stimulating!the!blood!samples! collected! at! baseline! and! 20! minutes! after! treatment,! prior! to! the!staining!for!immunophenotyping.!It!became!clear!that!performing!this!extra!step!with! the! 20Cminute! blood! samples! would! create! numerous! clashes! between!subsequent! laboratory! time!points.! Instead,! it!was!deemed!more! achievable! to!perform!the!postCtreatment!stimulation!using!the!1Chour!samples,!with! the!40Cminute!difference!between!these!two!time!points!unlikely!to!impact!the!ability!to!detect!any!clinically!significant!changes.!!!Likewise,!performing! two! final!wash! steps!on! the! flow!cytometry! samples!was!time!intensive!and!resulted!in!a!back!up!of!the!laboratory!work.!An!experiment!was! run! to! compare! samples! that! were! handled! according! to! our! standard!protocol,! involving! two! washes,! with! samples! that! were! washed! only! once.!Despite! a! slightly! higher! level! of! debris! being! present! in! the! latter! samples,!reducing! the! number! of! wash! steps! had! no! impact! on! the! final! data!measurements! (data! not! shown).! The! immunophenotyping! protocol! was!therefore! adjusted! to! include! only! one! wash! at! the! final! step,! keeping! the!laboratory!workflow!attainable.!!!!Performing!the!treatment!(control!or!RIPC)!immediately!after!the!baseline!blood!sample!collection!created!complications!with! the!sample!processing!due! to! the!short!gap!between!the!first!and!second!blood!samples.!This!issue!was!alleviated!by! inserting!a!10Cminute! ‘stand!down’!period!between!the!baseline!bloods!and!
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applying! the! treatment,! allowing! sufficient! time! to! process! the! bloods! to! a!consistent!standard.!!After! the! changes! to! the! laboratory! techniques! were! made,! a! final! laboratory!overview!was!produced!and!is!presented!in!Figure!3.20.!With!multiple!samples!being!handled!at!one!time,!and!the!strong!likelihood!that!any!differences!in!our!endpoints! following!RIPC!would! be! subtle,! it!was! essential! that! the! laboratory!procedures! were! as! consistent! as! practically! achievable,! between! both!participants!and!visits.!To!address! this,! a!detailed!ordered! laboratory! checklist!and!protocol!were!created!to!ensure!that!all!samples!were!handled!in!exactly!the!same!manner! during! each! study! visit.! In! addition! to! specifying!which! samples!should!be!prioritised!at!which!steps,! these!documents!ensured! that!equipment!and!buffers!were!calibrated!and!preCwarmed!at! the!correct! times,!and!were!an!essential!part!of!our!strategy!to!obtain!the!highest!quality!data.!Further,!all!study!sessions!were!scheduled! for! the!same!time!of!day!to!eliminate!any!variation! in!the!results!that!might!be!caused!by!circadian!rhythms.!!
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3.4.3.2 Flow,cytometry,data,analysis,A! substantial! volume! of! flow! cytometry! data! was! collected! during! the! study.!Intracellular!cytokine!staining!results!are!particularly!vulnerable!to!poor!gating!strategies!or!inconsistencies!during!data!analysis,!necessitating!the!development!of! standardised!protocols! (Nomura!et!al.,!2008;!Welters!et!al.,!2012).!This! task!was! tackled! by! generating! preCsaved! analysis! workspace! templates! for! the!software,! FlowJo,! and! creating! accompanying! stepCbyCstep! guides! used! to! gate!the!data! in! the!manner! shown! in! appendix! F.! These! guides!were!based!on! the!following!considerations.!!The! Guava! easyCyte! 8HT! is! a! unique! bench! top!microcapillary! flow! cytometry!system!that!works!with!fixed!voltages,!therefore!compensation!controls!are!not!technically! required! for! each! individual! experiment.! Given! the! particular!importance!of!accurate!compensation!when!working!with!autofluorescent!cells!such! as! neutrophils,! and! because! a! minor! amount! of! ‘drift’! may! occur! in! the!machine! settings! over! time,! we! elected! to! run! a! set! of! single! stained! samples!during!the!first!study!visit!for!each!participant.!These!samples!were!then!used!to!produce! compensation! matrices! that! were! used! for! the! immunophenotyping!flow!analysis!for!all!samples!from!each!participant.!When!the!FACSCanto™!II!was!used! to! acquire! the! intracellularly! stained! samples,! preCsaved! application!settings! were! applied! (as! described! in! section! 3.4.1.3.4)! and! compensation!controls!were!run!with!every!experiment.!!!For!all!analyses,!doublets!were!first!gated!out!using!a!plot!of!FSCCheight!(FSCCH)!vs.! FSCCarea! (FSCCA).! In! the! ICS! samples,! nonCviable! cells! were! also! excluded!prior!to!any!further!analysis!using!the!viability!dye!in!the!infrared!channel.!The!gating!hierarchy!was!optimised!for!each!panel!in!order!to!maximise!the!accuracy!and!resolution.!For!example,! in!panel!2,!which!focused!on!immunophenotyping!the!T!cell!subsets,!gating!on!the!CD3+!cells!first,!as!was!done!in!other!panels,!was!compromised! by! autofluorescence! from! the! neutrophils! in! the! nearCinfrared!(NIR)!channel.!Instead,!a!broad!FSC!vs.!SSC!lymphocyte!gate!was!applied!prior!to!using!a!histogram!gate!to!isolate!the!CD3+!events,!which!maintained!a!more!pure!population!(refer!to!appendix!F,!Figures!F.4!and!F.5).!!
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3.5 Discussion-The!work!conducted!in!this!chapter!was!focused!on!testing!a!series!of!laboratory!assays! and! designing! workflows! to! facilitate! sensitive! and! accurate!measurements! of! changes! to! the! immune! response.!We! found! PMA/I! induced!measurable! neutrophil! degranulation! where! the! traditionally! used! stimulant,!fMLP,! was! ineffective! in! our! laboratory.! We! tested! stimulation! protocols! and!protein!transport! inhibitors!to! finalise!a!protocol! for!the! intracellular!detection!of!ILC6!and!ILC8!in!cells!from!a!whole!blood!sample.!It!was!found!that!the!use!of!a!blocking!agent!and!viability!dye!in!immunophenotyping!flow!cytometry!samples!provided! no! additional! value! for! data! analysis;! however,! both! were! deemed!important! when! performing! intracellular! staining.! The! CyQuant! assay! was!adjusted! to! allow! for! the! detection! of! proliferation! in! more! concentrated! cell!samples,!and!was!used!to!test!culture!conditions!for!polyclonal!stimulation!of!T!cells,! and! a! novel! protocol! for! using! the! tetanus! vaccine! to! initiate! an! antigenCspecific! memory! T! cell! response.! Lastly,! we! developed! laboratory,! patientChandling,! and! data! analysis! workflows! to! minimise! the! effect! of! any! potential!experimental! variation.! One! important! limitation! of! this! work! was! that! the!experiments!were!not!repeated,!therefore!it!is!not!possible!to!conclusively!state!whether!the!parameters!selected!for!inclusion!in!the!final!assay!protocols!were!the!optimal!choice.!!!We! opted! to! perform! ICS! in! our! study! in! order! to! extend! our! investigation! of!RIPC! on! cytokine! production! beyond! looking! at! isolated! serum! levels.!Intracellular! staining! has! the! advantage! of! providing! the! means! not! only! to!detect! changes! in! the! amount! of! cytokines,! but! also!discern!which! cell! subsets!are! producing! them.! Neutrophils! are! a! major! source! of! tissue! damage! and!proinflammatory! mediators! following! cardiac! surgery,! therefore! adjusting! the!ICS!protocol!to!include!these!cells!was!a!priority!(Cassatella,!1995;!Warren!et!al.,!2009).!!There! is! limited! information! regarding! ICS! in! granulocytes! available! in! the!literature.! Neutrophils! are! highly! sensitive! and! capable! of! responding! to!numerous!types!of!stimuli,!making!them!vulnerable!to!activation!during!isolation!
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and! purification! procedures.! Previous! work! has! confirmed! that! isolation!protocols! lead! to! dramatic! increases! in! cell! surface! markers! indicative! of!activation,! including!C3b! receptors,!which! likely! alter! the! in# vitro! responses! of!these! cells! (Fearon! and!Collins,! 1983;! Freitas! et! al.,! 2008).! For! this! reason,!we!tested!an!ICS!protocol!that!bypassed!cell!purification!and!instead!utilised!whole!blood!samples.!!!At!the!other!end!of!the!spectrum,!the!common!antiCcoagulants,!EDTA!and!citrate,!appear! to! reduce! the! responsiveness! of! neutrophils! to! in# vitro# stimulation!(Engstad! et! al.,! 1997;! Freitas! et! al.,! 2008;! Repo! et! al.,! 1995).! Both! EDTA! and!citrate!are!calcium!chelators,!binding!free!calcium!ions!and!thus!removing!a!key!element!of!multiple!neutrophil!signalling!pathways!(Pfister!et!al.,!1984).!This!has!a! particularly! significant! impact! on! the! ability! of! the! cells! to! respond! to!stimulation! with! PMA.! Typically,! EDTA! is! the! antiCcoagulant! of! choice! for!neutrophil! studies! in!part!due! to! this! inhibitory!effect,!which!can!be!protective!during!purification!procedures;!however,! the! consequent!artificial! inhibition!of!neutrophil!function!was!not!suited!to!address!our!research!question.!!!Although!heparin!has!been!shown!to!upregulate!CD11b!expression,! it!does!not!appear! to! inhibit!neutrophil! responses! to! stimulation! (Freitas!et!al.,!2008).!We!therefore!used!heparinised!blood!samples!in!our!work,!and!sought!to!minimise!any! additional! potential! sources! of! neutrophil! activation,! such! as! temperature!fluctuations!and!mechanical!disturbances!from!repeated!pipetting!(Freitas!et!al.,!2008).!The!low!level!of!CD11b!expression!detected!in!our!unstimulated!samples,!compared! to! those! that! were! deliberately! stimulated,! suggested! the! heparinCtreated,! nonCpurified! neutrophils! processed! using! our! ICS! protocol! were!preserved! in! a! resting! state.! This! combination! of! heparin,! consistent!temperature,! and! minimal! manipulation! appeared! to! provide! us! with! the!greatest!ability!and!sensitivity!for!measuring!neutrophil!responses!to!RIPC.!!We!found!PMA/I!to!be!sufficient!stimulators!of!ILC6,!ILC8,!and!ILC10!production!in! all! of! the! leukocyte! subsets! examined.! LPS! is! the! most! commonly!recommended!stimulant!of!cytokine!production!in!monocytes;!however,!our!aim!
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was!to!use!ICS!to!assess!the!direct!effect!of!RIPC!on!cytokine!production,!rather!than!looking!at!the!way!it!modifies!the!response!to!an!ischaemic!injury.!In!order!to! assess! changes! in! intracellular! cytokine! production,! it! was! essential! to!stimulate! the!cells;! therefore!we!opted! to!use! the!nonCspecific!pharmacological!activators,! PMA/I,! rather! than!LPS,!which!mimics! a!pathophysiological! form!of!activation.!LPSCstimulated!cells!were!used!as!a!positive!control!for!ILC6!and!ILC8!production! in! monocytes! during! each! experiment;! however,! we! found! PMA/I!stimulation! appeared! to!be! capable! of! inducing! a! comparable! level! of! cytokine!production.!!!While!we!were!able! to!detect! intracellular! ILC10! in!monocytes! and!T! cells,! our!final! ICS! protocol! required! a! high! concentration! of! antibody! in! order! to!discriminate! a! reasonable! signal.! Our! experience! was! consistent! with! the!literature,! which! report! only! low! measurements! of! intracellular! ILC10! in!leukocytes.!Caraher!et#al.! (2000)#found!that!stimulating!rat!splenocytes!for! less!than!24!hours!with!PMA/I!did!not! induce!any! intracellular! ILC10!production! in!CD4! T! cells.! Instead,! a! 5! day! in# vitro#priming! and! reCstimulation! protocol!was!necessary! to! induce! a! modest! (3.19%)! population! of! ILC10! producing! cells!Likewise,!Muris!et#al.#(2012)!reported!only!0.45%!of!monensin!treated!human!T!cells! stained! positively! for! ILC10.! Interestingly,! this! study! also! found! that!monensin!significantly!reduced!the!number!of!ILC10!positive!cells,!and!brefeldin!A! had! an! even! more! detrimental! effect.! In! the! present! work,! we! also! found!monensin! slightly! preferable! to! brefeldin! A! for! ILC10! staining,! but! did! not!compare! either! to! samples! that! were! not! treated! with! a! protein! transport!inhibitor.!!Despite!monensin!reportedly!decreasing!the!overall!number!of!ILC10!producing!cells,!Muris!et#al.#noted! that! it!appears! to! increase! the!amount!of! ILC10! in!each!cell,! as! indicated! through! higher! MFI! levels.! In! the! absence! of! a! significant!population! of! cytokine! producing! cells,! MFI! is! the! most! sensitive! measure! of!changes! in! intracellular! cytokines.! With! this! in! mind,! and! the! knowledge! that!removal!of!monensin!from!the!cultures!would!have!a!detrimental!effect!on!ILC6!and! ILC8!measurements,! this! slightly! reduced! ILC10!detection! sensitivity!was! a!
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reasonable! compromise! for! the! purpose! of! our! study.!However,! ultimately! the!expense! associated! with! the! amount! of! antibody! required! for! the! full! trial!prevented! us! from! including! it! in! the! final! protocol.! Instead,!we! turned! to! the!serum!CBA!results!for!a!more!conclusive!indication!as!to!the!effect!of!RIPC!on!ILC10! production.! Any! future! attempts! to! examine! intracellular! ILC10! production!may!require!separate!detection!from!other!cytokines,!using!cultures!without!the!addition!of!a!protein!transport!inhibitor.!!!Although!not! fully!described! in! this! chapter,! significant! consideration!was! also!given! to! the! design! and! validation! of! the! flow! cytometry! panels! used! for!immunophenotyping! the! fresh!whole! blood! samples.! Antibodies,! fluorophores,!and!markers!were!selected!and!preCtitrated!using!wellCestablished!tenets!of!flow!cytometry! that! have!been!previously!published! in! the! literature,! therefore! this!data!was!not!presented!(Baumgarth!and!Roederer,!2000;!Mahnke!and!Roederer,!2007).!One!aspect!that!was!described!was!the!comparison!of!different!methods!for! blocking! nonCspecific! antibody! binding.! The! effect! of! blocking! Fc! receptors!appeared!negligible!in!our!immunophenotyping!samples,!which!is!not!surprising!given!we!were!staining!in!whole!blood.!Human!serum!contains!sufficient! levels!of! immunoglobulin!to!bind!the!Fc!receptors!present!on! leukocytes!and!prevent!nonCspecific! antibody! binding! (Sedlmayr! et! al.,! 2001).! In! contrast,! our! ICS!samples!were!washed!several!times!prior!to!extracellular!staining,!consequently!removing! the! serum!and!necessitating! the! incorporation!of! a! blocking! step! for!these!samples.!!!A!key!aim!of!our! immunophenotyping!assay!was!to!measure!any!RIPCCinduced!changes!in!neutrophil!activation.!CD63!is!found!in!the!membrane!of!azurophilic!granules!and!therefore!is!only!present!intracellularly!in!resting!neutrophils!and!monocytes! (Pfistershammer!et!al.,!2004).!Following!cell! stimulation,!exocytosis!of!these!granules!results!in!the!release!of!their!lysosomal!enzyme!contents,!and!expression!of!CD63!on! the!cell! surface,!making! it! a!useful!marker!of! activation!(Cham!et! al.,! 1994).! It!was! interesting! that! despite! successful! activation! of! the!cells,! as! shown! through! increased!CD11b! levels,!we!were!unable! to!detect! any!granule!exocytosis!in!neutrophils!using!fMLP,!the!agent!of!choice!for!such!assays!
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in! the! literature.! Simard! et# al.# (2010)! demonstrated! that! fMLP! stimulation! of!isolated!neutrophils!induces!a!significant,!transient!increase!in!CD63!expression,!peaking! at! five! minutes! and! returning! almost! to! baseline! levels! within! 30!minutes.!It!is!possible!that!we!missed!the!peak!expression!of!CD63!with!our!10!minute! stimulation! although! this! is! unlikely,! given!we! found!no! increase! at! all!compared!to!the!unstimulated!sample!levels.!!!Release!of!azurophilic!granules!requires!a!more!potent!stimulus!than!most!other!functional!neutrophil! responses! (Sengeløv!et!al.,!1993;!van!Eeden!et!al.,!1999).!The!majority!of!neutrophil!studies!work!with!isolated!cells,!raising!the!possibility!that! the! extra! cell! handling! involved! in! these! experiments! could! prime! the!neutrophils,! thus! reducing! the! stimulation! threshold! required! for! inducing!degranulation.! Irrespective! of! the! reason! for! the! lack! of! effect,! our! results!indicated!that!fMLP!was!not!an!appropriate!stimulant!for!use!in!our!study.!Using!PMA/I!treatment,!we!measured!CD63!expression!that!was!comparable!to!other!work,! and! therefore! used! these! alternative! agents! for! stimulating! the! study!samples!(Estensen!et!al.,!1974).!!The!majority!of!RIPC!mechanistic! research!has! focused!on! the! interaction!with!components!of!the!innate!immune!system;!however,!there!is!also!evidence!that!RIPC!may!affect!the!acquired!immune!response!(Sullivan!et!al.,!2009).!To!explore!this!possibility,!we!wanted!to!analyse!changes!in!T!cell!proliferation!and!cytokine!production.! Assays! for!measuring! such! responses! to! polyclonal! stimulants! are!well! described! in! the! literature;! however,! testing! the! T! cell! recall! response! to!tetanus! required! the!development!of! a!new!stimulation!protocol! (Kruisbeek!et!al.,!2004;!Trickett!and!Kwan,!2003).!!!We!elected!to!use!the!ADT!Booster!vaccine!to!stimulate!our!isolated!PBMC.!This!vaccine! consists! of! the! tetanus! toxoid! adsorbed! to! an! adjuvant,! aluminium!hydroxide! (Al(OH)3),! and!we! found! it! induced! a! level! of! proliferation! and! ILC6!production! in! our! PBMC! cultures! that! was! significantly! higher! than! what! we!would!have!expected!from!a!minor!population!of!tetanusCspecific!memory!cells.!Although!Al(OH)3!is!not!immunogenic!itself,!it!is!well!established!that!adsorption!
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of! the! tetanus! toxoid! onto! this! adjuvant!markedly! increases! antigenCinduced!T!cell! proliferation! (Mannhalter! et! al.,! 1985;! Ulanova! et! al.,! 2001).! It! has! been!shown! that! Al(OH)3! increases! the! attraction! and! antigen! uptake! of! APCs,!stimulates! monocytes! to! produce! key! cytokines! such! as! ILC1,! and! promotes!development!of!monocytes!and!macrophages!into!more!mature,!specialised!APCs!(Mannhalter! et! al.,! 1985;! Rimaniol! et! al.,! 2004;! Ulanova! et! al.,! 2001).! The! net!result! of! these! changes! is! a! more! pronounced! T! cell! response! compared! to!stimulation!with! the! soluble! tetanus! toxoid! alone,!which! could! account! for! the!substantial! responses! we! measured.! Further,! the! ADT! Booster! vaccine! also!contains! the! diphtheria! toxoid,! therefore! likely! stimulates! an! additional!population!of!memory!T!cells!in!vaccinated!individuals.!!Interestingly,! Ulanova! et# al.# have! reported! that! Al(OH)3! by! itself! upregulates!MHC!II!molecule!expression!on!monocytes,!and!induces!monocyte!and!Th1!type!cytokine!production!in!human!PBMC!cultures.!Consequently,!one!caveat!of!using!the! tetanus! booster! vaccine! to! stimulate! memory! T! cells! is! that! the! resulting!cytokine! production!must! be! analysed! in! the! context! of! the! enhanced! immune!response!to!the!adjuvant.!Interestingly,!we!did!not!detect!any!ILC6!production!in!the! tetanusCstimulated!cells! from! the! individual!who!had!not! received!a! recent!tetanus!booster! in!our!work,!supporting!the! idea!that!at! least!the!ILC6!cytokine!response!was!antigenCspecific.!However,!analysis!of!ILC6!production!from!further!donors!that!have!not!recently!received!a!tetanus!booster!would!be!necessary!to!conclusively!determine!that!the!ILC6!detected!is!the!result!of!an!antigenCspecific!response.!!According! to! the! literature,! the! potential! stimulatory! effect! of! the! adjuvant! on!cytokine! production! is! isolated;! it! appears! Al(OH)3! does! not! directly! elicit!proliferation,! suggesting! any! measured! changes! in! cell! numbers! can! be!attributed! solely! to! the! antigenic! response! (Ulanova! et! al.,! 2001).! In! order! to!confirm!this!in!the!current!work!we!would!have!also!needed!to!culture!cells!with!the!adjuvant! alone,!which!unfortunately!was!not! available.!The! combination!of!the! large! magnitude! of! the! proliferative! response! detected! and! the! lack! of! a!vehicleConly! control! in! our! testing! therefore! raises! the! possibility! that! the!
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proliferative! response! detected! in! our! PBMC! cultures! may! not! have! been!exclusively! antigenCspecific.! Further! work! to! validate! this! method,! such! as!through!the!use!of!tetramers!expressing!the!tetanus!antigen!and!flow!cytometry,!would!be!valuable!to!confirm!the!specificity!of!the!response.!!!A! particular! challenge! of! setting! up! our! study! in! healthy! volunteers! was! the!volume!of!laboratory!work!associated!with!each!participant,!which!required!they!be! recruited! individually.! Great! care! was! taken! to! ensure! consistency! in! the!measurement! of! endpoints! between! participants,! such! as! bulk! aliquoting! and!freezing!of!reagents!to!remove!even!the!minor!variability!associated!with!the!use!of! different! pipettes! and! freezeCthaw! cycles! of! reagents.! In! addition,! lab!workflows! that! specifically! described! the! timing! and! order! of! sample! handling!were!developed!and!tested!in!a!pilot!run.!These!protocols!were!an!essential!part!of! the!strategy! to!minimise!experimental!variation!and!guarantee! that! the!data!between!visits!could!be!appropriately!combined!and!compared.!!









4.1 Introduction-Our! next! line! of! research! utilised! the! assays! tested! in! the! previous! chapter! to!investigate! the! effects! of! RIPC! on! the! immune! response! in! healthy! volunteers.!The!results!of!this!study!are!presented!in!Chapters!4!C!6,!and!are!preceded!by!an!overview! of! what! was! known! about! the! relationship! between! the! immune!response!and!preconditioning!at!the!time!our!study!was!conceptualised.!!!Research!investigating!the!mechanisms!that!contribute!to!IPC!in!human!studies!has!been!somewhat!limited!by!the!feasibility!of!collecting!tissue!samples!and!the!variability!between!participants,!compared!with!animal!models.!The!majority!of!information! regarding! the! pathways! in! preconditioning! therefore! stems! from!preclinical! studies! in! animals;! however,! there! is! evidence! that! the! mediators!involved!in!preconditioning!may!differ!in!humans!(Heusch!et!al.,!2011).!Further,!although! models! of! RIPC! using! limb! ischaemia! have! more! recently! been!developed!in!rats!and!mice,!classical!IPC!is!simpler!to!apply!in!small!animals!and!the!majority!of!the!literature!has!focused!on!the!effects!of!direct!IPC.!At!present!it!is!not!fully!understood!what!differences!exist!between!the!processes!associated!with! IPC! and! RIPC.! Despite! the! variation! between! the! models! used! for!preconditioning!research,! it! is!clear!that!the!pathways!between!species!and!the!different! forms! of! preconditioning! overlap! in! many! respects;! therefore,! we!evaluated! all! of! the! available! literature! when! considering! how! RIPC! might!influence!the!human!immune!system!(Moskowitz!and!Waeber,!2011).!!!The!immune!system!encompasses!the!innate!immune!response,!which!provides!a!nonCspecific!first!line!of!defence!against!invading!pathogens,!and!the!adaptive!immune! response,! which! is! characterised! by! antigenCspecific! protection! and! a!memory!for!previously!encountered!pathogens.!The!focus!of!this!chapter!largely!concerns! the! innate! immune! response! and! how! preconditioning! may! induce!cardioprotection! by! altering! the! course! of! inflammation,! whereas! Chapter! 5!addresses! the! effect! of! RIPC! on! the! functional! response! of! the! cells,! with! a!particular!focus!on!cells!associated!with!the!adaptive!immune!system.!!!
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4.1.1 The-innate-immune-system-and-ischaemiaLreperfusion-injury-The! innate! immune! system! forms! the! body’s! first! protective! response! to!invading! pathogens! and! is! largely! mediated! by! monocytes,! macrophages,! and!neutrophils! (Janeway! and! Medzhitov,! 2002).! These! cells! are! capable! of!responding! to! a! broad! range! of! stimuli! including!many! that! the! body!may! not!have!previously!encountered.!This!is!achieved!through!the!membrane!bound!and!intracellular! expression! of! pattern! recognition! receptors! (PRRs)! that! detect!pathogenCassociated! molecular! patterns! (PAMPs)! (Chen! and! Nuñez,! 2010).!PAMPs!utilise!motifs!that!are!highly!conserved!amongst!classes!of!microbes!and!distinguishable!from!host!molecules.!Binding!of!these!PAMPs!to!PRRs!on!innate!immune!cells!triggers!a!signalling!cascade!that!results!in!transcription!of!the!key!genes!associated!with!host!defence!(Chen!and!Nuñez,!2010).!!Traditionally! the! immune! system! was! considered! to! rely! on! the! distinction!between! foreign! material! and! host! molecules! when! mounting! a! response;!however,!it!is!now!accepted!that!innate!immune!cells!can!also!be!stimulated!by!endogenous! dangerCassociated! molecular! patterns! (DAMPs)! released! from!damaged!host!tissues!(Matzinger,!2002).!For!instance,!one!class!of!PRRs,!tollClike!receptors!(TLRs),!have!been!shown!to!respond!to!heat!shock!proteins!60!and!70!and!highCmobility!group!box!1!protein,!following!their!release!from!necrotic!cells!(Basu!et!al.,!2000;!Ohashi!et!al.,!2000;!Park!et!al.,!2004;!Scaffidi!et!al.,!2002).!Such!immune! cell! activation! in! the! absence! of! an! infectious! agent! is! termed! ‘sterile!inflammation’,!and!is!the!critical!process!through!which!organ!damage!occurs!in!the!setting!of!I/R!injury!(Eckle!and!Eltzschig,!2011).!!!During! cardiac! surgery! the! innate! immune! system! responds! to! a! set! of! diffuse!stimuli!resulting!from!interactions!with!the!artificial!surface!of!the!CPB!machine!circuit! and! the! I/R! encountered! in! the! heart! and! other! tissues.! This! leads! to! a!systemic! inflammatory! response! involving! activation! of! complement,!upregulation!of!adhesion!molecules!on!immune!cells!as!well!as!myocytes!and!the!endothelium,! activation! and! tissue! infiltration! of! inflammatory! cells,! and!widespread! cytokine! release.! Although!monocytes! and! lymphocytes! contribute!to! these! processes,! neutrophils! are! the! main! effector! cells! involved! and! their!
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subsequent! production! of! reactive! oxygen! species! and! other! proinflammatory!mediators!propagates!the!detrimental!response!to!surgery!(for!a!comprehensive!review!refer!to!Warren!et!al.,!2009).!There!is!mounting!evidence!to!suggest!that!IPC! limits! this! periCoperative! organ! damage! by! modifying! the! course! of! the!innate!immune!response.!!!
4.1.2 Evidence-that-preconditioning-alters-the-innate-immune-response-!
4.1.2.1 Leukocyte,activation,and,infiltration,The!most!well!characterised!effect!of!IPC!on!the!immune!response!is!its!ability!to!reduce! neutrophil! infiltration! during! I/R! injury.! Extravasation! of! neutrophils!involves! several! key! phases,! including! rolling! of! the! neutrophil! along! the!endothelium! due! to! low! affinity! associations! with! selectin! molecules,! cell!immobilisation! through! high! affinity! binding! to! integrins,! and! finally!transmigration!between! the! endothelial! cells! into! the! interstitial! fluid! (Gearing!and!Newman,!1993).!!!In! murine! and! porcine! models,! classic! IPC! has! consistently! been! shown! to!significantly! decrease! neutrophil! infiltration! and! myeloperoxidase! (MPO)!activity! (an! indicator! of! polymorphonuclear! cell! accumulation)! in! the! lungs!following!I/R!(Harkin!et!al.,!2002;!Kinsey!et!al.,!2010;!Olguner!et!al.,!2006;!Peng!et! al.,! 2011).! The! reduction! in! neutrophil! extravasation! detected! in!preconditioned! animals! has! been! associated! with! decreased! adhesion! and!increased! leukocyte! rolling! velocity! in! murine! hepatic! sinusoidal! venules! and!feline! and! rat!mesentery! (Erling! et! al.,! 2010;! Howell! et! al.,! 2000;! Kubes! et! al.,!1998;!Tapuria!et!al.,!2009).!!!Davis!et#al.#(1999)!have!shown!that!IPC!completely!attenuates!the!increase!in!PCselectin!induced!following!I/R!injury!in!the!rat!jejunum,!and!attributed!this!to!a!change!in!expression!levels!on!the!vascular!endothelium.!Likewise,!IPC!reduces!PCselectin!expression!on!endothelial!cells!and!neutrophil!accumulation!in!remote!organs! following! hepatic! I/R! injury! (Linden! et! al.,! 2006).! Although! there! is!evidence! that! preconditioning! directly! alters! neutrophil! adhesion! molecule!
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expression,! these! studies! by! David! et# al.# and! Linden! et# al.# establish! that! the!endothelium!also!plays!a!critical!role!in!modulating!leukocyte!infiltration.!!!RIPC! in! healthy! volunteers! appears! to! have! similar! effects! on! neutrophils! to!those! reported! in! animal! studies! of! IPC,! reducing! adhesion,! CD11b,! and! kinin!receptor!expression!levels!during!the!delayed!preconditioning!window!24!hours!later! (Konstantinov! et! al.,! 2004;! Saxena! et! al.,! 2010b;! Shimizu! et! al.,! 2010).!Kharbanda!et#al.#(2001)!have!reported!that!RIPC!also!significantly!abrogates!I/R!induced! CD11b! expression! on! human! neutrophils! during! the! early! phase! of!preconditioning,! 15! minutes! after! reperfusion! of! a! minor! ischaemic! injury.!Further,! Shimizu! et# al.# have! demonstrated! that! repeated! RIPC! suppresses!neutrophil! phagocytic! activity.! Taken! together! these! studies! strongly! suggest!that! RIPC! exerts! a! protective! effect! by! reducing! the! ability! of! neutrophils! to!become!activated!and!infiltrate!tissues!in!the!setting!of!I/R!injury.!!The! effects! of! preconditioning! on! leukocytes! are! not! limited! to! neutrophils.!Delayed! IPC!has!been! shown! to! significantly! reduce!macrophage! infiltration!of!the! kidneys! in! rats,!which!was! accompanied! by! a! significant! decrease! in! renal!expression!of!the!adhesion!molecule,!ICAMC1!(Jiang!et!al.,!2007).!In!contrast,!Cho!
et#al.#(2010)!found!that!the!renal!protection!afforded!by!delayed!preconditioning!in!mice!was!associated!with!an! increase! in!CD11c+!macrophages!and!dendritic!cells!and! that!depletion!of! these!cells!partially!reversed! the!protective!effect!of!IPC.! The! reason! for! the! disparity! between! these! two! studies! is! unclear! and!further!research!is!needed!to!clarify!the!role!of!macrophages!and!dendritic!cells!in!the!response!to!preconditioning.!!!
4.1.2.2 Platelets,Mass!activation!of!platelets!during!cardiac!surgery!contributes!to!the!pathology!of! I/R! injury! through!both! the! formation!of!microemboli! that!can! interrupt! the!blood!supply,!and!the!release!of!preCformed!proinflammatory!mediators!stored!in!granules!(AbuCOmar!et!al.,!2004;!Weerasinghe!and!Taylor,!1998).!Two!studies!in! canines! have! established! that! IPC! significantly! reduces! plateletCmediated!thrombosis,!plateletCfibrinogen!binding,!and!the!formation!of!neutrophilCplatelet!
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aggregates!in!models!of!coronary!stenosis!(Hata!et!al.,!1998;!Linden!et!al.,!2006).!Equally,!RIPC!in!humans!attenuates!the!increase!in!monocyteCplatelet!aggregates!induced!by!I/R!injury!and!following!ex#vivo#stimulation!of!blood!from!coronary!artery!disease!patients!subjected!to!exercise!stress!tests!(Battipaglia!et!al.,!2011;!C.!M.!Pedersen!et!al.,!2011).!The!mechanism!through!which!IPC!reduces!platelet!activation! and! reactivity! is! unclear,! but! ultimately! appears! to! contribute! by!reducing!the!inflammatory!burden!following!ischaemic!injury.!!!
4.1.2.3 Transcription,factors,Some!of! the! strongest! evidence! to! suggest! preconditioning! affects! the! immune!system! stems! from! the! repeated! finding! that! both! IPC! and! RIPC! influence! the!activation! of! key! transcription! factors! associated! with! the! inflammatory!response,! including! NFCκB,! HIFC1α,! and! STAT! proteins.! The! classic! notion! that!RIPCCinduced! changes! in! gene! expression! are! limited! to! the! delayed! phase! of!preconditioning! was! challenged! by! the! finding! that! administration! of! a! nonCspecific! RNACsynthesis! inhibitor,! actinomycinCD,! completely! abolished! the!cardioprotection!induced!by!early!IPC!in!a!porcine!model!(Strohm!et!al.,!2002).!Changes!to!gene!transcription!thus!appear!to!be!relevant!during!both!windows!of!protection!afforded!by!IPC.!!!A! comprehensive! review!of! the! literature! implicating!NFCκB,!HIFC1α,!and!STAT!signalling! in! IPC! was! presented! in! Chapter! 1! and! strongly! suggests! that! the!protective! effects! of! preconditioning! are! mediated,! at! least! in! part,! through! a!reduction!in!activation!of!these!key!factors!and!the!resulting!suppression!of!the!inflammatory! genes! under! their! transcriptional! control.! This! hypothesis! is!consistent! with! a! key! study! performed! by! Konstantinov! et# al.# in! healthy!volunteers!that!demonstrated!RIPC!suppresses!numerous!genes!associated!with!cytokine!synthesis,!leukocyte!chemotaxis,!adhesion,!migration,!exocytosis,!innate!immunity! signalling! pathways,! and! apoptosis.! These! transcriptional! changes!were!significant!within!15!minutes!of!completing!the!preconditioning,!during!the!early!window!of!protection,!and!further!enhanced!after!24!hours,!corresponding!to!the!delayed!phase!of!RIPC!(Konstantinov!et!al.,!2004).!!!
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4.1.2.4 Toll>like,receptors,TLRs! are! widely! expressed! on! numerous! cell! types! including! neutrophils,!macrophages,! endothelial! cells,! and! myocytes! and! can! be! activated! by! a! wide!variety!of!products!released!from!damaged!and!necrotic!cells!(Boyd!et!al.,!2006;!Faure!et!al.,!2000;!Li!et!al.,!2001;!Sabroe!et!al.,!2002).!The!exact!role!of!TLRs!in!the! pathology! of! I/R! injury! is! unclear,!with! conflicting! reports! from! studies! in!animals!to!date.!It!appears!that!the!effect!of!TLR!activation!may!depend!on!both!the!tissue!examined!and!nature!of!the!injury!sustained!(Chao,!2009).!!!With! respect! to! the! heart,! TLR! signalling! results! in! NFCκB! activation! and!production! of! the! proinflammatory! cytokines! that! contribute! to! the! tissue!damage!elicited!by!I/R!(F.!Arslan!et!al.,!2010;!Li!et!al.,!2001).!Accordingly,!it!has!repeatedly!been!shown!that!deletion!of!certain!TLRs,!namely!TLR2!and!TLR4,!or!the! key! TLR! signalling! molecules,! MYD88! and! IRAKC4,! significantly! improves!outcome!and!reduces!the!infarct!size!sustained!following!myocardial!I/R!injury!in!mice!(Chong!et!al.,!2004;!Favre!et!al.,!2007;!Feng!et!al.,!2008;!Hua!et!al.,!2007;!S.CC.!Kim!et!al.,!2007;!Maekawa!et!al.,!2009;!Oyama!et!al.,!2004;!Riad!et!al.,!2008;!Shishido!et!al.,!2003;!Timmers!et!al.,!2008;!Zhao!et!al.,!2009).!Likewise,!inhibition!of!TLR4!with!the!antagonist!eritoran!decreases!infarct!size!and!NFCκB!activation,!and!administration!of!a!leukocyte!TLR2!signalling!inhibitor!treatment!improves!cardiac! function!during! I/R! (Fatih!Arslan!et! al.,! 2010;! Shimamoto!et! al.,! 2006).!The!protection!detected!in!these!studies!seems!to!be!associated!with!a!reduction!in! tissue! infiltration! of! inflammatory! cells,! cytokine! production,! and!cardiomyocyte!apoptosis!(Ha!et!al.,!2011).!!!Conversely,! a! number! of! studies! have! demonstrated! that! lowCdose! LPS!stimulation!of!TLR4!can!be!protective!against!a!subsequent! ischaemic! injury! in!the!isolated!heart,!and!TLR4CMyD88!signalling!reduces!cardiomyocyte!apoptosis!and!improves!function!(Song!et!al.,!1996;!Wang!et!al.,!2011;!X.!Zhu!et!al.,!2006).!Further,! administration! of! TLR2! ligands! in! mice! prior! to! myocardial! I/R!decreases!infarct!size!and!improves!recovery!of!cardiac!function!(Ha!et!al.,!2010;!Mersmann!et!al.,!2010).!These!discrepancies!may!be!partially!accounted! for!by!limitations!in!models!that!involve!systemic!deletion!of!TLR!genes,!as!inhibition!of!
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TLRs!on!endothelial!and! immune!cells!also! impairs!neutrophil!recruitment!and!the!resulting!detrimental!myocardial!inflammatory!response!(Chao,!2009).!!!Dong!et#al.#(2010)!found!the!effects!of!IPC!are!abolished!in!TLR2!deficient!mice,!suggesting! preconditioning! may! be! at! least! partly! mediated! through! TLR2!signalling.! Interestingly,! this! study! reported! that! the! cardioprotective! effect! of!IPC!was!unaltered!in!animals!lacking!TLR4,!yet!Yu!et#al.#(2010)#found!that!IPCCinduced! protection! was! associated! with! a! significant! decrease! in! expression!levels!of!TLR4!and!the!associated!cytokines,!TNFCα!and!ILC1β,!in!rats!subjected!to!myocardial! I/R.! In! addition,! TLR4Cdeficient! mice! show! a! reduced! ability! to!respond!to!IPCCinduced!neuroprotection!(Pradillo!et!al.,!2009).!Further!research!is!required!to!clarify!the!role!of!TLRs!in!IPC;!however,!it!seems!likely!that!these!receptors! may! link! the! stimuli! produced! by! ischaemic! tissue! to! the! NFCκB!activation!associated!with!preconditioning.!!!
4.1.2.5 Complement,Complement! activation! during! cardiopulmonary! bypass! contributes! to! tissue!injury! predominantly! through! the! activation! of! neutrophils! and! platelets,! and!production!of!the!membrane!attack!complex!(MAC)!that!causes!cell!lysis!(Miller!and! Levy,! 1997;! Warren! et! al.,! 2009).! Not! surprisingly,! administration! of! a!soluble! form!of!CR1,!which! inhibits! the!key!complement!proteins!C3b!and!C4b,!decreases! infarct! size! by! 44%! in! rats! subjected! to!myocardial! I/R! injury.! This!protection! was! associated! with! a! reduction! in! MAC! and! leukocyte! infiltration!within!the!infarct!zone!(Weisman!et!al.,!1990).!Treatment!of!rats!with!antibodies!against! a! different! complement! protein,! C5,! have! also! been! shown! to! reduce!infarct!size,!polymorphonuclear!cell!infiltration,!and!apoptosis!in!response!to!I/R!injury! (Vakeva! et! al.,! 1998).! Further,! similar! antibody! treatment! in! human!cardiac! surgery! patients! reduces!myocardial! damage! by! 40%! and! significantly!decreases! neutrophil! activation! (Fitch! et! al.,! 1999).! Tanhehco! et# al.# have!demonstrated!that!IPC!reduces!infarct!size!and!mRNA!levels!of!C1q,!C1r,!C3,!C8,!C9,!and!MAC!in!the!myocardial!area!at!risk!in!rabbit!hearts,!both!isolated!and!in#
vivo,! highlighting! another! potential!mechanism! through!which! preconditioning!may!limit!periCoperative!tissue!damage#(Tanhehco!et!al.,!2000,!1999).!
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4.1.2.6 Matrix,metalloproteinases,Matrix! metalloproteinases! (MMPs)! are! a! family! of! enzymes! produced! by!numerous!activated!cells,!including!leukocytes,!that!degrade!extracellular!matrix!proteins!(Parks!et!al.,!2004).!Levels!of!MMPC2!have!been!shown!to!increase!with!ischaemia! in! isolated! perfused! rat! hearts,! and! inhibition! of! MMPC2! improves!recovery!of!mechanical!function!(Cheung!et!al.,!2000).!In!pigs,!I/R!has!also!been!associated! with! a! significant! increase! in! MMPC9! activity! in! the! myocardium!(Danielsen!et!al.,!1998;!Lu!et!al.,!2000).!!!Zitta!et#al.#(2012)!established!a!role!for!MMPs!in!the!mechanism!of!RIPC!with!an!interesting! study! that!used! sera! collected! from!preconditioned! cardiac! surgery!patients! to! treat! an! intestinal! cell! line! subjected! to! hypoxia! in# vitro.! It! was!determined! that! samples! collected! one! hour! after! RIPC! demonstrated! reduced!MMPC2!and!9! activity! and!were! able! to!diminish!hypoxiaCinduced! cell! damage,!compared! to! samples! collected! prior! to,! or! directly! after,! preconditioning.!Further,!Konstantinov!et#al.#(2004)!reported!that!RIPC!significantly!upregulates!a!key! inhibitor!of!MMPC2!and!9,! tissue! inhibitor!of!metalloproteinasesC1,!both!15!minutes!and!24!hours!later.!Taken!together,!these!studies!strongly!suggest!that!regulation! of! MMP! activity! may! contribute! to! organ! protection! following!preconditioning.!!!
4.1.2.7 Cytokines,Cytokines! are! the! primary! signalling! molecules! used! by! the! innate! immune!system! to! direct! inflammation,! and! function! in! both! a! paracrine! and! autocrine!fashion!to!amplify!or!limit!the!cellular!response!(Valeur!and!Valen,!2009).!There!has! been! extensive! research! implicating! cytokines! in! preconditioning,! as! was!reviewed!in!Chapter!2.!Briefly,!animal!studies!have!established!that! ILC6,! ILC10,!and! TNFCα! are! essential! for! inducing! preconditioning,! yet! proinflammatory!cytokine! levels! are! generally! attenuated! during! I/R! injury! after! IPC! (Cai! et! al.,!2012;! Dawn! et! al.,! 2004;! Ren! et! al.,! 2004;! Smith! et! al.,! 2002;! Takeshita! et! al.,!2010;!Xu!et!al.,!2011).!!!
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It! is! possible! that! induction! of! cytokine!production!during! the!preconditioning!ischaemia!may!stimulate!a!negative!feedback!loop!that!decreases!the!response!to!subsequent! ischaemic! episodes.! Alternatively,! proinflammatory! cytokines!induced!during!the!mild!ischaemia!associated!with!preconditioning!may!activate!different!pathways,!compared!to! those!elicited!by!a!sustained! ischaemic! injury.!For!instance,!TNFCα!preconditioning!has!been!shown!to!selectively!modify!NFCκB!activity! to! inhibit! transcription! of! inflammatory! genes! while! maintaining!promotion!of!beneficial!genes,!such!as!the!antioxidant!enzyme,!MnSOD!(Ginis!et!al.,!2002).!Although!the!literature!regarding!cytokine!expression!with!RIPC!in!the!clinical! setting! is! limited! and! variable,! these! findings! from! the! animal! studies!suggest! that! cytokines! may! be! a! critical! mediator! involved! in! establishing!preconditioning.!!!
4.1.3 Rationale-for-the-study-The!results!of!trials!evaluating!RIPC!in!cardiac!surgery!patients!have!not!found!it!to! be! as! protective! or! consistent! as! was! shown! in! preCclinical! animal! studies.!Establishing!the!pathways!involved!in!the!induction!of!RIPC!will!be!essential! in!order! to! identify! and! address! the! hurdles! faced! in! the! clinical! setting! and! to!characterise!the!patient!population!that!will!benefit!most!from!this!intervention.!Work! in! animal! models! has! convincingly! demonstrated! that! IPC! modifies! the!innate!immune!response;!however,!it!remains!unclear!whether!RIPC!in!humans!functions!through!the!same!pathways.!In!addition,!it!is!not!known!which!of!these!effects! may! contribute! to! the! induction! of! preconditioningCinduced!cardioprotection,! and! which! are! simply! the! indirect! results! of! an! overall!reduction!in!tissue!damage.!Thus,! further!work!in!human!studies!is!required!to!fill!this!critical!gap!in!the!literature.!!!We! designed! the! present! study! to! investigate! the! mechanism! through! which!RIPC! operates! in! humans,!with! a! focus! on! the! early! immune! response.! A! clear!theme! has! emerged! from! the! previous! research! that! suggests! upregulation! of!components! of! the! immune! response! during! preconditioning! results! in!attenuation! of! the! same,! often! proinflammatory,! mediators! during! ischaemic!injury.!In!order!to!detect!whether!RIPC!induces!such!changes,!it!was!critical!the!
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study!design!maximised!the!ability!to!measure!subtle!and!direct!changes!to!the!immune!response.!Measurement!of!inflammatory!markers!in!the!typical!cardiac!surgery! patient! is! confounded! by! the! underlying! comorbidities! and!characteristics! in!this!population!that!alter!both!the!baseline!immune!state!and!the! inflammatory! response! to! surgery.! We! therefore! administered! the!intervention!to!healthy!volunteers!to!assess!the!direct!effect!of!RIPC!away!from!any!form!of!ischaemic!injury!or!comorbidities.!!!
4.2 Aims-
• To!determine! the!effect!of! the!RIPC! intervention!on!serum! levels!of!key!inflammatory!cytokines!and!biomarkers.!
• To! examine! changes! in! the! proportions! of! circulating! leukocyte! subsets!induced!by!RIPC.!
• To! investigate! whether! RIPC! alters! the! activation! state! of! peripheral!blood!leukocytes.!!!!!!!!!!!!!!!!!!!
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4.3 Methods-A! pairedCanalysis! trial! of! RIPC! was! performed! with! 10! healthy! volunteers!recruited!over!8!months!at!the!Medical!Research!Institute!of!New!Zealand.!The!study! was! registered! on! the! Australian! New! Zealand! Clinical! Trials! Registry!(ACTRN! 12611000856910)! and! received! ethics! approval! from! the! Central!Regional!Ethics!Committee!(CEN/11/06/034).!
-
4.3.1 Participants-Healthy!male!volunteers!who!had!received!a! tetanus!vaccine!or!booster!within!the! previous! 10! years! were! invited! to! participate! in! the! study! provided! they!were! over! the! age! of! 18! years,! did! not! have! peripheral! vascular! disease! or! an!acute! illness! (specifically! within! one! week! of! the! study! visits),! were! nonCsmokers,!and!not!taking!any!regular!medications.!Written!informed!consent!was!obtained!from!all!participants!by!a!study!investigator.!
-
4.3.2 Study-design-&-application-of-RIPC-In! this!unblinded,!pairedCanalysis! trial!all!participants!received! the!control!and!RIPC!treatment!during!two!separate!visits.!Because!the!effects!of!RIPC!have!been!reported! to! persist! for! several! weeks,! the! trial! was! designed! such! that! all!subjects! received! the! control! treatment! first! and! the! RIPC! during! the! second!visit.!A!study!investigator!administered!both!treatments.!On!day!0,!participants!received!the!control!treatment,!which!involved!a!tourniquet!being!placed!on!the!nonCdominant! upper! arm! for! 30!minutes,! without! inflation.! On! day! seven,! the!participants!returned!and!received!the!RIPC,!which!consisted!of!applying!the!cuff!to!the!same!arm!and!inflating!it!to!200!mmHg!for!5!minutes!(using!an!ATS!750!electric! tourniquet! system;! Zimmer),! followed! by! 5! minutes! of! deflation.! This!cycle! was! then! immediately! repeated! twice! more,! and! the! cuff! removed.! An!overview!of!treatment!application!during!each!study!visit!is!presented!in!Figure!4.1.!!
4.3.3 Blood-sample-collection-During! both! study! visits,! four! blood! samples! were! collected! from! the!contralateral! arm! at! baseline,! and! 20! minutes,! 1! hour,! and! 4! hours! after! the!
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treatment! using! separate! venepunctures! with! 23! gauge! needles! (Figure! 4.1,!Becton,! Dickinson,! and! Company).! Study! investigators! trained! in! phlebotomy!performed!the!procedures!and!particular!care!was!taken!to!minimise!the!use!of!a!bloodCtaking!tourniquet!during!sample!collection.!!!!
!
Figure- 4.1- Overview- of- treatment- administration- and- blood- sample-
collection-during-study-visits-Participants!had!baseline!blood!samples!collected!at!the!start!of!each!session!and!always! received! the! control! treatment! during! the! first! visit,! and! RIPC! at! the!second! visit.! Both! treatments! took! 30!minutes! to! apply,! including! the! final! 5Cminute! period! of! reperfusion!with! the!RIPC,! and! the! blood! sample! times!were!measured!from!the!completion!of!the!treatment.!!!!!
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4.3.4 Immunophenotyping-Blood! samples! for! flow! cytometry! were! collected! in! heparinised! vacutainers!(Becton,!Dickinson,!and!Company).!Where!a!stimulated!sample!was!indicated,!an!aliquot!of!blood!was!incubated!with!50!ng/mL!PMA!and!500!ng/mL!ionomycin!(Sigma!Aldrich)!for!15!minutes!at!37!°C,!and!cooled!on!ice!for!3!minutes!prior!to!staining.!Unstimulated!blood!was!kept!at!RT.!All!flow!cytometry!antibodies!were!preCtitrated! in! order! to!maximise! the! resolution! between! cell! populations! and!minimise!the!background!level!of! fluorescence,!and!all!samples!were!stained!in!duplicate.!Primary!antibody!mixes!were!diluted!in!FACS!buffer!to!a!total!volume!of! 25! μL,! and! were! then! mixed! with! an! equal! volume! of! fresh! whole! blood.!Following!a!20!minute!incubation!at!RT,!protected!from!light,!the!samples!were!mixed! with! FACS! lyse! (BD! Biosciences)! to! eliminate! the! red! blood! cells,! and!incubated!for!a!further!10!minutes!at!RT.!The!samples!were!then!centrifuged!at!300!x!g!for!5!minutes,!the!supernatant!aspirated,!and!cells!resuspended!in!FACS!buffer.!Samples!were!collected!on!a!Guava!easyCyte!8HT!using!InCyte!software!(Merck!Millipore),!and!the!data!was!analysed!using!FlowJo!7.6.1!software!(Tree!Star).!Refer! to!appendix!C! for! the!composition!of!buffers,! and!appendix!E! for!a!complete!list!of!antibodies!and!dilutions!used.!!
4.3.5 Serum-collection-Blood! for! serum! samples! was! collected! directly! into! silicaCcoated! vacutainers!(Becton,!Dickinson,!and!Company).!The!tubes!were!inverted!to!mix!several!times,!incubated!at!RT!for!60!minutes,!then!centrifuged!at!1500!x!g!for!12!minutes.!The!serum!was!aspirated!and!stored!in!aliquots!at!C80!°C!until!further!analysis.!!
4.3.6 Serum-cytokine-quantification-The!serum!cytokine!levels!were!quantified!using!a!human!inflammation!20plex!FlowCytomix! kit! (#BMS819FFRTU;! eBioscience).! The! kit! consisted! of! 20! bead!populations! of! two! sizes! with! distinct! fluorescence! intensities! that! could! be!resolved! in! the! red! flow! cytometer! channel.! Each! population!was! coated!with!capture!antibodies!specific!for!one!of!the!20!analytes:!ECSelectin,!GCCSF,!ICAMC1,!IFNCα,! IFNCγ,! ILC1α,! ILC1β,! ILC4,! ILC6,! ILC8,! ILC10,! ILC12p70,! ILC13,! ILC17A,! IPC10,!LAP,! MCPC1,! MIPC1α,! MIPC1β,! or! TNFCα.! The! beads,! together! with! biotinC
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conjugated! secondary! antiCanalyte! antibodies,! were! incubated! with! the! serum!sample.!Streptavidin!(SA)CPE!was!then!added!to!distinguish!the!cytokineCbound!beads!from!the!unbound!population!and!the!resulting!fluorescence!in!the!yellow!channel! used! to! determine! the! analyte! concentrations! within! each! sample,!relative!to!a!range!of!known!standards.!The!beads!were!mixed!and!diluted!2Cfold!with!assay!buffer!and!then!washed!by!centrifugation!at!3000!x!g!for!5!minutes,!aspiration!of! the!supernatant,!and!resuspension! in! the!same!volume!of!reagent!dilution! buffer.! The! biotinCconjugate! mixture! was! diluted! 2Cfold! with! assay!buffer.! The! standards! were! reconstituted! according! to! the! manufacturer’s!instructions! and! prepared! using! a! 3Cfold! serial! dilution.! Following! reagent!preparation,!25!µL!of!undiluted!serum!and!duplicate!standards!were!incubated!with! 25!µL! of!mixed! beads! and! 50!µL! of! biotin! conjugate!mix! in! a! 96Cwell! VCbottom!plate! for!2!hours!at!RT.!At! the!end!of! the! incubation! the!samples!were!washed! twice! by! the! addition! of! wash! buffer,! centrifugation! at! 400! x! g! for! 5!minutes,!and!aspiration!of!the!supernatant.!After!the!final!wash!all!but!100!µL!of!supernatant!was! removed! and!50!µL!of! SACPE! solution!diluted!1:62.5! in! assay!buffer!was! incubated!with! each! sample! for! a! further! hour! at! RT.! The! samples!were! then!washed! twice!more,! resuspended! in! assay!buffer! and!acquired!on! a!FACSCanto™! II! flow! cytometer! (BD! Biosciences)! set! up! according! to! the! kit!manufacturer’s! instructions.! The! data! was! analysed! with! BD! FACSDiva! (BD!Biosciences)!and!FlowCytomixPro!(eBioscience)!software.!!
4.3.7 Statistical-analysis-The! number! of! subjects! required! for! the! study! was! calculated! based! on! the!preliminary!analysis!performed!with!cytokine!data!from!the!first!32!patients!in!the!highCrisk!cardiac!surgery!with!RIPC!trial.!Using!paired!sample!tCtests,!it!was!determined! that! a! sample! size! of! 10! would! be! adequately! powered! (5%!significance,! 80%!power)! to! detect! differences! between! the! two! treatments! at!levels!as!low!as!1.7!pg/mL!for!ILC10,!and!4.3!pg/mL!for!ILC6!and!ILC8.!Differences!in! the! serum! cytokine! concentrations! of! a! lesser! magnitude! than! could! be!detected!using!10!participants!would!not!be!of!physiological!interest.!!!
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The!statistical!analysis!of!the!trial!results!was!performed!under!the!guidance!of!Dr! Dalice! Sim.! Serum! cytokine! concentrations,! proportions! of! immune! cell!subsets,!and!activation!marker!expression! levels! in!unstimulated!samples!were!compared!between!treatment!groups!and!time!points!using!a!repeated!measures!twoCway!ANOVA!with! the!GreenhouseCGeisser! correction! and!Bonferroni! postChoc! tests.! CD11b! and! CD63! expression! in! stimulated! blood! samples! was!compared!to!unstimulated!levels!using!repeated!measures!threeCway!ANOVA.!!!Graphs! were! produced! using! GraphPad! Prism! 5! (GraphPad! Software! Inc)! and!statistical! tests! were! performed! using! SPSS! Statistics! (IBM! Corporation).!Differences! corresponding! to! p! values! <! 0.05! were! considered! statistically!significant;!however,!the!high!number!of!statistical!tests!performed!for!the!study!was! also! taken! into! consideration!when! interpreting! the! results.! Comparisons!were!not!found!to!be!significant!unless!specified.!!!!!!!!!!!!!!!!!!!!!
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4.4 Results-!
4.4.1 Participants--10!healthy!male!volunteers!were!recruited!with!a!mean!age!of!23.3!years!(range!19.1! –! 29.4)! and! body! mass! index! of! 23.4! kg/m2! (range! 18.7! –! 30.6).! All!participants!had! received!a! tetanus!booster!vaccine!within! the! last!1!–!8!years!(mean!4.2),! and! showed!no! symptoms!of! acute! illness! at! the! time!of! the! study!visits.! The! RIPC! intervention! was! well! tolerated! by! all! participants,! with! no!adverse!effects.!!
4.4.2 The-effect-of-RIPC-on-serum-cytokine-levels-Following!on!from!the!results!of!our!cardiac!surgery!trial,!which!showed!a!slight!trend!towards!higher! levels!of! ILC6!and!ILC8! in!the!preconditioned!patients,!we!wanted!to!determine!if!the!RIPC!intervention!directly!altered!systemic!cytokine!levels.!Furthermore,!it!is!clear!that!induction!of!RIPC!involves!transmission!of!the!protective!signal! from!the!preconditioned! tissue! to! the!heart!and!other!remote!organs!by!an!undefined!humoral!mediator.!One!of!the!primary!aims!of!our!study!was!therefore!to!screen!serum!samples!for!increases!in!a!selection!of!cytokines!and!soluble!markers! that!may!be!relevant! to!eliciting! ischaemic! tolerance.!This!was! achieved! using! a! CBA! kit! to! assay! 20! key!mediators! of! the! inflammatory!response!in!samples!collected!up!to!four!hours!following!preconditioning.!!!There!were!two!participants! that!had!consistently!elevated! levels!of!prototypic!inflammatory! cytokines,! including! ILC12p70,! IFNCγ,! and! TNFCα,! at! both! the!baseline! and! postCtreatment!measures! during! the! control! and! RIPC! visits,! and!this! data! is! presented! in! appendix! G! (Figure! G.1).! Despite! screening! for!symptoms!of!acute!illness!at!the!start!of!each!study!session,!it!was!possible!that!these!participants!had!underlying!inflammatory!processes!occurring!at!the!time!of! the! blood! sampling! that! could! not! be! separated! from! the! effect! of! the!treatment;!therefore,!they!have!been!excluded!from!the!serum!cytokine!analyses!presented!in!the!following!sections.!!!
!!152!
4.4.2.1 Adhesion,molecules,We! found! measurable! levels! of! the! soluble! forms! of! both! adhesion! molecules!examined,!ICAMC1!and!ECselectin,!in!the!serum!from!our!healthy!volunteers!and!these! did! not! differ! between! the! control! and! RIPC! treatment! samples! (Figure!4.2A!and!C).!To!account!for!very!subtle!differences!in!the!baseline!levels!between!the! two! groups,! the! data! was! also! expressed! normalised! to! the! baseline!concentrations!(Figure!4.2B!and!D).!This!analysis!emphasised!the!slight!decrease!in!ICAMC1!expression!at!4!hours!in!the!preconditioned!group,!and!reductions!in!all!postCtreatment!measurements!of!ECselectin;!however,! these!trends!were!not!statistically!significant.!!!It!should!be!noted!that!one!participant!had!unusually!high!levels!of!ECselectin!in!every!sample!and!this!data!was!excluded!from!the!final!analysis!for!two!reasons.!First,! the! complete! dataset! was! considered! an! outlier,! relative! to! the! other!participants.! Second,! the! levels! exceeded! the!maximum! detection! range! of! the!assay,! and! therefore! lacked! accuracy.! The! slight! loss! of! statistical! power! from!this!exclusion!was!of!little!consequence!given!that!RIPC!did!not!appear!to!affect!serum! expression! of! the! cellular! adhesion! molecules! up! to! four! hours! postCtreatment.! The! ECselectin! data! for! all! participants! is! presented! in! appendix! G!(Figure!G.1A).!!
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Figure-4.2-Serum-levels-of-adhesion-molecules-following-RIPC-Blood! samples! were! collected! from! healthy! volunteers! at! baseline,! and! 20!minutes,! 1! hour,! and! 4! hours! after! control! or! RIPC! treatment! and! serum!biomarker!levels!were!quantified!using!a!CBA!and!flow!cytometry.!(A)!Absolute!ICAMC1!levels;!(B)!ICAMC1!levels!normalised!to!baseline!expression;!(C)!absolute!ECselectin!levels;!(D)!ECselectin!levels!normalised!to!baseline!expression.!A!twoCway! repeated!measures!ANOVA!was!used! to! compare! the! treatments!and! time!points.!Shown!are!the!means!and!SEM!for!n!=!8!for!the!ICAMC1!analysis,!and!n!=!7!for!ECselectin.!!!!!!!!!!
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4.4.2.1 Chemokines,Many! of! the! protective! effects! of! RIPC! correspond! to! activities! induced! by!chemokines;!therefore!their!levels!were!of!particular!interest!to!us!in!the!present!study.! We! detected! a! small! but! statistically! significant! reduction! in! MIPC1α!expression!following!preconditioning,!compared!to!the!control!treatment!(Figure!4.3A).!The!levels!appeared!to!decrease!from!baseline!concentrations!as!early!as!20! minutes,! and! stabilised! between! the! 1! and! 4! hour! samples! (Figure! 4.3B).!!Looking!at!the!total!change!between!the!levels!at!baseline!and!4!hours!for!each!participant!whilst!comparing!the!control!and!RIPC!visits,!it!appeared!this!change!in!the!pattern!of!MIPC1α!expression!was!very!subtle.!(Figure!4.3C).!!!!No! difference! in! MIPC1β! between! the! control! and! preconditioning! treatments!was! detected! with! the! absolute! levels;! however,! when! the! small! difference! in!baseline!expression!levels!between!the!groups!was!accounted!for!by!expressing!the! data! relative! to! the! preCtreatment! blood! samples,! there! was! a! significant!reduction! in! MIPC1β! after! RIPC! (Fig! 4.3D! and! E).! A! closer! look! at! the! 4Chour!measurements! showed! that! 6! out! of! 8! participants! had! increases! in! MIPC1β!levels!during! the!control!visit,!whereas!7!out!of!8! individuals!had!decreases! in!MIPC1β!following!the!preconditioning!(Figure!4.3F).!!!Levels! of! MCPC1! were! significantly! reduced! at! 1! and! 4! hours! postCtreatment,!compared! to! baseline,! but! did! not! differ! between! the! two! treatment! groups!(Figure!4.4A).!Expressing!the!MCPC1!levels!relative!to!the!baseline!concentration!for! each! individual! emphasised! the! decrease! across! the! time! points! and! a!significant! difference! was! detected! as! early! as! 20!minutes! after! treatment! for!both! groups! (Figure! 4.4B).! Likewise,! expression! of! IPC10! and! ILC8! was! not!affected! by! preconditioning! and!maintained! relatively! consistent! levels! across!the!4Chour!sampling!period!(Figure!4.4CCF).!When!the!ILC8!data!was!normalised!to! the! preCtreatment! levels! it! appeared! that! the! concentrations! during! the!control! visit! may! have! increased! at! 20! minutes! and! 1! hour! after! treatment,!compared!to!during!the!RIPC!visit;!however,!there!was!a!high!level!of!variability!in! the! response! between! individuals! and! this! difference! was! not! statistically!significant!(Figure!4.4F).!!
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Figure-4.3-Serum-levels-of-macrophage-inhibitory-protein-1-after-RIPC-Blood! samples! were! collected! from! healthy! volunteers! at! baseline,! and! 20!minutes,! 1! hour,! and! 4! hours! after! control! or! RIPC! treatment! and! serum!biomarker!levels!were!quantified!using!a!CBA!and!flow!cytometry.!Left:!MIPC1α!presented! (A)! as! absolute! levels,! (B)! normalised! to! baseline! expression,! (C)! as!total! change! from! baseline! to! 4! hours! for! each! participant.! Right:! MIPC1β!presented!(D)!as!absolute!levels,!(E)!normalised!to!baseline!expression,!(F)!as!4!hour! levels! expressed! relative! to! baseline! for! each! participant.! A! twoCway!repeated!measures!ANOVA!was!used!to!compare!the!treatments!and!time!points,!with!Bonferroni!postChoc!tests.!*!p!<!0.05.!Shown!are!the!means!and!SEM!for!n!=!8!participants.!!!!
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Figure-4.4-PostLRIPC-systemic-chemokine-levels-Blood! samples! were! collected! from! healthy! volunteers! at! baseline,! and! 20!minutes,! 1! hour,! and! 4! hours! after! control! or! RIPC! treatment! and! serum!biomarker! levels!were! quantified! using! a! CBA! and! flow! cytometry.! Expression!levels!are!presented! for! (A!and!B)!MCPC1,! (C!and!D)! IPC10,! and! (E!and!F)! ILC8.!Shown!are!absolute!concentrations!(A,!C,!and!E),!and!data!normalised!to!baseline!levels!(B,!D,!and!F).!A!twoCway!repeated!measures!ANOVA!was!used!to!compare!the!treatments!and!time!points,!with!Bonferroni!postChoc!tests.!*!p!<!0.05,!**!p!<!0.01,!and!***!p!<!0.001.!Shown!are!the!means!and!SEM!for!n!=!8!participants.!
!! 157!
4.4.2.1 T,cell,cytokines,Upon!activation,!T!cells!can!produce!numerous!cytokines!to!assist!and!direct!the!immune! response;! the! exact! profile! of!which! depends! on! the! type! of! response!elicited.! In!measuring! cytokines! commonly! associated!with!T! cells,!we! found! a!general! trend! towards!decreasing!serum! levels!of! ILC13!across! the! time!points,!but!this!trend!did!not!differ!between!the!groups!or!reach!statistical!significance!(p!=!0.087;!Figure!4.5A).!Similarly,! IFNCγ! levels!decreased!between!the!baseline!and!1Chour!samples!in!both!groups,!but!appeared!to!return!to!resting!levels!by!4!hours!(Figure!4.5C).!Although!the!theoretical!limit!of!detection!for!IFNCγ!with!the!CBA! kit! used! was! 1.6! pg/mL,! we! observed! that! any! samples! with! MFI! values!corresponding! to! concentrations! lower! than! 44.85! pg/mL! were! automatically!designated! as! ‘zeros’! by! the! software! analysis.! The! sensitivity! of! our! IFNCγ!measurements!was!therefore!inadequate!for!this!analysis!and!the!results!should!be!interpreted!with!caution.!Normalising!the!data!to!the!preCtreatment!cytokine!levels!did!not!alter!the!pattern!of!expression!seen!with!either!treatment!(Figure!4.5B!and!D).!!!ILC17A! levels! appeared! fairly! consistent! across! the! time! points! and! treatment!groups,! with! the! exception! of! notably! different! levels! in! the! baseline! samples!(Figure!4.5E).!When! this!was!accounted! for!by!normalising! the!data!relative! to!the!preCtreatment!ILC17A!levels,!there!was!a!trend!towards!lower!expression!in!the! preconditioned! participants! at! 20! minutes! and! 1! hour! after! treatment;!however,!this!trend!did!not!reach!statistical!significance!and!the!large!error!bars!in!the!control!group!data!suggested!there!was!a!high!level!of!variability!between!participants! (p!=! 0.064;! Figure!4.5E).!A! closer! look! at! the! individual! replicates!indicated! that! one! participant! had! remarkably! lower! baseline! ILC17A! levels!during! the! control! visit! and! when! the! data! was! expressed! relative! to! these!baseline! levels! the! values! for! the! subsequent! time! points! thus! appeared! to! be!inflated.! Removal! of! this! participant! markedly! reduced! both! the! difference!between! the!groups!and! the!variability! in! the! control! visit!mean!data! (refer! to!appendix!G,!Figure!G.2).!Overall,!it!appeared!that!RIPC!did!not!alter!serum!ILC17A!levels.!!
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Minimal!levels!of!ILC4!were!measured!and!most!fell!below!the!theoretical!limit!of!detection! for! the! assay! (20.8!pg/mL;! data! not! shown).!Of! notable! exception! to!this!were!the!levels!in!the!two!participants!that!were!excluded!from!the!analysis!due! to! heightened! baseline! inflammatory! marker! expression,! confirming! our!CBA! was! capable! of! measuring! ILC4! levels! when! they! were! present! (refer! to!appendix! G,! Figure! G.1R).! Our! results! did! not! suggest! the! T! cell! response!was!polarised!towards!any!particular!Th!cell!subtype.!!!!!!!!!!
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Figure-4.5-Serum-T-cell-cytokine-expression-after-RIPC-Blood! samples! were! collected! from! healthy! volunteers! at! baseline,! and! 20!minutes,! 1! hour,! and! 4! hours! after! control! or! RIPC! treatment! and! serum!biomarker! levels!were! quantified! using! a! CBA! and! flow! cytometry.! Expression!levels! are!presented! for! (A!and!B)! ILC13,! (C!and!D)! IFNCγ!along!with! the!assay!limit! of! detection! (LOD),! and! (E! and! F)! ILC17A.! Shown! are! absolute!concentrations!(A,!C,!and!E),!and!data!normalised!to!baseline!levels!(B,!D,!and!F).!A!twoCway!repeated!measures!ANOVA!was!used!to!compare!the!treatments!and!time!points.!Shown!are!the!means!and!SEM!for!n!=!8!participants.!
!!160!
4.4.2.2 General,inflammatory,cytokines,In! our! participants,! serum! levels! of! the! generally! proCinflammatory! cytokines!TNFCα! and! ILC1β,! pleiotropic! IFNCα,! and! regulatory! ILC10! did! not! significantly!change! between! the! treatment! visits! or! time! points! (Figure! 4.6ACE).! The! data!could!not!be!expressed!as!a!percentage!of!the!baseline!levels!for!TNFCα,!ILC1β,!or!ILC10,! as! numerous! participants! had! no! detectable! levels! prior! to! treatment.!There! was! a! slight! trend! towards! lower! expression! of! ILC1β! in! the!preconditioned!participants!at!4!hrs;!however,!this!trend!did!not!reach!statistical!significance!and!there!also!appeared!to!be!an!equal!but!opposite!difference!at!the!baseline!measure!(p!=!0.152;!Figure!4.6D).!The!actual!limit!of!ILC1β!detection!for!our! assay! run! was! notably! higher! than! the! theoretical! limit! reported! by! the!manufacturer,!and!this!reduction!in!sensitivity!may!have!contributed!to!the!high!level! of! variability! in! the! measurement! of! this! cytokine.! Of! note! was! that! the!circulating! levels! of! ILC10! were! very! low! both! before! and! after! treatment,!supporting!a!healthy!immune!status!for!our!participants!(Figure!4.5E).!!!Interestingly,! levels! of! ILC12p70,! which! is! typically! associated! with!proinflammatory!effects,!appeared!to!decrease!between!baseline!and!4!hours!in!the!preconditioned!participants!and!increase!for!the!control!group!(Figure!4.7A).!The!overall!levels!of!ILC12p70!were!low!and!variable,!leading!to!wide!error!bars!and!no!statistically!significant!difference!between!the!two!groups.!The!data!could!not! be! expressed! relative! to! the!baseline! levels,! as! several! participants! had!no!detectable! ILC12p70! prior! to! treatment;! however,! a! closer! look! at! the! overall!change!between!the!control!and!RIPC!treated!patients!indicated!that!the!majority!of!participants!individually!mirrored!the!relationship!seen!in!the!mean!data,!with!control! patients! showing! an! increase! in! ILC12,! and! the! preconditioned!participants!showing!a!reduction!(Figure!4.7B).!Although!the!levels!were!too!low!to!draw!conclusive! results! in! this!work,! these!data! suggest! ILC12p70!may!be!a!cytokine!of!interest!to!future!RIPC!studies.!!!Serum!LAP!expression!was!significantly! lower! in! the!1!and!4!hour!samples! for!both!treatment!groups!(Figure!4.7C).!The!baseline!levels!in!the!RIPC!group!were!slightly!higher!and!when!this!was!adjusted!for!by!expressing!the!data!relative!to!
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the! daily! baseline! value,! there!was! a! larger! decrease! in! LAP! expression! in! the!preconditioned!participants!(Figure!4.7D).!Nonetheless,!this!effect!did!not!reach!statistical! significance;! therefore,! overall! it! appears! RIPC! did! not! affect! LAP!concentrations.! Levels! of! GCCSF,! which! generally! functions! to! dampen! down!inflammation,!were!also!similar!between!the!two!groups!and!did!not!change!up!to! 4! hours! postCtreatment! (Figure! 4.7E).! Accounting! for! the! higher! baseline!levels! in! the! RIPC! group! by! normalising! the! data! suggested! there!was! a! slight!reduction! in!GCCSF! in! the!preconditioned!participants,!but! this!effect!was!small!and!again,!did!not!reach!statistical!significance!(Figure!4.7F).!!!The! serum! concentrations! of! ILC1α! and! ILC6,! which! are! regarded! as!proinflammatory!and!pleiotropic!cytokines,!respectively,!were!generally!close!to,!or!below,! the! limits!of!detection!of! the!assay! (0.5!and!1.2!pg/mL,! respectively;!data!not!shown).!However,!measurable! levels!of! these!cytokines!were!detected!in! the! participants! that! were! excluded! from! the! analysis,! confirming! the!capability! of!measuring! ILC1α! and! ILC6! levels! in! samples,! if! present,! using! our!methodology! (refer! to! appendix! G,! Figure! G.1S! and! T).! Overall,! our! results!provided!no! indication!that!RIPC!directly!promoted!a!proinflammatory!or!antiCinflammatory!cytokine!response.!!
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Figure-4.6-Systemic-levels-of-TNFα ,-ILL1β ,-IFNLα ,-and-ILL10-following-RIPC-Blood! samples! were! collected! from! healthy! volunteers! at! baseline,! and! 20!minutes,! 1! hour,! and! 4! hours! after! control! or! RIPC! treatment! and! serum!biomarker!levels!were!quantified!using!a!CBA!and!flow!cytometry.!Shown!are!(A)!the!absolute!levels!of!IFNCα;!(B)!IFNCα!levels!normalised!to!baseline!expression;!(C)!absolute! levels!of!TNFCα;! (D)!absolute! levels!of! ILC1β!and!the!assay! limit!of!detection! (LOD);! (E)! absolute! levels! of! ILC10.! A! twoCway! repeated! measures!ANOVA! was! used! to! compare! the! treatments! and! time! points.! Shown! are! the!means!and!SEM!for!n!=!8!participants.!!
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Figure-4.7-PostLRIPC-systemic-levels-of-ILL12p70,-LAP,-and-GLCSF-Blood! samples! were! collected! from! healthy! volunteers! at! baseline,! and! 20!minutes,! 1! hour,! and! 4! hours! after! control! or! RIPC! treatment! and! serum!biomarker! levels!quantified!using!a!CBA!and! flow!cytometry.!Expression! levels!are!presented!for!(A!and!B)!ILC12p70,!(C!and!D)!LAP,!and!(E!and!F)!GCCSF.!Shown!are! absolute! concentrations! (A,! C,! and! E),! and! the! change! in! ILC12p70! from!baseline!to!4!hours!for!each!participant!(B),!or!data!normalised!to!baseline!levels!(D! and! F).! A! twoCway! repeated! measures! ANOVA! was! used! to! compare! the!treatments!and!time!points,!with!Bonferroni!postChoc!tests.!**!p!<!0.01!and!***!p!<!0.001.!Shown!are!the!means!and!SEM!for!n!=!8!participants.!
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4.4.3 Immunophenotyping-of-peripheral-blood-cells-following-RIPC-To!determine!whether!RIPC!directly!altered!the!proportions!or!activation!states!of! circulating! peripheral! leukocytes,! we! performed! immunophenotyping! with!flow!cytometry!on!blood!samples!collected!at!baseline,!and!20!minutes,!1!hour,!and!4!hours!after!treatment.!!!Having! detected! high! baseline! cytokine! levels! in! two! participants! during! our!serum! analysis,! it!was! necessary! to! confirm! that! any! underlying! inflammatory!processes! in! these! individuals! did! not! affect! the! other! endpoints! of! the! study;!therefore,! the! entire! immunophenotyping! dataset! was! analysed! with! and!without! the! inclusion! of! these! two! participants.! Removing! the! participants,!which! equated! to! a! fifth! of! the! total! data,! significantly! reduced! the! statistical!power! but! had! only! subtle! effects! on! the! statistics! with! no! change! to! the!conclusions.! Therefore,! because! the! individual! results! obtained! from! these!participants!were!consistent!with!the!remaining!dataset!and!thus!did!not!appear!to! be! outliers,! they! were! included! in! the! final! analysis.! The! only! exception!occurred!with!the!T!cell!and!CD56+!subset!data.!One!of!the!participants!with!high!baseline!serum!cytokine! levels!did!not!stain!with!a!distinct!positive!population!for!CD3!with!any!of!the!antibodies!used!in!the!study!and!therefore!could!not!be!included!in!these!analyses.!!!
4.4.3.1 Monocytes,and,neutrophils,The! immunophenotyping! flow! cytometry!was! performed! on! a! Guava! easyCyte!8HT! (Merck! Millipore,! Germany).! This! machine! uses! a! capillary! system! that!requires! small! volumes! of! reasonably! dilute! samples! for! accurate! results.! The!effectiveness! of! the! red! blood! cell! lysis! step! varied! from! person! to! person;!therefore,! some! participants! had! a! higher! level! of! debris! in! the! samples! than!others.!For!this!reason,! the! forward!scatter! threshold!had!to!be! increased!for!a!number! of! samples! to! reduce! the! amount! of! debris! collected! and! ensure! an!adequate! number! of! leukocyte! events! were! acquired.! The! drawback! of! this!method!was!that!expressing!the!size!of!the!leukocyte!populations!as!a!proportion!of!the!total!singlet!events!was!not!comparable!between!all!participants.!Since!the!neutrophils!and!monocytes!are!clearly!identifiable!on!a!SSC!vs.!FSC!plot!and!are!
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unaffected! by! changes! in! the! FSC! threshold,! we! decided! to! express! the!proportion!of!neutrophils!and!monocytes!in!each!sample!relative!to!a!broad!total!neutrophil!and!monocyte!gate!that!was!constant!between!all!participants.!!The! proportion! of! circulating! CD14CCD16+! neutrophils! was! highly! consistent!across! the! time! points! examined,! whereas! there! was! a! significant! increase! in!CD14+CD16C/low! monocytes! at! 20! minutes,! which! appeared! to! return! to! the!baseline! levels! by! the! 4Chour! sample! (Figure! 4.8A! and! B).! There! was! no!difference! between! the! two! treatment! groups! in! the! proportions! of! either! cell!type.!The!total!neutrophils!and!monocytes!detected!at!each!time!point!accounted!for!approximately!85!–!90%!of!the!cells!contained!within!the!broad!SSC!vs.!FSC!gate.!The!unidentified!cells!did!not!express!any!of! the!markers!associated!with!the! subsets! examined! in! our! study! (T! cell! subsets,! NK! cells,! neutrophils,! and!monocytes)! therefore!were!most! likely! eosinophils,! and! immature! neutrophils!and!monocytes!not!yet!expressing!their!characteristic!cell!surface!markers.!!!The! expression! levels! of! the! activation! markers,! CD11b! and! CD63,! were! also!consistent! between! the! two! treatment! groups! in! both! cell! populations! (Figure!4.8C! –! F).! There! did,! however,! appear! to! be! a! fluctuation! in! the! overall! levels!between!time!points,!with!notably!higher!CD11b!and!CD63!detected!at!baseline!and!1!hour.!This!was!most!likely!attributable!to!a!small!difference!in!the!handling!procedure!for!these!two!time!points.!A!sample!of!the!blood!collected!at!baseline!and!1!hour!after!treatment!was!stimulated!for!15!minutes!to!examine!leukocyte!responsiveness.!During! the! stimulation,! the! remaining!blood!was!kept! at! room!temperature!and!this!extra!waiting!period!or!increase!in!handling!may!have!had!a! small! stimulatory! effect! on! some! of! the! blood! cells.! Although! this! makes! it!difficult!to!comment!on!the!impact!of!time!and!blood!sampling!on!resting!CD11b!and!CD63!levels! in!neutrophils!and!monocytes,! it! is!still!clear!that!RIPC!had!no!effect!on!these!markers,!compared!to!the!control!treatment.!!!!To! determine! whether! RIPC! altered! the! responsiveness! of! neutrophils! and!monocytes,! we! examined! activation! marker! expression! in! blood! samples!collected!at!baseline!and!1!hour,!and!stimulated!with!PMA/I!for!15!minutes.!This!
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brief! stimulation! resulted! in! a! significant! reduction! in! the! proportion! of! both!CD14CCD16+! neutrophils! and! CD14+CD16C/low! monocytes! (Figure! 4.9A! and! B).!This!change!most!likely!reflected!an!alteration!in!the!phenotypic!properties!used!to!gate!the!cell!subsets! following!stimulation!with!PMA,!as!has!been!previously!observed! in! both! monocytes! and! neutrophils! (Bazil! and! Strominger,! 1991;!Huizinga! et! al.,! 1990).! The! observed! change! in! proportions! of! the! cell! subsets!appeared!to!be!independent!of!RIPC!(Figure!4.9A!and!B).!!!PMA/I! stimulation! of! the! blood! significantly! increased! CD11b! and! CD63!expression! in! both! neutrophils! and!monocytes,! but! there! were! no! differences!between! the! two! treatment! groups! (Figure! 4.9C! –! F).! Interestingly,! the!neutrophil! CD63! levels!were! significantly! higher! in! the! samples! collected! at! 1!hour! postCtreatment,! compared! to! the! baseline,! irrespective! of! whether! the!sample!was!stimulated!or!not!(Figure!4.9E).!Given!this!effect!was!present!in!both!treatment! groups,! it! may! represent! a! minor! response! to! the! repeated! blood!sampling!and!confirms!the!ability!of!our!methods!to!detect!subtle!differences!in!CD63!expression.!!!
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Figure- 4.8- Size- and- activation- state- of- circulating- neutrophils- and-




after-RIPC-treatment-Blood!samples!were!collected!at!baseline!and!1!hour!after!treatment.!Following!rest! or! stimulation! with! PMA/I! (50! and! 500! ng/mL,! respectively),! cells! were!stained! in! duplicate! and! assessed! by! flow! cytometry.! Left:! CD14CCD16+!neutrophils!showing!(A)!total!proportion;!(C)!CD11b!MFI;!(E)!CD63!MFI.!Right:!CD16C/lowCD14+! monocytes! showing! (B)! total! proportion;! (D)! CD11b! MFI;! (F)!CD63! MFI.! A! threeCway! repeated! measures! ANOVA! was! used! to! compare! the!treatments!and!time!points,!with!Bonferroni!postChoc!tests.!*!p!<!0.05!and!***!p!<!0.001.!Shown!are!the!means!and!SEM!for!n!=!10!participants.!For!representative!data!plots!refer!to!appendix!F,!Figures!F.1!and!F2.!
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4.4.3.2 T,cell,subsets,Due!to!the!variability!in!the!FSC!threshold!between!participant!datasets!and!its!close! proximity! to! the! lymphocyte! population,! it! was! not! possible! to! create! a!general! lymphocyte! gate! using! SSC! vs.! FSC! that! was! comparable! between! all!individuals.!Because!of!this,!we!expressed!the!parent!CD3+!T!cell!population!as!a!proportion! of! the! total! singlet! events! collected,! as! this! measure! was! far! less!variable!between!participants.!All!subsequent!T!cell!subsets!were!expressed!as!a!percentage!of!the!total!CD3+!T!cells.!!!There! was! a! small! but! significant! reduction! in! CD3+! T! cells! after! 20! minutes,!irrespective!of!which! treatment! the!participants!received,!but!no!change! in! the!circulating!levels!of!CD3+CD4+!(CD4)!and!CD3+CD8+!(CD8)!T!cells!(Figure!4.10A,!C,!and!F).!A!small!population!of!double!positive!CD3+CD4+CD8+!T!cells!was!also!detected,! and! this! subset! did! not! appear! to! be! affected! by! preconditioning!(Figure! 4.10B).! Although! our! immunophenotyping! panels! included! CD25! as! a!marker!of!regulatory!cells,!the!poor!resolution!of!this!antibody!coupled!with!the!rare! expression! resulted! in! less! than! 3%! of! the! CD3+! cells! being! identified! as!CD25+.! This! low! number! of! events! was! insufficient! for! accurate! analysis! and!therefore!was!not!presented!in!this!thesis.!!!There! was! a! slight! reduction! in! the! proportion! of! CD4! T! cells! that! stained!positively!for!the!marker!of!naivety,!CD62L,!20!minutes!after!treatment!and!this!was!mirrored!by!a!significant!increase!in!the!CD62LC!CD4!T!cell!population!in!all!postCtreatment! samples! (Figure!4.10D!and!E).!The! change! in!proportion!of! the!CD62L!positive!and!negative!CD4!T!cell!subsets!was!the!same!with!and!without!preconditioning.!The!proportions!of! CD62L+! and!CD62LC! CD8! cells!were!highly!consistent!across!both!the!time!points!and!treatment!groups!(Figure!4.10G!and!H).!!!Expression! levels! of! the! early! T! cell! activation! marker! CD69! significantly!increased!in!the!CD4!T!cells!20!minutes!postCtreatment,!and!then!returned!back!to!baseline!levels!by!the!4!hour!time!point!(Figure!4.11A).!Both!the!CD62L+!and!CD62LC!CD4!T!cell!subsets!appeared!to!be!affected!equally!although,!as!expected,!
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the! effector!population!had! a! slightly!higher!baseline! level! of! CD69!expression!(Figure!4.11C!and!E).!In!contrast,!CD69!gradually!and!continually!declined!across!the! postCtreatment! time! points! in! both! the! CD62L+! and! CD62LC! CD8! T! cell!populations!(Figure!4.11B,!D,!and!F).!There!was!no!difference!between!the!two!treatments! with! respect! to! the! activation! states! for! any! of! the! T! cell! subsets!examined.!!!!!!!!!!!!!
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Figure-4.10-Proportions-of-circulating-T-cell-subsets-after-RIPC-Blood! samples! were! collected! from! healthy! volunteers! at! baseline,! and! 20!minutes,!1!hour,!and!4!hours!after!control!(grey!bars)!or!RIPC!treatment!(black!or! green! bars),! and! peripheral! leukocytes! were! assessed! in! duplicate! by! flow!cytometry.! (A)! Total! CD3+! lymphocytes;! (B)! double! positive! CD3+CD4+CD8+!lymphocytes;!(C)!total!CD3+CD4+!T!cells;!(D)!CD62L+!CD4!T!cells;!(E)!CD62LC!CD4!T!cells;!(F)!total!CD8+!T!cells;!(G)!CD62L+!CD8!T!cells;!(H)!CD62LC!CD8!T!cells.!A!twoCway! repeated!measures! ANOVA!was! used! to! compare! the! treatments! and!time!points,!with!Bonferroni!postChoc!tests.!*!p!<!0.05!and!***!p!<!0.001.!Shown!are!the!means!and!SEM!for!n!=!9!participants.!For!representative!data!plots!refer!to!appendix!F,!Figures!F.3,!F.4,!and!F.5.!!
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Figure-4.11-CD69-expression-in-T-cell-subsets-following-RIPC-treatment-Blood! samples! were! collected! from! healthy! volunteers! at! baseline,! and! 20!minutes,! 1! hour,! and! 4! hours! after! control! or! RIPC! treatment,! and! peripheral!leukocytes!were!assessed!in!duplicate!by!flow!cytometry.!Left:!CD69!MFI!in!CD4!T! cells! for! (A)! total! population;! (C)! CD62L+! subset;! (E)! CD62LC! subset.! Right:!CD69!MFI!in!CD8!T!cells!for!(B)!total!population;!(D)!CD62L+!subset;!(F)!CD62LC!subset.! A! twoCway! repeated! measures! ANOVA! was! used! to! compare! the!treatments! and! time! points,! with! Bonferroni! postChoc! tests.! *! p! <! 0.05,! **! p! <!0.01,!and!***!p!<!0.001.!Shown!are!the!means!and!SEM!for!n!=!9!participants.!For!representative!data!plots!refer!to!appendix!F,!Figures!F.4!and!F.5.!
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4.4.3.3 CD56+,cell,subsets,A! small! population! of! CD56+! cells! was! detected! amongst! the! lymphocytes,!comprising! approximately! 50! –! 60%!CD3CCD56+CD16+!NK! cells,! and!20! –! 30%!CD3+CD56+CD16C/+! NKT! cells.! Neither! population! significantly! changed! in! size!across! the! time! points,! or! between! the! control! and! RIPC! treatments! (Figure!4.11A! C! C).! Similarly! to! what! was! seen! with! the! CD4! T! cells,! NK! cell! CD69!expression!significantly!increased!20!minutes!postCtreatment!and!then!returned!back!to!baseline! levels!by!the!4!hour!time!point! in!both!groups!(Figure!4.11D).!This! change! in! activation! state!of! the!NK!cells!was! consistent!with! the!parallel!reduction! in! the! proportion! of! CD62L+! NK! cells! and! increase! in! CD62LC! NK!population!(Figure!4.11E!and!F).!!!!!!!!!!!!!!!
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!
Figure-4.12-Proportion-and-activation-of-circulating-CD56+-cells-after-RIPC-Blood! samples! were! collected! from! healthy! volunteers! at! baseline,! and! 20!minutes,!1!hour,!and!4!hours!after!control!(grey!bars)!or!RIPC!treatment!(black!or!coloured!bars),!and!peripheral!leukocytes!were!assessed!in!duplicate!by!flow!cytometry.! (A)! Total! CD56+! lymphocytes;! (B)! CD3+CD56+! NKT! cells;! (C)! total!CD3CCD56+CD16+! NK! cells! (D)! CD69!MFI! in! NK! cells;! (E)! CD62L+! NK! cells;! (F)!CD62LC!NK!cells.!A!twoCway!repeated!measures!ANOVA!was!used!to!compare!the!treatments!and!time!points,!with!Bonferroni!postChoc!tests.!*!p!<!0.05.!Shown!are!the!means!and!SEM!for!n!=!9!participants.!For!representative!data!plots!refer!to!appendix!F,!Figures!F.3!and!F.5.!
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4.5 Discussion-The! aim! of! this! chapter! was! to! investigate! the! direct! effect! of! RIPC! on! the!systemic!immune!response!in!healthy!volunteers.!We!found!that!preconditioning!reduced! the! expression! of! both! MIPC1α! and! MIPC1β,! but! did! not! alter! serum!concentrations! of! other! key! cytokines,! including! ILC6! and! ILC8.! RIPC! did! not!change! the! phenotype! of! resting! immune! cells,! nor! did! it! affect! the! ability! of!neutrophils!or!monocytes!to!become!activated!in!response!to!a!brief!stimulation.!Although! the! systemic! response! to! preconditioning! was! minimal,! numerous!changes! in! the! levels! of! inflammatory!markers!were!detected! across! the! study!time!points!for!both!treatments,!suggesting!the!influence!of!a!diurnal!rhythm,!or!that!the!venepunctures!alone!elicited!a!subtle!but!significant!immune!response.!!Our!study!is!the!first!to!show!that!RIPC!reduces!systemic!levels!of!both!MIPC1α!and! MIPC1β.! Increased! expression! of! the! MIP! family! of! chemokines! has! been!frequently! associated! with! responses! to! ischaemic! conditions! and! oxidative!stress! including! stroke,!myocardial! infarction,! and! cardiac! surgery! (de! Jager! et!al.,!2008;!Kim!et!al.,!2009;!Vandervelde!et!al.,!2007;!Zaremba!et!al.,!2006).!The!exact! role! of! MIPC1α! and! β! in! the! setting! of! ischaemia! is! not! clear,! but! these!proteins! are! most! commonly! known! for! their! trafficking! effects! on! T! cells,!monocytes,!dendritic!cells,!and!NK!cells,!and!have!also!been!implicated!in!driving!a! proinflammatory! Th1! response! through! modulating! helper! T! cell!differentiation!(Karpus!and!Kennedy,!1997;!Maurer!and!von!Stebut,!2004).!!!MIPC1αCinduced!chemotaxis!of!monocytes!may!have!a!beneficial! role! in!wound!repair;!however,!the!net!effect!of!MIPC1α!and!β!appears!to!enhance!and!facilitate!inflammatory!processes!(DiPietro!et!al.,!1998;!Maurer!and!von!Stebut,!2004).!It!is!therefore!not!surprising!that!MIPC1α!has!been!implicated!in!the!pathology!of!lung! I/R! injury,! and! that! antiCMIPC1α! therapy! significantly! decreases! vascular!permeability! and! neutrophil! infiltration,! reducing! lung! injury! by! 37%!(Krishnadasan! et! al.,! 2004).! Further,! I/R! injury! is! associated!with! polarisation!towards! a! Th1! response,! which! may! be! facilitated! by! MIPC1α! (Karpus! and!Kennedy,! 1997;! Sullivan! et! al.,! 2009).! Overall,! the! literature! suggests! that! a!reduction! in! MIPC1! levels! would! be! expected! to! be! protective! in! I/R! injury,!
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potentially!reducing!immune!cell!infiltration!and!lessening!the!magnitude!of!the!inflammatory!response.!!!Interestingly,! we! also! noted! a! trend! towards! a! reduction! in! circulating! GCCSF!levels! following!preconditioning.!GCCSF! is! the!primary!cytokine! involved! in! the!regulation!of!granulocytopoiesis!and!an!absence!of!GCCSF!results!in!neutropenia!(Lieschke! et! al.,! 1994).! A! decrease! in! circulating! GCCSF! could! result! from!increased!binding! to!receptors!on!precursor!cells! in! the!bone!marrow,!or! from!mechanisms! that! promote! its! degradation.! Neutrophils! are! shortClived! cells,!reportedly!surviving!between!10!hours!and!5!days!in!the!circulation!and!for!an!even!shorter!period!following!activation!and!infiltration!into!the!tissues!(Dancey!et! al.,! 1976;! Pillay! et! al.,! 2010).! Consequently,! up! to! 1011! new! neutrophils! are!produced! daily! in! healthy! individuals,! and! changes! to! granulocytopoiesis! can!significantly! alter! the! circulating! pool! of! cells! within! a! short! period! of! time!(Demetri! and! Griffin,! 1991).! It! is! not! possible! to! comment! on! whether! RIPC!altered!neutrophil!production!based!on!the!results!of!our!study,!but!our!finding!that!GCCSF! levels!may!be!decreased!following!preconditioning!warrants! further!investigation!in!future!work.!!!The!impact!of!RIPC!on!cytokine!expression!in!humans!is!a!contentious!topic,!with!little! agreement! between! the! studies! performed! to! date.! Konstantinov! et# al.#(2004)! reported! that! RIPC! leads! to! suppression! of! the! three! essential! kinases!involved! in! TNF! synthesis! during! both! the! early! and! late! phases,! suggesting!preconditioning! reduces! levels! of! at! least! one! key! inflammatory! cytokine.! This!work!was! supported! by! a! study! of! lateCRIPC! in! infants! undergoing! ventricular!septal!defect!repair!that!showed!a!reduction!in!postCoperative!levels!of!ILC6,!ILC8,!and!TNFCα!(Zhou!et!al.,!2010).!In!contrast,!a!recent!trial!in!adult!cardiac!surgery!patients!determined!that!RIPC!not!only!increased!systemic!levels!of!ILC1β,!ILC8,!and! TNFCα! levels! directly! after! the! intervention,! but! also! upregulated! postCbypass!ILC1β!levels!in!right!atrial!tissue!biopsies!(Albrecht!et!al.,!2013).!Further,!Shimizu!et#al.#(2010)!demonstrated!that!repeated!RIPC!increases!the!capacity!of!neutrophils!to!produce!ILC1β,!ILC6,!and!TNFCα!in!response!to!LPS!challenge.!!!
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Our!finding!that!RIPC!does!not!directly!increase!systemic!levels!of!a!range!of!key!cytokines! is! consistent! with! our! results! from! the! highCrisk! cardiac! surgery!patient!trial,!and!further!supports!our!assertion!that!a!cytokine!is!unlikely!to!be!the! humoral! factor! responsible! for! transmitting! an! immediate! protective! RIPC!signal.!In!particular,!the!lack!of!change!in!ILC6!and!ILC8!levels!in!the!present!study!verify! that! the! slightly! increased! levels! of! these! cytokines! detected! in! our!preconditioned!cardiac!surgery!patients!were!most!likely!either!unrelated!to!the!RIPC!treatment,!or!the!result!of!an!indirect!effect!of!the!intervention.!!!In!the!absence!of!a!critical!role!in!the!initiation!of!RIPC,!any!beneficial!functions!conferred!by!inflammatory!cytokines!during!I/R!injury!are!likely!outweighed!by!their! tissueCdestructive! effects.! Interestingly,! MIPC1! is! known! to! stimulate! the!release! of! ILC6;! therefore,! based! on! the! reduced! expression! of! MIPC1α! and! β!detected!in!our!healthy!volunteers,!it!would!be!reasonable!to!expect!that!the!ILC6!levels! induced! during! I/R! injury! would! be! lower! following! the! successful!application! of! RIPC! (Fahey! et! al.,! 1992).! In! addition,! many! of! the! pathways!implicated! in! the!mechanism!of!RIPC,! such!as! the!reduction! in!TLR!expression,!appear!to!converge!to!suppress!NFCκB!and!the!associated!inflammatory!response!genes,!which! include!numerous!cytokines! (Li!et!al.,!2001;!Morgan!et!al.,!1999).!We!believe!the!results!of!the!present!study!add!weight!to!the!existing!literature!supporting!the!argument!that!RIPC!either!does!not!directly!alter!cytokine!levels,!or!reduce!the!cytokine!response!to!I/R!injury.!!!There! is! mounting! evidence! that! RIPC! leads! to! increased! accumulation,!stabilisation,!and!activation!of!the!hypoxiaCtriggered!transcription!factor!subunit!HIFC1α! (Cai! et! al.,! 2012;! Kant! et! al.,! 2008;! Ke! and! Costa,! 2006).! Recently,!increased! levels! of! HIFC1α! have! even! been! measured! in! human! atrial! tissue!biopsies! directly! after! limb! RIPC,! prior! to! I/R! injury! (Albrecht! et! al.,! 2013).!Activated! HIFC1α! stimulates! expression! of! hundreds! of! genes,! including! the!cytokines! ILC1β,! MCPC1,! and! ILC10! (Cai! et! al.,! 2013;! MojsilovicCPetrovic! et! al.,!2007;! W.! Zhang! et! al.,! 2006).! Although! the! early! phase! of! RIPC! is! typically!associated! with! the! release! or! modification! of! preCformed! mediators,! it! is!interesting!to!note!that!we!found!no!change!in!the!circulating!levels!of!ILC1β!or!
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ILC10,! and! MCPC1! significantly! decreased! across! the! time! points! for! both!treatment!groups!in!our!study.!!!It! has! been! suggested! that! because! the! effects! of! HIFC1α! depend! on! gene!transcription!it!may!be!more!relevant!to!the!late!phase!of!RIPC,!rather!than!the!early!response!(Sadat,!2009).!We!sampled!serum!levels!up!to!4!hours!following!treatment,!which!is!slightly!beyond!the!reported!endpoint!of!the!early!window!of!protection,! and! could! theoretically! allow! sufficient! time! for! cellular! signalling,!gene!transcription,!mRNA!processing,!and!translation!of!a!measurable!amount!of!protein.!Although!total!protein!levels!may!be!significantly!higher!24!hours!later,!it! is! possible! that! subtle! changes! to! systemic! cytokine! transcription! and!expression!could!have!been!detectable!in!our!4Chour!samples.!It!therefore!seems!likely!that!the!impact!of!HIFC1α!activation!on!cytokine!production!may!be!tissue!specific,!and/or!of!a!magnitude!not!strong!enough!to!alter!systemic!levels!during!the!early!window!of!protection! (Stroka!et!al.,!2001).!Alternatively,!we!may!not!have!met!the!threshold!for!inducing!HIFC1α!with!our!preconditioning!regimen.!A!last!possibility!concerns!the!debate!regarding!the!exact!position!of!HIFC1α!in!the!RIPCCinduced!signalling!pathway!(Heusch,!2012).!Although!HIFC1α! is!known!to!stimulate! cytokine! production,! the! transcription! factor! can! also! be! induced! by!cytokines,!therefore!increased!HIFC1α!activity!may!not!precede!an!increase!in!ILC1β,!MCPC1,!and!ILC10!levels!during!preconditioning.!Regardless!of!the!underlying!mechanism,!we!did!not!find!any!indirect!suggestion!that!HIFC1α!might!contribute!to! the! induction! of! preconditioning! by! influencing! transcription! of! these!cytokines! during! the! early! window! of! protection,! using! the! standard! RIPC!stimulus.!!!Many!theories!have!been!proposed!regarding!how!RIPC!may!affect!neutrophils!in!order!to!blunt!the!damage!elicited!by!I/R!injury.!It!is!possible!that!RIPC!directly!activates! neutrophils,! leading! to! their! infiltration! of! the! preconditioned! tissue!and! thus! limiting! the! number! of! cells! available! to! cause! damage! in! organs!subsequently!exposed!to!prolonged!periods!of!ischaemia.!We!found!no!change!in!the!proportion!of!circulating!neutrophils,!or!any!of! the!other! leukocyte!subsets!examined,! indicating!that!RIPC!did!not!promote!extravasation!of!any!individual!
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immune!cell!populations.!Further,!we!found!no!change!in!expression!levels!of!the!activation! marker,! CD11b,! in! unstimulated! or! briefly! stimulated! neutrophils!following! RIPC! treatment.! Taken! together,! these! results! strongly! counter! the!suggestion!that!preconditioning!activates!and!sequesters!neutrophils.!!!The! lack!of! leukocyte! transmigration! following!RIPC!appeared! to!be! consistent!with! the! unaltered! levels! of! the! soluble! adhesion! factors! associated! with! cellCendothelial! interactions! that! were! measured! in! the! serum! samples.! ICAMC1!mRNA!levels!have!been!shown!to!significantly!increase!one!hour!after!I/R!injury!in!both!murine!and!canine!models,!and!the!protective!effect!detected!in!ICAMC1!depleted!or!deficient!animals!has!highlighted!the!critical!role!this!adhesion!factor!plays! in! I/R! induced! tissue!pathology! (Kelly! et! al.,! 1996;!Kukielka! et! al.,! 1993;!Rabb! et! al.,! 1995).! ICAMC1! is! constitutively! expressed!on! endothelial! cells,! and!the! upregulation! detected! following! I/R! appears! to! be! predominantly! from!cardiac!myocytes.!Extracellular!expression!of!ICAMC1!in!myocytes!is!measurable!within!six!hours!of! reperfusion;!however,! soluble! ICAMC1! levels!are!unlikely! to!mirror! this! increase!until! sufficient!proteolytic! cleavage!of! the!protein! into! the!circulation!occurs!(Kukielka!et!al.,!1993).!Similarly,!ECselectin! is!not!stored!and!therefore!must!be!produced!upon!stimulation.!Although!it!can!be!formed!within!two!hours!and!reaches!maximal!levels!four!to!eight!hours!after!induction,!newly!synthesised!ECselectin! is!not! shed! into! the!circulation!until!18!–!48!hours! later!(Pigott!et!al.,!1992).!!The! kinetics! of! ICAMC1! and! ECselectin! expression! suggest! that! even! if! RIPC!induced! a! significant! change! in! the! cellular! expression! of! these!molecules! that!contributed!to!the!early!window!of!protection,!the!time!points!in!our!study!most!likely!would!not!have!been!able!to!capture!this!change!through!the!measurement!of! serum! levels! of! the! soluble! forms.! Serum! samples! collected! 24! –! 48! hours!following!preconditioning!would!be!preferable!for!capturing!peak!soluble!ICAMC1!and!ECselectin!levels;!however,!this!endpoint!would!still!lack!the!information!to!decipher!when!cellular!expression!of! the!adhesion!molecules! increased,!and!on!which! cell! types.! Future! studies!where! ICAMC1! is! a!major! focus!would! benefit!from!the!use!of!flow!cytometry!to!perform!a!more!detailed!analysis!of!leukocyte!
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expression! levels.! From! the! present! study! we! can,! however,! rule! out! the!possibility! that! RIPC! induces! shedding! of! ICAMC1! and! ECselectin! into! the!circulation!within!4!hours!of!the!intervention.!!!!Our! finding! that! preconditioning! did! not! increase! CD11b! expression! on!peripheral! neutrophils! up! to! four!hours! following! treatment! is! consistent!with!three!previous!studies!also!performed!with!healthy!volunteers!(Kharbanda!et!al.,!2001;!Konstantinov!et!al.,!2004;!Shimizu!et!al.,!2010).! Interestingly,!Kharbanda!and! colleagues! followed! their! preconditioning! protocol! with! a! twenty! minute!sustained!inflation!of!the!blood!pressure!cuff!on!the!upper!arm!to!simulate!a!mild!I/R! injury,! and! found! that! IPC! attenuated! the! ischaemiaCinduced! increase! in!CD11b! expression.! In! contrast,! when!we! stimulated! RIPCCexposed! neutrophils!for!15!minutes! in#vitro!to!simulate!an!immune!stimulus,!we!found!no!change!in!the!ability!of!neutrophils! to!become!activated!after!preconditioning.!Shimizu!et#
al.# also! reported! a! similar! lack! of! change! in! CD11b! expression! with! fMLP!stimulation! of! neutrophils! sampled! one! day! postCpreconditioning.! Further,!Konstantinov! et# al.# found! that! although! CD11b! levels! were! unchanged! fifteen!minutes! after! treatment,! there! was! a! significant! reduction! in! CD11b! on!circulating!neutrophils!24!hours! later,! yet! Shimizu!et#al.# found!no! such! change!using!the!same!timeframe.!!!The! reason! for! the!discrepancies!between! the!RIPC!studies!with! respect! to! the!effect! on! neutrophils! is! unclear.! The! ex# vivo# treatment! of! neutrophils! using!pharmacological! stimulants! (PMA/I)! or! agents! derived! from! bacterial! origins!(fMLP)!may! signal! through! a! different! pathway! than! I/R! injury! and! therefore!elicit!different!results,!or!minor!differences!in!the!design!and!methodology!of!the!studies!may!have!contributed.!While!all!four!studies!conclude!that!RIPC!does!not!directly! alter! the! activation! state! of! circulating! neutrophils! during! the! early!window!of! protection,! further!work! is! required! to! clarify! how!preconditioning!impacts! these! cells! following! a! subsequent! stimulation! and!during! the!delayed!phase!of!protection.!!!
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After! stimulation! of! whole! blood! samples! as! part! of! our! immunophenotyping!protocol,! we! detected! a! significant! decrease! in! the! proportions! of! neutrophils!and!monocytes! in! the!samples.!Because! the!assay!was!performed! in#vitro,!with!nowhere!for!the!cells!to!migrate!and!insufficient!time!for!cellular!disintegration!in!cases!of!death,!there!was!no!physiological!explanation!for!the!decrease!in!the!size!of!these!populations.!Instead,!the!change!most!likely!reflected!a!difference!in!the!phenotypic!properties!of!the!stimulated!cells.!PMA!treatment!has!previously!been!shown!to!result!in!marked!CD14!shedding!in!monocytes,!with!a!30!minute!stimulation! leading! to! as! much! as! a! 60%! reduction! in! extracellular! CD14!expression! (Bazil! and! Strominger,! 1991).! Our! results! extend! this! time! range,!suggesting!that!significant!PMACinduced!CD14!shedding!can!occur!with!as! little!as! 15! minutes! of! treatment.! Huizinga! et# al.# (1990)! reported! a! significant!reduction! also! occurs! with! neutrophil! CD16! expression! in! response! to! a! 10!minute!PMA!stimulation.!The!reduction!in!neutrophils!and!monocytes!identified!by! flow! cytometry! in! our! study! following! PMA! treatment! was! thus! consistent!with!the!existing!literature,!and!appeared!to!be!independent!of!RIPC.!!Increased!CD63!expression!in!neutrophils!was!detected!by!Shimizu!et#al.#(2010)!24!hours!after!RIPC!and!we!were! interested!in!whether!this!change!might!take!effect!during! the!early!window!of!protection.!However,!we! found!no!change! in!CD63! expression! on! resting! or! stimulated! neutrophils! and!monocytes! up! to! 4!hours!postCRIPC,!suggesting!that!induction!of!neutrophil!exocytosis!is!limited!to!the! late! phase! of! RIPCCinduced! protection.! Interestingly,! there! is! increasing!evidence!that!the!impact!of!preconditioning!on!the!immune!response!in!general!may! be! more! relevant! during! the! second! window! of! protection.! Both! cardiac!surgery! and! gene! expression! studies! in! humans! have! suggested! inflammatory!cytokine!production!is!attenuated!20!–!24!hours!following!RIPC!administration,!during! the! late!phase! (Konstantinov!et! al.,! 2004;!Wei! et! al.,! 2001b;!Zhou!et! al.,!2010).! Further,! the! effects! of! RIPC! on! neutrophil! adhesion! and! kinin! receptor!expression!have!also!been!detected!the!day!following!RIPC!treatment!(Saxena!et!al.,!2010b;!Shimizu!et!al.,!2010).!The! time!points! in!our!study!were!selected! to!assess!the!effect!of!RIPC!on!the!first!phase!of!protection,!and!our!results!suggest!that! RIPC! has! only! minor,! subtle! effects! on! the! immediate! immune! response.!
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Further!work!will!be!required!to!determine!if!changes!to!the!immune!response!are!more!predominant!during!the!second!window!of!protection,!rather!than!the!early!phase!that!has!commonly!been!explored!in!cardiac!surgery!trials.!!An!unanticipated!finding!from!our!study!was!the!significant!change!in!numerous!variables,!independently!of!the!application!of!RIPC.!Serum!levels!of!MCPC1!were!significantly! decreased! in! both! treatment! groups,! along!with! reductions! in! the!proportion! of! circulating! CD3! and! CD8! T! cells,! and! naïve! NK! and! CD4! T! cell!populations.! In!contrast,! levels!of!monocytes,!CD4!T!cells,!and!CD69!expression!in! the!NK!population! significantly! increased!20!minutes!after!either! treatment,!and!higher!levels!of!effector!NK!and!CD4!T!cell!subsets!were!detected!at!all!postCtreatment!time!points.!Altogether,!these!changes!suggest!a!general!inflammatory!process! occurred! following! the! baseline! blood! sample! collection! during! both!study!visits.!Given!the!consistency!of!the!changes!between!the!participants,!this!most! likely! reflects! a! response! to! the! repeated! venipunctures! or! the! effects! of!circadian! rhythm.! Indeed,! it! is!well! established! that! small! changes! in! cytokine!expression! and! leukocyte! levels! follow! a! 24! hour! cyclical! pattern,! and! our!participants! all! started! their! study! visits! around! the! same! approximate! time;!however,! it! is!also!possible! that!stress!associated!with!participating! in! the! trial!may!have!contributed!(Born!et!al.,!1997).!!The! significant! inflammatory! response! detected! in! both! treatment! groups!highlights!the!necessity!of!carefully!designed!and!controlled!trials.!Had!we!relied!on!measuring!the!effects!of!RIPC!by!solely!comparing!postCtreatment!samples!to!the! baseline! results,! these! changes! could! have! easily! been! mistaken! for! the!effects! of! preconditioning.! Instead,! including! an! entirely! separate! control!treatment!for!each!participant!enabled!us!to!distinguish!the!legitimate!effects!of!RIPC! from! the! minor! inflammatory! response! to! blood! collection,! circadian!rhythm,! and/or! trial! participation.! Further,! these! findings! confirmed! that! our!assays!had!the!sensitivity!required!to!pick!up!subtle!changes!in!our!end!points,!as!per!the!goal!of!our!assay!testing!process.!!
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While! the! clinical! efficacy! of! RIPC! remains! to! be! determined,! no! trials! have!reported! any! adverse! effects! resulting! from! preconditioning! to! date.! The! nonCinvasive!nature!of!RIPC!coupled!with!its!consistent!track!record!means!that!it!is!widely!accepted!as!having!a!solid!safety!profile,!and!our!finding!that!RIPC!elicits!only!minor!direct! responses! from! the! immune! system!are! in!keeping!with! this!belief! (CamaraCLemarroy,! 2014;! Candilio! et! al.,! 2011).! However,! the! lack! of!change! in! systemic! cytokine! levels!and! immunophenotype!of! resting! cells!does!not! preclude! the! possibility! that! RIPC! alters! the! way! the! immune! system!responds! to! subsequent! challenges.! To! fully! characterise! the! impact! of!preconditioning,! it! will! be! necessary! to! assess! the! changes! in! functional!responses!of!the!immune!cells,!such!as!would!be!encountered!during!I/R!injury.!!!A!limitation!of!our!study!was!the!small!sample!size!and!high!number!of!statistical!tests! performed! on! the! data! set.! The! trial! was! designed! as! a! hypothesisCgenerating! study,! which! involved! measuring! a! broad! range! of! endpoints! at!multiple!time!points!to!increase!the!likelihood!of!capturing!any!small!changes!to!the! immune! response! induced! by! RIPC.! Analysing! our! full! dataset! from! both!Chapters!4!and!5!thus!necessitated!just!over!200!individual!ANOVAs!and!tCtests.!The! probability! of! encountering! a! type! I! error,! which! involves! an! incorrect!rejection!of!the!null!hypothesis,! is! increased!with!each!test!performed.!At!a!5%!significance! level,! we! would! expect! to! falsely! reject! the! null! hypothesis! (that!there! was! no! difference! between! the! treatment! groups! or! time! points)!approximately! 10! times.!We! found! statistically! significant! differences! in! vastly!more! than! 10! variables,! most! of! which! were! between! time! points! or! culture!conditions,!rather!than!the!control!and!RIPC!treatments.!Such!significant!changes!were!consistent!with!our!biological!expectations! for! the!samples!and! therefore!appeared! to! be! legitimate! differences;! however,! our! overall! results! must! be!considered!within!the!context!of!this!statistical!limitation!and!we!are!hesitant!to!draw!definitive!conclusions!about!the!direct!effect!of!RIPC!from!this!study.!Our!primary! aim! was! to! identify! parameters! of! interest! for! future,! more! focused!research,!and!our!analysis!was!appropriate!and!successful!for!this!purpose.!!!
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Our! sample! size!was!calculated! to!give!us!adequate!power! for!detecting! subtle!changes! in! serum!cytokine! levels;!however,! signs!of! inflammatory!processes! in!two! of! our! participants! led! to! the! exclusion! of! their! data! from! parts! of! the!analysis.! The! paired! nature! of! our! trial! design! strengthened! our! ability! to!measure! subtle! differences! in! the! responses! and,! indeed,! we! did! detect!significant!differences!between!the!groups!even!when!the!dataset!was!reduced!to!8!participants.!That!said,!collecting!data!from!a!higher!number!of!individuals!when!feasible!in!future!studies!would!be!advisable.!!!Many!of!our!endpoints!were!assessed!using!repeated!measures!ANOVA,!which!is!a! statistical! test!known! to!be!dependent!on!data! sphericity.!The!assumption!of!sphericity! requires! that! the! variances! of! the! differences! between! the! levels! of!each! variable! are! equal! (Field,! 1998).! This! assumption! can! be! tested! using!Mauchly’s!Test!of!Sphericity;!however,!this!method!performs!poorly!with!sample!sizes!as!small!as!those!used!in!the!present!study,!often!failing!to!detect!deviations!from! sphericity.! To! ensure! that! we! were! not! violating! the! assumptions!underlying! our! ANOVA! results,! we! used! the! GreenhouseCGeisser! correction! to!lower!the!degrees!of!freedom!and!increase!the!pCvalue,!thus!minimising!the!risk!of!a!type!I!error!(Greenhouse!and!Geisser,!1959).!!!The! GreenhouseCGeisser! correction! is! the! most! conservative! method! for!calculating! pCvalues! without! assuming! sphericity;! therefore,! one! drawback! of!this! approach! is! that! we! may! have! reduced! our! power! to! detect! significant!differences! in! our! dataset! (Field,! 1998;! Greenhouse! and! Geisser,! 1959).!Ultimately,! finding! the! balance! between! maintaining! statistical! power! and!offsetting! the! likelihood! of! a! type! I! error! when! analysing! data! from! an!exploratory! study! is! challenging! and,! despite! the! steps! undertaken! to!appropriately!manage!the!statistical!analyses,!our!results!must!be!interpreted!in!the!context!of!this!issue.!!!Lastly,! the!methodology! for!measuring! CD11b! and! CD63! in! both! unstimulated!and! stimulated! neutrophils! and! monocytes! using! the! same! samples! could! be!improved! for! future! studies.! Either! the! pipetting! associated!with! removing! an!
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aliquot! of! blood! for! the! stimulation,! or! the! twenty! minute! delay! where! the!‘unstimulated’! blood! was! left! at! room! temperature,! resulted! in! a! substantial!increase! in! MFI! for! both! markers,! compared! to! the! time! points! where! only!unstimulated!blood!was!used!and!samples!were!stained! immediately.!Although!we!are!reasonably!confident!that!RIPC!did!not!alter!the!expression!of!CD11b!or!CD63,!this!difference!did!reduce!our!ability!to!measure!subtle!changes.!Staining!the!unstimulated! samples! immediately!after! collection!and! the! stimulated!cells!separately! could! have! circumvented! this! issue! and! would! be! preferable! for!future!experiments.!Of!note!is!that!the!error!bars!for!these!measurements!were!small,! confirming! that! the! effect! was! similar! for! all! participants! and! that! our!development!of!protocols! to!ensure!samples!were!handled! identically!between!visits!was!effective.!!!










5.1 Introduction-Although! the! majority! of! the! literature! addressing! I/R! injury! focuses! on! the!damage! mediated! by! the! innate! immune! response,! the! cells! of! the! adaptive!immune!system!also!play!a!crucial!role.!The!main!cells!of!the!adaptive!response!are!the!B!and!T!lymphocytes,!although!there!is!increasing!evidence!that!NK!cells!also!exhibit!many!of!the!traits!associated!with!the!acquired!arm!of!the!immune!system! (Vivier! et! al.,! 2011).! The! adaptive! immune! system! predominantly!responds! to! specific! foreign! antigens! and! develops! an! immunological!memory!that! enables! faster! future! responses! to! infection! with! the! same! pathogen;!however,! under! certain! circumstances! including! during! I/R! injury,! T! cells! can!also! be! activated! in! an! antigenCindependent! fashion! (Strainic! et! al.,! 2008;!Unutmaz!et!al.,!1994).!!!
5.1.1 Evidence-that-preconditioning-alters-the-adaptive-immune-response-Studies!investigating!the!time!course!of!RIPC!found!the!protection!might!persist!for!several!weeks,!which!seemed!unlikely!to!be!mediated!by!the!shortClived!cells!of!the!innate!immune!response!and!thus!highlighted!a!potential!role!for!the!cells!of! the! adaptive! system! (Neckár! et! al.,! 2004;!Park! et! al.,! 2003).! Further,!BurneCTaney!et#al.#(2006)!demonstrated!that!adoptive!transfer!of!immune!cells!from!a!wild! type! (WT)! mouse! subjected! to! renal! I/R! into! a! nude! mouse,! which! are!deficient! in!T!cells,!was!protective!against!a!subsequent! ischaemic! injury!in!the!recipient.!This!protection!was!observed!using!cells! transferred!5!days!after! the!initial! insult! and! was! not! associated! with! a! reduction! in! neutrophil! and!macrophage!infiltration!in!the!nude!mice,!suggesting!the!effect!was!mediated!by!cells!of!the!adaptive!immune!system.!Similarly,!Ascon!et#al.#(2006)!found!transfer!of!lymphocytes!isolated!from!the!kidney!24!hours!postCI/R!injury!into!nude!mice!reduced! the! extent! of! damage! from! I/R! induced! 24! hours! later.! Despite! these!initial! promising! studies,! there!was! limited! literature! evaluating! the! impact! of!IPC! on! the! adaptive! immune! response! at! the! time! we! designed! our! study;!however,!what!was!available!suggested!there!were!important!links!between!IPC!and!the!responses!of!certain!T!cell!subsets!during!I/R.!!!!
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5.1.1.1 Regulatory,T,cells,Delayed! ischaemic!preconditioningCinduced! increases! in!Treg!populations!have!been!associated!with!a!protective!response! in!two!murine!studies.!Kinsey!et#al.#(2010)! found! that! IPC! significantly! reduced! kidney! damage! caused! by! an! I/R!injury!induced!7!days!later!and!this!was!associated!with!an!increase!in!Treg!and!CD4+CD25+!ILC10!producing!cells!in!the!outer!medulla!interstitium!of!the!kidney,!which!is!the!region!most!vulnerable!to!ischaemic!damage.!This!protective!effect!was!not!detected!when! the! I/R!was! inflicted!3!days!after! IPC,!before! the! renal!Treg!accumulation!occurred.!Antibody!depletion!of!the!Treg!population!partially!reversed! this! beneficial! effect! and! increased! neutrophil! infiltration,! whereas!adoptive! transfer! of! Tregs! prior! to! I/R! in! nonCpreconditioned!mice! induced! a!similar! antiCinflammatory! protective! effect! in! the! kidney! to! that! seen!with! IPC!(Kinsey!et!al.,!2010).!!!!Similar! results! were! seen! in! a! study! by! Cho! et# al.# (2010),! where! IPC! was!associated!with! an! increase! in! the! number! of! kidney!Tregs! and! a! reduction! in!renal! damage! and! inflammation! following! I/R! induced! one! week! later.!Splenocytes! from! preconditioned! animals! showed! reduced! proliferation! and!inflammatory!cytokine!production!in!response!to!ex#vivo#T!cell!receptor!(TCR)!or!LPS! stimulation,! compared! to! the! sham! operated! mice.! There! was! also! a!reduction! in! the! in# vivo# neutrophil! infiltration! of! the! kidney.! Depletion! and!adoptive! transfer! of! Tregs! partially! attenuated,! and! then! reinstated,! the!protective!effects!of!the!IPC!(Cho!et!al.,!2010).!!!A!study!investigating!the!use!of!an!adenosine!A1!receptor!agonist!as!a!means!of!pharmacologically! preconditioning! mice! against! lymphocyteCmediated!inflammation!reported!an!inhibitory!effect!that!was!associated!with!an!increase!in! Tregs! following! ex# vivo! stimulation! of! isolated! splenocytes! (Naamani! et! al.,!2014).!Further,! IPC!has!been!shown! to! induce!CD39!expression!during!hepatic!protection! against! I/R! (Hart! et! al.,! 2010).! CD39! is! a!membraneCbound! protein!frequently!found!on!Tregs,!which!hydrolyses!extracellular!ATP!and!ADP!to!AMP!(Dwyer!et!al.,!2007).!Thus,!CD39!contributes!to!the!antiCinflammatory!effects!of!Tregs! by! both! reducing! the! circulating! levels! of! proinflammatory! ATP! and!
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through!generating!AMP,!which!is!subsequently!degraded!into!adenosine.!Given!the!reported! involvement!of!adenosine!signalling! in! the! induction!of! IPC,! these!studies! add! further! weight! to! research! suggesting! an! increase! in! Tregs! may!contribute!to!the!delayed!window!of!protection!with!preconditioning.!!
5.1.1.2 Helper,and,cytotoxic,T,cell,responses,There!has!been!limited!research!investigating!the!effect!of!IPC!on!CD4!and!CD8!T!cell!responses;!however,!a!clinical!study!in!patients!undergoing!cruciate!ligament!surgery!has!suggested!preconditioning!modulates!helper!T!cell!responses!while!having! only! minor! effects! on! the! cytotoxic! T! cell! population! (Sullivan! et! al.,!2009).!IPC!was!associated!with!a!significant!reduction!in!circulating!CD4!but!not!CD8!T! cells! compared! to! both! baseline! and! the! control! group,! 4! and! 24! hours!after!reperfusion.!Systemic!levels!of!ILC2!were!also!lower!and!expression!of!the!death!receptor,!CD95,!on!CD4!and!CD8!T!cells!was!higher,!24!hours!postCsurgery!in! the! patients! that! received! IPC.! Expression! levels! of! CD45RO,! which! is!indicative!of!activated!and!memory!T!cells,!were!reduced!on!CD4!and!increased!on! CD8! cells,! following! preconditioning! (Sullivan! et! al.,! 2009).! Taken! together,!these! results! strongly! suggest! that! IPC! may! exert! a! protective! effect! through!suppressing!the!helper!T!cell!response,!but!not!cytotoxic!T!cells.!!!The!idea!that!IPC!exerts!a!protective!effect!through!inhibition!of!the!T!helper!cell!response! is!consistent!with!a!study!that! found!IPC!was!associated!with!a! trend!towards! reduced! PCselectin! expression! in! dogs! (Linden! et! al.,! 2006).!Upregulation!of!PCselectin!expression!during!I/R!facilitates!entry!of!Th1!and!Th2!cells! into! sites! of! inflammation,! propagating! the! inflammatory! response! and!ensuing!tissue!damage!(Bonder!et!al.,!2005).!In!contrast,!Wei!et#al.#(2012)!found!that! RIPC! inhibited! expression! of! T! cell! immunoglobulin! domain! and! mucin!domain!3!(TIMC3)!and!its!ligand,!galectinC9,!which!are!associated!with!inducing!death!in!Th1!cells.!Although!the!precise!effects!of!RIPC!on!the!adaptive!immune!response! are! not! clear,! overall! these! early! studies! strongly! suggest! that!preconditioning!may!alter!the!course!of!I/R!injury!through!modification!of!CD4!T!cell!function.!!!
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5.1.2 T-cells-and-I/R-injury-Given!the!limited!research!addressing!the!role!of!the!adaptive!immune!system!in!RIPC,!we! looked! to!what!was!known!about! the! involvement!of! lymphocytes! in!the!pathology!of! I/R!to! identify! further!processes!that!might!be!relevant!to!our!study.! T! cells!were! initially! connected! to! the! pathology! of! I/R! by! a! number! of!gene! deletion! studies! in!mice.!Horie! et# al.# (1999)!were! the! first! to! report! that!mice!with!severe!combined!immunodeficiency!(which!therefore!lack!functional!B!and!T! cells)! showed!a!blunted! inflammatory! response! to! I/R! injury! in! the! gut.!Similar! responses!were! seen! in! renal! and! hepatic! I/R!models,! and! Yang! et# al.#(2005)!were!the!first!to!demonstrate!that!mice!lacking!recombination!activating!gene! (RAG)C1! (which! results! in! the! loss! of! mature! B! and! T! cells)! were! also!protected!from!myocardial!I/R!injury,!with!a!significantly!reduced!infarct!size!in!the!lymphocyte!deficient!animals!(Burne!et!al.,!2001;!Day!et!al.,!2006;!Geudens!et!al.,!2007;!Rabb!et!al.,!2000;!Shen!et!al.,!2002;!Zwacka!et!al.,!1997).!!Importantly,! the!myocardial,! intestinal,! renal,! and! hepatic! protection! seen! in!T!cell! or! lymphocyte! deficient! animals! could! be! consistently! reversed! by! the!transfer! of! wild! type! (WT)! splenocytes! or! restoration! of! the! CD4+! T! cell!population!(Horie!et!al.,!1999;!Khandoga!et!al.,!2006;!Yang!et!al.,!2006;!Zwacka!et!al.,! 1997).! Lappas! et# al.# (2006)! found! that! the! protection! against! hepatic! I/R!injury!in!RAGC1!knockout!mice!could!also!be!reversed!by!the!adoptive!transfer!of!NKT!cells.!In!a!murine!model!of!stroke,!RAGC1!deficient!mice!showed!increased!resistance!to!neurological!injury!and!this!was!attributed!to!the!loss!of!both!CD4+!and! CD8+! T! cells,! whereas! depletion! of! B! cells! alone! did! not! confer! a! benefit!(Yilmaz!et!al.,!2006).!Taken!together,!these!studies!clearly!indicate!a!pathogenic!role!for!CD4+!T!cells!during!I/R!injury!in!multiple!organs,!and!potentially!for!NKT!cells!in!the!liver!and!CD8+!cells!in!the!brain.!!!Both!Savransky!et#al.#(2006)!and!Hochegger!et#al.#(2007)! found!deletion!of! the!TCR! αβ,! or! γδ! protein! chains! reduced! renal! injury! and! cytokine! expression,!suggesting! that! T! cell! activation! during! I/R! is! TCRCdependent.! This! was!supported!by!a!study!that!showed!adoptive!transfer!of!T!cells!with!a!limited!TCR!repertoire! (i.e.! expressing! a! transgenic! ovalbuminCspecific! TCR)! into! T! cell!
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deficient!mice! lessened!the!extent!of!renal!I/R!injury!compared!to!animals!that!received! WT! cells! (Satpute! et! al.,! 2009).! Furthermore,! blockade! of! the! coCstimulatory!CD28CB7!and!CD154CCD40!pathways!is!protective!during!ischaemia!and! although! these! pathways! are! essential! to! the! activation! of! naïve!T! cells,! it!should!be!noted!that!these!molecules!exert!additional!functions!beyond!solely!T!cell! activation! (De! Greef! et! al.,! 2001;! Shen! et! al.,! 2002;! Takada! et! al.,! 1997).!Despite! this!mounting! evidence! of! antigenCspecific! activation! of! T! cells! during!ischaemia,!the!particular!stimuli!responsible!have!not!yet!been!identified.!!!While!the!previous!studies!demonstrated!a!role!for!antigenCspecific!T!cells!in!I/R!injury,! Shen! et# al.# (2009)! found! that! blocking! of! antigenCspecific! CD4! T! cell!responses! without! depletion! of! the! cells! was! not! sufficient! to! protect! against!liver! I/R! injury,! suggesting! antigen! nonCspecific! CD4! T! cell! activation! was!involved! in! the! I/R! injury.! Indeed,! T! cells! have! been! shown! to! be! activated!independently! of! their! TCR! through!ROS,! inflammatory! cytokines,! chemokines,!and!complement,!and!all!of!these!are!present!in!high!levels!during!I/R!(Strainic!et! al.,! 2008;!Unutmaz! et! al.,! 1994).! Although!which! of! these! components! drive!antigenCindependent!T!cell!mediated!I/R!injury!has!not!been!identified,!it!seems!likely! that! both! antigenCdependent! and! independent! pathways! are! involved! in!the!activation!of!T!cells!following!ischaemia.!!As!indicated!by!the!benefit!seen!in!studies!described!above,!T!cells!are!generally!associated!with!exacerbation!of! I/R! injury,!and!several!studies!have! linked!this!damage!to!the!release!of!ILC17.!In!a!murine!model!of!stroke,!ILC17!production!by!γδ!T!cells!located!in!the!infarct!boundary!zone!during!the!late!response!to!injury!increases!the!production!of!neurotoxic!factors!such!as!ILC1β,!TNFCα,!and!MMPs,!which,! in!turn,!promote!neuronal!apoptosis!(Shichita!et!al.,!2009).!Similarly,!ILC17!production!from!T!cells!contributes!significantly!to!intestinal!I/R!injury,!with!mice!lacking!ILC23,!and!therefore!having!reduced!ILC17,!showing!lower!levels!of!injury! compared! to!WT! animals! (Edgerton! et! al.,! 2009).! Lastly,! in! the!murine!lung,! targeted!deletion!of! the! invariant!NKT!(iNKT)!cell!population!reduces!I/R!injury,!and!this!effect! is!reversed!by!the!adoptive!transfer!of!WT!but!not!ILC17Cdeficient!iNKTs!(Sharma!et!al.,!2011).!!
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In!addition!to!ILC17!production,!T!cells!may!contribute!to!I/R!by!interacting!with!various!innate!immune!cells.!For!example,!multiple!studies!have!correlated!T!cell!depletion! with! a! reduction! in! neutrophil! infiltration! of! the! ischaemic! tissue,!suggesting!T! cells!may!participate! in! their! recruitment! (Khandoga! et! al.,! 2006;!Lappas!et!al.,!2006;!Rabb!et!al.,!2000;!Zwacka!et!al.,!1997).!Further,!Khandoga!et#
al.#demonstrated!that!during!hepatic!I/R,!CD4+!T!cells!infiltrate!the!sinusoids!and!exacerbate! microvascular! and! hepatocellular! damage! by! increasing! plateletCendothelial! cell! interactions.! Finally,! Shen! et# al.# (2009)! found! that! CD4! T! cell!expression! of! the! coCstimulatory!molecule,! CD154,! was! critical! for! stimulating!CD40!on!innate!liver!cells,!resulting!in!higher!levels!of!injury.!!!In!contrast,!there!have!been!a!limited!number!of!studies!indicating!a!protective!role! for! certain! T! cell! subsets! during! I/R.! Lieszi! et# al.! (2009)# found! Treg!production!of!ILC10!was!critical!during!ischaemic!stroke!in!mice,!reducing!infarct!size! by! suppressing! the! proinflammatory! cytokines,! TNFCα,! ILC1β,! and! IFNCγ.!Epigenetic!modification,!in!part!through!histone!acetylation,!has!been!associated!with! the! stabilisation! of! Foxp3! transcription! and! Treg! function! (Floess! et! al.,!2007).!Accordingly,!administration!of!an!inhibitor!of!histone!deacetylase!in!mice!was! shown! to! enhance! Treg! suppressive! activity! and! improve! cardiac! graft!survival,!which!may!be!equally!relevant!during!myocardial!I/R!in!the!absence!of!transplantation!(Tao!et!al.,!2007).!Selective!activation!of!resident!liver!NKT!cells!shortly!before! an! ischaemic! insult! has! also!been! shown! to! limit!hepatic! injury.!This!protective!effect!was!dependent!on!NKTCinduced!increases!in!ILC13!and!the!adenosine!A2A!receptor!expression!levels!(Cao!et!al.,!2009).!!!Our!knowledge!regarding!the!mechanisms!through!which!T!cells!mediate!tissue!damage!during! I/R! is! incomplete!but,! taken! together,! the!previously!described!studies!suggest!that!they!are!likely!to!be!complex!and!multifactorial.!Overall,!the!literature!addressing!the!role!of!the!adaptive!immune!system!during!I/R!injury!highlights! the! involvement! of! T! cells! in! both! pathological! and! protective!functions,!defining!them!as!important!potential!targets!for!modulation!by!RIPC.!!!
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5.2 Aims-





5.3.1 Intracellular-cytokine-staining-Heparanised!whole!blood!was!diluted!5:1!with!CTCM!with!or!without!50!ng/mL!PMA!and!500!ng/mL! ionomycin! (4!hour! cultures;! Sigma!Aldrich)!or!10!ng/mL!PMA!and!500!ng/mL!ionomycin!(27!hour!cultures;!Sigma!Aldrich)!and!incubated!at!37!°C!with!5%!CO2.!A!monensin!based!protein!transport! inhibitor,!GolgiStop!(BD!Biosciences),!was!added!for!the!final!4!hours!of!culture.!The!4!hour!culture!samples!were!extracellularly!stained!and!fixed,!then!stored!overnight!at!4!°C.!The!27Chour! samples!were! processed! the! following! day,!with! intracellular! staining!and! acquisition! carried! out! at! the! same! time! for! all! samples.! RBC! were! lysed!using!a!15!minute!incubation!with!Pharm!Lyse!(BD!Biosciences)!at!RT!followed!by!centrifugation!at!400!x!g!for!5!minutes,!and!the!samples!washed!twice!in!PBS.!The! cells! were! stained! in! duplicate! with! fixable! viability! dye! eFluor! 780!(eBioscience)!for!30!minutes!on!ice!in!a!96Cwell!roundCbottom!plate!and!washed!once!with!PBS.!Samples!were!incubated!with!antiCCD16!antibody!or!FACS!buffer!for! 20! minutes,! FC! receptor! blocked! with! 2! mg/mL! intragam! P! (CSL)! for! 10!minutes,!then!stained!with!the!remaining!extracellular!marker!antibodies!for!20!minutes,!all!at!RT,!protected!from!light.!Cells!were!washed!once! in!FACS!buffer!and! then! fixed! in! 4%! paraformaldehyde! for! 15! minutes.! Samples! were! then!washed! twice! with! FACS! buffer,! resuspended! in! 0.2%! saponin! buffer! for! 10!minutes,!then!centrifuged!at!400!x!g!for!5!minutes!and!the!supernatant!aspirated.!The! samples! were! incubated! with! intracellular! staining! mixes! prepared! in!saponin!buffer!in!a!total!volume!of!50!μL!for!20!minutes!at!RT,!washed!once!with!saponin!buffer!and!once!with!FACS!buffer.! Samples!were! resuspended! in!FACS!buffer!and!filtered!before!acquisition!on!a!FACSCanto™!II!with!Diva!software!(BD!Biosciences).!The!data!was!analysed!with!FlowJo!7.6.1!software!(Tree!Star).!!!
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5.3.2 Culture-of-PBMC-!
5.3.2.1 PBMC,isolation,PBMC!were! isolated! following! the! manufacturer’s! instructions.! Briefly,! freshly!collected! heparinised! blood! was! diluted! 3:5! with! dPBS! without! calcium! or!magnesium!(Life!Technologies),!and!carefully!layered!on!top!of!RT!HistopaqueC1077!(Sigma!Aldrich).!The!sample!was!centrifuged!at!400!x!g!for!30!minutes!at!RT,! and! the! upper! layer! of! supernatant! discarded.! The! middle! opaque!mononuclear! cell! layer! was! collected! and! washed! three! times! in! dPBS!(centrifuged! at! 250! x! g,! 5!minutes)! and! resuspended! in! CTCM.! The! viable! cell!concentration!was!determined!by!mixing!a!sample!of!cells!1:1!with!0.4%!Trypan!blue! (Sigma!Aldrich)! and! counting!on!an! improved!Neubauer!haemocytometer!with!a!compound!microscope!(CX41;!Olympus).!!
5.3.2.2 T,cell,stimulation,Isolated!PBMC!were!cultured!in!triplicate!in!a!final!volume!of!200!uL!in!96Cwell!flatCbottom!plates,!with!or!without! stimulants.!A! total! of! 1! x!105! cells! per!well!were! stimulated! with! a! final! concentration! of! 5! ng/mL! PMA! and! 200! ng/mL!ionomycin! (Sigma! Aldrich),! or! the! tetanus! toxoidCcontaining! ADT! Booster!vaccine!(CSL)!diluted!1:5.!AntiCCD3/28!Expander!Beads!(Life!Technologies)!were!cultured! 1:1! with! PBMC! plated! at! 8! x! 104! per! well,! and! were! prepared! by!washing!in!dPBS,!pelleting!for!1!minute!on!a!magnet,!aspirating!the!supernatant,!and!resuspending!in!CTCM.!The!PMA/I,!and!dynabead!stimulated!samples!were!incubated! for! 24! hours! at! 37! °C,! 5%! CO2,! then! centrifuged! at! 400! x! g! for! 5!minutes.!The!supernatant!was!harvested!and!stored!at! C20!°C,!and! the!pelleted!cells! at! C80! °C,! for! further! analyses.! The! tetanusCstimulated! samples! were!cultured!for!7!days!and,!due!to!the!opacity!of!the!tetanus!vaccine!and!the!effect!of!this! on! the! subsequent! assay,! the! tetanus! vaccine! was! added! to! the! control!unstimulated!samples!immediately!prior!to!centrifugation.!The!supernatant!and!cells!were!stored!as!described!above.!!!
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5.3.3 CyQuant-proliferation-assay-The! CyQuant! reagent! (Life! Technologies)!was! prepared! at! 2X! concentration! in!cell! lysis! buffer! and! nuclease! free! distilled! water,! as! per! the! manufacturer’s!instructions.!The!cell!samples!were!thawed!and!200!uL!of! the!CyQuant!reagent!was! added! per! well,! and! left! to! equilibrate! in! the! dark! for! 3! minutes.! The!fluorescence!was!measured!at!excitation!of!480!nm!and!emission!of!520!nm!on!an! EnSpire! 2300! multilabel! plate! reader! (PerkinElmer),! and! the! background!absorbance! level! (taken! from! the! control! wells! without! cells)! was! subtracted!from!the!samples.!The!stimulation!index!was!calculated!by!expressing!the!MFI!of!each!replicate!as!a!ratio!to!that!of!the!corresponding!control.!!!!
5.3.4 Cell-culture-supernatant-cytokine-quantification-The! culture! supernatant! cytokine! levels! were! quantified! using! a! human!Th1/Th2/Th9/Th17/Th22!13plex! FlowCytomix! kit! (#BMS817FF;! eBioscience).!The!kit!consisted!of!13!bead!populations!of!two!sizes!with!distinct!fluorescence!intensities! that! could! be! resolved! in! the! red! flow! cytometer! channel.! Each!population! was! coated! with! capture! antibodies! specific! for! one! of! the! 13!analytes:! IFNCγ,! ILC1β,! ILC2,! ILC4,! ILC5,! ILC6,! ILC9,! ILC10,! ILC12p70,! ILC13,! ILC17A,!ILC22,! or! TNFCα.! The! beads,! together! with! biotinCconjugated! secondary! antiCanalyte!antibodies,!were!incubated!with!the!supernatant!sample.!SACPE!was!then!added! to! distinguish! the! cytokineCbound! beads! from! the! unbound! population,!and! the! resulting! fluorescence! in! the! yellow! channel! used! to! determine! the!analyte! concentrations! within! each! sample,! relative! to! a! range! of! known!standards.!The!beads!were!mixed!at!a!final!dilution!of!1:80!and!then!washed!by!centrifugation! at! 3000! x! g! for! 5! minutes,! aspiration! of! the! supernatant,! and!resuspension! in! the! same! volume! of! reagent! dilution! buffer.! The! biotinCconjugates!were! also!mixed! and!diluted! 1:80!with! assay! buffer.! The! standards!were! reconstituted! according! to! the!manufacturer’s! instructions,! and!prepared!using!a!3Cfold!serial!dilution.!Following!reagent!preparation,!25!µL!of!undiluted!culture!supernatant!and!duplicate!standards!were!incubated!with!25!µL!of!mixed!beads!and!50!µL!of!biotin!conjugate!mix!for!2!hours!at!RT!in!a!96Cwell!VCbottom!plate.! At! the! end! of! the! incubation! the! samples! were! washed! twice! by! the!addition!of!wash!buffer,!centrifugation!at!400!x!g!for!5!minutes,!and!aspiration!of!
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the!supernatant.!After!the!final!wash,!all!but!100!µL!of!supernatant!was!removed!and! 50!µL! of! SACPE! solution! diluted! 1:125! in! assay! buffer!was! incubated!with!each!sample!for!a!further!hour!at!RT.!The!samples!were!then!washed!twice!more,!resuspended! in! assay!buffer,! and! acquired!on! a! FACSCanto™! II! flow! cytometer!(BD! Biosciences)! set! up! according! to! the! kit! manufacturer’s! instructions.! The!data! was! analysed! with! BD! FACSDiva! (BD! Biosciences)! and! FlowCytomixPro!(eBioscience)!software.!!
5.3.5 Statistics-The!statistical!analysis!of!the!trial!results!was!performed!under!the!guidance!of!Dr! Dalice! Sim.! The! intracellular! cytokine! concentrations! and! supernatant!cytokine!levels!were!compared!between!treatment!groups!and!conditions!using!twoCway!repeated!measures!ANOVA!with!the!GreenhouseCGeisser!correction!and!Bonferroni! postChoc! tests.! For! the! ICS,! the! 4Chour! and! 27Chour! culture! results!were!analysed!separately.!PBMC!proliferation!levels!were!compared!using!a!twoCtailed!paired! tCtest.!Graphs!were!produced!using!GraphPad!Prism!5! (GraphPad!Software! Inc)! and! statistical! tests! were! performed! using! SPSS! Statistics! (IBM!Corporation).! Differences! corresponding! to! p! values! <! 0.05! were! considered!statistically!significant,!and!comparisons!were!not!found!to!be!significant!unless!specified.!!!!!!!!!!!!!!
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5.4 Results-!
5.4.1 Intracellular-cytokine-production-in-whole-blood-cultures-In! our! trial! of! RIPC! in! highCrisk! cardiac! surgery! patients,! we! found! a! general!trend! towards! slightly! increased! levels! of! ILC6! and! ILC8! in! the! preconditioned!group!as!early!as!1!hour!following!bypass!(p!=!0.09!and!0.10!for!the!unadjusted!differences!for!ILC6!and!ILC8!1!hour!after!crossCclamp!removal,!respectively).!We!were!therefore!interested!in!whether!RIPC!could!directly!alter!the!ability!of!key!immune! cells! to! produce! these! cytokines,! and! which! cell! types! might! be!contributing!to!the!increased!levels.!To!address!this!question,!we!performed!ICS!using!whole!blood!from!samples!collected!one!hour!after!treatment!during!each!visit.!!!In! Chapter! 4,! we! observed! that! there!were! two! participants! with! consistently!elevated!levels!of!serum!cytokines!at!both!the!baseline!and!postCtreatment!time!points! during! both! study! visits.! The! entire! ICS! dataset!was! analysed!with! and!without!the!inclusion!of!these!two!participants,!and!their!exclusion!was!found!to!have! only! subtle! effects! on! the! statistical! analysis! that! did! not! change! the!conclusions! drawn! from! the! data.! The! individual! results! obtained! from! these!participants!were!consistent!with!the!remaining!dataset!and!did!not!appear!to!be!outliers;! therefore! they! were! included! in! the! final! analysis! presented! in! the!following!sections.!!!
5.4.1.1 Monocytes,and,neutrophils,Monocytes! and! neutrophils! are! rapidly! activated! during! cardiac! surgery! and!mediate! much! of! the! tissue! damage! sustained! in! the! postCoperative! period;!therefore,! their! potential! contribution! to! cytokine! production! during! both! the!early!and!late!phases!of!RIPCCinduced!protection!were!of!particular!interest.!To!determine!the!effect!of!RIPC!on!neutrophil!and!monocyte!function,!whole!blood!was! stimulated! for! 4! or! 27! hours! with! PMA/I.! This! stimulation! induced!significant! changes! in! the! proportion! of! live! cells,! CD11b! expression,! and!intracellular!cytokine!production,!as!expected.!!!
!!200!
Following! a!4Chour! culture!period,! neutrophils! constituted! approximately!60%!of! the! total! live! leukocytes!assessed! from!the!unstimulated!blood!samples,! and!there! was! a! slight! reduction! in! the! proportion! of! viable! neutrophils! in! the!samples! stimulated! with! PMA/I! (Figure! 5.1B).! In! contrast,! the! monocyte!population!represented!between!6!–!8%!of!the!total!leukocytes!and!there!was!a!slight! increase! in! the! proportion! following! 4! hours! of! stimulation,!which!most!likely!was!due!to!the!reduction!in!neutrophils!(the!most!predominant!leukocyte!subset)! rather! than! an! increase! in! the! absolute! number! of!monocytes! (Figure!5.1A).! The! level! of! cell! survival! in! neutrophils! stimulated! for! 27! hours! was!similar! to! that! detected! in! the! shorter! cultures;! however,! there! was! a! slight!reduction! in! viable! cells! in! the! unstimulated! sample! (Figure! 5.1F).! In! contrast,!there! was! a! substantial! decrease! in! live! monocytes! following! 27! hours!stimulation;! whereas,! the! proportion! of! cells! in! the! unstimulated! cultures!seemed! largely! unchanged! (Figure! 5.1E).! The! size! of! the! viable!monocyte! and!neutrophil!populations!were!not!affected!by!preconditioning.!!!There! was! a! notable! trend! towards! reduced! CD11b! expression! in! cultured!monocytes,! following! RIPC.! This! affect! was! most! pronounced! in! the! 4Chour!cultures,! although! the! difference! between! the! treatment! groups! did! not! reach!statistical!significance!(4!hours:!p!=!0.094;!27!hours:!p!=!0.265;!Figure!5.1C!and!G).!A!similar!trend!of!reduced!CD11b!expression!was!observed!in!the!neutrophils!from!preconditioned! participants;! however,! this! effect! appeared! limited! to! the!stimulated! samples,! suggesting! RIPC! may! reduce! the! ability! of! neutrophils! to!become! activated! in! response! to! subsequent! stimulation! (Figure! 5.1D! and! H).!The! difference! between! the! groups! appeared! largest! after! 27! hours! of! culture,!but!did!not!reach!statistical!significance!(4!hours:!p!=!0.06;!27!hours:!p!=!0.058).!!In! both! the! 4! and! 27Chour! cultures,! monocytes! were! found! to! predominantly!produce!ILC8,!and!only!very!low!levels!of!ILC6!(Figure!5.2A!and!C,!and!Figure!5.3A!and! C).! Notably,! monocyte! ILC8! production! was! higher! in! the! unstimulated!samples,! suggesting! this! expression! was! constitutive.! The! percentage! of!unstimulated!viable!monocytes!that!stained!positively!for!ILC8!increased!from!10!–!20%!at!4!hours,!to!30!–!40%!after!27!hours!(Figure!5.2C!and!Figure!5.3C).!The!
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pattern! of! neutrophil! cytokine! production!was! similar! between! the! 4! and! 27Chour!cultures,!with!enhanced!responses!in!the!latter!samples.!Between!5!–!10%!of!neutrophils!produced!ILC6!constitutively!after!4!hours!culture,!whereas,!10!–!15%!of!neutrophils!stained!positively!for!intracellular!ILC8!following!stimulation!(Figure! 5.2B! and! D).! Very! little,! if! any,! ILC8! production! was! detected! in! the!unstimulated! neutrophils! and! only! a! minor! population! of! monocytes! and!neutrophils!simultaneously!produced!ILC6!and!ILC8!(<!1%!in!the!4!hour!cultures!and!<!10%! in! the!27!hour!cultures;!Figure!5.2E!and!F,!and!Figure!5.3E!and!F).!RIPC! did! not! significantly! alter! ILC6! or! ILC8! production! in! unstimulated! or!stimulated!monocytes!and!neutrophils,!with!either!duration!of!cultures.!Thus,!it!appears!that!monocytes!and!neutrophils!do!not!produce!increased!levels!of!ILC6!or!ILC8!following!RIPC!and!may,!in!fact,!be!suppressed!by!the!intervention.!!!!!!!!!!!!
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Figure- 5.1- Size- and- activation- state- of- monocyte- and- neutrophil-




monocytes-and-neutrophils-Blood!was!collected!1!hour!after!treatment;!cultured!for!4!hours!with!or!without!50! ng/mL!PMA,! 500! ng/mL! ionomycin,! and!GolgiStop! (1:1000);! then! assessed!for!intracellular!cytokines!with!flow!cytometry.!(A!and!B)!Percentage!of!ILC6+/ILC8C!monocytes!(purple)!and!neutrophils!(blue);!(C!and!D)!ILC6C/ILC8+!cells;!(E!and!F)!ILC6+/ILC8+!cells.!Cells!are!expressed!as!the!percentage!of!the!total!live!parent!population.!TwoCway!repeated!measures!ANOVA!with!Bonferroni!postChoc!tests!were!used!to!compare!the!treatments!and!culture!conditions.!*!p!<!0.05!and!**!p!<!0.01.!Samples!were!prepared!in!duplicate!and!shown!are!the!group!means!and!SEM!for!n!=!10.!For!representative!data!plots!refer!to!appendix!F,!Figures!F.6!and!F.7.!!
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Figure- 5.3- Late- stage- intracellular- ILL6- and- ILL8- production- in- cultured-
monocytes-and-neutrophils-Blood! was! collected! 1! hour! after! treatment;! cultured! for! 27! hours! with! or!without!10!ng/mL!PMA,!500!ng/mL! ionomycin,!and!GolgiStop!(1:1000)! for! the!final!4!hours;! then!assessed! for! intracellular! cytokines!with! flow!cytometry.! (A!and!B)!Percentage!of! ILC6+/ILC8C!monocytes!(purple)!and!neutrophils!(blue);!(C!and!D)! ILC6C/ILC8+! cells;! (E! and! F)! ILC6+/ILC8+! cells.! Cells! are! expressed! as! the!percentage! of! the! total! live! parent! population.! TwoCway! repeated! measures!ANOVA!with!Bonferroni!postChoc!tests!were!used!to!compare!the!treatments!and!culture! conditions.! *! p! <! 0.05! and! **! p! <! 0.01.! Samples! were! prepared! in!duplicate!and!shown!are!the!group!means!and!SEM!for!n!=!10.!For!representative!data!plots!refer!to!appendix!F,!Figures!F.6!and!F.7.!
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5.4.1.2 T,cell,subsets,In! addition! to! investigating! the! effect! of! RIPC! on! neutrophil! and!monocytes! in!PMA/ICstimulated! whole! blood! samples,! the! effect! on! T! cells! was! also!determined.!T!cell!responses!are!believed!to!be!more!relevant!during!the!delayed!phase!of!preconditioning,!and!in!support!of!this,!cytokine!production!following!4!hours! of! culture! was! not! altered! by! preconditioning! in! our! trial! (refer! to!appendix! H! for! the! full! dataset;! Ascon! et! al.,! 2006;! Sullivan! et! al.,! 2009).!Therefore,!we!focused!on!the!T!cell!cytokine!responses!in!the!27Chour!cultures.!Because! the! CD4! population! could! not! be! clearly! resolved! for! one! participant,!their!data!was!not!included!in!portions!of!the!analysis,!reducing!the!sample!size!to! 9! for! those! parameters! as! noted! in! the! figure! legends.! Finally,! as! with! the!monocyte! and! neutrophil! analyses,! PMA/I! caused! clear! changes! in! the!expression! of! T! cell!markers! of! activation! and! cytokine! production! in! samples!from!both!control!and!RIPCCtreated!participants.!!On!average,!CD3+!T!cells!constituted!approximately!26%!of!the!viable!leukocyte!population! after! 27! hours! culture,! and! this! proportion! was! slightly! reduced!following!stimulation!with!PMA/I!in!both!groups!(Figure!5.4A).!The!levels!of!the!CD4+! and! CD8+! subsets! were! very! consistent! between! visits! and! culture!conditions! (Figure! 5.4B! and! C).! The! CD4+! cells! were! the! predominant! subset,!accounting!for!around!53%!of!the!total!CD3+!cells,!on!average.!RIPC!did!not!alter!the!proportions!of!any!of!these!populations,!compared!to!the!control!visit.!!Although! there! was! a! high! level! of! variation! between! participants,! expression!levels! of! CD25! and! another! T! cell! activation! marker,! CD69,! were! both!substantially!increased!in!the!CD4!and!total!T!cell!populations,!respectively,!after!stimulation! with! PMA/I! (Figure! 5.4D! and! E).! This! finding! confirmed! the!successful! activation! of! these! cells! using! our! ICS! protocol.! There! was! a! trend!towards! an! increased! level! of! T! cell! activation! in! the! stimulated! cultures!following!RIPC!but! this!difference!did!not!reach!statistical!significance.!CD69! is!an!early!marker!of!T!cell!activation!and!a!significant!upregulation!of!CD69!was!also! detectable! in! the! PMA/I! stimulated! cultures! after! 4! hours;! however,! the!
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difference! between! the! treatment! groups! was! only! observed! in! the! 27! hour!cultures!(refer!to!appendix!H,!Figure!H.1E).!!!A! notable! population! of! the! unstimulated! CD4! T! cells! were! positive! for!intracellular!ILC6,!and!this!proportion!was!increased!following!stimulation!with!PMA/I! (Figure! 5.5A).! Interestingly,! the! MFI! of! ILC6! staining! did! not! differ!between!the!unstimulated!and!stimulated!CD4!T!cells,!suggesting!that!a!greater!number! of! cells!were! individually! producing! a! lower! amount! of! ILC6! following!stimulation,!compared!to!the!constitutive!production!in!unstimulated!cells!(refer!to!appendix!H,!Figure!H.3A).!A!small!population!of!CD8!T!cells!also!produced!ILC6,!with!and!without!stimulation,!but!to!a!lesser!extent!than!was!detected!in!the!CD4! subset! (Figure! 5.5C).! ILC8! production! in! both! the! CD4! and! CD8! T! cell!populations! was! very! low,! with! less! than! 1%! of! cells! staining! positively! for!intracellular!levels!(Figure!5.5B!and!D).!Expression!levels!of!both!ILC6!and!ILC8!in!T!cells!did!not!change!with!RIPC.!!Taken!together,!these!results!suggest!that!RIPC!may! increase! the! propensity! of! T! cells! to! become! activated,! but! that! this!enhanced!activation!does!not!result!in!increased!production!of!the!inflammatory!cytokines,!ILC6!and!ILC8.!!!!!
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Figure- 5.4- T- cell- subset- proportions- and- activation- state- after- 27- hours-
culture-Blood! was! collected! 1! hour! after! treatment;! cultured! for! 27! hours! with! or!without!10!ng/mL!PMA,!500!ng/mL! ionomycin,!and!GolgiStop!(1:1000)! for! the!final! 4! hours;! then! assessed! for! intracellular! cytokines! with! flow! cytometry.!Proportions!of!cell!populations!are!shown!for!(A)!CD3+!cells;!(B)!CD4+!T!cells;!(C)!CD8+!T!cells;!(D)!CD4+CD25+!T!cells;!(E)!CD69+!T!cells.!CD3+!cells!are!expressed!as! the! percentage! of! the! total! live! leukocytes,! and! the! remaining! subsets! as! a!percentage!of!the!CD3+!parent!population.!TwoCway!repeated!measures!ANOVA!with!Bonferroni!postChoc!tests!were!used!to!compare!the!treatments!and!culture!conditions.!*!p!<!0.05!and!**!p!<!0.01.!Samples!were!prepared! in!duplicate!and!shown!are!the!group!means!and!SEM!for!n!=!10!for!A,!C,!and!E,!and!n!=!9!for!B!and! D.! For! representative! data! plots! refer! to! appendix! F,! Figures! F.8,! F.9! and!F.10.!!
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Figure-5.5-Late-phase- intracellular- ILL6-and- ILL8-production- in-cultured-T-
cell-subsets-Blood! was! collected! 1! hour! after! treatment;! cultured! for! 27! hours! with! or!without!10!ng/mL!PMA,!500!ng/mL! ionomycin,!and!GolgiStop!(1:1000)! for! the!final! 4! hours;! then! assessed! for! intracellular! cytokines! with! flow! cytometry.!Percentages!of!CD4!T!cells!(A!and!B)!and!CD8!T!cells!(C!and!D)!stained!positively!for! ILC6! (A! and! C)! and! ILC8! (B! and! D)! are! shown.! Cells! are! expressed! as! the!percentage!of!the!total!live!parent!CD3+!population.!TwoCway!repeated!measures!ANOVA!with!Bonferroni!postChoc!tests!were!used!to!compare!the!treatments!and!culture!conditions.!*!p!<!0.05.!Samples!were!prepared!in!duplicate!and!shown!are!the! group!means! and! SEM! for! n! =! 9! for! A! and!B,! and! n! =! 10! for! C! and!D.! For!representative!data!plots!refer!to!appendix!F,!Figures!F.8!and!F.9.!!!!!!!!!!!
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5.4.1.3 CD56+,cell,subsets,In! the!whole! blood! cultures,! CD3CCD56+! NK! cells! accounted! for! approximately!2.7%!of!the!total!viable! leukocytes!after!27!hours!without!stimulation,!and!this!was! reduced! to! less! than! 2%! following! treatment! with! PMA/I! (Figure! 5.6A).!Intracellular! levels! of! ILC6! and! ILC8! were! very! low! in! this! subset,! but! ILC8!production!was!induced!in!2!–!3%!of!NK!cells!following!stimulation,!and!ILC6!was!also!significantly!but!modestly!induced!with!PMA/I!(Figure!5.6B!and!C).!!!A! very! minor! population! of! CD3+CD56+! NKT! cells! (<! 1%! of! the! total! live!leukocytes)!was!present!in!the!unstimulated!samples!cultured!for!27!hours,!and!was!slightly!reduced! following!stimulation!(Figure!5.7A).!The!majority!of! these!NKT!cells!expressed!CD8,!and!a!smaller!population!were!positive!for!CD4!(Figure!5.7B!and!C).!Unstimulated!NKT!cells!appeared!to!be!a!minor!source!of!ILC6!and!ILC8,!and!the!number!of!cytokine!producing!cells!was!increased!following!PMA/I!treatment,!although!the!response!was!variable!between!individuals!(Figure!5.7D!and!E).!!!Cytokine!production!in!the!CD56+!subsets!was!negligible!after!4!hours!of!culture!(refer!to!appendix!H!for!data,!Figures!H.4!and!H.5).!Overall,!while!PMA/I!had!a!significant!effect,!RIPC!did!not!alter!the!size!of!the!NK!and!NKT!populations,!or!their! constitutive! or! induced!production! of! ILC6! and! ILC8! during! either! culture!period.!!!!!!!!!!!!!
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Figure- 5.6- Intracellular- cytokine- production- in- NK- cells- cultured- for- 27-
hours-Blood! was! collected! 1! hour! after! treatment;! cultured! for! 27! hours! with! or!without!10!ng/mL!PMA,!500!ng/mL! ionomycin,!and!GolgiStop!(1:1000)! for! the!final!4!hours;!then!assessed!for!intracellular!cytokines!with!flow!cytometry.!(A)!Proportion! of! CD3CCD56+! NK! cells;! (B)! percentage! of! ILC6+! NK! cells;! (C)!percentage!of! ILC8+!NK! cells.! Cells! are! expressed!as! the!percentage!of! the! total!live! parent! population.! TwoCway! repeated! measures! ANOVA! with! Bonferroni!postChoc!tests!were!used!to!compare!the!treatments!and!culture!conditions.!*!p!<!0.05,! **! p! <! 0.01,! and! ***! p! <! 0.001.! Samples!were! prepared! in! duplicate! and!shown!are! the!group!means!and!SEM! for!n!=!10.!For! representative!data!plots!refer!to!appendix!F,!Figure!F.12.!!!!!!!!!!
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Figure-5.7-Cytokine-production-in-NKT-cells-after-27-hours-of-culture-Blood! was! collected! 1! hour! after! treatment;! cultured! for! 27! hours! with! or!without!10!ng/mL!PMA,!500!ng/mL! ionomycin,!and!GolgiStop!(1:1000)! for! the!final!4!hours;!then!assessed!for!intracellular!cytokines!with!flow!cytometry.!(A)!Proportion!of!CD3+CD56+!NKT!cells;!(B)!CD4+!NKT!cells;!(C)!CD8+!NKT!cells;!(D)!percentage! of! ILC6+! NKT! cells;! (E)! percentage! of! ILC8+! NKT! cells.! Cells! are!expressed! as! the! percentage! of! the! total! live! parent! population.! TwoCway!repeated!measures!ANOVA!with!Bonferroni!postChoc!tests!were!used!to!compare!the!treatments!and!culture!conditions.!*!p!<!0.05!and!***!p!<!0.001.!Samples!were!prepared!in!duplicate!and!shown!are!the!group!means!and!SEM!for!n!=!10.!For!representative!data!plots!refer!to!appendix!F,!Figures!F.11!and!F.12.!!!
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5.4.2 PBMC-proliferative-response-Given! T! cells! have! been! implicated! in! both! detrimental! and! beneficial! roles!during! I/R! injury! and! recovery,! we! were! particularly! interested! in! how! RIPC!might! alter! the! capacity! of! this! cell! population! to! divide! and! expand.! To!investigate! proliferation,! PBMC! were! stimulated! with! PMA/I! (nonCspecific!pharmacological! stimulus),! antiCCD3/CD28! antibodies! (antigenCindependent! T!cell! receptor! stimulus),! and! the! ADT! (tetanus! and! diphtheria)! Booster! vaccine!(antigenCspecific!T!cell!receptor!stimulus).!!The! majority! of! participants! showed! a! significant! increase! in! lymphocyte!proliferation! in! response! to! the! pharmacological! stimulants,! PMA/I,! after!RIPC!(Figure!5.8A).!This! trend!did!not! reach!statistical! significance,!however,!as! two!participants! showed! a! notable! decrease! in! their! proliferative! response! (p! =!0.116).!One!of! these!participants! showing!a! reduction! in!PMA/ICinduced!PBMC!proliferation!following!RIPC!was!also!one!of!the!participants!with!high!levels!of!inflammatory!baseline! serum!cytokine! levels.!Exclusion!of! the! two!participants!with! the! high! serum! cytokine! levels! reduced! the! p! value! for! the! difference! in!PMA/I! induced!proliferation!between! treatments! to!0.014;!however,! there!was!no!evidence!from!the!remainder!of!our!study!that!these!participants!had!altered!PBMC!responses,!therefore!they!were!included!in!the!final!analysis.!!Treatment!with! antibodies! that! bind! the! T! cell! receptorCCD3! complex! and! coCstimulatory! CD28! molecule! specifically! activate! T! cells! in! a! physiologically!relevant! manner.! The! T! cell! proliferative! response! to! CD3/28! stimulation! in!PBMC! cultures! was! variable! between! both! participants! and! study! visits,! with!approximately!equal!numbers!of!participants!showing!increases!or!decreases!in!proliferation! after! RIPC! treatment! (Figure! 5.8B).! It! was! not! possible! to!distinguish! any! effect! of! the! preconditioning! from! random! variability! in! the!proliferative! response! to! polyclonal! stimulation! of! T! cells.! Lastly,! a! strong!antigenCspecific! proliferative!memory!T! cell! response! to! the! tetanus! toxin!was!detected! in! all! participants! after! 6! days! of! culture,! and! did! not! appear! to! be!altered!by!RIPC!(Figure!5.8C).!!
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Figure-5.8-PBMC-proliferative-responses-following-RIPC-treatment-PBMC!were! isolated! from!blood!collected!1!hour!after! treatment,! and!assessed!for! proliferation! with! the! CyQuant! assay! following! culture! with! various!stimulants.! (A)!Cells!plated!at!1!x!105!cells/well!with!or!without!5!ng/mL!PMA!and!200!ng/mL!ionomycin!for!24!hours.!(B)!Cells!plated!8!x!104!cells/well!plated!with!or!without!antiCCD3/28!dynabeads!at!a!1:1!bead!to!cell!ratio!for!24!hours.!(C)!Cells!plated!at!1!x!105! cells/well!with!or!without!a!1:5!dilution!of! the!ADT!booster! vaccine! for! 6! days.! The! stimulation! index! represents! the! level! of!proliferation! relative! to! the! unstimulated! control! sample.! TwoCtailed! paired! tCtests! were! used! to! compare! the! treatment! groups.! Shown! are! the! means! of!triplicates!for!n!=!10!participants.!!!!!!!!!!!!!!!!!!!
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5.4.3 PBMC-and-polyclonal-T-cell-cytokine-responses--We!examined! the! cytokine! levels! in! supernatants! from! the! cell! cultures! in! our!proliferative!assays!to!determine!whether!RIPC!altered!the!general!PBMC!and!T!cell! cytokine! responses,! or! polarised! them! towards! a! particular! subset! of! T!helper! cells! (e.g.! Th1).! Because! two! participants! had! high! baseline! serum!cytokine! levels! (Chapter! 4),! a! selection! of! endpoints! were! tested! with! and!without!the!inclusion!of!their!data;!however,!their!results!had!only!subtle!effects!on!the!analysis!and!did!not!alter!the!interpretation!of!the!data.!Therefore,!these!participants! were! included! in! the! final! analysis! presented! in! the! following!sections.!!!
5.4.3.1 PBMC,responses,to,PMA/I,stimulation,PMA/I! treatment! induced! significant! production! of! most! of! the! cytokines!examined! after! 24! hours.! With! respect! to! the! cytokines! associated! with! the!typical!Th1! response,! very!high! levels!of!both! ILC2!and! IFNCγ!were!detected! in!the!stimulated!cultures!and!were!absent!in!the!unstimulated!samples!(Figure!5.9!A!and!C).!ILC12p70!was!also!present!but!only!at!very!low!concentrations!(Figure!5.9B).!PMA/I!stimulation!significantly!increased!production!of!the!Th2!cytokines,!ILC4,! ILC5,! ILC6,! ILC10,! and! ILC13,! and! constitutive! expression! of! ILC13! was!detected!in!the!unstimulated!samples!(Figure!5.10A!–!E).!Lastly,!pharmacological!stimulation!with!PMA/I!also!induced!significant!levels!of!ILC1β,!ILC17,!and!TNFCα,!which! are! associated!with! the! proinflammatory! Th17! subset! (Figure! 5.11A,! B,!and!D).!A! low!level!of!constitutive!production!of! ILC1β!was!also!detected!in!the!unstimulated! samples! while! the! moderate! constitutive! levels! of! ILC22! were!unaltered!by!stimulation!(Figure!5.11A!and!C).!ILC9!was!generally!below!the!level!of! detection! (1.5! pg/mL;! data! not! shown).! In! comparing! the! two! treatment!groups,!no!differences!in!the!levels!of!cytokine!production!were!detected!with!or!without!PMA/I!stimulation.!Finally,!neither!RIPC!nor!PMA/I!treatment!appeared!to!bias!the!T!helper!cell!response!toward!Th1,!Th2,!Th17,!Th22,!or!Th9!cells.!!!!
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Figure-5.9-Production-of-Th1-type-cytokines-in-PMA/I-stimulated-PBMC-PBMC!were!isolated!from!blood!collected!1!hour!after!treatment!and!plated!at!1!x! 105! cells/well,! in! triplicate,! with! or! without! 5! ng/mL! PMA! and! 200! ng/mL!ionomycin,!for!24!hours.!Supernatant!cytokine!levels!were!assessed!with!a!CBA!and! flow! cytometry.! (A)! ILC2;! (B)! ILC12p70;! (C)! IFNCγ.! TwoCway! repeated!measures! ANOVA! with! Bonferroni! postChoc! tests! were! used! to! compare! the!treatments!and!culture!conditions.!**!p!<!0.01!and!***!p!<!0.001.!Shown!are!the!means!of!triplicates!for!n!=!10!participants.!!!!
!
Figure- 5.10- Levels- of- Th2- type- cytokines- in- PMA/I- stimulated- PBMC-
cultures-PBMC!were!isolated!from!blood!collected!1!hour!after!treatment!and!plated!at!1!x! 105! cells/well,! in! triplicate,! with! or! without! 5! ng/mL! PMA! and! 200! ng/mL!ionomycin,!for!24!hours.!Supernatant!cytokine!levels!were!assessed!with!a!CBA!and! flow! cytometry.! (A)! ILC4;! (B)! ILC5;! (C)! ILC6;! (D)! ILC10;! (E)! ILC13.!TwoCway!repeated!measures!ANOVA!with!Bonferroni!postChoc!tests!were!used!to!compare!the!treatments!and!culture!conditions.!*!p!<!0.05,!**!p!<!0.01,!and!***!p!<!0.001.!Shown!are!the!means!of!triplicates!for!n!=!10!participants.!!
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Figure- 5.11- Th9/Th17/Th22- type- cytokines- in- PMA/I- stimulated- PBMC-
cultures-PBMC!were!isolated!from!blood!collected!1!hour!after!treatment!and!plated!at!1!x! 105! cells/well,! in! triplicate,! with! or! without! 5! ng/mL! PMA! and! 200! ng/mL!ionomycin,!for!24!hours.!Supernatant!cytokine!levels!were!assessed!with!a!CBA!and! flow! cytometry.! (A)! ILC1β;! (B)! ILC17;! (C)! ILC22;! (D)! TNFCα.! TwoCway!repeated!measures!ANOVA!with!Bonferroni!postChoc!tests!were!used!to!compare!the!treatments!and!culture!conditions.!*!p!<!0.05!and!**!p!<!0.01.!Shown!are!the!means!of!triplicates!for!n!=!10!participants.!!! !!!!!!!!!!
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5.4.3.2 Response,to,anti>CD3/28,dynabead,stimulation,Stimulation! of! T! cells! with! antiCCD3/28! dynabeads! was! associated! with! a!substantial! cytokine! response.! High! levels! of! ILC2,! ILC12p70,! and! IFNCγ! were!detected!following!stimulation,!compared!to!very!minor!or!no!expression!in!the!unstimulated! samples! (Figure! 5.12A! –! C).! Dynabead! activation! also! induced!moderately!high! levels!of! the! typical!Th2!cytokines,! ILC5,! ILC6,! ILC10,!and! ILC13!(Figure!5.13A!C!D).!As!was!seen!in!the!PMA/I!stimulated!samples,!a!low!level!of!ILC13!was!produced!constitutively! in! the!unstimulated!cultures! (Figure!5.13D).!Significant! levels! of! ILC1β,! ILC9,! ILC17,! ILC22,! and! TNFCα! were! also! detected!following! culture! with! dynabeads,! and! lower! levels! of! ILC1β! and! ILC22! were!measured! in! the! unstimulated! samples! (Figure! 5.14A! –! E).! There! was! no!significant! difference! in! cytokine! responses! between! the! control! and! RIPC!treatments!with!antiCCD3/stimulation!of!T!cells.!!The!pattern!of!cytokine!expression!was!slightly!different!between!the!dynabead!and!PMA/I!cultures.!Although!still!substantial,!the!concentrations!of!ILC2!and!ILC6! measured! following! dynabead! activation! were! approximately! one! third! and!one! quarter! of! the! levels! detected! with! PMA/I! stimulation,! respectively.! In!contrast,! ILC10! levels!were! approximately! 4Cfold! higher,! and!TNFCα!was! 3Cfold!higher! after! antiCCD3/28! dynabead! stimulation.! Overall,! the! cytokine! profile!associated!with!the!dynabead!treatment!was!consistent!with!the!more!balanced!Th1/Th2!type!response!expected!towards!a!physiological!stimulus.!!!!!!!!!!!!!
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Figure- 5.12- Levels- of- Th1- type- cytokines- in- antiLCD3/28- dynabead-
stimulated-PBMC-PBMC!were!isolated!from!blood!collected!1!hour!after!treatment!and!plated!at!8!x! 104! cells/well,! in! triplicate,!with! or!without! antiCCD3/28! dynabeads! at! a! 1:1!ratio!with!cells,! for!24!hours.!Supernatant!cytokine!levels!were!assessed!with!a!CBA! and! flow! cytometry.! (A)! ILC2;! (B)! ILC12p70;! (C)! IFNCγ.! TwoCway! repeated!measures! ANOVA! with! Bonferroni! postChoc! tests! were! used! to! compare! the!treatments!and!culture!conditions.!**!p!<!0.01!and!***!p!<!0.001.!Shown!are!the!means!of!triplicates!for!n!=!10!participants.!!!
!
Figure- 5.13- Production- of- Th2- type- cytokines- in- antiLCD3/28- dynabead-




stimulated-with-antiLCD3/28-dynabeads-PBMC!were!isolated!from!blood!collected!1!hour!after!treatment!and!plated!at!8!x! 104! cells/well,! in! triplicate,!with! or!without! antiCCD3/28! dynabeads! at! a! 1:1!ratio!with!cells,! for!24!hours.!Supernatant!cytokine!levels!were!assessed!with!a!CBA! and! flow! cytometry.! (A)! ILC1β;! (B)! ILC9;! (C)! ILC17;! (D)! ILC22;! (E)! TNFCα.!TwoCway!repeated!measures!ANOVA!with!Bonferroni!postChoc! tests!were!used!to!compare!the!treatments!and!culture!conditions.!*!p!<!0.05,!**!p!<!0.01,!and!***!p!<!0.001.!Shown!are!the!means!of!triplicates!for!n!=!10!participants.!!!!!!
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5.4.4 AntigenLspecific-T-cell-cytokine-response-To!more!specifically!determine!if!RIPC!could!effect!cytokine!production!and!thus!T! cell! biasing! in! an! antigenCspecific! response,! PBMC!were! cultured! for! 6! days!with! ADT! Booster! vaccine.! Overall,! the! cytokine! levels! in! these! culture!supernatants! were! pronounced,! which! along! with! the! proliferative! response!suggests!antigenCspecific!activation.!Because!the!vaccine!antigens!only!activate!a!small! population! of! memory! cells,! the! cytokine! responses! were! significantly!more!modest!than!those!seen!with!the!24Chour!polyclonal!responses.!As!with!the!previous!analysis,!exclusion!of! the!two!participants!with!high!baseline! levels!of!serum!cytokines!did!not!significantly!alter!the!results,!and!so!they!were!included!in!the!final!analysis.!!!There! were! notably! higher! levels! of! the! Th1! cytokines! ILC2! and! IFNCγ! in! the!stimulated!samples,!compared!to!the!unstimulated!cultures;!however,!due!to!the!high! level! of! variability! between! participants,! the! differences! did! not! reach!statistical! significance! (Figure! 5.15A! and!C).!Moderate! levels! of! ILC2! and! IFNCγ!were!also!detected!in!the!unstimulated!samples!while!ILC12p70!levels!were,!on!average,! low! but! detectable!with! no! difference! induced! by! stimulation! (Figure!5.15A!–!C).!!!The!majority!of! the!cytokines!associated!with!a!Th2!type!response!were!below!the!level!of!detection,!including!ILC4,!ILC5,!and!ILC6!(data!not!shown).!There!was,!however,!a!significant!increase!in!the!antiCinflammatory!cytokines,!ILC10!and!ILC13,! in! the! samples! cultured! with! the! tetanus! antigen! (Figure! 5.16A! and! B).!Production!of!these!cytokines!in!the!absence!of!stimulation!was!extremely!low.!!!ILC1β!levels!appeared!to!increase!following!stimulation!with!the!tetanus!antigen,!but! did! not! reach! statistical! significance,! and!TNFCα!was!measurable! in! all! the!samples!but!highly!variable!between!participants!and!conditions!(Figure!5.17A!and!C).!The!levels!of!ILC9!and!ILC17!were!below!the!level!of!detection!of!the!assay!(data! not! shown).! Interestingly,! there!were! significantly! higher! levels! of! ILC22!detected! in! the! samples! after!RIPC,! compared! to! the! control! treatment! (Figure!5.17B).! This! effect!was! seen! in! both! the! unstimulated! and! stimulated! cultures,!
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suggesting!it!was!independent!of!the!activation!induced!by!the!tetanus!antigen.!As!the!ILC22!production!was!not!induced!as!part!of!the!antigenCspecific!response,!it! may! have! originated! from! multiple! cell! subsets,! rather! than! just! the! T! cell!population.! Preconditioning! did! not! alter! the! levels! of! any! other! cytokines!measured!in!these!6Cday!cultures.!!!!
!
Figure-5.15-Th1-type-cytokine-production-in-tetanus-stimulated-PBMC-PBMC!were!isolated!from!blood!collected!1!hour!after!treatment!and!plated!at!1!x!105!cells/well,!in!triplicate,!with!or!without!the!ADT!vaccine!diluted!1:5,!for!6!days.!Supernatant!cytokine!levels!were!assessed!with!a!CBA!and!flow!cytometry.!(A)! ILC2;! (B)! ILC12p70;! (C)! IFNCγ.! TwoCway! repeated! measures! ANOVA! with!Bonferroni! postChoc! tests! were! used! to! compare! the! treatments! and! culture!conditions.!Shown!are!the!means!of!triplicates!for!n!=!10!participants.!!!!
!





PBMC-PBMC!were!isolated!from!blood!collected!1!hour!after!treatment!and!plated!at!1!x!105!cells/well,!in!triplicate,!with!or!without!the!ADT!vaccine!diluted!1:5,!for!6!days.!Supernatant!cytokine!levels!were!assessed!with!a!CBA!and!flow!cytometry.!(A)! ILC1β;! (B)! ILC22;! (C)! TNFCα.! TwoCway! repeated! measures! ANOVA! with!Bonferroni! postChoc! tests! were! used! to! compare! the! treatments! and! culture!conditions.!*!p!<!0.05.!Shown!are!the!means!of!triplicates!for!n!=!10!participants.!!!!!!!!!!!!!!!!!!!!!!
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5.5 Discussion-The! aim!of! this! chapter!was! to! investigate! the! effect! of!RIPC!on! the! functional!responses! of! peripheral! immune! cells! in! healthy! volunteers.!We! found! a! trend!towards! reduced! expression! of! the! activation! marker,! CD11b,! in! cultured!monocytes! and! neutrophils! after! preconditioning,! but! no! change! in! the!intracellular! production! of! ILC6! and! ILC8! in! these! cells.! Overall,! PBMC! isolated!following! RIPC! did! not! show! an! altered! proliferative! response! to! stimulation!with!PMA/I,!antiCCD3/28!expander!beads,!or! the! tetanus! toxin.!There!was!also!no! evidence! that! RIPC! polarised! the! T! helper! cell! response! or! affected! T! cell!cytokine!production!following!culture!with!polyclonal!or!antigenCspecific!stimuli;!however,! RIPC! did! result! in! a! marked! and! significant! increase! in! basal! ILC22!production!in!PBMC!cultured!for!6!days.!!RIPC! has! previously! been! associated!with! a! decrease! in! CD11b! expression! on!neutrophils! in!humans! (Kharbanda! et! al.,! 2001;!Konstantinov! et! al.,! 2004).!We!found! a! general! trend! towards! reduced! CD11b! levels! on! both! monocytes! and!stimulated! neutrophils! following! culture! for! 4! or! 27! hours,! although! this!difference! did! not! reach! statistical! significance.! To! the! best! of! our! knowledge,!such!a!change!in!CD11b!expression!on!monocytes!following!preconditioning!has!not! previously! been! reported.! While! we! cannot! definitively! say! that! RIPC!decreased! CD11b! expression! in! our! study,! it! would! be! equally! premature! to!conclude!that!it!did!not.!Given!the!hypothesis!generating!nature!of!this!trial,!the!reduced! expression! of! CD11b! on! neutrophil! and! monocytes! following! RIPC!merits!further!investigation.!!CD11b! is! an! integrin! family! member,! and! facilitates! adhesion! and! migration!through!binding!to!ICAMC1!on!the!vascular!endothelium!(Diamond!et!al.,!1990).!In! addition,! CD11b! is! the! receptor! for! the! complement! protein,! C3bi,! which!facilitates!phagocytosis!of!bacteria!and! their! components! through!opsonisation!(Stossel!et!al.,!1975;!Wright!et!al.,!1983).!This!process!becomes!relevant!during!cardiac! surgery! in! response! to! endotoxins! released! into! the! circulation! most!likely!due!to!ischaemia!of!the!bowel!(Andersen!et!al.,!1993;!MartinezCPellús!et!al.,!1997;!Watarida!et!al.,!1994).!CD11b!also!binds!a!key!component!of!clots,!fibrin,!
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and!this!interaction!contributes!to!the!dual!role!of!neutrophils!in!both!thrombus!development!and!dissolution!(Wright!et!al.,!1988).!Neutrophils!enhance!the!early!stage!of!clot!formation!through!the!release!of!tissue!factor!and!serine!proteases!that!degrade!the!key!inhibitor!of!clot!formation,!tissue!factor!pathway!inhibitor!(Massberg! et! al.,! 2010;! Maugeri! et! al.,! 2006).! In! the! case! of! infection,! this!response! is!protective! in! smaller!vessels!by! restricting! the!passage!of!bacteria;!however,!it!is!largely!detrimental!during!cardiac!surgery.!In!contrast,!during!the!later! stage! of! clot! formation,! neutrophils! appear! to! degrade! thrombi! through!phagocytosis! of! fibrin! and! the! release! of! neutrophil! elastase! and! cathepsin! G!(Plow,! 1986;! Rábai! et! al.,! 2010;! Riddle! and! Barnhart,! 1964).! CD11b,! thus,!mediates! several! important! and! diverse! functions! of! neutrophils! during! the!inflammatory!response.!!!CD11b! is! regarded! as! a! general! activation! marker! for! monocytes! and!neutrophils;!however,!the!change!in!CD11b!levels!detected!in!our!volunteers!did!not! correspond! to! a! change! in! their! capacity! to! synthesise! ILC6! and! ILC8.! It! is!therefore! difficult! to! comment! on! whether! this! change! represents! an! overall!suppression! of! neutrophil! activity,! or! a! specific! effect! on! the! functions! that!depend! on! CD11b! as! a! receptor.! Saxena! et# al.# have! associated! RIPC! with! a!decrease! in! neutrophil! kinin! receptor! expression,! supporting! the! former!possibility;! however,! further!measures! of! neutrophil! function!will! be! required!for!a!conclusive!answer!(Saxena!et!al.,!2013,!2010b).!Regardless,!in!the!setting!of!cardiac! surgery,! a! reduction! in! CD11b! is! likely! to! decrease! tissue! infiltration,!complementCmediated! phagocytosis! by! neutrophils,! and! thrombus! formation,!reducing!the!overall!inflammatory!burden.!!!It! is! interesting!that!we!did!not!see!a!similar!reduction! in!CD11b!expression! in!our!immunophenotyping!samples!collected!at!the!same!time!point!and!assessed!with! and! without! a! brief! 15Cminute! stimulation! (Chapter! 4,! Figure! 4.9).! The!immunophenotyping!samples!were!acquired!on!a!Guava! flow!cytometer,!which!has!a!slightly!lower!level!of!resolution!and!this!lower!resolution!may!reduce!the!ability! to!measure!subtle!differences;!however,! this!explanation!seems!unlikely!given! that! the! effect! in! the! cultured! cells! was! quite! pronounced.! It! therefore!
!! 225!
appears! that! the! neutrophils! and!monocytes! required! a! period! of! time! longer!than! 15! minutes! to! enact! this! change,! and! suggests! the! mechanism! could!potentially! depend! on! an! alteration! in! gene! expression,! rather! than!straightforward!receptor!endocytosis!or!shedding!via!preCformed!mediators.!!!Of! particular! note! is! that! adenosine,! which! has! been! identified! as! both! an!initiator!and!mediator!of!RIPC,!has!been!shown!to!reduce!CD11b!expression!on!neutrophils! (Thiel! et! al.,! 1996;! Wollner! et! al.,! 1993).! Adenosine! can! either!activate!or!suppress!neutrophil!functions!depending!on!the!concentration!in!the!microcirculation! and! the! receptor! expression! profile! of! the! cells.! More!specifically,! low! concentrations! of! adenosine! operate! through! the! A1! and! A3!receptors! to! stimulate! chemotaxis! and! phagocytosis,! whereas! higher!concentrations! act! through! the!A2A! and!A2B! receptors! to! inhibit! key!neutrophil!activities!such!as!granule!and!inflammatory!mediator!release,!and!the!oxidative!burst!(Chen!et!al.,!2006;!Cronstein!et!al.,!1990;!McColl!et!al.,!2006;!Salmon!and!Cronstein,! 1990;! Visser! et! al.,! 2000).! It! is! therefore! possible! that! a! change! in!neutrophil!CD11b!expression!following!RIPC!may!be!secondary!to!an!alteration!in!adenosine!levels!and/or!neutrophil!adenosine!receptor!expression.!!!We!detected! the! decrease! in! CD11b! levels! after! 4! hours! culture,! but! the! effect!may!take!place!more!quickly.!In!cardiac!surgery!patients!this!fits!with!the!timing!of! the! reperfusion! injury! relative! to! the! administration! of! RIPC,! but! is! less!applicable! in!animal!models!where!the! injury! is!often! induced!shortly!after! the!intervention.!A!change!to!neutrophil!infiltration!during!I/R!injury!therefore!may!not! be! the! primary! mechanism! of! protection! in! such! animal! studies.!Interestingly,! a! recent! clinical! trial! by! Albrecht! et# al.# detected! increased! MPO!activity!in!right!atrial!tissue!samples!following!RIPC!in!cardiac!surgery!patients,!and!this!was!associated!with!a!cardioprotective!response.!The!authors!noted!that!an! initial! transient! increase! in!neutrophil! infiltration!of! the!myocardium!might!actually! be! beneficial! during! reperfusion! (Albrecht! et! al.,! 2013).! Alternatively,!alterations! to! neutrophil! extravasation! shortly! after! preconditioning! may! be!dependent! on! prompt! changes! to! adhesion!marker! expression! on! the! vascular!endothelium,!and!the!later!alterations!to!leukocyte!CD11b!expression!may!then!
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further!enhance!this!effect!(Davis!et!al.,!1999;!Linden!et!al.,!2006).!In!summary,!although!RIPC!appears!to!affect!neutrophil!and,!potentially,!monocyte!expression!of!CD11b,! the!exact!kinetics!and!resulting!effects!of! this!alteration!are!not! fully!understood!and!require!further!investigation!in!humans.!!!One! of! the! most! interesting! findings! from! our! study! was! that! RIPC! increased!basal! production! of! ILC22! in! PBMC! cultured! for! 6! days.# ILC22! can! play! a!dichotomous! role! during! inflammation,! but! is!more! frequently! associated!with!tissue!protective! functions,! such!as!wound!healing! and! tissue!homeostasis! and!repair! (Rutz! et! al.,! 2013).! The! majority! of! ILC22! receptors! are! present! on!keratinocytes,!hepatocytes,!and!epithelial!cells!of! the! intestines!and!respiratory!system! and! accordingly,! ILC22! exerts! some! of! its! major! functions! in! the! liver,!lung,!and!kidney!(Ki!et!al.,!2010;!Kulkarni!et!al.,!2014;!Sonnenberg!et!al.,!2010;!Wolk!et!al.,!2004).!ILC22!has!been!shown!to!stimulate!epithelial!cell!proliferation!and! endurance! in!numerous!organs! and!has! a!particularly!wellCdefined! role! in!protection!of!the!liver!(Ki!et!al.,!2010;!Radaeva!et!al.,!2004).!In!a!murine!model!of!hepatitis,! administration! of! recombinant! ILC22! attenuates! hepatocyte! damage!and! increases! STAT3! signalling.! In# vitro! culture! of! human! hepatocellular!carcinoma! HepG2! cells! with! ILC22! related! this! increased! level! of! STAT3! to!enhanced!expression!of!antiCapoptotic!and!mitogenic!proteins!that!promote!cell!survival! (Radaeva! et! al.,! 2004).! ILC22! has! also! been! identified! as! having!protective! functions! during! numerous! other! pathological! conditions,! including!graftCversusChost! disease,! models! of! autoimmune! myocarditis,! and!inflammationCinduced!pulmonary!fibrosis!(Chang!et!al.,!2006;!Kapessidou!et!al.,!2008;!Simonian!et!al.,!2010).!!!The! change! in! ILC22! detected! in! our! study! occurred! in! the! absence! of! an!ischaemic!injury!and!no!increase!was!detected!in!the!24Chour!PBMC!cultures,!or!in!the!serum!shortly!after!preconditioning.!Taken!together,!these!results!strongly!imply!that!changes!in!ILC22!are!specific!to!the!later!phase!of!preconditioning!and!are! not! connected! to! the! biphasic! mode! of! expression! seen! with! many! other!cytokines.!Nonetheless,!clearly!the!signals!required!for!altering!ILC22!production!in!the!PBMC!occurred!within!the!first!hour! following!RIPC!while!the!cells!were!
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still!in#vivo.!Our!study!is!the!first!to!link!ILC22!with!RIPC!and!raises!a!number!of!new!hypotheses!regarding!the!delayed!phase!of!preconditioning.!!The!second!window!of!IPC!is!generally!reported!as!lasting!up!to!72!hours,!owing!to!a!study!from!Baxter!et#al.#in!1997!which!reported!significant!cardioprotection!in!rabbits!24,!48,!and!72!hours!following!preconditioning,!but!not!after!96!hours.!Subsequent! studies! have,! however,! demonstrated! that! hypobaric! hypoxia! and!longer!durations!of!IPC!are!associated!with!protective!effects!that!persist!up!to!5!and!12!weeks,!respectively!(Neckár!et!al.,!2004;!Park!et!al.,!2003).!Accordingly,!work! in!murine!models!has! found!that!preconditioning!using!an! initial!20!–!25!minute!period!of! ischaemia! significantly! improves!measures!of! kidney!damage!and!function!following!an!ischaemic!injury!induced!4!or!7!days!later!(Jiang!et!al.,!2007;! Kinsey! et! al.,! 2010).! The! exact! mechanisms! involved! in! this! extended!window! of! protection! induced! by! late! preconditioning! are! unclear;! however,!Kinsey!et#al.#found!the!renal!protection!observed!7!days!after!IPC!was!dependent!on!the!induction!of!Tregs,!which!are!known!to!induce!ILC22!production!through!interactions!with!CD4+!T!cells!and!promote!Th17!cell!differentiation!(Kinsey!et!al.,!2010;!Pandiyan!et!al.,!2011).!Further,!Xu!et#al.#(2014)!recently!demonstrated!for! the! first! time! that! overexpression!of! ILC22! in!mice! increased! survival! rates!following!renal!I/R,!and!lowered!levels!of!tubular!cell! injury,!inflammation,!and!apoptosis! in! the! kidneys.! It! therefore! seems! highly! likely! that! delayed! renal!protection!could!be,!at!least!in!part,!mediated!by!an!increase!in!ILC22!levels,!such!as!was!detected!during!the!corresponding!timeframe!in!the!present!work.!!!There! are! a! number! of! possibilities! for! the! disparity! between! the! study!suggesting! that! delayed! preconditioning! wanes! after! 72! hours! and! those!reporting! beneficial! effects! several! weeks! later.! First,! there! may! not! be! one!unilateral!process!that!evokes!organ!protection!at!both!24!hours!and!12!weeks!following! the! intervention.! The! underlying! processes! that! contribute! to! the!protective!effects!may!shift!over!the!course!of!the!delayed!window!with!periods!of! ‘downtime’! as! one! pathway! resolves! and! another! takes! over.! Second,! late!preconditioning! may! selectively! protect! against! specific! processes! associated!with!I/R!injury.!For!instance,!delayed!IPC!may!not!reduce!myocardial!infarct!size,!
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as!was!the!primary!endpoint!in!Baxter’s!study,!but!help!maintain!the!structural!integrity!of! the!kidneys,!such!as!was!seen!by! Jiang!et#al.#These!possibilities!are!not!mutually!exclusive!and!are!consistent!with!our!finding!that!ILC22!production!was! increased! after! 6! days! but! not! 24! hours! in! culture! and! the! literature!associating! ILC22! with! direct! renal! but! not! myocardial! protection! (Rutz! et! al.,!2013).!!!While! ILC22! can! exert! both! pro! and! antiCinflammatory! effects,! the! choice! of!effects! appears! to! be! somewhat! dependent! on! the! coCexpression! of! ILC17.! For!instance,! in! a! mouse! model! of! airway! inflammation! induced! by! bleomycin,!knockout!of!either!the!ILC17!or!ILC22!genes!attenuates!inflammation,!implicating!both! cytokines! in! the!pathological!process;! however,! higher! levels! of! ILC22!are!produced! in! ILC17! deficient!mice! and! are! associated!with! resistance! to! airway!inflammation.!Further,!treatment!with!a!neutralising!antiCILC22!antibody!in!ILC17!knockout!mice! reverses! this! protective! effect,! and! reinstates! the! inflammatory!response! to! bleomycin! (Sonnenberg! et! al.,! 2010).! This!work! strongly! suggests!that! ILC22! is! tissueCprotective! in! the! absence! of! ILC17,! and! proinflammatory!when!the!two!cytokines!are!coCexpressed.!!!Traditionally,! ILC22! has! been! considered! a! cytokine! of! Th17! cells! that! is!expressed!in!tandem!with!ILC17.!In!humans,!however,!ILC22!producing!cells!often!do! so! independently! of! other! cytokines;! in! fact,! as!many! as!37! –!63%!of! ILC22!producing! CD4+! T! cells! in! human! peripheral! blood! do! not! coCexpress! ILC17!(Duhen! et! al.,! 2009).! This! finding! is! consistent! with! the! relatively! recent!identification!of!a!new!subset!of!CD4+!T!cells!capable!of!producing!ILC22! in!the!absence!of!ILC17,!designated!the!Th22!subset!(Eyerich!et!al.,!2009).!In!addition,!ILC22! can! be! secreted! independently! by! a! wide! variety! of! immune! cells! in!humans,!including!Th1,!CD8+,!and!certain!NK!cells!(Cella!et!al.,!2009;!Ortega!et!al.,!2009;!Wolk!et!al.,!2002).!No!ILC17!was!detected!in!our!6Cday!cultures,!suggesting!RIPC! either! enhanced! the! Th22! response,! and/or! altered! ILC22! expression! in!multiple! immune! cell! subsets,! rather! than! targeting! the! Th17! population.!Further,! the! lack! of! ILC17! in! our! cultures! indicates! that! the! induction! of! ILC22!following!RIPC!is!more!likely!to!be!associated!with!antiCinflammatory!effects.!!!
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If! ILC22! does! provide! protection! during! delayed!RIPC,! it! raises! the! question! of!when! is,! exactly,! the! most! beneficial! time! to! apply! preconditioning! in! cardiac!surgery!patients.!While!it!is!possible!that!having!increased!levels!of!ILC22!at!the!time!of!I/R!may!be!beneficial,!it!is!likely!that!the!more!intense!effects!associated!with! the! first!phase!of!RIPC!could!provide!greater!protection!during! the! initial!insult.! A! delayed! increase! in! ILC22! production! once! the! initial! inflammatory!response!to!surgery,!which!likely!includes!an!upregulation!of!ILC17,!has!at!least!partially!resolved!may!be!safer!and!more!beneficial!during!wound!repair.!!!One! limitation! of! our! study! was! the! sensitivity! of! the! ILC22! measurements.!Although!the!theoretical!limit!of!detection!for!the!assay!was!2.5!pg/mL,!we!found!that! the! signal! strength! at! the! lower! end! of! the! standard! curve!was! poor! and!therefore!lacked!the!ideal! level!of!sensitivity!for!measuring!subtle!changes.!The!use! of! an! alternative! method! for! determining! the! culture! supernatant! ILC22!levels,! such! as! an! ELISA,! would! be! valuable! to! confirm! our! results.! Also,! as!previously!discussed!in!Chapter!4,!the!large!number!of!statistical!tests!performed!for!the!study!is!associated!with!an!increased!likelihood!of!type!I!error,!therefore!the!results!should!also!be!interpreted!in!this!context.!!!In!our!previous!trial,!we!found!a!general!trend!towards!higher!circulating!levels!of! ILC6,! ILC8,! and! ILC10! in! cardiac! surgery! patients! that! received! the!preconditioning,! compared! to! the! controls.! Following!on! from! this!work,! a! key!aim! of! our! study! in! healthy! volunteers! was! to! identify! whether! RIPC! directly!impacted!cytokine!expression!in!the!absence!of!ischaemic!injury.!We!addressed!this!by!not!only!measuring!serum!cytokine!levels!following!preconditioning,!but!also!using!ICS!to!investigate!which!populations!of!cells!might!be!contributing!to!any!increased!cytokine!levels.!We!did!not!detect!a!change!in!intracellular!ILC6!or!ILC8! production! in! any! of! the! peripheral! leukocyte! populations! examined! and,!although!we!were!unable!to!examine!ILC10!intracellularly,!there!was!no!change!in!ILC10!production!in!PBMC!cultured!with!or!without!PMA/I!for!24!hours!either.!These! results! are! consistent!with!our! earlier! assessment! that!RIPC!either!does!not! increase! cytokine! production,! or! else! predominantly! affects! cytokine!
!!230!
expression! in! cells! that! are! not! of! hematopoietic! origin,! such! as! myocytes! or!endothelial!cells.!!!Independently!of!RIPC,!our! ICS!results!did! indicate! that! resting!monocytes!and!stimulated! neutrophils! are! likely! to! be! major! sources! of! ILC8,! and! that!unstimulated!neutrophils!are!notable!producers!of!ILC6.!The!finding!that!neither!population! appeared! to! produce! ILC6! and! ILC8! simultaneously! is! interesting,!particularly!with!respect!to!neutrophils!which!stained!positively!for!both!albeit!in!separate!populations.!This!suggests!that!induction!of!ILC6!and!ILC8!synthesis!is!not!coupled!within!these!cells.!The!effector!functions!of!neutrophils!in!the!setting!of!cardiac!surgery!may!depend!on!their!individual!cytokine!expression!profile.!!!Stimulation! of! PBMC! with! the! tetanus! antigen! is! associated! with! a! mixed!Th1/Th2!type!response!including!production!of!ILC2,!IFNCγ,!TNFCβ,!ILC4,!and!ILC10!(Larsen!et!al.,!2000).!We!saw!similar!results!in!our!study;!however,!we!did!not!detect!any!ILC4!or!significant!levels!of!several!other!key!cytokines.!The!ability!to!measure! cytokine! levels! in! culture! supernatants! is! limited!by! the! role! of! these!molecules! as! immunoregulatory! hormones,! which! means! they! are! often!promptly! taken! up! or! degraded! (Akdiş! et! al.,! 1995).! For! instance,! ILC4! is!produced! by! activated! Th2! and! NKT! cells! but! is! rapidly! consumed! by! cells!expressing! the! ILC4! receptor,!particularly!activated!T!and!B! cells! (Akbari! et! al.,!2003;! Broere! et! al.,! 2011;! Ohara! and! Paul,! 1988).! Although! we! did! detect! a!significant! cytokine! response! in! our! 6Cday! cultures,! especially! considering! we!were!targeting!a!small!population!of!antigenCspecific!cells,!this!explains!why!we!did!not! find!measurable! ILC4! levels.!The!genes! for! the! common!Th2Cassociated!cytokines,! ILC4,! ILC5,! and! ILC13! are! clustered! and! often! subject! to! coordinate!regulation;!therefore,!levels!of!ILC5!and!ILC13!are!useful!as!surrogate!markers!of!ILC4! expression! and! were! detected! more! consistently! in! our! study! (Kelly! and!Locksley,!2000).! It! should!be!noted! that!one!weakness!with!our!assay!utilising!the!ADT!Booster!vaccine!for!stimulating!T!cells!was!the!inability!to!conclusively!determine!that!the!resulting!proliferation!and!cytokine!production!were!antigenCspecific!responses.!!Further!work!to!determine!the!specificity!of!this!assay!would!be!valuable!to!confirm!our!methods.!!!
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We!also!only!detected!low!levels!of!ILC12p70!in!our!PBMC!culture!supernatants,!despite!there!being!high!levels!of!ILC2!and!IFNCγ!present!in!the!same!samples.!ILC12p70! is!a!heterodimer!composed!of! the!smaller!p35!and!p40!subunits,! and! is!the!biologically!active!form!of!the!cytokine.!The!p40!subunit!has!been!associated!with! ILC12! antagonism! due! to! its! ability! to! bind! to! the! ILC12! receptor! as! a!homodimer,! blocking! ILC12p70! binding! (Gately! et! al.,! 1996;! Ling! et! al.,! 1995).!The!p40!subunit!also!appears!to!exert!some!biological!effects!as!a!monomer,!and!forms!part! of! the! ILC23! heterodimer! (Hamza! et! al.,! 2010;!Khader! et! al.,! 2006).!The!ILC12p40!subunit!is!thus!present!in!higher!concentrations!and!more!readily!detectable! than! ILC12p70! and,! despite! its! lower! specificity! compared! to! the!active!form!of!ILC12,! it! is!often!used!as!a!marker!of!ILC12!levels!(Dobreva!et!al.,!2008).!Performing!an!additional!assay!on!our!samples!to!measure!ILC12p40!may!provide! a!more! sensitive! indication! of! whether! RIPC! altered! ILC12! serum! and!supernatant!levels.!!!T! cell!proliferation! to!physiological! and!antigenCspecific! stimuli! seemed! largely!unaffected! by! RIPC;! however,! there! was! a! slight! trend! towards! an! increased!proliferative! response! to! stimulation! with! PMA/I.! The! pharmacological!stimulants,!PMA/I,!activate!cells!in!a!nonCspecific!fashion!independently!of!the!T!cell! receptor,! thus! can! also! affect! other! mononuclear! leukocytes! such! as!monocytes! and! B! cells.! However,! only! a! small! portion! of! circulating! human!monocytes!retain!the!ability!to!proliferate;!therefore,!the!vast!majority!of!PMA/ICinduced! proliferation! in! PBMC! cultures! can! be! attributed! to! lymphocyte!responses! (Clanchy! et! al.,! 2006).! Furthermore,! the! predominant! cell! subset! in!isolated!PBMC!are!the!CD3+!T!cells,!which!represent!approximately!70!–!85%!of!the! total! lymphocytes.!T! cells! are!estimated! to!have!a!doubling! time!anywhere!between!6!and!15!hours,!depending!on! the!stimulus!(Boer!et!al.,!2003;!MuraliCKrishna!et!al.,!1998).!Our!culture!period!of!24!hours!was!primarily!selected!for!measuring! cytokine! responses,! and! may! not! have! allowed! sufficient! time! for!multiple! doublings! of! the! cells.! A!more! conclusive! indication! of! whether! RIPC!alters! T! cell! proliferation! in! response! to! pharmacological! stimuli! could! be!achieved! with! a! longer! culture! period! and! greater! number! of! participants! to!account!for!interCindividual!variability!in!responses.!!
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Interestingly,!we!detected!a! trend! towards! increased!T!cell! activation! in!whole!blood! cultured! for! 27!hours!with!PMA/I! following!RIPC.! The! level! of! response!was!highly!variable!between! individuals! and! therefore!did!not! reach! statistical!significance;! however,! the! effect! was! consistent! across! the! study! participants.!Although!there!was!significant!upregulation!of!CD69!expression!following!PMA/I!stimulation!in!cultures!incubated!for!only!4!hours,!a!difference!between!the!RIPC!and!control!treatments!was!not!apparent!until!the!later!time!point.! It!therefore!appears! that!RIPC!may!augment!T!cell!activation!during! the!second!window!of!protection,! but! not! during! the! early! phase.! Further! investigation! as! to! which!subsets!of!T!cells!show!enhanced!CD69!expression!and!whether!this!correlates!to!a!change! in! their! function!will!be!necessary! to!understand! the! impact! that! this!change!could!have!on!the!progression!of!I/R!injury.!Aside!from!this!enhanced!T!cell!CD69!expression,!increase!in!ILC22!production,!and!potential!trend!towards!enhanced!proliferation!after!24!hours!stimulation!in#vitro,!there!were!no!further!changes!to!T!cell!function!detected!following!RIPC.!!!







6.1 Introduction-The!previous!two!chapters!explored!the!effect!of!RIPC!on!the!immune!response!in!healthy!volunteers!by!assaying!a!series!of! individual!endpoints.!Our!analysis!detected! a! number! of! interesting! changes! following! RIPC;! however,! the! large!dataset!made! it!difficult! to! identify!overall! trends! in! the!response! to! treatment!and!between!the!participants.!In!light!of!the!difficulties!translating!RIPC!into!the!clinical! setting,! it! is! possible! that! certain! individuals! may! not! respond! to! the!treatment! owing! either! to! genetic! differences! or,! potentially,! perturbations! in!their! baseline! physiological! state.!We!were! therefore! particularly! interested! in!examining! how! the! global! response! to! RIPC! varied! amongst! the! healthy!volunteers!in!our!study!and!investigated!this!question!through!the!use!of!a!nonCimmune!marker!of!ischaemia!and!multivariate!statistical!analysis.!!!
6.1.1 A-potential-biomarker-of-successful-preconditioning-A!particular!limitation!with!RIPC!trials!to!date!is!that!no!reliable!marker!capable!of! confirming! the! successful! application!of!preconditioning! ischaemia!has!been!established.!Identifying!a!positive!control!for!RIPC!in!humans!would!be!useful!for!a! number! of! reasons.! First,! although! inflation! of! the! tourniquet! in! conscious!healthy!volunteers!can!be!easily!monitored,! it! is!possible! that! the!extent!of! the!restriction!of!blood!flow!during!the!intervention!may!vary!between!participants.!For!instance,!most!clinical!trials!have!inflated!the!tourniquet!to!a!predetermined!constant!pressure!of!200!mmHg;!however,!some!trials!adjust!this!value!to!ensure!it!sits!at!least!15!–!20!mmHg!above!the!systolic!arterial!pressure!for!each!patient.!The!majority!of!studies,!including!our!own,!have!used!the!former!strategy,!which!allows! for! the! possibility! that! the! extent! of! the! preconditioning! may! vary!between!participants!according!to!their!blood!pressure.!Second,!in!the!absence!of!the!full!knowledge!of!the!pathways!through!which!RIPC!operates,!it!is!impossible!to!know!whether! all! individuals! are! capable!of! responding! to! the! intervention.!Where!trial!participants!are!identified!as!‘nonCresponders’!it!would!be!useful!to!be! able! to! exclude! the! possibility! that! the! intervention! was! not! successfully!administered.!!
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In! the! clinical! setting,! ischaemia! is!most! commonly! confirmed! using!measures!that! are! specific! to! cardiac!muscle,! such! as! troponin! elevation! or! ECG! changes!(Jaffe!et!al.,!2000;!Thygesen!et!al.,!2007).!These!types!of!endpoints!are!not!useful!for!assessing!ischaemia!in!alternative!tissues,!such!as!skeletal!muscle;!therefore,!detecting! the! ischaemia! elicited! by! RIPC! requires! an! alternative! marker.! One!potential!candidate!involves!the!major!protein!in!the!circulation,!albumin.!!!Under!normal!conditions,!the!NCterminus!of!the!human!serum!albumin!protein!is!capable! of! binding! transition! metals,! such! as! cobalt! (Sadler! et! al.,! 1994).!Following!the!observation!that!patients!with!ischaemia!exhibited!reduced!cobalt!binding! to! albumin! in! serum! samples,! BarCOr! et# al.# hypothesised! that!modifications!to!this!binding!site!during!ischaemia,!most!likely!in!the!form!of!NCacetylation!of!critical!residues,!decreased!the!metal!binding!capacity!of!albumin!(BarCOr!et!al.,!2001a).!The!group!went!on!to!design!a!unique!assay!to!exploit!this!property!and!quantify!the!extent!of!ischaemiaCmodified!albumin!(IMA)!in!serum!samples! (BarCOr! et! al.,! 2000).! This! assay! has! been! shown! to! reliably! detect!ischaemia!in!patients!with!acute!myocardial!ischaemia;!however,!the!theory!that!the!NCterminus!metal! binding! ability! of! albumin!was! altered! by! ischaemia! has!since!been!disproved!by!the!original!authors!(BarCOr!et!al.,!2008).!Regardless!of!the!mode!of!action!involved!the!cobaltCalbumin!binding!assay!is!still!considered!a!valuable! method! for! detecting! ischaemia,! as! established! by! several! trials!(reviewed!in!Sbarouni!et!al.,!2008),!and!has!received!approval!from!the!US!Food!and!Drug!Administration;! therefore,!we! believe! it!may! also! be! appropriate! for!measuring!a!response!to!RIPC.!!!
6.1.2 Statistical-methods-for-detecting-patterns-in-the-response-to-RIPC-Although!we! found!a!number!of!our!study!endpoints!were!significantly!altered!by!RIPC!according!to!the!mean!group!data,!there!was!a!high!level!of!variability!in!the! individual! responses,! with! some! participants! showing! substantial! changes!and! others! only! subtle! alterations.! Further,! with! the! large! amount! of! data!collected,!it!was!difficult!to!discern!whether!the!changes!detected!following!RIPC!occurred! consistently! within! a! particular! subset! of! individuals,! or! fluctuated!between!all!of!the!study!participants.!!
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There!are!a!number!of!statistical!procedures!available!for!determining!whether!study! participants! can! be! clustered! into! different! subsets! based! on! patterns!within!their!respective!datasets.!Some!of!the!more!common!methods,!such!as!KCmeans! or! hierarchical! clustering,! are! limited! in! their! power! for! small! sample!sizes,! and!require!a! certain! level!of!knowledge!of! the! relationship!between! the!variables! prior! to! the! analysis! in! order! to! specify! the! ideal! number! of! target!clusters! or! the! relative! importance! of! each! variable.! These! methods! were!therefore! not! ideal! for! the! present! study.! One! available! alternative! method! is!multidimensional! scaling! (MDS),! which! is! not! subject! to! such! restrictions! and!provides! a! visual! representation! of! the! overall! level! of! similarity! between!datasets.!!!Comparisons! between! treatment! groups! and! individual! participants! are!generally! investigated!using!common!ANOVA!techniques.!These! tests!assume!a!normal! distribution! of! the! data! and! are! highly! vulnerable! to! violations! of! this!assumption,! whereas! many! of! the! nonCparametric! alternatives! are! not!compatible! with! multiCfactorial! analysis! (Anderson,! 2001;! Johnson! and! Field,!1993).! These! techniques! are! not! well! suited! to! many! biological! datasets;!however,!permutationCbased!ANOVA!(PERMANOVA)!is!an!alternative!that!uses!a!unique! method! to! calculate! a! ‘pseudo’! test! statistic! that! is! analogous! to! the!standard!F0statistic,!and!then!compares!it!to!a!distribution!created!by!running!a!high! number! of! permutations! of! the! observations,! thus! does! not! depend! on!normality!of!the!data!(Anderson,!2001).!!Combining!MDS!with!PERMANOVA!and!similarity!percentage!(SIMPER)!analysis!provides! the! ability! to! detect! differences! between! datasets! grouped! by!experimental!factors!or!the!MDS!analysis,!and!identify!the!relative!contribution!of! the! various! endpoints! to! these! differences,! respectively! (Anderson,! 2001;!Clarke,!1993).!These!methods!were!developed! for!use!with!ecological!datasets,!but! are! applicable! to! a! wide! range! of! studies! and! were! deemed! the! most!appropriate! for! our! data! and! research! question,! therefore! were! used! in! the!following!analysis.!!
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6.2 Aims-
• To! evaluate! the! use! of! ischaemiaCmodified! albumin! as! a! marker! of! the!successful!application!of!RIPC.!
• To! determine! whether! the! changes! in! inflammatory! endpoints! detected!following! RIPC! appear! to! be! related! and! altered! consistently! in! certain!individuals,!or!show!a!random!pattern!of!change!across!the!participants.!




6.3.1 IschaemiaLmodified-albumin-assay-An! assay! to! measure! ischaemiaCinduced! changes! to! binding! of! free! cobalt! in!serum! samples!was! performed! as! first! described! by! BarCOr! et# al.! (2000)!with!minor!adjustments!to!allow!highCthroughput!in!96Cwell!flatCbottom!plates.#Forty!μL! of! each! serum! sample! was! gently!mixed! with! 10! μL! of! 0.1%! CoCl2! (Sigma!Aldrich),!and!incubated!for!10!minutes.!Ten!μL!of!1.5!mg/mL!dithiothreitol!(DTT;!Merck!Millipore)!was!then!added!and!the!reaction!stopped!two!minutes!later!by!the! addition! of! 200! μL! of! 0.9%! NaCl.! The! absorbance! of! the! samples! was!measured!at!470!nm!on!an!EnSpire!2300!multilabel!plate!reader!(PerkinElmer)!and! compared! to! blanks! prepared! using! the! same! serum! sample,! without! the!addition!of!DTT.!!!As!a!positive!control! for! ischaemia,!serum!samples!were!also!collected!from!11!patients!with!acute!coronary!syndrome!(ACS)!presenting!at!Wellington!Hospital!with!symptoms!of!ischaemia!lasting!for!more!than!10!minutes!and!scheduled!to!undergo!coronary!angiography,!with!or!without!PCI.!The!incidence!of!ischaemia!was!confirmed!by!troponin!elevation,!or!ECG!changes!such!as!a!new!ST!deviation,!or!T!wave!inversion!(Thygesen!et!al.,!2007).!Blood!samples!were!collected!before!angiography,!or!in!the!cardiac!catheterisation!laboratory!from!the!arterial!sheath!after! insertion,! and! before! administration! of! heparin.! These! samples! were!generously!provided!by!the!Wellington!Cardiovascular!Research!Group,!using!a!subset!of!patients!from!a!larger!study,!which!received!ethics!approval!from!the!Upper! South! A! Regional! Ethics! Committee! (URA/11/05/016)! and! obtained!written! informed! consent! from! all! patients.! An! additional! 5! volunteers! ageCmatched!to!the!ACS!patient!cohort,!but!without!any!symptoms!or!history!of!ACS,!were!also!recruited!under!the!ethics!approval!for!the!trial!in!healthy!volunteers!(CEN/11/06/034)!to!investigate!the!effect!of!age!on!IMA!levels.!!The!IMA!levels!were!compared!between!treatment!groups!and!time!points!using!twoCway! repeated! measures! ANOVA! with! the! GreenhouseCGeisser! correction,!and! the! levels!between! the!ACS!patients!and! the!ageCmatched!volunteers!were!
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compared! using! an! independent! samples! tCtest.! Graphs! were! produced! using!GraphPad!Prism!5!(GraphPad!Software!Inc)!and!statistical!tests!were!performed!using!SPSS!Statistics!(IBM!Corporation).!Differences!corresponding!to!p!values!<!0.05!were!considered!statistically!significant.!!






Supernatant#Cytokines# ! !ILC6!from!24!hr!antiCCD3/28!stimulated!!!!!!cultures! 44.46!(36.07)! 59.28!(25.84)!ILC22!from!6!day!unstimulated!cultures! 49.19!(42.31)! 79.14!(38.25)!
TNFCα!from!6!day!unstimulated!cultures! 71.60!(83.01)! 25.64!(33.07)!ILC1β!from!6!day!tetanusCstimulated!cultures! 51.48!(42.45)! 39.45!(33.52)!ILC10!from!6!day!tetanusCstimulated!cultures! 222.50!(347.55)! 101.28!(109.76)!
Intracellular#Cytokines# ! !Total!%!of!ILC8+!monocytes!from!4!hr!unstimulated!cultures! 13.29!(7.63)! 18.55!(15.39)!
Cellular#Activation#Markers# ! !CD11b!(%!Δ!from!control)!in!neutrophils!from!4!hr!unstimulated!cultures! 1691.55!(205.36)! 1494.65!(298.06)!CD11b!(%!Δ!from!control)!in!monocytes!from!4!hr!unstimulated!cultures! 1136.18!(484.32)! 916.73!(290.93)!T!cell!CD69!MFI!in!PMA/ICstimulated!27!hr!cultures! 104.82!(57.61)! 202.97!(158.61)!
T#Cell#Proliferation# ! !PMA/ICinduced!proliferative!index!in!24!hr!cultures! 114.39!(25.90)! 130.52!(21.39)!
Ischaemia#Marker# ! !
IMA!(%!change!from!BL!to!4!hrs)! 90.12!(17.64)! 105.13!(24.52)!
Table-6.1-Variables-included-in-the-multivariate-analysis-A!total!of!13!endpoints!that!showed!either!a!statistically!significant!difference,!or!a! trend! towards! a! difference,! between! the! control! and! RIPC! treatment! groups!were!selected!for!inclusion!in!the!analysis.!AUC!=!area!under!the!curve.!
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6.4 Results-!
6.4.1 IschaemiaLmodified-albumin-expression-following-RIPC-The! IMA! assay! was! performed! to! determine! whether! the! preconditioning!ischaemia! encountered! during! RIPC! induced! a! measurable! change! in! the!circulating! albumin! that! could! be! used! as! a! positive! biomarker! for! the!intervention.!There!was!no!significant!difference!in!IMA!levels!detected!between!the! control! and! RIPC! groups! when! comparing! the! blankCcorrected! OD470!measurements! with! a! twoCway! repeated! measures! ANOVA! (Figure! 6.1).!However,! there!was!a!notable!difference! in! the!baseline! levels!of! IMA!between!the! two!groups!and!when! this!was!accounted! for!by!expressing! the! levels! at!4!hours!as!a!percentage!of! the!preCtreatment! IMA! level,! there!did!appear! to!be!a!slight!trend!towards!a!higher!amount!of!IMA!in!the!preconditioned!participants!(Figure!6.2).! The!majority! of! the!participants! showed! a!decrease! in! IMA! levels!following! the! control! treatment,! whereas! the! median! IMA! level! in! the! RIPC!participants!was!notably!greater!than!the!baseline!measurement!(Figure!6.2).!To!avoid!the!inflated!type!1!error!risk,!this!observation!was!not!statistically!tested.!!Two!additional!sets!of!samples!were!collected!from!ACS!patients!hospitalised!for!a!recent!ischaemic!episode,!and!from!ageCmatched!healthy!volunteers.!The!mean!age!in!the!two!groups!was!similar!(57!years!in!the!ACS!patients!vs.!55!in!the!ageCmatched!controls),!and!substantially!higher!than!in!the!healthy!volunteers!from!the!RIPC!study!(23!years;!Table!6.2).!Nine!of!the!11!ACS!patients!recruited!were!diagnosed!with!ST!segment!elevation!MI!(STEMI),!and!2!with!nonCSTEMI,!and!all!of!the!patients!experienced!troponin!elevations!(Table!6.3).!The!IMA!level!in!the!ACS! patient! group! was! significantly! higher! than! in! the! ageCmatched! controls,!demonstrating!that!the!assay!was!performing!as!expected!and!that!IMA!levels!do!not!appear! to!naturally! increase!with!age! in! individuals!without!any!history!of!heart!disease!(Figure!6.1).!Interestingly,!the!baseline!OD470!values!in!the!healthy!volunteers! that!participated! in! the!RIPC!study!were!higher! than! the!mean! IMA!level!for!the!older!healthy!volunteers!recruited!as!an!ageCmatched!control!for!the!ACS! patients! (Figure! 6.1).! This! most! likely! relates! to! changes! in! the! samples!resulting!from!different!lengths!of!storage!prior!to!the!analysis.!!
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! n- Age-!!!!!!!!!!!!!!!!Mean!(SD)- Male-sex--!!!!!!!!!%!(number)-
RIPC-study-volunteers- 10! 23!(3.19)! 100!(10)!




Table-6.2-Baseline-demographics-of-participant-groups-Baseline! demographics! for! the! ACS! patients,! ageCmatched! healthy! volunteers,!and!the!healthy!volunteers!that!participated!in!the!RIPC!study.!!!!
! Number-(%)-----------------
n=11-
Clinical-presentation- !!!!STEMI! 9!(82)!!!!NonCSTEMI! 2!(18)!!!!Ischaemic!markers! !!!!!!!!ECG!changes! 8!(73)!!!!!!!!Troponin!elevation! 11!(100)!!!!!!!!Peak!troponin!(mean!(SD))! 5435!(14838)!
Comorbidities- !!!!Hypertension! 3!(27)!!!!Diabetes! 1!(9)!
Smoking-history- !!!!Current! 2!(18)!!!!Former! 2!(18)!!!!Never! 6!(55)!




Figure-6.1-Levels-of-ischaemiaLmodified-albumin-in-study-participants-Serum!samples!were!collected!from!ACS!patients!(n!=!11),!ageCmatched!healthy!volunteers!(‘No!ACS’;!n!=!5),!and!the!healthy!volunteers!that!participated!in!the!RIPC!study!(n!=!10),!and!assessed! for!IMA.!The!study!participants!received!the!control!and!RIPC!treatments!on!separate!visits!and!had!samples!collected!at!BL,!and!20!minutes,!1!hour,!and!4!hours!postCtreatment.!Shown!are!the!means!and!SEM! of! the! blankCcorrected! data.! The! difference! between! the! ACS! and! ageCmatched! healthy! volunteers! was! compared! using! a! tCtest,! and! the! differences!between! the! treatments! and! time! points! for! the! RIPC! study! participants!were!compared!using!a!twoCway!repeated!measures!ANOVA.!**!p!<!0.01.!!!!!
!
Figure-6.2-Total-change-in-ischaemiaLmodified-albumin-from-baseline-to-4-
hours-after-treatment-Serum!samples!were!collected!and!assessed!for!IMA!levels,!before!and!after!the!control!and!RIPC!treatments.!Shown!is! the!total!%!change! in! IMA!from!BL!to!4!hours!after!treatment.!The!box!displays!the!median!and!first!and!third!quartiles,!with!the!minimum!and!maximum!values!shown!by!the!whiskers.!N!=!10.!!!
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6.4.2 Multivariate-analysis-of-the-response-to-RIPC-!
6.4.2.1 Visual, representation,of, the,differences,between, the, treatments,




































































































































































































































































































































study,participants,,Following! on! from! the!MDS! analysis,! we! investigated! whether! the! differences!between!the!treatments!and!individual!participants!were!statistically!significant.!A!PERMANOVA!run!with!999!permutations!determined! there!was!a! significant!difference! between! the! treatment! groups! (p! =! 0.012),! and! the! individual!participants! (p! =! 0.01),! with! respect! to! the! overall! changes! in! the! 13! key!endpoints!included!in!the!analysis.!!In!order!to!determine!which!endpoints!contributed!to!the!differences!observed!between!the!treatments!and!participants,!we!performed!a!SIMPER!analysis.!The!most!important!variable!for!establishing!the!difference!between!the!control!and!RIPC! treatments!was! the! level! of! CD11b! expression! on! neutrophils! stimulated!with!PMA/I!for!4!hours!of!culture,!which!accounted!for!approximately!14.95%!of!the! variation! detected! between! the! treatment! groups! (Table! 6.4).! CD69!expression!on!T!cells!cultured!with!PMA/I!for!27!hours,!and!serum!MIPX1β!levels!(represented! by! the! total! area! under! the! curve! for! data! expressed! as! a!percentage!of!the!baseline!levels)!were!also!important!contributors,!accounting!for! 11.6! and! 11.26%! of! the! variation,! respectively.! Levels! of! ILX22! from!supernatants!of!6!day!unstimulated!PBMC!cultures,!and!serum!MIPX1α!were!the!next! most! important! variables,! explaining! 8.96! and! 8.43%! of! the! variation,!respectively.! A! number! of! other! variables,! including! ILX1β,! ILX10,! and! TNFXα!levels! from! 6Xday! tetanusXstimulated! PBMC! cultures,! PMA/IXinduced! T! cell!proliferation,!CD11b!expression!in!PMA/IXstimulated!monocyte!4Xhour!cultures,!and! ischaemiaXmodified! albumin! (expressed! as! the! total! %! change! from!baseline)! also! contributed! to! the! differences! and! individually! accounted! for!between!4.77!and!7.84%!of!the!detected!variation!(Table!6.4).!!!To! investigate! the! factors! that! differed! between! participants,! the! SIMPER!analysis! averaged! the! observations! collected! at! the! control! and!RIPC! visits! for!each!participant!and! then!performed!pairXwise!comparisons!between!all!of! the!participants.!Our!MDS!analysis!indicated!that!participants!3,!5,!6,!8,!9,!and!10!had!similar! responses,! whereas! participants! 1,! 2,! 4,! and! 7! showed! marked!
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Effect(Neutrophil!CD11b!expression! 14.95! 14.95! ↓ T!cell!CD69!expression! 11.60! 26.55! ↑ Serum!MIPX1β!levels! 11.26! 37.81! ↓ Culture!ILX22!levels! 8.96! 46.77! ↑ Serum!MIPX1α!levels! 8.43! 55.20! ↓ Culture!ILX10!levels! 7.84! 63.03! ↓ T!cell!proliferation! 7.45! 70.48! ↑ Culture!TNFXα!levels! 5.88! 76.37! ↓ Culture!ILX1β!levels! 5.21! 81.57! ↓ Monocyte!CD11b!expression! 5.20! 86.78! ↓ IschaemiaXmodified!albumin! 4.77! 91.54! ↑ 
Table( 6.4( Variables( responsible( for( the( difference( between( control( and(






(out(of(6(comparisons)(T!cell!CD69!expression! 6!Monocyte!CD11b!expression! 5!ILX8+!monocytes! 3!Neutrophil!CD11b!expression! 2!T!cell!proliferation! 2!IschaemiaXmodified!albumin! 2!
1(
Culture!ILX1β!levels! 1!Monocyte!CD11b!expression! 5!Culture!ILX6!levels! 5!Neutrophil!CD11b!expression! 5!Culture!ILX1β!levels! 4!IschaemiaXmodified!albumin! 2!
2(
Culture!ILX22!levels! 1!Culture!ILX10!levels! 6!Culture!TNFXα!levels! 6!Culture!ILX6!levels! 2!Monocyte!CD11b!expression! 1!4( IschaemiaXmodified!albumin! 1!ILX8+!monocytes! 6!Serum!MIPX1α!levels! 6!Serum!MIPX1β!levels! 4!T!cell!proliferation! 3!7( Culture!ILX22!levels! 4!
Table( 6.5( Variables( responsible( for( the( differences( between( study(
participants(Participants! 1,! 2,! 4,! and!7!were! each! compared!with! the! datasets! obtained! for!participants!3,!5,!6,!8,!9,!and!10!using!SIMPER!analysis,!and!the!frequency!with!which!a!particular!endpoint!was!detected!as!contributing!to!greater!than!10%!of!the!observed!distance!between!the!datasets!was!noted.!A!total!of!6!comparisons!were!made!for!each!of!the!4!individually!clustered!participants.!!!
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6.5 Discussion(The!aim!of!this!chapter!was!to!analyse!the!overall!effect!of!RIPC!by!looking!at!a!marker!of!ischaemia!and!more!closely!examining!the!pattern!of!changes!in!a!set!of! key! endpoints! that! appeared! to! be! affected! by!RIPC.!We! confirmed! that! the!IMA!assay!could!detect!changes!in!albumin!following!an!acute!cardiac!ischaemic!episode!but!did!not!find!a!difference!in!the!circulating!levels!of!IMA!between!the!control!and!RIPC!treatments.!The!multivariate!analysis!determined!there!was!a!significant! difference! in! the! overall! responses! between! the! treatment! groups,!which!was! largely!accounted! for!by!changes! in!neutrophil!and!T!cell!activation!and! the! production! of! the! cytokines,! MIPX1β! and! ILX22.! There! was! also! a!significant! difference! in! the! responses! between! the! participants,! the! source! of!which!varied!between!the!individual!comparisons.!!The! lack! of! change! in! the! ischaemiaXmodified! albumin!measurements! between!the! treatment! groups! suggests! that! the! assay! does! not! have! the! sensitivity! to!detect!a!response!to!preconditioning!ischaemia.!The!significant!increase!in!IMA!levels!seen!in!the!ACS!patients!compared!to!the!ageXmatched!controls!confirmed!the!assay!was!performing!as!expected;!however,! it!was!not!anticipated!that!the!OD470! levels! in!the!RIPC!study!participants!at!baseline!would!be!notably!higher!than! those!detected! in! the!older!healthy! volunteer!population.!The!most! likely!explanation!for!this!anomaly!lies!in!the!principal!reactions!involved!in!the!assay.!!!The!IMA!assay!depends!on!a!redox!reaction!between!the!transition!metal,!cobalt,!and!the!two!sulfhydryl!groups!present!in!the!reducing!agent,!DTT.!This!reaction!results! in! the! formation!of!a! strong!brown!solution! that! can!be!measured!on!a!spectrophotometer! (BarXOr! et! al.,! 2000).! Although! the! exact!mode! of! action! of!the! assay! has! not! yet! been! identified,! alterations! to! albumin! and,! potentially,!other! proteins! present! in! the! serum! following! ischaemia! appear! to! reduce! the!amount!of!free!cobalt!left!available!to!react!with!the!DTT!(BarXOr!et!al.,!2008).!In!normal! plasma! samples,! a! certain! level! of! interaction! between! cobalt! and! the!single! sulfhydryl! group! present! in! the! amino! acid,! cysteine,! also! occurs,! and!results!in!the!formation!of!a!pale!yellow!product.!Interactions!between!cysteine!
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and!cobalt! thus!reduce!the!amount!of!cobalt!able!to! interact!with!the!DTT,!and!lower!the!IMA!assay!readings!(BarXOr!et!al.,!2008).!!!The! effect! of! the! cysteineXcobalt! interactions! is! relatively! consistent! in! healthy!individuals;!however,!following!significant!oxidative!stress!or!prolonged!storage!of!the!samples!there!is!increased!oxidation!of!both!albumin!and!cysteine!(BarXOr!et!al.,!2008;!Oettl!and!Marsche,!2010).!The!increased!cysteine!oxidation!results!in!interactions!with!itself!and!other!small!molecules!to!form!cystine!and!additional!derivatives! which! contain! disulfide! bonds! that! render! the! sulfhydryl! groups!unavailable!for!transition!metal!binding!(BarXOr!et!al.,!2008).!Furthermore,!both!extended!storage! time!and! freezeXthawing!of!samples!decrease! the!presence!of!free!sulfhydryl!groups!present!in!plasma!and!serum,!which!may!also!increase!the!level!of!unbound!cobalt!detected!during!the!assay!(Goldblum!et!al.,!1954).!These!two!mechanisms! thus! are! likely! to! contribute! to! a! nonXspecific! increase! in! the!IMA!assay!readings!for!older!samples.!!!We!performed!the!IMA!assay!on!all!of!our!samples!at!the!same!time,!in!order!to!maintain!comparability!between!the!measurements! in! the!absence!of!a!defined!standard.! The! samples! from! the! ACS! patients! and! ageXmatched! controls! were!assayed!within!two!weeks!of!their!collection!whereas!the!samples!from!the!RIPC!study! were! stored! at! X80! °C! for! upwards! of! one! year! prior! to! the! analysis.!Further,!there!was!approximately!8!months!between!obtaining!the!samples!from!the!first!and!last!study!participants.!This!most!likely!was!the!cause!for!the!higher!IMA!values!in!the!RIPC!study!samples,!compared!to!the!fresher!samples!collected!from! the! older! population! of! healthy! volunteers! and! may! have! reduced! our!ability!to!detect!a!difference!between!the!treatments.!!!Another!possible!explanation!is!that!our!samples!were!not!collected!during!the!optimal! time! range! for! detecting! an! increase! in! IMA! levels! induced! by!preconditioning;! however,! this! seems! unlikely.! BarXOr! et# al.# investigated! the!kinetics! of! ischaemia! marker! levels! following! percutaneous! transluminal!coronary! angioplasty! and! found! a! significant! increase! in! IMA! immediately!following!the!procedure,!which!returned!back!to!baseline!levels!before!the!next!
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time!point,!6!hours!later!(BarXOr!et!al.,!2001b).!We!collected!our!first!samples!20!minutes! following! the! completion! of! RIPC! and! our! last! samples! after! 4! hours,!covering! a! comparable! time! range.! If! the! main! change! in! IMA! levels! was! so!transient! that! it! could! not! be! detected! as! early! as! 20!minutes! after! treatment,!then!this!assay!would!not!be!suitable!for!our!intended!purpose.!The!sensitivity!of!the!IMA!assay!could!potentially!be!improved!with!further!optimisation;!however,!the! results! from! the! present! study! suggest! that! IMA! is! not! appropriate! as! a!biomarker!of!successful!preconditioning.!!It! is! interesting! to! consider! that! the! ACS! patients! likely! share! similar!characteristics! to! many! members! of! the! cardiac! surgery! patient! population!commonly!used!in!RIPC!clinical!trials.!If!patients!have!already!recently!endured!an! ischaemic! episode,! it! is! not! currently! known! whether! RIPC! can! have! any!incremental! effect.! Further,! if! a! previous! exposure! to! ischaemia! does! elicit! a!protective!effect!similar!to!that!of!RIPC,!inclusion!of!such!patients!in!the!control!groups! will! confound! trial! analysis.! Measurement! of! a! nonXspecific! marker! of!ischaemia! prior! to! the! intervention! in! future! clinical! trials! would! be! very!informative!in!these!respects.!It!seems!reasonable!to!speculate!that!innate!forms!of!preconditioning!in!humans!may!be!another!key!difference!between!the!animal!and!clinical!studies!and!one!of!the!critical!questions!addressed!in!future!research!should! be! whether! or! not! a! patient! with! ongoing! ischaemic! disease! can,! in!reality,!be!preconditioned!against!a!larger,!planned,!acute!ischaemic!injury.!!!Our!univariate!analysis!of!the!study!endpoints!in!Chapters!4!and!5!highlighted!a!number!of!immune!parameters!that!appeared!to!be!affected!by!preconditioning;!however,! the! large! dataset! and! number! of! statistical! tests! performed! made! it!difficult! to! comment! on! whether! these! were! legitimate! biological! effects,! or!random!fluctuations!and!type!I!errors.!We!addressed!this!issue!by!performing!a!multivariate! analysis! and! limited! the! data! that! was! included! to! address! two!specific!research!questions.!The!first!investigated!whether!there!was!a!consistent!pattern! of! response! to! RIPC! treatment,! and! the! second! looked! for! potential!differences!in!the!type!of!response!between!the!participants.!!!
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The! results! indicated! that! there! was! a! significant! difference! in! the! overall!measure! of! similarity! in! the! datasets! for! the! participants! between! the! control!and!RIPC!visits.!This!finding!is!extremely!encouraging!and!suggests!that!although!the!results!we!measured!in!our!study!were!individually!quite!subtle,!they!were!part!of!a!legitimate!direct,!systemic!response!to!RIPC.!Approximately!55%!of!the!difference!in!the!response!between!the!treatment!groups!was!accounted!for!by!changes! in! neutrophil! and! T! cell! activation!marker! expression,! serum!MIPX1α!and! β! levels,! and! PBMC! production! of! ILX22.! While! the! changes! in! cytokine!production! stood! out! as! significant! in! the! univariate! analysis,! the! two! most!important! factors,!neutrophil!CD11b!and!T!cell!CD69!expression! levels,!did!not!reach! statistical! significance! individually.! This! may! be! more! to! do! with! the!variability!in!the!level!of!response!between!participants,!rather!than!a!reflection!of! the! magnitude! of! the! effect,! and! highlights! the! usefulness! of! carefully!considered!multivariate!analysis!techniques!in!exploratory!trials.!!!Interestingly,! the! multivariate! analysis! confirmed! that! in! our! study,! RIPC! was!associated!with! suppression!of!neutrophil! activation!during! the!early! response!to! preconditioning! and! with! enhanced! T! cell! activation! during! the! delayed!window!of!protection.!Immediately!following!reperfusion!of!ischaemic!tissue,!the!majority! of! leukocyte! subsets! play! a! detrimental! role! in! the! ensuing!inflammatory! response! (Warren! et! al.,! 2009).! Suppression! of! these! cells,!particularly! the! innate! populations! such! as! neutrophils! and!monocytes,! which!have! the! greatest! capacity! to! inflict! damage! under! these! circumstances,! is!therefore!likely!to!be!beneficial.!The!effects!of!leukocytes!during!the!later!stages!of! recovery! are! more! diverse,! however,! and! certain! subsets! of! T! cells! are!beneficial! for!assisting! in!tissue!repair!and!wound!healing!(Burzyn!et!al.,!2013;!Eyerich! et! al.,! 2009;! Hofmann! et! al.,! 2012;! Toulon! et! al.,! 2009).! The! increased!level! of! T! cell! activation! detected! in! cells! stimulated! for! 27! hours! ex# vivo! is!consistent!with!the!increased!production!of!ILX22!detected!in!the!PBMC!culture!supernatant!6!days!postXRIPC,!which!may!also!exert!a!protective!effect.!Although!these!changes!to!cellular!activation!may!seem!paradoxical!at!first!glance,!they!are!both!likely!to!have!beneficial!effects.!!!
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The!multivariate!analysis!also!determined!that!there!was!a!significant!difference!in!the!responses!seen!between!participants.!Despite!attempts!to!recruit!a! fairly!homogenous!participant!population!by!restricting!key!characteristics!such!as!age!and!sex,!this!result!was!not!surprising.!A!multitude!of!factors!can!alter!the!course!of! the! immune!response,!ranging! from!polymorphisms!through!to! lack!of!sleep!or!even!the!ingestion!of!caffeine!(Born!et!al.,!1997;!Horrigan!et!al.,!2006;!Jin!and!Wang,! 2003).! Of! particular! interest!was! the! finding! that! the! four! datasets! that!were!significantly!dissimilar!to!the!main!cluster!of!participants!were!also!distinct!from! each! other.! Furthermore,! two! of! these! datasets! were! collected! during! a!control!visit,!and!the!other!two!were!collected!from!different!participants!during!RIPC! visits.! Taken! together,! these! observations! strongly! suggest! that! the!differential! responses! were! due! to! perturbations! in! the! participants’! immune!response!at!the!time!of!the!corresponding!study!visit,!rather!than!an!alternative!form!of!response!to!the!treatment.!The!analysis!did!not!identify!a!second!cluster!of!participants!that!appeared!to!be!‘nonXresponders’!to!the!treatment.!!!Interestingly,!none!of!the!four!individually!clustered!datasets!belonged!to!either!of! the! participants! that! were! found! to! have! particularly! high! serum! cytokine!levels,! compared! to! the! other! study! participants.! This! would! suggest! that! the!altered! serum! cytokine! levels! detected! in! these! individuals! were! part! of! an!isolated! effect! that! did! not! necessarily! spill! over! into! the! other! immune!parameters.! This! finding! also! reinforces! our! decision! not! to! exclude! these!participants!from!the!remaining!data!analyses!presented!in!Chapters!4!and!5.!!!A! key! limitation! of! the! multivariate! analysis! was! that! we! treated! the! data!collected! from! the! control! and! RIPC! visits! for! each! participant! as! though! they!were!independent.!We!elected!to!perform!the!analysis!this!way!as!it!enabled!us!to!investigate!whether!the!overall!responses!from!each!participant!during!their!RIPC! study! visit! were! more! similar! to! other! participants! receiving! the! RIPC!treatment,!or! to! the!data!collected! from!the!same! individual!during! the!control!treatment!visit.!Ultimately,! our!analysis! suggested! that!participants!were!more!likely!to!be!clustered!based!on!the!treatment!received,!therefore!the!correlation!between!the!paired!datasets!did!not!appear!to!significantly!impact!the!analysis.!!
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The! results! of! cluster! analyses! are! also! highly! dependent! on! the! variables!included.! Given! the! size! of! our! full! set! of! data! relative! to! the! number! of!participants,!we!did!not!have!sufficient!power!to!perform!the!analysis!using!all!of!our!endpoints.!Further,!the!multiple!time!points!and!conditions!used!to!examine!changes! in! leukocyte! populations! and! cytokine! production! created! a! level! of!redundancy!in!our!dataset!that!could!have!biased!the!results!if!included!without!substantial!editing.!Instead,!we!focused!on!a!set!of!key!endpoints!that!appeared!to!be!altered!by!RIPC!for!the!purpose!of!identifying!whether!these!changes!were!consistent! following! treatment,! or! fluctuated! randomly! between! participants.!While!the!overall!analysis!both!complemented!and!reinforced!the!findings!of!our!univariate! testing! from!Chapters! 4! and! 5,! the! accuracy! of! the! estimates! of! the!importance! for! each! individual! variable! included! in! the! model! should! be!interpreted!with!caution.!!!








7.1 Research(motivation(Complications! following! cardiac! surgery! are! not! only! detrimental! to! patient!outcome!and! the! incidence!of!mortality,!but!pose!a!significant!drain!on! limited!hospital!resources.!Poor!postXoperative!recovery!of!myocardial!contractility!and!the!incidence!of!acute!kidney!injury!are!two!such!major!factors!that!significantly!increase!the!duration!of!stay!in!the!ICU,!at!a!cost!of!approximately!$3500!per!day.!Further,!a!lack!of!available!space!or!nurses!in!the!ICU!has!been!identified!as!the!most!significant!issue!with!cardiac!surgery!services!in!New!Zealand,!and!leads!to!a! high! rate! of! cancellation! of! scheduled! elective! surgeries! (Ministry! of! Health,!2008).!PostXoperative!complications!thus!not!only!attract!increased!costs!of!care,!but!negatively!impact!the!productivity!of!surgical!units.!This!issue!is!particularly!prevalent!in!the!patient!population!aged!70!years!and!over,!which!is!estimated!to!require!91%!more!care!and!clinical!resources!following!cardiac!surgery!and!are!increasingly!presenting!for!these!procedures!(Ngaage!et!al.,!2011).!!!There! is! a! clear! need! for! novel! cardioprotective! techniques! beyond! those!currently! used! in! clinical! practice! to! reduce! the! incidence! of! postXoperative!complications!and!improve!both!patient!outcome!and!the!productivity!of!cardiac!surgery! facilities! (Hausenloy!et!al.,!2010).!RIPC! is!one!such!strategy,! and!holds!enormous! potential! to! significantly! progress! clinical! practice.! RIPC! has! been!shown!to!dramatically!reduce!the!size!of!myocardial!infarct!sustained!following!an!ischaemic!episode!in!numerous!animal!models,!and!several!clinical!trials!have!also!demonstrated!the!ability!of!this!technique!to!reduce!postXoperative!troponin!release!and!the!incidence!of!AKI.!However,!a!number!of!clinical!studies!have!not!detected!an! improvement! in!such!surrogate!endpoints!(Costa!et!al.,!2013;!Kaur!Randhawa!et!al.,!2014).!!!Repetitive!studies!of!RIPC!in!similar!patient!populations!with!slight!variations!in!trial! design!and!methods!are!no! longer! significantly! advancing!our!knowledge.!Instead,!new!research!needs!to!address!the!efficacy!of!RIPC!in!different!patient!populations! and! applications,! and! determine! whether! it! is! capable! of!significantly! improving! longXterm! primary! clinical! outcomes! following! cardiac!surgery.!The!design!and!interpretation!of!such!work!will!be!greatly!facilitated!by!
!! 261!
expanding!our!understanding!of! the!mechanisms! through!which!RIPC!operates!in!humans.!!!
7.2 Overview(of(results(We! performed! the! first! study! of! RIPC! in! a! highXrisk! cardiac! surgery! patient!population,! and! did! not! detect! a! change! in! a!marker! of!myocardial! damage! or!clinical! outcome! endpoints! in! the! preconditioned! patients! (Chapter! 2).! This!study!was!one!of! the! first! in! the!RIPC! field! to!use!a!doubleXblinded!design!and!report! a! neutral! clinical! result,! second! only! to! a! large! trial! by! Rahman! et# al.#(2010),! but! has! been! followed! by! several! other! trials! that! also! failed! to!demonstrate! a! benefit! from! RIPC! in! adult! cardiac! surgery! patients! using! a!rigorous!blinding!protocol!(Meybohm!et!al.,!2013;!Saxena!et!al.,!2013;!Zitta!et!al.,!2014).! Both! these! studies,! and! our! own,! add! weight! to! the! growing! body! of!literature! that! one! could! reasonably! argue! establishes! that! RIPC! does! not!consistently! benefit! the! general! cardiac! surgery! population.! Given! the! positive!results! seen! in! some! clinical! trials! and! the! potential! of! this! technique!demonstrated! in! animal! studies,! it! seems! that! RIPC! could! work! effectively! in!certain! individuals;! however,! in! the! absence! of! a! full! understanding! of! the!pathways! through! which! RIPC! functions,! we! can! only! speculate! as! to! what!factors!may! enable! some! patients! to! respond! to! the! intervention! and! prevent!others! from! being! preconditioned! (Hausenloy! et! al.,! 2007;! Thielmann! et! al.,!2013;!Venugopal!et!al.,!2009).!!!One!of!the!key!aspects!of!RIPC!that!has!perplexed!researchers!is!the!identity!of!the!humoral!messenger!purported!to!be!involved!in!transmitting!the!protective!signal!from!the!preconditioned!tissue!to!the!heart!and!other!organs!of!the!body!(Hausenloy!and!Yellon,!2008).!Work!in!animal!studies!suggests!this!mediator!is!hydrophobic!and!of!a!low!molecular!weight!somewhere!in!the!range!of!3.5!–!15!kDa! (Lang! et! al.,! 2006;! Serejo! et! al.,! 2007;! Shimizu! et! al.,! 2009).! Based! on! the!involvement!of!immune!cells!and!changes!in!their!gene!transcription!profiles!in!response! to! RIPC,! we! hypothesised! that! this! factor! might! be! a! cytokine!(Konstantinov!et!al.,!2004).!No!significant!change!in!the!serum!levels!of!a!set!of!key! inflammatory!cytokines!was!detected! in!our!highXrisk! cardiac! surgery! trial!
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patients! following! RIPC;! however,! there! was! a! slight! trend! towards! increased!levels! of! ILX6! and! ILX8! in! the!preconditioned!patients! (Chapter!2).! To! separate!the!influence!of!surgery!and!comorbidities!on!cytokine!expression!and!obtain!a!more!conclusive!result,!we!then!examined!the!effect!of!RIPC!on!serum!levels!of!a!range! of! cytokines! and! chemokines! critical! to! the! inflammatory! response! in!healthy!male!volunteers,!and!also!found!no!significant!increase!in!any!of!the!20!key!analytes!assessed!(Chapter!4).!!!The! findings! from! our! studies! in! both! cardiac! surgery! patients! and! healthy!volunteers!strongly!suggest!that!a!cytokine!is!not!the!missing!humoral!mediator.!Our! results! are! also! consistent! with! two! recently! published! studies! that!examined!changes!in!the!plasma!and!serum!proteome!of!human!volunteers!after!RIPC,!which!predominantly!found!significant!alterations!in!the!levels!of!proteins!associated!with!the!immune!response!and!apoptosis,!but!no!changes!to!cytokine!expression! (Hepponstall! et! al.,! 2012;! Pang! et! al.,! 2013).! Similarly,! Hibert! et# al.!(2014)# found! no! changes! in! cytokine! levels! amongst! the! plasma! proteome!following!RIPC!in!rats,!suggesting!the! lack!of! induction!of!cytokines!detected!in!humans!was!not!a!speciesXspecific!occurrence.!!We! did! detect! a! significant! reduction! in! the! serum! levels! of! MIPX1α! and! β!following!preconditioning! in! the!healthy!volunteers,! and! it! is!possible! that! this!represents! increased!uptake!of! these! cytokines!by! cellular! targets! (Chapter!4).!However,!this!would!be!dependent!on!an!increase!in!receptor!expression,!which!does! not! explain! why! transfusion! of! plasma,! coronary! effluent,! or! blood! from!preconditioned!animals!can!elicit!protection! in!a!RIPCXnaïve!recipient!(Dickson!et! al.,! 1999a,! 1999b;! Shimizu! et! al.,! 2009).! The! changes! associated! with! this!reduction! in! MIP! levels! are! thus! unlikely! to! be! related! to! the! signalling!mechanism!involved!in!establishing!RIPC.!!!Overall,! it! was! determined! that! RIPC! elicits! direct! but! subtle! effects! on! the!immune!response!in!healthy!volunteers.! In!the!timeframe!corresponding!to!the!early! phase! of! protection,! in! addition! to! the! decrease! in! serum! MIP!concentrations,! there! was! a! trend! towards! a! reduction! in! the! ability! of!
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monocytes!and!neutrophils!to!become!activated,!but!no!other!significant!changes!(Chapters! 4! and! 5).! The!majority! of! clinical! trials! to! date! have! focused! on! the!utility!of!this!early!phase!of!RIPC!to!provide!organ!protection!in!cardiac!surgery!patients.! Although! neutrophils! are! a! major! mediator! of! periXoperative! tissue!damage!and!their!suppression!is!likely!to!limit!the!level!of!injury!sustained,!it!is!highly! unlikely! that! this! effect! solely! accounts! for! the! dramatic! reduction! in!troponin! release! detected! by! the! early! clinical! trials! (Korthuis! and! Granger,!1993).!This!idea!is!supported!by!the!particularly!high!levels!of!ILX6!and!ILX8!that!were! detected! in! the! highXrisk! cardiac! surgery! patients,! which! indicate! a!substantial!general!inflammatory!response!during!surgery,!with!or!without!RIPC!(Chapter! 2).! In! the! presence! of! such! a! strong,! systemic! immune! response,! a!subtle!alteration!to!one!or!two!leukocyte!populations!is!likely!to!translate!to!only!a!limited!effect.!!A!marked!increase!in!T!cell!activation!was!detected!in!cells!cultured!for!27!hours,!and!higher! levels!of!basal! ILX22!production! in!PBMC!cultured!for!6!days,! in!the!preconditioned!healthy!volunteers!(Chapter!5).!Although!the!timing!of!these!two!endpoints! corresponds! to! the! delayed! window! of! preconditioning,! ILX22!production!was! not! altered! in! 24Xhour! cultures;! therefore! these! effects! do! not!appear! to! overlap.! This! finding! raises! the! question! of! whether! the! second!window! of! RIPC! protection! can! be! further! temporally! divided! based! on! the!unique! processes! involved! and! the! potentially! different! types! of! protection!afforded! by! each! stage.! The! late! phase! of! preconditioning! is! also! generally!associated! with! changes! in! gene! transcription;! however,! the! proteome!experiment! by! Hepponstall! et# al.# (2012)! found! only! a! minor! population! of!proteins! were! upregulated,! whereas! a! substantial! number! of! proteins! were!downregulated!during! this! delayed!window! (Costa! et! al.,! 2013).! It! is! therefore!particularly! interesting! that! we! detected! the! stimulation,! rather! than!suppression,!of!these!immune!processes.!!!Three! clinical! trials! have! investigated! the! effects! of! delayed! RIPC! in! cardiac!surgery,!two!of!which!were!in!children,!and!have!shown!mixed!results!(Pavione!et!al.,!2012;!Wagner!et!al.,!2010;!Zhou!et!al.,!2010).!It!is!possible!that!changes!to!T!
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cell! activation! and! ILX22! production!may! elicit! protective! effects,! but! relevant!measures!at!time!points!corresponding!to!when!these!changes!were!observed!in!the!healthy!volunteers!have!not!been!included!in!most!clinical!trials.!A!beneficial!contribution!of!ILX22!to!tissue!and!wound!repair!could!significantly!improve!the!clinical!course!of!recovery!and!in!the!future,!studies!that!investigate!ILX22!levels!in!tandem!with!more!direct!clinical!outcome!measures,!such!as!30Xday!mortality,!will!be!better!suited!to!determine!whether!this!is!the!case.!!!A! multivariate! analysis! confirmed! that! the! subtle! changes! detected! following!RIPC! in! the! healthy! volunteers! amounted! to! a! significantly! different! response,!compared! to! the! control! treatment! (Chapter! 6).! Despite! this! clear! finding! that!RIPC! does! alter! the! immune! response,! these! changes! may! not! necessarily!contribute! to! the! protective!mechanisms! involved!with! preconditioning! in! the!setting! of! ischaemic! injury.! Our! research! was! designed! to! be! hypothesis!generating!and!was!performed!in!healthy!volunteers,!thus!does!not!include!any!clinical! outcome! measures! with! which! to! correlate! the! changes! that! were!detected.!While!these!alterations!may!positively!alter!the!course!of!I/R!injury,!it!is! also! possible! they! might! be! insignificant! in! the! face! of! the! systemic!inflammatory!burden!induced!by!the!majority!of!cardiac!surgical!procedures!or,!alternatively,! may! be! secondary! to! nonXimmune! changes! resulting! from! RIPC!that!were!not!measured!in!our!study.!!!
7.3 Alternative(mechanisms(that(may(contribute(to(RIPC(RIPC!was!found!to!have!only!subtle!effects!on!both!the!direct!immune!response!(Chapter!4)!and!the!function!of!peripheral!leukocytes!in!response!to!subsequent!
in# vitro# stimulation! (Chapter! 5).! These! small! alterations! may! dampen! the!inflammatory!response!during!I/R!injury,!but!are!unlikely!to!provide!the!level!of!organ! protection! detected! during! the! early! phase! of! RIPC! in! positive! clinical!trials.!!Previous!research!has!established!that!one!of!the!major!end!effectors!of!RIPC!is!the! alteration! of! ATP! sensitive! potassium! channels! present! in! the! plasma!membrane!of!cardiomyocytes!and!the!inner!mitochondrial!membrane!(Beavis!et!
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al.,!1993;!Loukogeorgakis!et!al.,!2007).!Opening!of!the!channels!reduces!the!rate!of! ATP! depletion,! decreases! the! intracellular! calcium! level,! and! results! in!vasodilation! (Costa! et! al.,! 2013;!Dos! Santos! et! al.,! 2002;!Kaur!Randhawa! et! al.,!2014).!Through!the!intracellular!loss!of!ATP,!I/R!appears!to!inhibit!the!opening!of! these! KATP! channels,! leading! to! accumulation! of! calcium! and! a! loss! of!mitochondrial! integrity,!whereas!RIPC!activates! the!channels!and!restores! flow!mediated!vasodilation!(Beavis!et!al.,!1993;!Costa!et!al.,!2013;!Loukogeorgakis!et!al.,!2007).!Further,! through!activation!of!PKC,!RIPC!may!also! inhibit!opening!of!the!mPTP! during! reperfusion,! thus! preventing!mitochondrial! swelling,! plasma!membrane!rupture,!and!cell!death!(Argaud!et!al.,!2005;!Baines!et!al.,!2003;!Costa!et! al.,! 2013).! These! combined! effects! are! likely! to! have! a! significant! direct!cardioprotective! effect! and! in! the! absence! of! a! strong! impact! on! the! immune!response! such! as! is! suggested! by! the! present! work,! are! likely! the! major!mechanisms! through!which! RIPC! confers! protection! during! the! early! phase! of!protection.!!!IPC!has!been!associated!with! the!activation!and!subsequent!suppression!of! the!major! inflammatory! gene! transcription! factor,! NFXκB;! therefore! it! has! been!suggested! that! RIPC! could! exert! a! protective! effect! through! suppressing!inflammation! (Funaki! et! al.,! 2002;! Li! et! al.,! 2006;! Takeshita! et! al.,! 2010).! It! is!interesting! that! this! mechanism! did! not! appear! to! translate! to! a! significant!alteration! in! the! function! of! immune! cells! isolated! from! the! blood! of! healthy!volunteers!during!the!early!phase!following!RIPC!in!our!study.!Previous!research!demonstrating!this!altered!NFXκB!activity!has!detected!differences!in!numerous!preconditioned! tissues! including! the! heart,! skeletal!muscle,! kidneys,! liver,! and!small!intestine!(Funaki!et!al.,!2002;!Jiang!et!al.,!2007;!Li!et!al.,!2006;!Takeshita!et!al.,! 2010).! It! is! therefore! possible! that! RIPC! may! still! limit! the! inflammatory!response! but! through! mechanisms! elicited! in! the! actual! organs,! rather! than!through!changes!to!the!circulating!leukocytes.!!!Lastly,! it! is! possible! that! B! cells! may! also! respond! to! RIPC.! B! cells! were! not!investigated!as!part!of! the!present!study! in!healthy!volunteers!due! to!practical!limitations! and! their! apparent! minimal! involvement! in! I/R! according! to! the!
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available! literature.! However,! administration! of! repetitive! hypobaric!preconditioning! (RHP)! in! mice! over! a! 2Xweek! period! was! recently! shown! to!significantly! alter! the! B! cell! response! to! a! subsequent! I/R! injury! in! the! brain.!RHP,! which! has! been! shown! to! have! a! neuroprotective! effect,! was! associated!with!suppression!of!the!resident!B!cell!population!and!induction!of!a!regulatory,!ILX10!producing!B!cell!subset!(Monson!et!al.,!2014;!Stowe!et!al.,!2011).!Although!the!RHP!model!involves!a!notably!stronger!stimulus!compared!with!either!form!of!IPC,!it!is!possible!that!these!findings!could!extend!to!RIPC.!!In!summary,!the!early!phase!of!protection!afforded!by!RIPC!is!most!likely!largely!independent! of! changes! to! the! peripheral! blood! leukocytes,! and! dependent! on!changes!to!metabolism!and!gene!expression!in!the!target!cells.!Alterations!to!the!immune!response!may!be!more!significant!during!delayed!preconditioning!and!could! involve! B! cells,!which!may! also! facilitate! longer! term!wound! repair! and!recovery! from! surgery.! The! most! pressing! unresolved! question! regarding! the!early! phase! of! RIPC! now! is! how! exactly! the! signal! is! transferred! from! the!preconditioned!tissue!to!the!heart!and!other!organs!of!the!body.!!!
7.4 Comparison(between(animal(and(human(models(of(RIPC(Translation! of! RIPC! from! simplified! and! easily! controlled! animal! models! into!highly!variable!patient!populations!has!encountered!several!obstacles!that!have!not!yet!been!overcome.!Our!research!highlighted!a!number!of!key!areas!which!may! contribute! to! the! different! results! seen! between! the! animal! and! human!studies,! which! could! help! to! isolate! the! limitations! of! RIPC! in! clinical!applications.!!Several! cytokines,! including! ILX6,! ILX10,! and! TNFXα,! have! been! shown! to! be!essential! for! inducing! IPC! in!animal!models,!yet!we!did!not!detect!a! significant!increase! in! the!circulating! levels!of! the! same,!or!other,!key!cytokines! following!RIPC!in!healthy!volunteers!(Chapter!4;!Cai!et!al.,!2013,!2012;!Dawn!et!al.,!2004;!Ren! et! al.,! 2004;! Smith! et! al.,! 2002).! In! animal! studies,! increased! STAT3!activation,! which! transduces! signals! for! the! ILX6! and! ILX10! cytokine! family!members,! has! accordingly! been! associated!with! the! protective! effects! of! RIPC,!
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whereas! deletion! of! the! STAT3! gene! abolishes! RIPCXmediated! protection!(Goodman!et!al.,!2011;!Hattori!et!al.,!2001;!Kim!et!al.,!2004;!Schindler!et!al.,!2007;!Xuan!et!al.,!2001).!Interestingly,!an!increase!in!STAT3!phosphorylation!could!not!be! detected! in! human! myocardial! biopsies! from! preconditioned! patients,!compared! to! the! control! treatment,! but! STAT5! activation! was! significantly!enhanced! (Heusch! et! al.,! 2011).! The! role! of! STAT5! in! animal! models! of!preconditioning! is! less! clear,! with! one! study! suggesting! STAT5! activation! is!insufficient! to! compensate! for! deletion! of! STAT3,! and! another! finding! that! IPC!was! ineffective! in!STAT5!knockout!mice!(Goodman!et!al.,!2011;!Yamaura!et!al.,!2003).!Overall,! these!studies!suggest! that! the! transcription! factors!activated!by!IPC!and!RIPC!may!differ!between!species,!which!could!likely!also!alter!the!effects!induced!by!the!preconditioning!ischaemia.!!!ILX8!is!a!critical!mediator!of!the!periXoperative!immune!response,!in!part!due!to!its!significant!roles!in!neutrophil!chemotaxis!and!propagating!the!inflammatory!response!(Kawamura!et!al.,!1993;!Larsen!et!al.,!1989).!Accordingly,!we!detected!high!levels!of!ILX8!in!all!of!our!highXrisk!cardiac!surgery!patients!and!there!was!a!slight! trend! towards! higher! levels! expressed! in! the! preconditioned! patients!(Chapter! 2).! A! subtle! increase! in! ILX8! levels! 12! hours! after! RIPC! was! also!reported!by!a!study!in!healthy!volunteers,!which!corresponded!to!an!increase!in!circulating! progenitor! CD34+! cells! (Czeiger! et! al.,! 2011).! Taken! together,! these!findings!allude!to!a!possible!role!of!ILX8!during!RIPC;!but!it!is!important!to!note!that! the! gene! for! ILX8! has! been! deleted! from! the!muroid! rodent! lineage.! Two!functional!homologs!in!mice!and!rats,!MIPX2!and!KC,!have!been!identified!but!it!is!unclear! whether! these! mediators! perform! the! same! roles! in! I/R! injury! and!preconditioning! (Modi! and!Yoshimura,! 1999).! It! is! therefore! necessary! to! take!particular!care!when!comparing!ILX8Xmediated!pathways!in!humans!to!findings!from!rodent!models.!!A!wide!variety!of! factors!can! influence! the! immune!response,! including!genetic!and!environmental!alterations.!These!elements!of!variation!less!commonly!affect!mice! and! rat! models,! where! the! animals! are! genetic! clones! maintained! in!regulated!sterile!environments,!but!are! rife! in! the!human!population.!This!was!
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clearly!demonstrated!by!the!multivariate!analysis!in!our!study,!which!indicated!that!four!of!the!ten!participants!showed!significantly!different!responses!during!one!of! the! study! visits,! compared! to!both! the! remaining!participants! and! their!own! data! collected! from! the! alternative! treatment! (Chapter! 6).! It! is! unclear!whether! day! to! day! variability! in! the! immune! response! has! the! potential! to!attenuate!or!augment!the!effect!of!RIPC,!but!it!will!almost!certainly!increase!the!variability! of! the! interXindividual! responses! and! necessitate! the! use! of! much!larger!sample!sizes!in!human!studies!to!achieve!the!statistical!power!required.!!!Transient! periods! of! ischaemia! can! be! encountered! endogenously! through! a!number!of!processes,!including!episodes!of!angina!and!vigorous!exercise,!which!may!induce!IPC.!Indeed,!it!has!been!observed!that!patients!with!unstable!angina!or! those! participating! in! a! strenuous! exercise! program! show! a! preconditioned!type!of!protective!effect!in!response!to!cardiac!surgery!or!cardiac!events!(Abete!et! al.,! 1997;! RockXWilloughby! et! al.,! 2013;! Wang! et! al.,! 2007).! We! detected! a!significant!increase!in!IMA!in!patients!with!ACS,!confirming!a!systemic!exposure!to! ischaemia! (Chapter! 6).! It! seems! likely! that! many! of! the! cardiac! surgery!patients! recruited! into! RIPC! clinical! trials! are! likely! to! overlap! with! this! ACS!patient!population,!and!therefore!may!not!necessarily!be!preconditioning!naïve.!!!The! implications! of! these! innate! forms! of! preconditioning! on! the! effect! of!subsequently! applied! RIPC! are! unclear.! A! study! that! administrated! RIPC! to!healthy! volunteers! for! 10! consecutive! days! found! significant! changes! in!neutrophil! adhesion,! phagocytosis,! and! cytokine! production,! some! of! which!appeared! to! be! cumulative! (Shimizu! et! al.,! 2010).! Kharbanda! et# al.! (2009)#postulated! that! there!must!be! a!downside! to!maintaining! cells! in! a! chronically!preconditioned! state,! otherwise! it!would!be!expected! that!humans!would!have!evolved!to!sustain!this!intrinsic!protection.!Clearly!continued!suppression!of!the!immune! system! would! be! detrimental! to! host! defence! against! infection,! but!overlapping!periods!of!preconditioning!may!also!have!a!negative! impact!of! the!benefits! afforded! by! the! intervention! itself.! While! the! complications! of! innate!forms!of!preconditioning! in!regards! to!applying!RIPC!are!not!known,! it! is!clear!that!this!confounding!effect!is!not!encountered!in!the!animal!models.!!
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A! variety! of! additional! cardioprotective! strategies! are! utilised! in! the! clinical!setting! that! are! unlikely! to! be! included! in! the!majority! of! animal! studies.! The!development! of! improved! cardioplegia! strategies,! and! the! use! of! heparin! and!volatile!anaesthetics!have!all!been!established!as!capable!of!reducing!myocardial!dysfunction!following!cardiac!surgery!(Aldea!et!al.,!1996;!Chambers!and!Fallouh,!2010;! Friedrichs! et! al.,! 1994;! Landoni! et! al.,! 2007).! Further,! commonly!prescribed! medications,! such! as! statins,! may! also! enhance! clinical! outcome!(Chopra!et!al.,!2012).!The!improvement!and!rate!of!use!of!all!of!these!techniques!has!steadily!increased!over!the!last!10!years,!whereas!the!frequency!of!positive!RIPC!studies!has!declined.!!!There! is! evidence! that! many! of! these! cardioprotective! techniques,! including!RIPC,! share! overlapping! pathways;! therefore! it! is! possible! that! they! may!competitively!inhibit!each!other.!Indeed,!we!were!not!able!to!detect!a!reduction!in!myocardial!damage!in!our!own!RIPC!clinical!trial!that!included!the!use!of!the!volatile!anaesthetic,!isoflurane!(Chapter!2).!Thus,!RIPC!in!animals!may!stimulate!a!cardioprotective!effect!that! is!already!activated,!either!partially!or!maximally,!in! humans! by! alternative! interventions.! If! the! effects! of! RIPC! are! not!supplementary!or!synergistic!with!existing!cardioprotective!techniques,!there!is!still! potential! for! it! to! improve! clinical! practice.! Pharmaceutical! forms! of!cardioprotection! are! associated! with! a! range! of! side! effects! and! are! often!contraindicated! in! certain! populations.! For! instance,! the! use! of! volatile!anaesthetics! is! not! recommended! in! patients! with! cardiovascular! instability;!therefore! these! patients! could! receive! a! more! significant! benefit! from! the!alternative!use!of!RIPC!(Jakobsen!et!al.,!2007).!!!Lastly,! age! and! comorbidities! may! significantly! impair! or! alter! the! pathways!through!which!RIPC!operates,!limiting!its!effectiveness!in!certain!patient!groups!(Abete! et! al.,! 1997;! Hu! et! al.,! 2002;! Lavi! and! Lavi,! 2011).! For! instance,! type! 2!diabetics!appear!to!have!a!natural!resistance!to!I/R!injury,!which!is!in!part!due!to!suppression! of! the! mPTP! (Costa! et! al.,! 2013).! Since! RIPC! partially! operates!through!the!same!mechanism,!there!does!not!appear!to!be!any!additional!benefit!from!applying!the!intervention!in!these!patients!(Jensen!et!al.,!2013).!Similarly,!
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hypercholesterolemia,!diabetes,!and!some!treatments!for!comorbidities,!such!as!the! sulfonylureas! used! in! type! 2! diabetics,! also! inhibit! another! key! pathway!involved! in!RIPC! that! affects! the!mitochondrial!KATP! channels! (Cleveland! et! al.,!1997;!Genda!et!al.,! 2002;!Smith!and!Wahler,!1996).!Although!patients!who!are!taking! sulfonylureas! and! other! medications! known! to! interfere! with! KATP!channels!are!commonly!excluded!from!clinical!trials,!untreated!type!2!diabetics!are!often!included!and!many!other!comorbidities!and!medications!may!interfere!with!RIPC!that!have!not!yet!been!identified.!Again,!this!source!of!variability!is!not!contended!with!in!animal!models.!!Overall,! there! are! a! number! of! critical! differences! between! animal! and! patient!RIPC! studies,!many! of!which! have! been! shown! to! impact! the! ability! to! induce!preconditioning! and! could! explain! the!discrepancy! in! results! between! the!preXclinical! and! clinical!work.! Although! animal!models! are! a! valuable! resource! for!exploratory!research,!the!results!of!such!studies!cannot!consistently!be!extended!to! human! applications! and! advancement! of! RIPC! research! will! require! more!work!be!completed!in!human!studies.!!!
7.5 Future(directions(The! research! presented! in! this! thesis! has! highlighted! a! number! of! immune!parameters! that! are! significantly! altered! by! RIPC! which! merit! further!investigation.! Firstly,! the! apparent! suppression! of! monocyte! and! neutrophil!activation!during! the!early!window!of!protection,!and! increased!activation!of!T!cells! during! the! late! phase,! could! potentially! modify! the! extent! of! I/R! injury.!Further! work! in! healthy! human! volunteers! would! be! beneficial! to! determine!whether! these! changes! in! activation!marker! expression! correspond! to! altered!function!of!these!cell!subsets.!!!The!neutrophil! functions!most! relevant! to! their! ability! to! inflict! tissue!damage!during!I/R!are!migration!into!tissues,!and!production!of!ROS,!making!them!ideal!parameters!to!assess.!Kusek!et#al.!(2014)#recently!described!a!coXculture!system!capable! of! measuring! neutrophil! transXepithelial! migration! by! establishing!polarised!epithelial!monolayers!on!permeable! transwell! filters,!and!quantifying!
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the!number!of!neutrophils!that!migrate!across!the!cell!layer!into!the!well!below!by! assessing! MPO! levels.! This! method! was! developed! to! assess! the! migration!response!of!neutrophils! to!various!pathogenic!bacteria;!however,! other! stimuli!such! as! cytokines! or! ROS! could! be! substituted! to! mimic! the! activation! of!epithelial! cells! sustained! during! I/R.! The! extent! of! the! oxidative! burst! in!neutrophils!can!also!be!readily!assessed!using!a!tetrazolium!salt,!WSTX1,!which!is!reduced! by! superoxide! to! form! a! stable! product! that! can! be! measured! in! a!microplate!reader!(Tan!and!Berridge,!2000).!Neutrophils!can!be!quickly!isolated!from!human!blood!with!minimal!disturbance!using!a!density!gradient!medium!known! as! Polymorphprep! for! use! in! these! assays! (Degel! and! Shokrani,! 2010).!Comparison! of! the! level! of! neutrophil! migration! and! superoxide! production!detected!before!and!after!RIPC!would!provide!a!solid!indication!of!the!ability!of!these!cells!to!infiltrate!the!lungs!and!kidneys!and!cause!damage!in!the!setting!of!I/R.!!!While!our!study!in!healthy!volunteers!assessed!the!responses!of!cells!using!time!points! corresponding! to! the! delayed!window!of! protection! (24!hours! –! 6! days!postXRIPC),! the! cells!were! all! isolated! from! the!body!during! the! early!phase!of!RIPC.!Whether!continued!signalling!in#vivo!further!alters!the!state!of!these!cells,!or!the!changes!detected!are!established!within!this!immediate!response!to!RIPC!is!unclear.!Having!now!identified!that!RIPC!has!a!significant!impact!on!immune!cell! function!that!comes! into!effect!≥!24!hours! following!treatment,!subsequent!studies! could! more! appropriately! characterise! the! effect! on! the! late! immune!response!by!collecting!samples! in! the!days! following! the!application!of!RIPC! in!healthy! volunteers.! Key! parameters! of! interest! would! include! serum! levels! of!MIPX1α!and!β,!ILX22!production,!and!T!cell!activation.!!!More!inXdepth!characterisation!of!the!T!cells!during!the!late!response!to!RIPC!(>!24! hrs)! would! be! worthwhile,! given! the! increased! expression! of! the! early!activation!marker,!CD69,!detected!in!the!CD3+!population!in!our!study.!To!start,!using! flow! cytometry! with! additional! cell! markers! to! identify! if! a! particular!subset! of! T! cells! was! more! affected! by! the! RIPC! than! others,! and! correlating!changes! in! CD69! with! other! activation! markers,! such! as! CD45RO,! would! be!
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useful.! Given! the! particular! importance! of! CD4! T! cells! in! the! pathology! of! I/R!injury,! changes! in! the! functional! properties! of! this! subset! are! particularly!relevant! and! performing! ICS! to! assess! IFNXγ! production! in! samples! collected!within! 4! hrs! of! RIPC,! and! the! following! day,! would! provide! further! valuable!knowledge!as!to!the!effect!on!these!cells!(Linfert!et!al.,!2009).!!!One!of!the!key!findings!from!our!study!was!that!RIPC!increased!basal!expression!of! ILX22! in!PBMC!cultured! for!6!days.!Again,! it!would!be!useful! to!determine! if!this!effect!was!maintained!or!potentially!amplified!when!cells!are!not!collected!until! during! the!delayed!window!of!RIPC,! and! to! identify!which! subset! of! cells!were! responsible! for! the! production! of! ILX22! using! intracellular! cytokine!staining.! The!most! pressing! questions! regarding! the! increased! ILX22! levels! are!whether! this! effect! also! occurs! in! cardiac! surgery! patients,! and! whether! it!corresponds! to! a! benefit! in! terms! of! clinical! outcome! and! recovery.! In! this!respect,! measurement! of! serum! ILX22! and! ILX17! levels! in! control! and! RIPC!treated!cardiac!surgery!patients! in! the!week! following!the!procedure!would!be!extremely! interesting.! Examining! the! coXexpression! of! ILX17! would! be!informative! for! determining!whether! increased! levels! of! ILX22! are! likely! to! be!associated!with!anti!or!proinflammatory!effects!during!recovery.!!!Lastly,! identification!and!development!of!methods!for!measuring!biomarkers!of!the!biological!effects!of!cardioprotective!strategies!was! identified!as!a!research!priority! at! the! National! Heart! Blood! and! Lung! Institute! Workshop! on!cardioprotection! in! 2010! (Schwartz! Longacre! et! al.,! 2011).! Our! study! has!highlighted!a!number!of!potential!candidates!for!such!a!marker,! including!MIPX1α!and!β,!which!warrant!further!investigation!to!see!if!they!are!correlated!with!a!beneficial!effect!from!RIPC.!It!is!interesting!to!note!that!Hepponstall!et#al.#(2012)!observed! incremental! increases! in! plasma! protein! expression! levels!with! each!cycle!of!RIPC.!Further,!two!clinical!trials!involving!concurrent!or!combined!upper!and!lower!limb!RIPC!have!both!reported!positive!results,!suggesting!the!standard!stimulus! may! not! reach! the! required! threshold! for! protection! in! humans! and!could!be!improved!upon!(Candilio!et!al.,!2014;!Q.!Wu!et!al.,!2011).!It!is!possible!that!more!significant!benefits!and!changes!in!the!immune!response!could!occur!
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with!a!stronger!stimulus,!although!it!is!equally!possible!that!too!many!cycles!or!too! long! a! period! of! ischaemia! could! have! the! opposite! effect! and! negate! the!protective!response.!Identification!of!an!easily!measurable,!robust!and!consistent!marker!of!effective!preconditioning!is!necessary!so!that!the!optimal!application!method!of!RIPC!can!be!identified,!and!changes!in!the!levels!of!MIPX1α!and!β!may!be!useful!in!this!respect.!!!
7.6 Clinical(significance(and(final(remarks(Despite! the! challenges! encountered! translating! RIPC! into! human! applications,!this!intervention!still!holds!promise!for!dramatically!improving!clinical!practice!in! a! number! of! areas.! The! results! of! recent! trials! have! suggested! that! the!protection!afforded!by!RIPC!is!unlikely!to!benefit!all!cardiac!surgery!patients,!but!rather! a! specific! subset! of! individuals! with! the! necessary! characteristics! to!respond! to! the! stimulus.! However,! the! final! word! on! whether! RIPC! could! be!utilised!as!an!intervention!for!the!general!cardiac!surgery!patient!population!will!likely! be! provided! by! the! results! of! two! large! multiXcentre! doubleXblind!randomised! controlled! phase! III! trials,! known! as! the! ERICCA! and! RIPHeart!studies,! which! are! due! in! 2015.! These! studies! not! only! have! substantially!increased! statistical!power!with!plans! to! recruit!3680!cardiac! surgery!patients!between! them,! but! also! will! be! collecting! information! on! longXterm! clinical!outcomes,!which!represent! the! true!real!potential!benefit! to!be!gained!by!RIPC!(Hausenloy! et! al.,! 2012;! Meybohm! et! al.,! 2012).! Plans! for! a! further! trial!investigating!the! impact!of!RIPC!on!neuroprotection,!called!the!RIPCAGE!study,!have!also!recently!been!described!(Gasparovic!et!al.,!2014).!!Overall,! the!work! in! this! thesis!has!extended!and!refined!what! is!known!about!the!effect!of!RIPC!on!the!immune!response!in!humans!and!identified!a!number!of!critical!parameters!to!guide!future!mechanistic!research.!Whether!the!change!in!inflammation! induced! by! RIPC! will! translate! to! a! significant! cardioprotective!effect!during!I/R!is!unclear,!but!these!findings!do!support!potentially!expanding!the! use! of! RIPC! to! investigate! its! efficacy! for! treating! general! inflammatory!conditions.!Further!carefully!designed!research!to!expand!our!understanding!of!
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the! pathways! involved! in! RIPC!will! facilitate! the! translation! of! this! promising!technique!into!standard!clinical!practice.!!
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Appendix(A. Standardised( trial( protocols( for( peri4operative(
management(of(cardiac(surgery(patients(
(
(The! following! anaesthesia! protocol! was! developed! by! Dr! Paul! Dalley,! and! the!haemodynamic!protocols!by!Dr!Paul!Young.!!
(
Pre$operative+Care+ACE!inhibitors,!diuretics!and!alpha!blockers!were!withheld!on!the!day!of!surgery!except! in! cases! of! severe! diastolic! hypertension! or! poorly! controlled! left!ventricular! failure.! All! other! cardiac! medications,! including! beta! blockers,!calcium! channel! blockers! and! statins,! were! given! as! usual.! Half! the! usual!morning! beta! blocker! dose!was! administered! if! heart! rate! (HR)!was! below!55!and! for! those! patients! taking! warfarin,! treatment! was! ceased! 5! days! prior! to!surgery! and! a! baseline! international! normalised! ratio! measure! of! coagulation!was! checked! prePoperatively.! Clopidogrel! and,! in! patients! without! recent!symptoms!of!angina,!aspirin!were!similarly!withheld! for!5!days!before!surgery!wherever!possible.!Low!molecular!weight!heparin!was!stopped!a!minimum!of!24!hours! prePoperatively! and,! in! patients! with! ongoing! unstable! angina,! was!substituted! with! unfractioned! heparin! to! maintain! an! activated! partial!thromboplastin!time!(ACT)!between!60!P!80!seconds.!Metformin!and!other!oral!hypoglycaemic!agents!were!stopped!the!night!before!and!on!the!day!of!surgery,!respectively.!Patients!with!diabetes!mellitus!were! treated!with!glucosePinsulinPpotassium!therapy!as!necessary!to!maintain!a!target!blood!sugar!level!of!4!P!10!mmol/L.! Sildenafil! (50!mg)!was! administered! prePoperatively! to! patients!with!chronic!pulmonary!hypertension,!defined!as!pulmonary!artery!systolic!pressure!>!60mmHg.!!!
Anaesthesia+PrePmedications! consisted! of! zopiclone! (7.5! P! 15!mg)! the! night! before! surgery!with!or!without!midazolam!(3.75!P!15!mg)!and!oxygen!(6!L/min!via!face!mask)!on! the!morning! of! the! operation,! depending! on! the! patient’s! age! and! physical!state.!Anaesthesia!was!induced!with!midazolam!(0.05!P!0.15!mg/kg)!and!fentanyl!(5! P! 15!mcg/kg),! with! vecuronium! (0.1! P! 0.2!mg/kg)! or! rocuronium! (0.5! P! 1.5!mg/kg).! Before! cardiopulmonary! bypass! (CPB),! anaesthesia! was! maintained!with!isoflurane!(0.3!P!2.0%)!to!keep!the!bispectral!index!≤!60.!Propofol!infusion!(2!mg/kg/h)!was!given!with!additional!boluses!of! fentanyl! (100! P!250!mcg)!as!required,! up! to! a! total! dose! of! 2000!mcg.! At! commencement! of! CPB,! prior! to!aortic! crossPclamping,! morphine! (20!mg)! was! administered! and! further! doses!given!(10!P!20!mg)!if!necessary.!Anaesthesia!while!on!CPB!consisted!of!isoflurane!(0.3! P! 3.0%)! and! propofol! infusion! (2! mg/kg/h).! In! addition! to! routine!monitoring,!a!SwanPGanz!catheter!(Edwards!Lifesciences,!CA,!USA)!was!inserted!into! the! internal! jugular! vein! to! continuously! monitor! cardiac! output! and!haemodynamic!pressures.! Cefazolin! (2! g)!was! administered!on! induction,!with!further! doses! in! the! perfusion! pump! prime! (1! g),! and! the! earlier! of! 4! h! post!induction! or! separation! from! CPB.! Subsequent! doses!were! 4! hourly! while! the!sternum! remained! open,! then! 8! hourly! for! 2! final! doses.! In! patients! with!
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penicillin!allergy,!antibiotic!treatment!consisted!of!vancomycin!(1!g!over!30!min)!and!gentamicin!(4!mg/kg!over!30!min).!A!bolus!of!tranexamic!acid!(20!mg/kg),!was! given! on! induction,! followed! by! smaller! doses! at! the! start! of! CPB! and! for!each!hour!of!CPB!(10!mg/kg).!Heparin!(350!U/kg)!was!given!and!supplemented!as!needed!to!maintain!an!ACT!≥!480!s!until!reversal!with!protamine!(1!mg/100!U!of!estimated!residual!heparin).!Actrapid!insulin!was!infused!as!necessary!to!keep!blood! sugar! level! ≤! 10!mmol/L.! Glucocorticoids!were! not! administered! unless!there! was! evidence! of! adrenal! suppression.! Before! CPB,! PlasmaLyte! 148! was!used! to! replace! prePoperative! fluid! deficits! and! ongoing! insensible! losses!with!additional! boluses! in! cases! of! hypovolemia.! Post! CPB,! PlasmaLyte! was!administered!as!necessary!to!assist!with!optimal!ventricular!filling.!!
Perfusion+NonPpulsatile!perfusion!was!performed!using!a!VHK!Venous!Hardshell!Reservoir,!Quadrox! oxygenator! system,! Jostra! Rotaflow! centrifugal! pump! head! (Macquet,!Rastatt,! Germany),! Affinity! 38! micron! inPline! arterial! filter! (Carmeda,! AB,!Sweden)! and! Softline! coated! biocompatible! tubing! (Macquet).! The! pump! was!primed!with! PlasmaLyte! 148! (2! L)! and! heparin! (10,000! U)! without!mannitol,!HCO3g,!or!colloid.!Tepid!bypass!(32!P!34ºC!nasopharyngeal)!was!performed,!with!a! pump! flow! of! 2.4! L/min/m2.! ACT!was! kept! ≥! 480! s,! and! checked! at! 30!min!intervals.! AlphaPstat!management! was! used! to! evaluate! pH! levels.! Cardiotomy!suction!was!reserved! for! fresh!bleeding!directly! from!the!heart!or!aorta,! and!a!cell!saver!was!used!for!pooled!blood!collected!from!the!mediastinum!and!pleura!which,! together! with! the! remaining! pump! blood,! was! washed! and! reinfused!following!CPB.!A!“hotshot”!of!normothermic!blood!was!given!immediately!before!removal! of! the! aortic! crossPclamp,! and! rewarming! to!36.5ºC!was! induced!with!the!application!of!a!sterile!forced!air!blanket!to!the!patient’s!lower!body!prior!to!separation! from! CPB.! Metabolic! acidosis! was! treated! by! HCO3g,! or!haemofiltration.!Haemoglobin!was!kept!at!≥!70!g/L!while!on!CPB,!and!anaemia!was!treated!with!packed!red!blood!cells!or!haemoconcentration,!as!appropriate.!The! cardioplegia! solution! contained! potassium! chloride! (KCl;! 50! mmol/L),!MgSO4! (20! mmol/L),! 8.4%! NaHCO3! (20! mmol/L)! with! 5%! dextrose! and! was!infused! at! 400! ml/h! into! tepid! blood! flowing! at! 300! ml/min.! Induction!cardioplegia! consisted! of! 4!min! antegrade,! then! retrograde,! perfusion!with! an!additional! 1! P! 2! min! if! required! to! achieve! electrical! silence.! Maintenance!cardioplegia!was!administered!every!15!P!25!min!for!2!min!to!reach!a!coronary!sinus!pressure!of!20!P!60!mmHg.!!!
Haemodynamic+Management+The!haemodynamic!aims!during!surgery!of!maintaining!a!mean!arterial!pressure!(MAP)! ≥! 65! mmHg,! CI! ≥! 2! L/min/m2,! SVO2! ≥! 65%! and! Hb! ≥! 70! g/L! were!considered!violated!in!the!event!of!failure!to!achieve!acceptable!values!despite!5!min!of!maximal!appropriate!therapy.!The!nature!and!duration!of!any!violations!were! documented! in! the! patient! data.! Briefly,! MAP! was! increased! in! cases! of!hypotension! prior! to! CPB! using! phenylephrine! (0.01! P! 1!mcg/kg/min).! During!and! following! CPB,! phenylephrine! (250! mcg! boluses! up! to! every! 2! min),!noradrenaline! infusion! (0.05! P! 0.4! mcg/kg/min),! vasopressin! (2! P! 3! U/h),! or!
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12(hours(following(cardiac(surgery(Patients!should!be!maintained!in!sinus!rhythm!at!80!P!110!bpm.!If!the!rate!is!<!80!then!DDD!pacing! is! the! preferred!mode.! If!HR!<! 80,! sinus! rhythm!may! still! be!preferred!to!VVI!if!there!are!no!atrial!wires.!Maintenance! fluid! is! dextrose! 5%! in! water! at! 0.8! mL/kg/hr! (rounded! to! the!nearest!10!mLs).!!All! dosing! on! the! protocol! is! based! on! the! patient’s! actual! prePoperative! body!weight.!!1! A! sustained! rise! in! CVP! or! PA! diastolic! in! response! to! fluid! boluses! usually!indicates!adequate!volume!resuscitation.!!If!the!patient!develops!new!‘instability’!and!filling!pressures!have!not!dropped,! it!may!be!appropriate!to!omit!step!1!of!the!algorithm.!A!straight! leg!raise!may!give!you!an!idea!of!the!patient’s!volume!responsiveness!and!may!be!performed!at!step!1! if! the!patient! is! felt! to!be! ‘well!
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filled’.! If! the!BLOOD!PRESSURE!does!not!rise! in!response!to!a!straight! leg!raise!the!patient!is!unlikely!to!be!volume!responsive.!2! If! the! cardiac! index! is! >! 3.5! and! the! mixed! venous! is! adequate,! positive!inotropes! (milrinone,! adrenaline,! dobutamine,! dopamine)! should! be! weaned.!Milrinone!can!generally!be!ceased!without!weaning!due!to! its! long!half! life.! !An!intraPaortic!balloon!pump!should!be!considered!if!adequate!cardiac!index!is!not!achieved!with! adequate! fluid! resuscitation! and!milrinone! at! 0.75!mcg/kg/min.!Unexpected!low!cardiac!output!should!be!evaluated!by!echocardiography.!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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Appendix(B. Criteria(for(EuroSCORE(and(RIFLE(Evaluations(!!
EuroSCORE(!The! logistic! EuroSCORE! was! used! to! evaluate! the! operative! risk! of! patients!recruited!to!the!trial!of!RIPC! in!highPrisk!cardiac!surgery!patients,!according!to!the! following! formula! and! the! variables! presented! in! Table! B.1! (Nashef! et! al.,!1999;!Roques!et!al.,!2003).!!Predicted!mortality!=!!!!!e!(βo+++Σ+βi+Xi)!!!! ! ! !!1!+!e!(βo+++Σ+βi+Xi)!!Where:!! e!is!the!natural!logarithm!! ! βo!is!the!constant!of!the!logistic!regression!equation!(P4.789594)!! ! βi!is!the!coefficient!of!the!variable!Xi!in!the!logistic!regression!!! ! ! equation!provided!in!Table!B.1!! ! Xi!=!1!if!a!categorical!risk!factor!is!present!and!0!if!it!is!absent!! ! For!age,!Xi+=!1!if!patient!age!<!60;!Xi+increases!by!one!point!per!!! ! ! year!thereafter!!!!!!!!!!!!!!!!!
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Patient4related(factors( β"Age! Continuous! 0.0666354!Sex! Female! 0.3304052!Chronic!pulmonary!disease! Longterm!use!of!bronchodilators!or!steroids!for!lung!disease! 0.4931341!




Cardiac4related(factors(Unstable!angina! Rest!angina!requiring!iv!nitrates!until!arrival!in!the!anaesthetic!room! 0.5677075!LV!dysfunction! Moderate!or!LVEF!30P50%! 0.4191643!! Poor!or!LVEF!<30! 1.094443!Recent!myocardial!infarct! (<90!days)!!! 0.5460218!Pulmonary!hypertension! Systolic!PA!pressure>60!mmHg! 0.7676924!
Operation4related(factors!Emergency! Carried!out!on!referral!before!the!beginning!of!the!next!working!day! 0.7127953!Other!than!isolated!CABG! Major!cardiac!procedure!other!than!or!in!addition!to!CABG! 0.5420364!Surgery!on!thoracic!aorta! For!disorder!of!ascending,!arch!or!descending!aorta! 1.159787!Postinfarct!septal!rupture! !!!! 1.462009!
Table(B.1(Beta(coefficients(for(the(logistic(regression(model(of(EuroSCORE(
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RIFLE(!The! RIFLE! classification! of! acute! kidney! injury! was! used! to! evaluate! postPoperative!renal!damage!in!the!trial!of!RIPC!in!highPrisk!cardiac!surgery!patients,!as!detailed!in!Table!B.2!(Bellomo!et!al.,!2004).!!!
Class( GFR( UO(Risk! ↑!SCr!×!1.5!or!↓!GFR!>25%! <0.5!mL/kg/h!×!6!h!Injury! ↑!SCr!×!2!or!↓!GFR!>50%! <0.5!mL/kg/h!×!12!h!
Failure! ↑!SCr!×!3!or!↓!GFR!>75%!or!if!baseline!SCr!≥353.6!μmol/L!(≥4!mg/dL)!↑!SCr!>44.2!μmol/L!(>0.5!mg/dL)! <0.3!mL/kg/h!×!24!h!or!anuria!×!12!h!Loss!of!kidney!function! Complete!loss!of!kidney!function!>4!weeks! !EndPstage!kidney!disease! Complete!loss!of!kidney!function!>3!months! !
Table(B.2(RIFLE(classification(criteria(GFR!=!glomerular!filtration!rate,!UO!=!urine!output,!SCr!=!serum!creatinine.!Note:!a!patient!can!fulfil!the!criteria!through!changes!in!SCr!or!changes!in!UO,!or!both.!The! criteria! that! lead! to! the!worst! possible! classification! should! be! used.!Note!that!the!F!component!of!RIFLE!is!present!even!if!the!increase!in!SCr!is!under!3Pfold,!as!long!as!the!new!SCr!is!greater!than!4.0!mg/dL!(350!mol/L)!in!the!setting!of!an!acute!increase!of!at!least!0.5!mg/dL!(44!mol/L).!The!designation!RIFLEPFC!should!be!used!in!this!case!to!denote!'acutePonPchronic'!disease.!Similarly,!when!the!RIFLEPF! classification! is! achieved!by!UO!criteria,! a!designation!of!RIFLEPFO!should!be!used!to!denote!oliguria.!There!is!a!decrease!in!sensitivity!and!increase!in!specificity!with!each!progressive!RIFLE!stage.!!!!!!!!!!!!!
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Appendix(C. Recipes(!!
PBS((10X)(NaCl! ! ! ! ! ! ! ! 170!g!Na2HPO4.12H2O! ! ! ! ! ! 62.32!g!NaH2PO4.2H2O! ! ! ! ! ! 4.04!g!ddH2O!! ! ! ! ! ! ! 2!L!Solution!was!sterilised!by!autoclaving!prior!to!use.!!
FACS(Buffer((v/v)(FCS! ! ! ! ! ! ! ! 2%!Sodium!azide!! ! ! ! ! ! 0.1%!PBS! ! ! ! ! ! ! ! 97.9%!!
0.2%(Saponin(Buffer(Bovine!serum!albumin! ! ! ! ! 0.5!g!Saponin! ! ! ! ! ! ! 1!g!Hepes!(10!mM)! ! ! ! ! ! 1.19!g!Sodium!azide!! ! ! ! ! ! 0.05!g!ddH20!! ! ! ! ! ! ! 500!mL!
(
4%(Paraformaldehyde((w/v)(Paraformaldehyde! ! ! ! ! ! 4%!1X!PBS! ! ! ! ! ! ! 96%!Once!dissolved,!pH!adjusted!to!7.4.!!
ELISA(Capture(Buffer(Na2HPO4! ! ! ! ! ! ! 0.1!M!Solution!was!dissolved!in!ddH20!and!adjusted!to!pH!6.0!or!9.0.!!
ELISA(Stop(Solution!H2SO4! ! ! ! ! ! ! ! 0.18!M!Prepared!in!ddH20.!!
Complete(T(Cell(Media((CTCM;(v/v)(Dulbecco’s!Modified!Eagle!Medium!! ! ! 85.9%!Fetal!calf!serum! ! ! ! ! ! 10%!LPglutamate!(200!mM)! ! ! ! ! 1%!Penicillin/Streptomycin!(10,000!U/mL/10!mg/mL)! 1%!HEPES!buffer!(1!M)! ! ! ! ! ! 1%!ΒPMercaptoethanol! ! ! ! ! ! 0.1%!NonPessential!amino!acids!(10!nM)!! ! ! 0.1%! ! !! ! !!!
!! 333!















































Specificity( Fluorophore( Clone( Isotype( Manufacturer(
Optimal(
Final(
Dilution(CD3! PE! UCHT1! Mouse!IgG1! BD!Pharmingen! 1:100!CD3! PE/Cy7! UCHT1! Mouse!IgG1! Biolegend! 1:100!CD3! APC/H7! SK7! Mouse!IgG1! BD!Pharmingen! 1:100!CD4! APC/H7! RPAPT4! Mouse!IgG1! BD!Pharmingen! 1:100!CD4! V500! RPAPT4! Mouse!IgG1! BD!Horizon! 1:50!CD8a! AF488! HIT8a! Mouse!IgG1! Biolegend! 1:800!CD11b! AF488! ICRF44! Mouse!IgG1! Biolegend! 1:400!CD14! APC! M5E2! Mouse!IgG2a! Biolegend! 1:200!CD14! PerCP! MOP9! Mouse!IgG2b! BD!Biosciences! 1:25!CD14! PerCP/Cy5.5! M5E2! Mouse!IgG2a! BD!Pharmingen! 1:200!
CD16! PE/Cy7! 3G8! Mouse!IgG1! Biolegend! 1:800!(PBMC)!or!1:3000!(Neutrophils)!CD16! V450! 3G8! Mouse!IgG1! BD!Horizon! 1:800!CD25! AF488! BC96! Mouse!IgG1! Biolegend! 1:100!CD45! PE/Cy7! HI30! Mouse!IgG1! Biolegend! 1:200!CD56! PerCP/Cy5.5! HCDP56! Mouse!IgG1! Biolegend! 1:150!CD62L! APC! DREGP56! Mouse!IgG1! Biolegend! 1:40!CD63! PE! MEMP259! Mouse!IgG1! Biolegend! 1:10!CD69! PE! FN50! Mouse!IgG1! Biolegend! 1:100!ILP6! APC! MQ2P13A5! Rat!IgG1! Biolegend! 1:25!ILP8! PE! E8N1! Mouse!IgG1! Biolegend! 1:25!ILP10! BV421! JES3P9D7! Rat!IgG1! Biolegend! 1:25!AF488! MOPCP21! Mouse!IgG1! Biolegend!APC! MOPCP21! Mouse!IgG1! BD!Pharmingen!APC! G155P178! Mouse!IgG2a! BD!Pharmingen!APC! RTK2071! Rat!IgG1! Biolegend!APCPH7! MOPCP21! Mouse!IgG1! BD!Pharmingen!BV421! RTK2071! Rat!IgG1! Biolegend!PE! MOPCP21! Mouse!IgG1! BD!Pharmingen!PE! MOPCP21! Mouse!IgG1! Biolegend!PE/Cy7! MOPCP21! Mouse!IgG1! Biolegend!PerCP! MPCP11! Mouse!IgG2b! Biolegend!PerCPPCy5.5! MOPCP21! Mouse!IgG1! Biolegend!V450! MOPCP21! Mouse!IgG1! BD!Horizon!
Isotype!Controls!














Neuts"Green/AF488! CD25! CD8! CD8! CD11b!
Yellow/PE! CD69! CD69! CD3! CD63!
Red/PerCP!or!PerCP/Cy5.5! CD56! CD56! CD56! CD14!Blue!(488)! Infrared/PEPCy7! CD3! CD16! CD16! CD16!










Neuts"Blue/BV421! ILP10! ILP10! ILP10!Violet!(405)! Green/V500! CD4! P! P!
Green/AF488! CD25! CD8! CD11b!
Yellow/PE! ILP8! ILP8! ILP8!
Red/PerCP!or!PerCP/Cy5.5! CD56! CD56! CD14!Blue!(488)! Infrared/PEPCy7! CD3! CD3! CD16!









and(neutrophils(during(immunophenotyping(Whole!blood!was!prepared!as!described! in! section!4.3.4.! Staining! is! shown! for!IgGPPE!(blue)!vs.!CD63PPE!(red)!in!monocytes!(A!and!E)!and!neutrophils!(B!and!F),!in!unstimulated!(A!and!B)!and!PMA/I!stimulated!(E!and!F)!samples;!and!IgGPAF488!(blue)!vs.!CD11bPAF488!(red)!in!monocytes!(C!and!G)!and!neutrophils!(D!and! H),! in! unstimulated! (C! and! D)! and! PMA/I! stimulated! (G! and! H)! samples.!Shown! is! representative! data! taken! from!one!participant! following! the! control!treatment.!
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!
Figure(F.3(Gating(of(total(T(cell(populations(and(CD56+(cells(in(panel(3(Whole!blood!was!prepared!as!described!in!section!4.3.4.!(A)!Singlet!events!were!first! isolated! using! FSCPA! vs.! FSCPH;! (B)! cells! staining! positively! for! CD3!were!gated! (red)! and! compared! to! the! isotype! control! (blue);! (C)! the! CD3+!lymphocytes!were!gated!using!FSCPH!vs.!SSCPH;!(D)!the!CD3+!T!cells!were!sorted!into!CD4,!CD8,!and!double!positive!populations,!compared!to!the!isotype!control!stained!samples!(E);!(F)!a!broad!gate!was!used!to!isolate!the!lymphocyte!subset!of!singlet!events!on!FSCPH!vs.!SSCPH;!(G)!CD56+!stained!lymphocytes!(red)!were!gated!using!the!isotype!control!(blue);!(I)!the!CD56+!lymphocyte!population!was!further!separated!into!CD3+CD16P/+!NKT!cells!and!CD3PCD16+!NK!cells,!compared!to!isotype!control!stained!samples!(H).!Shown!is!representative!data!taken!from!one!participant!following!the!control!treatment.!!!!!!!
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Figure* F.6* Gating* of* total* live* leukocytes,* monocytes,* and* neutrophils* in*
panel*7*during*ICS*Whole!blood!was!prepared!as!described!in!section!5.3.1.!In!samples!cultured!for!4!hrs!in!media!(A!–!D)!or!27!hrs!with!PMA/I!(E!–!H):!(A!and!E)!singlet!leukocyte!events!were!gated;!(B!and!F)!a!broad!gate!was!used!to!separate!the!monocytes!and! neutrophils;! (C! and! G)! dead! cells! were! excluded;! (D! and! H)! CD14RCD16+!neutrophils! and! CD14+CD16R/low!monocytes!were! gated.! Total! leukocytes!were!also! gated! (I)! and! assessed! for! viability! (J).! Representative! plots! of! CD11b!staining! in! 4! hr! unstimulated! (blue)! and! stimulated! (red)! monocytes! (K)! and!neutrophils! (L).! Shown! is! representative! data! from! one! participant! during! a!control!visit.!
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!
Figure*F.7*Gating*of*intracellular*cytokines*in*monocytes*and*neutrophils*Whole! blood! was! prepared! as! described! in! section! 5.3.1.! Monocytes! (A)! and!neutrophils! (B)! were! gated! in! a! stimulated! intracellular! PE! and! APC! isotype!control! sample!with! CD14! and! CD16! staining,! and! used! to! set! quadrant! gates.!Shown!is!ILR6!vs.!ILR8!staining!in!samples!cultured!for!4!hours!(C!–!F)!or!27!hours!(G!–!J),!in!monocytes!(C,!D,!G,!and!H)!and!neutrophils!(E,!F,!I,!and!J),!in!media!(C,!G,!E,!and!I)!or!with!PMA/I!(D,!H,!F,!and!J).!Shown!is!representative!data!from!one!participant!during!a!control!visit.!!
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*
Figure*F.8*Gating*of*intracellular*cytokines*in*CD4*T*cells*in*panel*5*Whole! blood!was! prepared! as! described! in! section! 5.3.1.! (A)! Singlet! leukocyte!events! were! gated;! (B)! a! broad! gate! was! used! to! separate! the! lymphocyte!population;! (C)! dead! cells! were! excluded;! (D)! CD3+! lymphocytes! (red)! were!gated!against!the!isotype!control!(blue);!(E)!CD4+!T!cells!(red)!were!gated!using!an! isotype! control! (blue);! (F)! CD4+CD25+! cells! were! identified! (red)! by! gating!against!an!isotype!control!sample!(blue);!(H)!representative!plot!of!CD4+CD25+!T!cells!in!unstimulated!(blue)!and!stimulated!(red)!cells;!ILR6!and!ILR8!levels!in!the!CD4!T!cell!population!(I!and!K)!were!gated!using!the!isotype!control!samples!for!reference!(H!and!J)!in!unstimulated!(H!and!I)!and!stimulated!(J!and!K)!samples.!Shown! are! representative! plots! from! one! participant! following! the! control!treatment!(no!RIPC)!in!cells!cultured!for!27!hours.!The!samples!shown!in!plots!A!–!F!were!unstimulated.!!! !
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Figure'G.1'Serum'cytokine'levels'for'all'study'participants'Blood! samples! were! collected! from! healthy! volunteers! at! baseline,! and! 20!minutes,! 1! hour,! and! 4! hours! after! control! or! RIPC! treatment! and! serum!biomarker!levels!were!quantified!using!a!CBA!and!flow!cytometry.!Shown!are!the!absolute!concentrations!for!the!participants!with!high!levels!of!cytokines!before!and! after! treatment! that! were! excluded! from! the! main! analysis! (03! and! 08;!represented!by!the!normal!and!inverted!triangles),!compared!to!the!mean!levels!for! the! remaining! 8! participants.! In! the! case! of! ECselectin! (A),! one! additional!participant!who!had! levels! that! exceeded! the!detection! range! of! the! assay! and!was! excluded! from! the! analysis! is! also! shown! separately! from! the! remaining!participants!(06,!represented!by!the!squares).!!!!!
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Figure' H.1' T' cell' subset' proportions' and' activation' state' after' 4' hours'
culture'Blood!was!collected!1!hour!after!treatment;!cultured!for!4!hours!with!or!without!50! ng/mL!PMA,! 500! ng/mL! ionomycin,! and!GolgiStop! (1:1000);! then! assessed!for! intracellular! cytokines!with! flow!cytometry.!Proportions!of! cell!populations!are!shown!for!(A)!CD3+!cells;!(B)!CD4+!T!cells;!(C)!CD8+!T!cells;!(D)!CD4+CD25+!T!cells;! (E)!CD69+!T!cells.!CD3+!cells!are!expressed!as! the!percentage!of! the! total!live! leukocytes,! and! the! remaining! subsets! as! a! percentage! of! the! CD3+! parent!population.!Samples!were!prepared! in!duplicate!and!shown!are! the!means!and!SEM!for!n!=!10!for!A,!C,!and!E,!and!n!=!9!for!B!and!D.!*!p!<!0.05.!
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!
Figure'H.2' Intracellular' ILJ6'and' ILJ8'production' in'T' cells' cultured' for'4'




cultured'for'27'hours'Blood! was! collected! 1! hour! after! treatment;! cultured! for! 27! hours! with! or!without!10!ng/mL!PMA,!500!ng/mL! ionomycin,!and!GolgiStop!(1:1000)! for! the!final!4!hours;!then!assessed!for!intracellular!cytokines!with!flow!cytometry.!ILC6!MFI!in!CD4!(A)!and!CD8!(C)!T!cells;!ILC8!MFI!in!CD4!(B)!and!CD8!(D)!T!cells.!Cells!are!expressed!as!the!percentage!of!the!total!live!parent!population.!Samples!were!prepared!in!duplicate!and!shown!are!the!group!means!and!SEM!for!n!=!9!for!A!and!B,!and!n!=!10!for!C!and!D.!**!p!<!0.01!and!***!p!<!0.001.!!!!!!!!!!!
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Figure' H.4' Intracellular' cytokine' production' in' NK' cells' cultured' for' 4'
hours'Blood!was!collected!1!hour!after!treatment;!cultured!for!4!hours!with!or!without!50! ng/mL!PMA,! 500! ng/mL! ionomycin,! and!GolgiStop! (1:1000);! then! assessed!for!intracellular!cytokines!with!flow!cytometry.!(A)!Proportion!of!CD3CCD56+!NK!cells;!(B)!percentage!of!ILC6+!NK!cells;!(C)!percentage!of!ILC8+!NK!cells.!Cells!are!expressed! as! the! percentage! of! the! total! live! parent! population.! Samples!were!prepared!in!duplicate!and!shown!are!the!group!means!and!SEM!for!n!=!10.!!!!!!!!!
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Figure'H.5'Cytokine'production'in'NKT'cells'after'4'hours'of'culture'Blood!was!collected!1!hour!after!treatment;!cultured!for!4!hours!with!or!without!50! ng/mL!PMA,! 500! ng/mL! ionomycin,! and!GolgiStop! (1:1000);! then! assessed!for! intracellular! cytokines! with! flow! cytometry.! (A)! Proportion! of! CD3+CD56+!NKT!cells;!(B)!CD4+!NKT!cells;!(C)!CD8+!NKT!cells;!(D)!percentage!of!ILC6+!NKT!cells;!(E)!percentage!of!ILC8+!NKT!cells.!Cells!are!expressed!as!the!percentage!of!the!total!live!parent!population.!Samples!were!prepared!in!duplicate!and!shown!are!the!group!means!and!SEM!for!n!=!10.!!!!
